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Lung cancer remains a leading cause of cancer-related mortality, accounting for an 
estimated 1.4 million deaths in 2010. In recent years, major advances have been made in 
the identification of oncogenic driver mutations in lung cancer. Genomic analyses of 
adenocarcinoma of the lung have yielded significant strategies against pathway activation 
to improve treatment, but these efforts have been less successful in lung squamous cell 
carcinoma (SCC). It is generally considered that SCC is associated with few genetic 
aberrations that are actionable with targeted small molecule compounds or antibodies. 
Hence, platinum-based chemotherapy remains the standard-of-care treatment for 
metastatic SCC. However, drug resistance inevitably develops and curtails the efficacy of 
chemotherapy. Therefore, there is an urgent need to develop novel combinations for the 
treatment of lung SCC that leverage on understanding the pathways underpinning 
cisplatin resistance, and to establish predictive biomarkers that could be subjected to 
therapeutic intervention and facilitate treatment selection. 
In this study, Next Generation sequencing technology revealed that aberrant activations 
in oncogenic pathways by EGFR mutations and ALK fusions were rare in lung SCC. Cell 
lines with inherent resistance to cisplatin were first identified with cell proliferation 
assays. To elucidate mechanisms that mediate resistance to cisplatin, drug-induced 
perturbations to gene and protein expression were compared between cisplatin-sensitive 
and –resistant SCC cells, and identified MAPK/Erk pathway up-regulation and activation 
in drug-resistant cells. Erk-induced resistance appeared to be activated by Son of 
Sevenless (SOS) upstream, and mediated through Bim degradation downstream. 
Clinically, elevated p-Erk expression was associated with shorter disease-free survival in 
patients with locally advanced head and neck SCC treated with concurrent 
chemoradiation. Inhibition of MEK/Erk, but not that of EGFR or RAF, augmented 
cisplatin sensitivity in vitro. Collectively, these findings suggest that up-regulation of the 
MAPK pathway through SOS-mediated MEK/Erk activation confers resistance to 
cisplatin treatment, and MEK inhibition may augment patient responses to cisplatin 
treatment. 
Parallel investigations were conducted to identify the potential chemosensitizing 
mechanism(s) in lung SCC. Belinostat, a pan HDAC inhibitor, was found to exhibit 
strong synergy with cisplatin in cisplatin-resistant cell lines. Importantly, belinostat 
treatment suppressed p44/42 MAPK signalling dose-dependently through abrogation of 
SOS, which led to Bim up-regulation and apoptosis. These observations suggested that 
 XII 
 
belinostat could attenuate SOS/MAPK-mediated cisplatin resistance. Furthermore, 
combination of cisplatin together with a clinically tolerable dose of belinostat (0.1μM) 
significantly induced cell death in several lung SCC cell lines. Using H2170 cell lines as 
study model, synergistic cytotoxicity of belinostat and cisplatin was correlated with 
acetylation of mutant p53 (R158G), and was rescued when p53 was silenced. Conversely, 
ectopic expression of mutant p53 in Calu-1 cells (p53 null, cisplatin-resistant) effectively 
increased cisplatin sensitivity. The cell death observed in p53 mutant cells after 
combination treatment of belinostat and cisplatin was further associated with acetylation 
of p53. Moreover, tenovin-6, a specific acetylator of p53, concomitantly induced p53 
acetylation and cellular apoptosis in p53 mutant cells. Taken together, these findings 
proposed a therapeutic strategy that targets p53 mutant SCC cells through activation of 
p53-mediated apoptosis. 
In summary, this study has described a cisplatin resistance mechanism involving the up-
regulation of SOS/MAPK/Erk signalling that is activated under treatment pressure. Such 
perturbation could be subjected to therapeutic intervention using MEK inhibitors or 
belinostat. More crucially, this study describes a novel gain-of-function event in p53 
mutant cells that is responsible for belinostat/cisplatin-induced cell death. This thesis 
proposed two promising combination strategies for SCC patients: one targeting tumours 
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CHAPTER 1  INTRODUCTION 
1.1  Lung Squamous Cell Carcinoma 
1.1.1  The Disease and its Prevalence 
Lung cancer is the leading cause of cancer-related death worldwide, and is accounted for an 
estimated 1.4 million deaths in 2010, thus exceeding the combined mortality of breast, 
colorectal and prostate carcinomas (World Health Organisation 2013). In Singapore, the 
incidence and mortality rates for lung cancer have been on the increasing trend through most 
of last century and it is now among the most frequently diagnosed cancer in both male and 
female population with a five-year overall survival rate of less that 15% (Teo and Soo 2013). 
Lung cancer comprises of tumours that arise from cells lining the airway of the respiratory 
system. It is generally classified into 2 main types: small cell lung cancer and non-small cell 
lung cancer (NSCLC) based on clinicopathological features. NSCLC constitutes 85-90% of 
all lung cancer cases with squamous cell carcinoma (SCC) and adenocarcinoma being two 
of the major subtypes (30% and 40%) (TCGA 2008). Lung SCC is clinically and 
histopathologically distinct from adenocarcinoma, as two subtypes are varied in shape, size, 
site-of-origin and even therapeutic options. Although adenocarcinoma has replaced lung 
SCC as the most common histology subtype for all lung cancer cases (Travis, Cancer, 1995), 
lung SCC prevails as a major public health concern worldwide due to its low 5-year overall 
survival rate (Sato, Shames et al. 2007).   
In general, symptoms of lung SCC include but not limited to, persistent cough, coughing out 
blood, chest pain, wheezing, hoarseness, pneumonia and haemoptysis (A.D.A.M., 2011). 
Since lung SCC tends to develop near to the larger air passages, its symptoms tend to 
surface earlier than other form of lung cancer. However, despite the continual development 
of diagnosis platforms, majority of the lung cancer patients are only diagnosed at advanced 
stages. The initial detection of lung cancer involves chest X-ray and bronchoscopy. In cases 
whereby a mass in the lungs or swollen chest lymph nodes were identified, further tests that 
include computed tomography (CT), magnetic resonance imaging (MRI) and needle biopsy 
are conducted to determine the nature of the mass by pathologists. As lung SCC often arises 
in the central bronchi, while its carcinoma in situ is asymptomatic and generally 
undetectable on X-ray, the diagnosis for this disease is made difficult. More importantly, the 
poor diagnosis of lung SCC directly attributes to the poor prognosis. Upon detection, the 
stages of the lung tumours will be classified based on the TNM [size of the primary tumour 
(T), presence of regional lymph node (N) and distant metastasis (M)] staging system 




Figure 1.1: Histology tissue section from samples of squamous cell carcinoma stained 
with Mayer’s haematoxylin and eosin.  
A, Photomicrograph revealed carcinoma in situ (CIS) of SCC. B, Photomicrograph revealed 
early stage SCC, with keratin pearls surrounded by tumour cells. C, Photomicrograph of 
poorly differentiated late stage SCC. All photomicrographs where taken in 200x 






1.1.2  Clinicopathology of lung SCC 
NSCLC originates from lung epithelial cells of the central bronchi to terminal alveoli. The 
histological classification of NSCLC is very much dependent on the site-of-origin. Unlike 
lung adenocarcinoma that is usually located at outer part of the lung, SCC usually arises 
from central bronchus, where it originates from the squamous tissue along the airway of the 
lung and lines bronchi that link up the trachea to the lung. This tumour is slow-growing, and 
requires years to develop from confined metaplasia and dysplasia to carcinoma in situ 
(Saccomanno, Archer et al. 1974) (Figure 1.1 A), before eventually developed into invasive 
cancer. The hallmark of SCC is the presence of keratinisation, which leads to either the 
formation of keratin pearls that are surrounded by tumour cells (Figure 1.1 B), or 
intercellular bridges that link adjacent cells. At early stages, lung SCC are well-
differentiated and keratin pearls are usually found; while at late stages, these tumours are 
poorly differentiated with minimal squamous cell features (Saccomanno, Archer et al. 1974) 
(Figure 1.1 C). 
Lung SCC is inherently heterogeneous and this variability often leads to differential 
prognosis. Based on their histopathological appearances, lung SCC is further divided into 4 
variants: papillary, small cell, clear cell and basaloid. Several reports have demonstrated the 
variability in drug response among these variants, with high-grade basaloid variants being 
demonstrated to have poorer prognoses that the overall population of lung SCC (Wang, 
Wang et al. 2011). More recently, lung SCC are stratified into 4 genetic subtypes (primitive, 
classical, secretary and basal) based on their mRNA expression profile (Wilkerson, Yin et al. 
2010). These subtypes are further shown to have differential survival outcomes, biological 
processes, and could predict drug response  to various therapy (Wu, Pang et al. 2013). 
 
1.1.3  Etiology of lung SCC 
Cigarrettes smoking is the primary risk factor for lung cancer as patterns of disease 
occurrence are, to a large extent, determined by tobacco exposure (Molina, Yang et al. 
2008). However, other studies have reported 10 - 40% of NSCLC cases occur in patients 
with no history of smoking (Subramanian and Govindan 2007). Inherent genetic 
susceptibility and environmental exposure, that include tobacco smoke, radon gas, asbestos, 
toxic chemical entities, air pollution and ionising radiation, have also been shown to 
increase risk of NSCLC (Govindan, Ding et al. 2012). Among these factors, the habit of 
tobacco smoking is most strongly associated with lung SCC. Thus, the incidence of lung 
SCC decreases in recent years as consequence of changes in smoking habit and construction 
of new formulation for cigarette content. 
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Similar to other types of cancer, development and progression of NSCLC is a multi-stage 
process (Wistuba, Behrens et al. 1999, Yokota and Kohno 2004). It has been shown that the 
molecular pathways leading to the pathogenesis are relatively different across lung 
adenocarcinoma and lung SCC. While Kras and β-catenin mutations are common in 
adenocarcinoma (Yokota and Kohno 2004), loss-of-heterozygosity of chromosome 3p is 
frequently detected (>80%) in lung SCC (Wistuba, Behrens et al. 1999, Zabarovsky, 
Lerman et al. 2002). The deletion of chromosome 3p is also accompanied by the p16 
abnormalities and alterations of p53 pathways during the development of squamous 
dysplasia from normal lung epithelium (Shiseki, Kohno et al. 1996). Furthermore, sub-
classification of a group of SCC based on their bronchial sites (central, intermediate and 
peripheral bronchi) reveals certain trends for p53 mutational spectra of these tumours in 
specific location (Shimmyo, Hashimoto et al. 2006). This study proposed that investigation 
of the link between p53 mutational status and smoking history may provide insights to 
etiological factors of lung SCCs. In addition, the progression of confined tumours to 
metastatic SCC requires sequential aberrations that include allelic loss of chromosome 2q, 
9p, 18q and 22q (Shiseki, Kohno et al. 1994, Nishioka, Kohno et al. 2002). 
 
1.1.4  Staging of lung SCC 
Defining the stage classification is an important process in patients with cancer, as it often 
affects the treatment options. Similar to most cancers, the classification of NSCLC is based 
on the TNM system (Detterbeck, Boffa et al. 2009). The T descriptor defines the extent of 
the primary tumour; N descriptor the involvement of regional lymph node; and the M 
descriptor the presence of distant metastasis (Goldstraw, Crowley et al. 2007). The various 
type of staging could be assessed by clinical staging, which could be determined with 
magnetic resonance imaging (MRI), computed tomography (CT) scan, positron emission 
tomography (PET) scan, or endoscopic ultrasound; and pathological stagining, which is 
usually determined after a resection has been performed (Detterbeck, Boffa et al. 2009). 
Based on the T, N and M descriptors, NSCLC can be staged as follow: stage 0 is the 
formation of carcinoma in situ; in stage I, cancer has formed but has not spread to lymph 
nodes; in stage II, tumour has expanded (5 – 7 cm) and spread to nearby lymph nodes; in 
stage IIIA, cancer has spread to regional lymph nodes on the same side of the chest as the 
tumour; in stage IIIB, cancer has spread to regional lymph nodes above the collarbone or on 
the opposite side of the chest as the tumour; and in stage IV, cancer has spread to both side 




1.2  Conventional chemotherapies in lung SCC 
Treatment of lung cancer is dependent on the stage of the disease upon diagnosed, which are 
generally assessed by CT, MRI and needle-biopsy. At early stages, surgical resection is 
usually performed with options of adjuvant chemotherapy. However, as discussed in the 
previous chapter, early diagnosis of lung tumours is limited by current diagnostic techniques. 
For many years, treatment of advanced lung cancer has been highly-dependent on 
chemotherapy as the first-line therapy. Chemotherapies are non-targeting cytotoxic or 
genotoxic agents that either kill or inhibit proliferation of tumour cells. Cancer cells are 
characterized by their aberrant proliferation. Thus, most chemotherapies are designed to 
target rapidly dividing cells by impairing mitosis, a crucial cell division mechanism, of 
cancer cells. However, healthy cells that divide rapidly, such as hair follicles, bone marrow 
and digestive tract, are also affected by chemotherapeutic agents. These non-specific 
targeting of chemotherapies on non-malignant cells give rise to common side effects such as 
alopecia, mucositis and myelosuppression (Peters 1994, Wong and Giandomenico 1999). 
Chemotherapy may be used as a single agent or in combinations with other agents. Several 
meta-analysis studies have reported the slight advantage of chemotherapy in advanced 
NSCLC (Grilli, Oxman et al. 1993, Marino, Pampallona et al. 1994). Commonly used 
chemotherapies for NSCLC include DNA damaging agents, anti-metabolites, and mitotic 
inhibitors. In a randomized study, four chemotherapeutic regimens (cisplatin and paclitaxel, 
cisplatin and gemcitabine, cisplatin and docetaxel, carboplatin and paclitaxel) offered 
comparable treatment outcomes in advanced NSCLC patient with no significant advantages 
over one another (Schiller, Harrington et al. 2002). 
 
1.2.1 DNA-damaging agents: platinum-containing compounds 
Despite the rapid development of anti-neoplastic agents, platinum-based compounds remain 
as one of the most commonly used and effective treatment options for cancer patients. It has 
displayed broad spectrum efficacy in a wide range of malignancies such as lung, ovarian, 
testicular, bladder and head and neck carcinomas (Lebwohl and Canetta 1998, Wang and 
Lippard 2005). Cisplatin, also known as cis-diamminedichloridoplatinum(II) (CDDP), is the 
first platinum-based drug that was discovered back in the 1960s when it showed inhibitory 
effect of DNA synthesis in Escherichia coli (Rosenberg, Van Camp et al. 1967). Due to its 
efficacy as an anti-cancer agent, newer generation of platinum-containing compounds with 
lower toxicity have been developed that include carboplatin, oxaliplatin, picoplatin, 
satraplatin and more recently aroplatin and AP5346 (Kelland 2007, Eckardt, Bentsion et al. 
2009) (Figure 1.2). Interestingly, some of these analogues display differential sensitivities 
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among cancer cells. For instant, carboplatin has been shown to exhibit cross-resistance to 
cisplatin (Rixe, Ortuzar et al. 1996, Johnson, Laub et al. 1997), but oxaliplatin is found to be 
effective in cancer cells with acquired resistance to cisplatin (Raymond, Faivre et al. 2002) 
while picoplatin induces cytotoxicity in cisplatin/carboplatin-resistant NSCLC (Tang, 
Parham et al. 2011). 
Platinum drugs are a class of alkylating agents that are capable of forming DNA adducts and 
leading to cellular cytotoxicity. The interaction with DNA requires intracellular activation of 
platinum drug under aqueous condition, whereby the chlorine ligands are replaced with 
hydroxyl group to form the positively charged aquated species that covalently bind to DNA, 
thus forming intrastrand cross-link adducts (Huang, Zhu et al. 1995, Jamieson and Lippard 
1999). These adducts result in distortions within the DNA, and impede cellular processes 
which require separation of DNA, such as DNA replication and transcription (Siddik 2003). 
This induces genotoxic stress within the cellular body that triggers the activation of DNA 
repair pathways (Zamble, Mu et al. 1996). Importantly, the eventual cellular outcome of 
platinum-based compounds is generally apoptotic cell death (Eastman 1990). Cisplatin and 
carboplatin are widely used in the treatment of ovarian, cervical, head and neck and NSCLC 
(Jamieson and Lippard 1999). Particularly in testicular cancer, cisplatin has an overall cure 
rate exceeding 90% (Raghavan 2003).  
 
1.2.2 Microtubule targeting agents: taxanes 
Taxanes are mitotic inhibitors that inhibit the process of cell division by disruption of 
microtubule function (Abal, Andreu et al. 2003). Microtubules are highly dynamic cellular 
polymers that are essential for cell division by facilitating the arrangement of dividing 
spindle and integrity of segregated DNA (Sharp, Rogers et al. 2000). Taxanes stabilize the 
GDP-bound tubulin and prevent it from disassembly. This inhibits the configuration of 
metaphase spindle, thus blocks progression of mitosis, induces cell cycle arrest and triggers 
apoptosis (Abal, Andreu et al. 2003, Mollinedo and Gajate 2003). 
Paclitaxel (Taxol) is the first isolated taxanes and is seen as the prototype of the anti-cancer 
taxane family drugs (Wani, Taylor et al. 1971). The anti-neoplastic effects of taxanes were 
illustrated by the tumour-suppressive effects in leukemic and xenograft models (Wani, 
Taylor et al. 1971).  Initial therapeutic responses were first observed in melanoma and 
refractory ovarian cancer patients (McGuire, Rowinsky et al. 1989, Wiernik and Einzig 
1993). Currently, paclitaxel is among the first-line chemotherapies for melanoma, breast, 
prostate and NSCLC patients (Perez 1998, Obasaju and Hudes 2001, Hodi, Soiffer et al. 





Figure 1.2: The structures of several platinum-based chemotherapies with the history 
and rationale behind their development.  
The dates indicate the time when each agent was first administered to patients. Improvement 
made on each generation of platinum-containing compound is demonstrated. [Adapted from 
(Kelland 2007)] 
 
1.2.3 Anti-metabolites: Gemcitabine 
Anti-metabolite drugs are among the first effective chemotherapeutic agents identified. The 
structure of this class of compounds mimics the naturally found molecules that are essential 
in nucleic acid synthesis (ELION, HITCHINGS et al. 1951). The main representatives of 
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these drugs are purine analogues, pyrimidine analogues and folic acid. These analogues are 
structurally similar to naturally occurring purines and pyrimidines (Montgomery, Elliott et 
al. 1978). During DNA replication, the incorporation of anti-metabolites into DNA or RNA 
of tumour cells lead to growth arrest and apoptosis (Plunkett, Huang et al. 1995). A key 
factor that affects the efficacy of anti-metabolite drugs is the rate of facilitated diffusion of 
both normal and analogue nucleosides in and out of the cells. A wide range of cancer cell 
lines have been reported to contain transport systems that promote active removal of anti-
metabolites (Paterson, Kolassa et al. 1981). 
Gemcitabine (dFdC) is a pyrimidine analogue that is a first-line treatment of NSCLC. This 
compound was first synthesized in 1986 as an antiviral agent. Its subsequent demonstration 
of anti-neoplastic activities in murine xenograft models led to its evaluation as a 
chemotherapeutic agent (Hertel, Boder et al. 1990, Lund, Kristjansen et al. 1993). Apart 
from forming building blocks in nucleic acids, gemcitabine also targets the ribonucleotide 
reductase (RNR). Irreversible inactivation of RNR inhibits the synthesis of 
deoxyribonucleotides that are essential for DNA replication and thus induces cell death 
(Cerqueira, Fernandes et al. 2007). Gemcitabine has been shown to achieve 20 - 26% 
response rate in NSCLC patients (Abratt, Bezwoda et al. 1994, Anderson, Lund et al. 1994), 
while co-administration with cisplatin generated response rate as high as 50% (Abratt, 
Bezwoda et al. 1997, Crinò, Scagliotti et al. 1997).   
 
1.2.4  Programmed cell death by conventional chemotherapies 
1.2.4.1 Autophagy, necrosis and apoptosis 
The eventual goal of chemotherapy is the killing of tumour cells. Death of tumour cells via 
programmed cell death can be mediated by extensive regulation of intracellular signalling 
(Lockshin and Beaulaton 1974). Years of research have identified various types of cell death 
which are classified based on their distinct molecular characteristics. Among them, 
apoptosis, necrosis and autophagy are commonly related to cancer therapeutics (Galluzzi, 
Vitale et al. 2012). Briefly, autophagy is a homeostatic process in which cellular degradation 
of cytoplasmic organelles within the same cell is carried out through lyzosomal activities 
(Levine and Klionsky 2004). However, the role of autophagy as a protective adaptation 
response that promotes cell survival (Lum, DeBerardinis et al. 2005), or as a programmed 
cell death mechanism remains debatable (Levine and Yuan 2005). Increasing evidences 
have been demonstrated in support of autophagic cell death as response to chemotherapies 
(Kanzawa, Kondo et al. 2003, Notte, Leclere et al. 2011). Necrosis is a cell death 
mechanisms that is morphologically characterized by cell swelling, rupture of plasma 
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membrane and release of cellular components into extracellular matrix (Majno and Joris 
1995). Although being initially believed to be unregulated and accidental, necrotic cell death 
has been recently found to be actively regulated by several factors, which include exposure 
to DNA alkylating agents (Vandenabeele, Galluzzi et al. 2010, Baritaud, Cabon et al. 2012). 
Despite the improved understandings of autophagy and necroptosis in drug-induced cell 
death, apoptosis remains as the most extensively characterized form of programmed cell 
death. Apoptosis was first described in 1972 as a form of cell death that is distinguishable 
by cell shrinkage, blebbing of plasma membrane, condensation and fragmentation of DNA 
(Kerr, Wyllie et al. 1972). Apoptotic cell death has since been demonstrated as an important 
check-point for maintenance of homeostasis and cellular development, with its 
dysregulation often leads to neurodegenerative disease, autoimmunity and tumourigenesis 
(Fuchs and Steller 2011). In general, apoptosis is a universal outcome of chemotherapy. 
 
1.2.4.2  Molecular mechanisms of apoptosis 
Earlier studies on Caenorhabditis elegans (C. elegans) have provided insights into the key 
molecular processes that are involved in apoptosis (Ellis and Horvitz 1986, Horvitz 1999).  
The identification of CED-3, and subsequently caspases, paves the direction for further 
understanding on the cellular components of apoptosis (Yuan, Shaham et al. 1993). 
Apoptosis have been distinctly classified into two main types: the mitochondria-mediated 
intrinsic pathway and the death receptor-mediated extrinsic pathway (Nagata 1997, Shi 
2001). Briefly, extrinsic apoptosis is controlled by extracellular signals such as hormones, 
growth factors and cytokines, while intrinsic apoptosis is modulated by intracellular stress 
responses, such as nutrient deprivations, viral infection and radiation  (Nagata 1997, Shi 
2001). Caspases are the main effectors that drive apoptosis and 14 isoforms have been 
identified (Alnemri 1997). Caspases are being synthesized as zymogens (pro-caspases). 
Apoptotic stimuli trigger the proteolytic cleavage and heterodimerization of pro-caspases. 
Subsequently, functional tetramers were formed by two heterodimers (Earnshaw, Martins et 
al. 1999). Caspases are classified into initiator caspases (caspase 2, 8, 9, 10) and effector 
caspases (caspase 3, 6, 7) based on their respective functions in apoptosis (Alnemri, 
Livingston et al. 1996, Alnemri 1997). The catalytic activities of caspases are crucial in the 
induction of apoptosis when initiator caspases trigger the activation of effector caspases, 
which then lead to the cleavage of vital cellular substrates that include poly(ADP-ribose) 
polymerase (PARP), a DNA repair enzyme (Fesik 2000). 
 10 
 
Although both intrinsic and extrinsic pathways eventually cleave PARP and caspase 3/7, 
there are different in terms of initiation and execution. Extrinsic apoptotic pathway is 
directly initiated through binding of tumour necrosis factor (TNF), Fas ligand (FasL) and 
TNF-related apoptosis-inducing ligand (TRAIL) to death receptors known as the TNF 
receptor superfamily (Wajant 2002). Binding of ligands triggers the recruitment of adaptor 
proteins such as Fas-associated death domain (FADD) as well as pro-caspase 8 to form 
death-inducing signalling complex (DISC) (Muzio, Stockwell et al. 1998, Wajant 2002). As 
pro-caspase 8 molecules are brought to close proximity by DISC, this promotes its auto-
activation through proteolytic cleavage (Muzio, Stockwell et al. 1998). 
Intrinsic apoptotic pathway is primarily regulated by mitochondria (Li, Nijhawan et al. 
2004). Disruption of mitochondria membrane potential as a result of the formation of 
mitochondrial apoptosis-induced channel (MAC) is regulated by the pro-apoptotic and anti- 
apoptotic B-cell lymphoma 2 (Bcl-2) family proteins (Dejean, Martinez-Caballero et al. 
2006). Anti-apoptotic Bcl-2 family members (Bcl-2, Bcl-xl, Bcl-w) maintain the integrity of 
mitotochondria outer membrane by directly inhibiting the pro-apoptotic Bcl-2 proteins 
(Chipuk and Green 2008). The pro-apoptotic Bcl-2 family members can be further divided 
into two subgroups: the effector proteins (BAX, Bak, Bok) and the BH3-only proteins (Bid, 
BAD, Bim, PUMA, Noxa). Briefly, BH3-only proteins function as sensors of death signals 
and facilitate apoptosis by activating Bcl-2-associated X (BAX)/Bcl-2 homologous 
antagonist killer (Bak) as well as neutralizing the anti-apoptotic Bcl-2 proteins (Luo, 
Budihardjo et al. 1998, Wei, Lindsten et al. 2000, Kim, Tu et al. 2009). The oligomerization 
of BAX/Bak complex forms pores on the mitochondria outer membrane. Thus, the balance 
between pro-apoptotic and anti-apoptotic Bcl-2 proteins determines the assembly of MAC 
(Dejean, Martinez-Caballero et al. 2006). This leads to the loss of mitochondria membrane 
potential and increase in membrane permeability, thus the sequential release of 
mitochondria-bound Smac/DIABLO (small-mitochondria-derived activator of caspases/ 
direct inhibitor of apoptosis-binding protein with low pI) and cytochrome c into the cytosol 
(Zhou, Zhou et al. 2005). Smac/DIABLO functions by deactivating inhibitor of apoptosis 
proteins (IAPs), such as X-linked IAP (XIAP), that are known to block apoptosis by binding 
to caspases (Vucic, Deshayes et al. 2002, Eckelman, Salvesen et al. 2006). Cytochrome c 
functions differently by initiating the formation of apoptosome, a complex comprises of 
apoptotic protease activating factor-1 (Apaf-1) and pro-caspase 9, that results in the auto-
activation of caspase 9 (Srinivasula, Ahmad et al. 1998, Jiang and Wang 2000). 
Both intrinsic and extrinsic apoptotic pathways leads to activation of caspase 3 and 7 
(Hammerman, Sos et al. 2011), and eventually cell death (Porter and Jänicke 1999). In 
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addition, convincing evidences have suggested that these two pathways are not mutually 
exclusive, as the activation of tBid by extrinsic pathway has been shown to trigger intrinsic 
pathway (Li, Zhu et al. 1998, Shi and Shen 2008). Figure 1.3 illustrates the key regulators of 




Figure 1 3: Overview of both intrinsic and extrinsic pathways of apoptosis.  
Two major apoptotic pathways (intrinsic and extrinsic) leading to apoptosis are illustrated. 





1.3  Cisplatin: Standard-of-care treatment for NSCLC 
The clinical outcomes of the above mentioned chemotherapies have initially been reported 
to be comparable and undifferentiated (Schiller, Harrington et al. 2002). Thus, treatment 
decision is generally dependent on previous treatment history and clinicopathological 
parameters. In the case of NSCLC, adjuvant chemotherapies have been suggested to yield 
significant survival benefit over surgery alone (Johnson 2000, Hotta, Matsuo et al. 2004). 
Furthermore, increasing evidence suggests that platinum-based regimens provide 
significantly higher responses when compared to non-platinum-based chemotherapies in 
NSCLC (D'Addario, Pintilie et al. 2005, Jiang, Liang et al. 2007). Some studies have even 
suggested that cisplatin-based singlet and doublet chemotherapies are associated with 
improved survival advantage over carboplatin-containing regimens (Go and Adjei 1999, 
Hotta, Matsuo et al. 2004, Rajeswaran, Trojan et al. 2008). Over the years, cisplatin has 
been established as the standard of care treatment for NSCLC patients (Schiller 2001). 
 
1.3.1 Cellular processing of cisplatin 
DNA damage induced by platinum compounds activates several signalling pathways. 
Cellular responses to platinum compounds are different in individual tumour cells (Chu 
1994). In general, treatment of platinum-based chemotherapy induces cell cycle arrest, cell 
survival or cell death depending on the activated molecular mechanisms (Wang and Lippard 
2005). Understanding the mechanisms by which tumour cells retain and process cisplatin 
reveals important insights on the regulation of cell death or cell survival. In this chapter, the 
transport mechanisms and biotransformation of cisplatin, as well as the signal transduction 
and cellular responses to cisplatin will be discussed. 
 
1.3.1.1 Cellular transportation and biotransformation of cisplatin 
The uptake of cisplatin is regulated both passively and actively. Early studies suggested that 
entry of cisplatin into cells is mainly dependent on passive diffusion as cellular 
accumulation of cisplatin increases linearly over time until it reaches a saturated point. 
Furthermore, the transport of cisplatin occurred independently of molecular structure of 
various analogues (Hromas, North et al. 1987, Binks and Dobrota 1990). However, recent 
studies have revealed a direct relation between active transporter and cellular accumulation 
of cisplatin. For instance, deletion or mutation of the CTR1 gene, which encodes for the 
copper transporter 1, reduced intracellular platinum levels in yeast and mouse cells; while 
overexpressing CTR1 increased influx of cisplatin (Ishida, Lee et al. 2002, Holzer, Samimi 
et al. 2004). In addition, several efflux transporters, such as copper-transporting P-type 
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adenosine triphosphate (ATP7B) and ATP-binding cassette sub family C2 (ABCC2), were 
found to enhance cisplatin removal from tumour cells (Cui, König et al. 1999, Payen, 
Sparfel et al. 2002, Miyashita, Nitta et al. 2003). 
As cytoplasmic concentration of chloride ions is low, cisplatin is activated spontaneously 
upon entering the cells through aquation of the chloride leaving groups to form form cis-
[Pt(NH3)2Cl(OH2)]+ and cis-[Pt(NH3)2(OH2)]2+. The aquated cisplatin molecules are highly 
reactive and thus susceptible to interaction with several cytoprotective proteins (Eastman 
1987, el-Khateeb, Appleton et al. 1999). Despite being highly reactive to the cellular 
components, these aquated platinums are reportedly more selective towards DNA (Eastman 
1987, Jamieson and Lippard 1999). The activated cisplatin covalently binds to the N7 
position of purine bases and results in the formation of intra-strand and inter-strand 
crosslinks (Huang, Zhu et al. 1995) (Figure 1.4). These crosslinkings modify the structure of 
the double-helix DNA and expose a minor groove region that attracts that binding of high-
mobility group (HMG) box-proteins, DNA repair proteins, histone H1, and transcription 
factors (Pil and Lippard 1992, Farid, Bianchi et al. 1996, Vaisman, Lim et al. 1999, 
Kartalou and Essigmann 2001, Zdraveski, Mello et al. 2002, Yaneva, Paneva et al. 2007) 
(Figure 1.4). Binding of these cellular proteins to DNA facilitates the initiation of DNA 




Figure 1.4: Cisplatin crosslinks DNA at N7 position of purine bases and attracts the 
binding of cellular proteins.  
TF: transcription factors; HMG:  high-mobility group box-proteins; Repair protein: DNA 




1.3.1.2 Cisplatin and cell cycle arrest 
The crosslinking of DNA distorts DNA structure and induces genotoxic stress to the cells. 
Damage sensor proteins such as ATM (Ataxia telangiectasia mutated) and ATR (Ataxia 
telangiectasia and Rad3-ralated) identify this improper order of event and arrest cell cycle to 
allow for DNA repair to occur (Harper and Elledge 2007, Ashwell and Zabludoff 2008).  
Cisplatin induces both G1/S and G2 arrest via different mechanisms. G1/S checkpoint 
ensures that the damaged DNA is not replicated through DNA amplification (Bartek and 
Lukas 2001). Induction of G1/S arrest is initiated by ATM, which then recruits Chk2 and 
activates p53 (Banin, Moyal et al. 1998, Matsuoka, Huang et al. 1998). G2/M checkpoint 
prevents cells carrying DNA lesions to progress into mitosis. On the contrary, G2 arrest is 
mediated by ATR-Chk1 cascades. Activated Chk1 prevents dephosphorylation and 
activation of cyclin-dependent kinase 1 (CDK1) through inhibition of a protein phosphatase, 
cdc25 (Peng, Graves et al. 1997, Yang, Winkler et al. 1999) and activation of p53 (Tibbetts, 
Brumbaugh et al. 1999).  
The fate of the cisplatin-treated cells is determined during the period when the cell cycle is 
arrested (Figure 1.5). It has been previously described that cell cycle arrest at G2 phase is an 
important event in cisplatin-induced cell death  (Dasika, Lin et al. 1999). The dose of the 
administered cisplatin and the activity of signal transduction directly influence the cell 
response to cisplatin (Wang and Lippard 2005).  
 
1.3.1.3 Cisplatin and DNA damage repair 
The perturbations of cell cycle allow for the activation of DNA repair mechanisms to 
remove the crosslinks. Among the four major DNA-repair mechanisms [nucleotide-excision 
repair (NER), base-excision repair (BER), mismatch repair (MMR), double-strand 
homologous recombination (HR)], NER is recognized to be the primary mechanism that 
removes cisplatin lesions from DNA (Zamble, Mu et al. 1996, Wang, Hara et al. 2003). 
DNA repair mechanism of NER is hugely dependent on the excision repair cross-
complementing 1 (ERCC1), which stabilizes the endonuclease activity of xeroderma 
pigmentosum complementation group F (XPF) (Ferry, Hamilton et al. 2000). The 
heterodimer of ERCC1 and XPF incises the 5’ and 3’ sides of the DNA respectively and 
removes the DNA lesion, while the repair is completed by DNA synthesis to reconstitute 
genetic integrity (Hanawalt 2002, Gillet and Schärer 2006). However, it has been well 
documented that the recruitment of HMG proteins, which binds to the DNA crosslinks, 
shields them from the repair machinery and inhibits the repair mechanisms (Huang, Zamble 
et al. 1994, Zamble, Mu et al. 1996, Zamble, Mikata et al. 2002). Furthermore, MMR repair 
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machinery has been shown to participate in the recognition but not repair of cisplatin-
induced DNA lesions (Vaisman, Varchenko et al. 1998, Lin and Howell 2006), while HR 
machinery is responsible for the resolution of cisplatin-induced double-strand break (Smith, 
Tho et al. 2010). 
 
1.3.1.4 Cisplatin and cell death 
Cell death is triggered when attempts to repair DNA failed. Cisplatin induces both apoptosis 
and necrosis, while the mode of cisplatin-induced cell death is dependent on the dose of 
cisplatin exposure (Gonzalez, Fuertes et al. 2001). Cisplatin has been reported to activate 
necrotic cell death in vitro when used at high concentrations; whereas apoptosis is induced 
progressively over time at low cisplatin concentration (Lieberthal, Triaca et al. 1996). 
Furthermore, excessive DNA damage was shown to cause increased activation of PARP, 
which depletes NAD+ and ATP, and subsequently induces necrotic cell death (Herceg and 
Wang 2001). However, the induction of apoptosis by cisplatin is a more complicated 
process. It was first revealed that cisplatin-induced apoptosis is mitochondria-dependent as 
both the release of cytochrome c and activation of caspase 9 are essential to trigger cell 
death (Kojima, Endo et al. 1998, Blanc, Deveraux et al. 2000). Subsequently, other reports 
have demonstrated that cisplatin activates death receptor-mediated cell death via-up-
regulation of Fas and FasL, as well as activation of caspase 8 (Fulda, Los et al. 1998, Seki, 
Yoshikawa et al. 2000). Cisplatin thus regulates cell death through both intrinsic and 
extrinsic apoptotic pathways. On the contrary, some studies have shown that cisplatin 
mediates apoptosis in ovarian and renal cancer cell lines via caspase 3-independent 
mechanisms (Henkels and Turchi 1999, Cummings and Schnellmann 2002), suggesting the 
broad spectrum of cytotoxicity effects of cisplatin. 
 
1.3.1.5 Cisplatin and signal transduction of PI3K and MAPKs 
Generally, cells that manage to repair the cisplatin-induced DNA lesions are released from 
the state of arrest and progressed into mitosis. Activation of key signalling pathways could 
determine the fate of tumours cells. Years of research have revealed that cisplatin treatment 
regulates multiple signal transduction mechanisms. In this chapter, on two major signalling 
cascades were investigated: phosphoinositide 3-kinase (PI3K) and mitogen-activated protein 
kinase (MAPK) pathways. 
Activation of PI3K pathway is well characterized to promote cell survival and inhibit 
apoptosis through modulation of a key downstream effector, Akt (Datta, Brunet et al. 1999). 
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Phosphorylations of Akt are shown to protect cells from cisplatin-induced apoptosis (Datta, 
Brunet et al. 1999), because of its abilities to inhibit the degradation of X-linked inhibitor of 
apoptosis (XIAP) (Fraser, Leung et al. 2003, Dan, Sun et al. 2004), activated pro-survival 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signalling (Mabuchi, 
Ohmichi et al. 2004), and regulate expression of apoptotic modulators (Guinea Viniegra, 
Hernández Losa et al. 2002). 
Members of the MAPK signalling pathways are important cellular modulators that mediate 
the balance between cell proliferation, cell survival, cell metabolism, and cell death (Chang 
and Karin 2001). The MAPK family members comprise of kinases that induce sequential 
phosphorylation of respective target substrates and regulate cellular activities (Chang and 
Karin 2001, Johnson and Lapadat 2002). There are three well-characterized MAPK sub-
families: extracellular-signal regulated kinases (Erks), c-Jun N-terminal kinases (JNKs) and 
p38 mitogen-activated protein kinases (p38 MAPKs). Although all three MAPK families are 
responsive to extracellular stimuli, Erks are highly inducible by growth stimuli, while 
activation of JNKs and p38 MAPKs are more dependent on stress signals, such as UV 
irradiation and TNF (Olson and Hallahan 2004, Wada and Penninger 2004). Growing 
evidences have suggested that cisplatin triggers the activation of Erk, JNK and p38 MAPK 
kinases in tumour cell lines in a dose-dependent and time-dependent manner (Wang, 
Martindale et al. 2000, Hernández Losa, Parada Cobo et al. 2003).  
Unlike the PI3K/Akt signalling, regulation of cellular responses to cisplatin by MAPK 
pathway(s) is less direct. Sustained activation of p38 MAPKs is reported to be responsible 
for cisplatin cytotoxicity in tumour cells, while abrogation of p38 function attributes to 
cisplatin resistance (Hernández Losa, Parada Cobo et al. 2003, Mansouri, Ridgway et al. 
2003). However, there are conflicting reports on the nature of Erks and JNKs in influencing 
cell survival of cisplatin-treated cells. Some studies have associated Erk and JNK activation 
with improved survival after cisplatin treatment (Potapova, Haghighi et al. 1997, Hayakawa, 
Ohmichi et al. 1999, Persons, Yazlovitskaya et al. 1999). On the contrary, several studies 
have provided compelling evidences that both Erk and JNK contribute to cisplatin-induced 
apoptosis in various cancer types, and the abrogation of these MAPKs resulted in cisplatin-
resistant phenotype (Potapova, Haghighi et al. 1997, Levresse, Marek et al. 2002, Yeh, 
Chuang et al. 2002). Therefore, the relative contribution of MAPK activation to cellular 




Figure 1.5: Cellular processing of cisplatin.  
The efficacy of cisplatin is dependent on its cellular uptake and biotransformation. Cell 
cycle is arrested when DNA damage is detected through ATM/Chk2 and ATR/Chk1 
machinery. Excessive DNA damage will not be repaired, but apoptosis or necrosis will be 
triggered. Cisplatin also activates PI3K and MAPK pathways. Dotted lines indicate 
mechanisms with conflicting findings being reported. 
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1.3.2 Cisplatin and the p53 network 
1.3.2.1  Overview of p53: the shift from oncogene to tumour suppressor  
The p53 protein was first discovered in 1979 by the culmination of two different studies: 
firstly, a 55 kDa peptide was found to be a target of simian virus 40 (SV40), a strain that is 
related to tumour development (Lane and Crawford 1979, Linzer and Levine 1979); 
secondly, this SV40-related protein was detected in the serum of the mouse infected with 
tumourigenic cell lines (DeLeo, Jay et al. 1979, Kress, May et al. 1979). After human TP53 
gene was successfully cloned (Zakut-Houri, Bienz-Tadmor et al. 1985), several other studies 
have proceeded to further characterize the role of p53 in tumourigenesis. At that time where 
limited details were available regarding the mutational status of TP53 gene, p53 was 
initially presumed to be an oncogene due to its high expression in tumours, but not in 
normal tissue (DeLeo, Jay et al. 1979, Rotter 1983). Furthermore, antibodies against p53 
were detected in sera of breast cancer patients (Crawford, Pim et al. 1982). Works by 
several groups have demonstrated that introducing either p53 antibodies or antisense 
inhibited cellular growth in tumour cells, suggesting p53 as a positive regulator of cell 
proliferation (Mercer, Avignolo et al. 1984, Reich and Levine 1984, Shohat, Greenberg et al. 
1987, Deppert, Buschhausen-Denker et al. 1990). This notion was strengthened when in 
vitro insertion of cloned p53 cDNAs was shown to transform primary cells in the presence 
of oncogenic Ras (Eliyahu, Raz et al. 1984). Therefore, p53 protein was considered as a 
proto-oncogene during the early stages of investigation after its discovery. 
However, the notion that p53 is an oncogene was challenged when several contradictory 
findings were reported. Conflicting reports were published regarding the capability of p53 to 
transform primary cells, and the genetic differences among the cloned p53 cDNAs were 
soon revealed (Levine and Oren 2009). Detailed investigations on the TP53 gene were 
conducted by infection with Friend virus, whereby p53 was reported to be rearranged at one 
allele, and lost in the second allele through loss of chromosome or gene deletion (Mowat, 
Cheng et al. 1985, Munroe, Rovinski et al. 1988). These genetic aberrations resulted in the 
absence of protein expression or synthesis of a mutated or truncated protein. Interestingly, it 
was further shown that differences in codon sequences of murine p53 cDNA occurred at a 
particular region that is highly conserved (Soussi, Caron de Fromentel et al. 1987, Soussi, 
Caron de Fromentel et al. 1990). Subsequently, it was revealed that the early experiments 
were performed on cloned p53 cDNAs isolated from tumourigenic cells, which are likely 
mutant p53 (Levine and Oren 2009). Moreover, overexpression of wild-type p53 suppressed 
the malignant transformation of mutant p53 and oncogenic Ras in rat embryonic fibroblast 
cells (Eliyahu, Michalovitz et al. 1989, Finlay, Hinds et al. 1989). These observations 
somewhat overturned the then-believed notion that p53 is an oncogene. 
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The p53 protein was first described as a tumour suppressor gene in 1989 by Baker and 
Fearon by demonstrating the loss of heterozygosity in colorectal carcinoma (Baker, Fearon 
et al. 1989). In addition to the fact that wild-type p53 inhibited Ras-induced cellular 
transformation (Eliyahu, Michalovitz et al. 1989, Finlay, Hinds et al. 1989), p53-deficient 
mice convincingly demonstrated the tumour suppressive effect of p53. Genetically modified 
p53 null (p53-/-) mice developed malignant tumours shortly after birth (4-6 months), while 
heterozygous p53+/- mice developed spontaneous tumours with a longer latency period 
(Donehower, Harvey et al. 1992, Harvey, McArthur et al. 1993, Purdie, Harrison et al. 
1994). These findings conclusively indicated that p53 is a tumour suppressor, and this 
protein is now considered by many as the “guardian of the genome” (Lane 1992).  
 
 
Figure 1.6: The main domains of the p53 protein.  
The p53 molecule comprises of 393 amino acid residues and usually forms tetramer. The 
key domains of p53 include: the transactivation domain, proline-rich domain, DNA-binding 
domain, oligomerization domain, and the C-terminal regulatory domain. Several regions 
containing the nuclear localization signal (NLS) and nuclear export signal (NES) are 
identified. [Adapted and modified from p53 Knowledgebase (URL:http://p53.bii.a-
star.edu.sg/aboutp53); assessed on December 2013]. 
 
The p53 protein contains 393 amino acid residues that comprises of several domains that 
contribute to protein stability and specific tumour-suppressive activity. These domains 
include: the N-terminal transactivation domain, a proline-rich domain, the core DNA-
binding domain (DBD), and the C-terminal domain that contains an oligomerization domain 
and a regulatory domain (Joerger and Fersht 2008, Joerger and Fersht 2010). The 
transactivation domain is responsible for the stability of p53 protein and activation of 
downstream target genes (Lees-Miller, Sakaguchi et al. 1992, Kussie, Gorina et al. 1996). 
The prolife-rich region is found to mediate p53-induced apoptosis in response to DNA 
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damage (Venot, Maratrat et al. 1998). The DNA binding domain is highly conserved region 
that allows for recognition and interaction with specific response elements (Pavletich, 
Chambers et al. 1993, Wang, Schwedes et al. 1995). The oligomerization domain at the C-
terminus allows for tetramerization of p53 (Chène 2001, Veprintsev, Freund et al. 2006), 
thus promotes binding affinity to DNA. Furthermore, three putative nuclear localization 
signals (NLS) and a nuclear export signal (NES) have been identified at the C-terminal 
regulatory domain that regulate p53 nuclear translocation (Liang and Clarke 1999, Stommel, 
Marchenko et al. 1999). However, in most cases, the conformational structure of p53 masks 
the exposure of the NES, thus retains the p53 in the cell nuclei (Stommel, Marchenko et al. 
1999). Furthermore, a second DNA-binding region has been found within the C-terminal 
region that recognizes and repairs damaged DNA (Jayaraman and Prives 1995, Zotchev, 
Protopopova et al. 2000). 
 
1.3.2.2  Activation of p53 signalling by cisplatin  
In healthy cells, p53 activity is kept at bay by its negative regulator, mouse double minute 2 
homolog (MDM2). The MDM2 molecule is an E3 ubiquitin-protein ligase that binds to the 
transactivation domain of p53 (Momand, Zambetti et al. 1992, Kussie, Gorina et al. 1996). 
The MDM2-p53 interaction induces p53 ubiquitination, inhibits the nuclear-cytoplasmic 
shuttling of p53 and signals for the its proteosomal degradation (Haupt, Maya et al. 1997). 
Interestingly, expression of MDM2 is primarily controlled by transactivation of p53 (Barak, 
Juven et al. 1993). Furthermore, Akt has been shown to phosphorylate MDM2 at Ser166 
and Ser186, which then enhance MDM2-induced unbiquitination and degradation of p53 
(Zhou, Liao et al. 2001, Ogawara, Kishishita et al. 2002). The basal p53 activity and 
regulation of signal transduction will constitutively trigger the activation of MDM2, which 
then suppress p53 expression. Thus, under unstressed conditions, p53 protein is detected at 
low level and its pathway is kept inactivated. 
Cisplatin causes DNA lesions by binding to the N7 position of purine bases (Huang, Zhu et 
al. 1995). As described in Chapter 1.3.1.1, the intra-strand crosslinks invite binding of HMG 
proteins (Farid, Bianchi et al. 1996). The interaction of HMG proteins with DNA alters the 
chromosomal structure of DNA (Pil and Lippard 1992). It was then discovered that HMG1 
is a co-activator of p53, with the interaction of p53-DNA being stimulated by HMG-1 and 
vice versa (Jayaraman, Moorthy et al. 1998, Imamura, Izumi et al. 2001). The binding of 
HMG-1 is able to bend the DNA further, thus causes structural changes in the target DNA 
and promotes the binding of various transcription factors that include p53 (Stros 1998). 
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Furthermore, apart from recruiting p53, HMG-1 also promotes the assembly of p53 tetramer 
at the DNA and modulates its interaction with DNA (Jayaraman, Moorthy et al. 1998). 
Post-translational modifications that take place in both the N- and C-terminus of p53 
molecules are deemed responsible for the activation of p53 signalling (Sakaguchi, Herrera et 
al. 1998). The primary signalling cascade that links up cisplatin-induced DNA damage with 
p53-mediated responses involves both ATM/ATR and Chk1/2. The initiation of ATM/Chk2 
and ATR/Chk1 signalling cascades constitutively phosphorylates p53 at the N-terminal 
transactivation domain (Banin, Moyal et al. 1998, Lakin, Hann et al. 1999, Tibbetts, 
Brumbaugh et al. 1999) (Figure 1.7). In addition, DNA-dependent protein kinase (DNA-PK) 
is shown to induce p53 phosphorylation at Ser15 and Ser37 (Lees-Miller, Sakaguchi et al. 
1992) (Figure 1.7). Phosphorylation of p53 abrogates the MDM2-mediated degradation, 
thus enhances p53 activity (Shieh, Ikeda et al. 1997, Siliciano, Canman et al. 1997). 
Furthermore, phosphorylation of MDM2 on Ser395 residue by ATM reduces the 
degradation of p53 by MDM2 (Maya, Balass et al. 2001). These findings suggest that 
activation of p53 by DNA damage is achieved partly through attenuation of the inhibitory 
effect of MDM2. 
While phosphorylation at N-terminal transactivation domain inhibits binding on MDM2, 
post-translational modification at the C-terminus is associated with cytoplasmic to nuclear 
shutting and sequence-specific binding potential of p53. Phosphorylations of p53 at the 
oligomerization domain and regulatory domain are induced by cyclin dependent kinases 
(CDKs), casein kinases (CKs), and protein kinase C (PKC). These phosphorylated p53 
proteins are shown to activate in vitro sequence specific DNA binding ability (Price, 
Hughes-Davies et al. 1995, Takenaka, Morin et al. 1995, Wang and Prives 1995, Hall, 
Campbell et al. 1996, Blaydes and Hupp 1998, Pospísilová, Brázda et al. 2004). In addition 
to these findings, acetylation of p53 is a critical modulation of p53-mediated transactivation 
(Sakaguchi, Herrera et al. 1998, Tang, Zhao et al. 2008). The histone acetyl-transferases 
(HATs) p300, p300/CBP-associated factor (PCAF) and Tip60 are responsible for the in vivo 
acetylation of p53 at various lysine residues upon DNA damage (Liu, Scolnick et al. 1999, 
Tang, Luo et al. 2006) (Figure 1.7). Acetylation of p53 at the N-terminus is shown to affect 
its transcriptional activity by activating the sequence-specific binding to DNA (Gu and 
Roeder 1997, Lill, Grossman et al. 1997, Liu, Scolnick et al. 1999); whereas acetylation at 
the DBD, in particular K120 residues, is related to p53-dependent apoptosis (Tang, Luo et al. 
2006). Furthermore, p300 and PCAF acetylates p53 at Lys320 and Lys382 respectively, and 
both these resides are located within the NLS of p53, thus suggesting that acetylation is 
essential for nuclear translocalization of p53 (Sakaguchi, Herrera et al. 1998). In addition, 
p53 is believed to be the downstream target for several members of the histone deacetylase 
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(HDAC) family, which include the HDAC1, HDAC3 and sirtuin 1 (Luo, Su et al. 2000, 
Vaziri, Dessain et al. 2001, Ito, Kawaguchi et al. 2002, Karagianni and Wong 2007). These 
HDACs are able to cause p53 deacetylation and reduce its transcriptional activity. Thus, 
inhibition of HDACs is believed to be a probable mechanism of p53 acetylation. However, a 
link between DNA damage and inhibition of HDAC activity has yet to be established. 
 
1.3.2.3 Regulation of cellular responses by p53 pathway 
Activation of p53 is associated with the increase in protein levels and ability to induce 
multiple downstream effects that include DNA damage repair, cell cycle arrest and cell 
death (Lakin and Jackson 1999). The broad spectrum of p53 functions thus regulates the 
response to cisplatin-induced DNA damage. It is interesting to note that the mutational 
status of p53 and its activity is positively correlated with sensitivity towards cisplatin across 
a panel of tumour-derived cell lines (O'Connor, Jackman et al. 1997). 
The binding of p53 to the DNA and its subsequent activation through post-translational 
modifications first initiates the DNA repair mechanisms. While other repair mechanisms 
have been linked with p53, lesions caused by DNA-damaging chemotherapeutic agents are 
usually fixed by p53-regulated NER (Levine 1997, Smith and Seo 2002). First evidence of 
the involvement of p53 in NER repair mechanisms was shown in UV-irradiated cells, as 
wild-type p53 efficiently repair pyrimidine dimers but the transcription-coupled repair (TCR) 
is lacking (Ford and Hanawalt 1997, Zhu, Wani et al. 2000). Subsequently, it was shown 
that p53 facilitates NER mechanisms through binding to components of the NER complex, 
such as transcriptional factor II Human (TFIIH) (Smith, Chen et al. 1995, Léveillard, 
Andera et al. 1996). Moreover, several NER components are regulated by transactivation of 
p53: two xeroderma pigmentosum proteins (p48XPE and XPC) and Gadd45 (Carrier, 
Georgel et al. 1999, Hwang, Ford et al. 1999, Adimoolam and Ford 2002). These proteins 
are involved in the early recognition of bulky DNA adduct during the process of NER. 
Upon detection of DNA damage, transient cell cycle arrests occur in the G1, S, and G2 
phases of the cell cycle (O'Connor, Ferris et al. 1992, Agarwal, Agarwal et al. 1995). These 
perturbations presumably delay the DNA replication process to allow for repair mechanisms 
to take place, thus preventing the transfer of heritable genetic alterations to the daughter 
cells (Little 1968). It is now known that p53 regulates both the reversible G1 and G2/M 
growth arrests through stimulating the synthesis of various inhibitors of CDKs (Kuerbitz, 
Plunkett et al. 1992, Agarwal, Agarwal et al. 1995). The cyclin-dependent kinase inhibitor 1 
(p21WAF1/CIP1) is encoded by the CDKN1A gene, a downstream transcription target of p53. 
p21 protein is an universal cyclin kinase inhibitor and has been shown to be an effector of 
 23 
 
G1 arrest (Di Leonardo, Linke et al. 1994, Waldman, Kinzler et al. 1995). The cyclin 
D/CDK4 complex is strongly implicated as the regulator of G1 progression (Sherr 1993), 
whereas p21 is able to form a multi-protein complex with both cyclin D and CDK4 (Xiong, 
Zhang et al. 1992, Xiong, Zhang et al. 1993, LaBaer, Garrett et al. 1997). When 
accumulated at high level, p21 blocks the cell cycle progression through inhibition of CDK4, 
thus induces G1 arrest (Harper, Adami et al. 1993). Furthermore, p21 induces the activation 
of the retinoblastoma (RB) protein by inhibiting CDKs that phosphorylate and inhibit RB 
activity (Slebos, Lee et al. 1994). Activated RB binds and inhibits the transcription factor 
E2F (Narita, Nũnez et al. 2003), thus represses proteins that are cell cycle facilitator (c-Fos, 
cyclin A, cyclin B), and results in abrogation of cell cycle progression at G1 phase (Seshadri 
and Campisi 1990, Stein, Drullinger et al. 1991, Campisi and d'Adda di Fagagna 2007, 
Garner and Raj 2008). The mechanism of p53 in blocking cells at the G2/M phase involves 
the inhibition of CDK1, the crucial modulator of mitosis (Zhan, Antinore et al. 1999, Taylor 
and Stark 2001). Binding of CDK1 to cyclin B1 is required for its function. The p53 protein 
represses the cdc2 gene (that encodes for CDK1 protein), and induces the expression of 
Gadd45 that further inhibit CDK1/cyclin B1 kinase activity (Wang, Zhan et al. 1999, Zhan, 
Antinore et al. 1999, Jin, Tong et al. 2002). Furthermore, deficiency in either p53 or Gadd45 
impaired G2/M checkpoint arrest (Wang, Zhan et al. 1999, Jin, Tong et al. 2002).  
Among the various functions of p53, the most prominent downstream activity of p53 
signalling is the activation of apoptosis. When DNA damage is deemed to be beyond repair, 
the stressed cells are released from cell cycle arrest and progressed into cellular senescence, 
and subsequently apoptosis. As demonstrated in Chapter 1.2.4.2, apoptosis could be 
regulated either by extrinsic pathway that involves the formation of DISC and activation of 
caspase 8, or intrinsic pathway that mainly depends on the release of mitochondria 
cytochrome c and the apoptosome complex (Figure 1.3). It is now certain that DNA 
damage-induced apoptosis is highly regulated by p53, and the lethal functions of p53 could 
be regulated via both transcriptional-dependent and –independent mechanisms. It was 
earlier shown that p53 plays an essential role in mediating death receptor signalling. Firstly, 
transcriptomic expression and activation of Fas reportedly regulated by wild type p53 
(Owen-Schaub, Zhang et al. 1995, Müller, Strand et al. 1997, Bouvard, Zaitchouk et al. 
2000). Then, p53 protein is also associated with the transient cell surface trafficking of Fas 
from Golgi complex and the binding of Fas to FADD (Bennett, Macdonald et al. 1998). 
Concurrently, p53 response elements were identified in the promoters of Bcl-2 protein BAX 
and the BH3-only proteins p53-up-regulated modulator of apoptosis (PUMA) and Noxa 
(Miyashita and Reed 1995, Oda, Ohki et al. 2000, Nakano and Vousden 2001, Thornborrow, 
Patel et al. 2002). These pro-apoptotic proteins are able to inhibit the pro-survival Bcl-2 
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proteins, form MAC on mitochondria surface, induce the release of cytochrome c and 
trigger apoptosis. Moreover, it was first reported in 1994 that p53 could mediate apoptosis 
without initiating transcription of apoptotic genes (Caelles, Helmberg et al. 1994). The 
direct binding of p53 to BAX and caspases, and therefore the induction of mitochondria-
mediated apoptosis, is well-characterized now (Ding, Lin et al. 2000, Chipuk, Kuwana et al. 
2004). A schematic diagram that summarizes these p53-mediated cellular responses is 





Figure 1.7:  p53-mediated cellular response to DNA damage induced by cisplatin.  
The DNA lesions induced by cisplatin initiate binding of p53 (by HMG proteins) and 
activation of p53 through post-translational modifications (by DNA-PK, ATM, ATR, HATs 
and HDACs). Several cellular responses to the activated p53, both transcription-dependent 
and –independent, have been described. Doted line indicates pathway that has not been 
comprehensively established. 
 
1.3.3 Clinical limitations of cisplatin: Adverse side effects and drug resistance 
Since its approval for clinical use in 1978, the advancement and clinical efficacy of cisplatin 
is severely limited by two factors: adverse side effects and cisplatin resistance (Lebwohl and 
Canetta 1998). The common side effects of cisplatin include nephrotoxicity (kidney injury), 
neurotoxicity (damage to peripheral nerve), ototoxicity (hearing loss), nausea and vomiting 
(Kelland 2007, Macciò and Madeddu 2013). As kidney is the major excretory organ of 
cisplatin, nephrotoxicity is a major concern for patients treated with cisplatin. As cisplatin 
also causes renal vasculature injury, a culmination of these events can result in acute renal 
failure (Pabla and Dong 2008). In addition, common neurological adverse effects of 
cisplatin include hearing and visual disorders, as well as numbness in the four limbs (Kedar, 
Cohen et al. 1978). Signs of neuronal injury are observable as soon as the first 
administration of cisplatin (Milosavljevic, Duranton et al. 2010, Pace, Giannarelli et al. 
2010). As these adverse effects of cisplatin are dose-dependent, this thus limits the dosage 
of administrated cisplatin and restricts its therapeutic efficacy. 
Another factor that restricts the clinical usage of cisplatin is the development of resistance. 
At the initial phase of clinical usage, cisplatin often provides favourable therapeutic 
response and disease stabilization (Lebwohl and Canetta 1998). However, a subset of 
patients, in particular those with colorectal, prostate or lung cancer, are intrinsically less 
responsive to cisplatin-based chemotherapies (Giaccone 2000, Köberle, Tomicic et al. 2010). 
Moreover, patients with initial response to cisplatin eventually relapse with more aggressive 
tumours that are resistant to cisplatin (Giaccone 2000). Intensive researches for over 30 
years have provided detailed insights on the cellular activities of cisplatin, thus allowing for 
better understanding on the molecular mechanisms that account for resistance in tumour 
cells. Several inherently detected or acquired genetic aberrations are associated to intrinsic 
and extrinsic resistance to cisplatin will be discussed in the next chapters. Molecular 
mechanisms of cisplatin resistance can be classified into four main classes: reduction of 
cisplatin accumulation, increase in DNA repair pathways, attenuation of cell death 




1.3.3.1  Cisplatin resistance: Reduced cellular accumulation of cisplatin 
The first class of mechanisms that induces cisplatin resistance is the reduction of cisplatin 
accumulation in the cells. This can be achieved by reducing influx, increasing efflux and 
increasing inactivation of cisplatin. It has been reported that a transmembrane copper 
transporter, CTR1, is involved in the active uptake of cisplatin (Ishida, Lee et al. 2002, 
Holzer, Samimi et al. 2004). Several findings have demonstrated that inhibition of CTR1 
activity led to decrease cisplatin accumulation (Ishida, Lee et al. 2002, Katano, Kondo et al. 
2002, Holzer, Samimi et al. 2004). Furthermore, increased competitive binding of copper 
protects cells from cisplatin toxicity (More, Akil et al. 2010), whereas chelating copper 
increases cisplatin accumulation and toxicity (Ishida, McCormick et al. 2010). More 
importantly, high CTR1 expression was associated with better clinical response to platinum-
based chemotherapy in ovarian cancer (Lee, Choi et al. 2011). Interestingly, continuous 
exposure to cisplatin reportedly suppress CTR1 by inducing its internalization and 
degradation (Holzer and Howell 2006). This mechanism may partially account for the 
development of acquired cisplatin resistance. 
Despite so, cisplatin is still capable to enter cells via passive diffusion across plasma 
membrane. Accompanying the discovery on the correlation of CTR1 and cisplatin resistance, 
its copper-exporting counterpart, ATP7B, was shown to be up-regulated in cisplatin-
resistant cell lines (Miyashita, Nitta et al. 2003, Safaei, Holzer et al. 2004). Earlier studies 
have suggested the role of ATPase-like multidrug resistance protein (MRP) family, in 
particular MRP2, in mediating cisplatin efflux (Koike, Kawabe et al. 1997, Cui, König et al. 
1999, Borst, Evers et al. 2000). The expression of MRP2 in tumours is recently been 
reported as a prognostic marker for platinum-based chemotherapies (Cui, König et al. 1999, 
Korita, Wakai et al. 2010, Yamasaki, Makino et al. 2011).  
As discussed in Chapter 1.3.1.1, aquated cisplatin has high reactivity with cytoplasmic 
nucleophilic proteins, which include glutathione (GSH) and metallothioneins (Eastman 
1987, el-Khateeb, Appleton et al. 1999). Both GSH and metallothioneins are cytoplasmic 
scavengers that bind to aquated platinum and promote cisplatin efflux or inactivation, 
leading to cisplatin resistance (Hamilton, Winker et al. 1985, Kelley, Basu et al. 1988, 
Lewis, Hayes et al. 1988, Kasahara, Fujiwara et al. 1991, Ishikawa 1992). Furthermore, two 
GSH-related proteins, gamma-glutamyl cysteine synthetase (γ-GCS), that catalyzes GSH 
synthesis, and glutathione-S-transferse (GST), that conjugate cisplatin and GSH, are 
positively correlated to cisplatin-resistant cell lines and tumours (Lewis, Hayes et al. 1988, 
Kigawa, Minagawa et al. 1998, Shiga, Heath et al. 1999, Cullen, Newkirk et al. 2003, 
Pasello, Michelacci et al. 2008). 
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1.3.3.2 Cisplatin resistance: Activation of DNA repair machinery 
The distortions in DNA caused by cisplatin-induced lesions are repaired predominantly by 
NER machinery, with MMR and HR playing a lesser role (Zamble, Mu et al. 1996, Vaisman, 
Varchenko et al. 1998, Smith, Tho et al. 2010). Since the persistent formation of DNA 
adducts leads to induction of apoptosis, the ability of the cell to repair these crosslinks will 
result in development of cisplatin resistance. In most cases, damaged nucleotides are excised 
from the DNA through incision on both sides of the lesions by ERCC1 and XPF (Hanawalt 
2002). The endonuclease pair of ERCC1-XPF has been characterized as one of the rate-
limiting factors for NER machinery (Ahmad, Robinson et al. 2008). Several in vitro studies 
have shown the influences of ERCC1 proficiency on cisplatin resistance (Li, Gardner et al. 
1998, Ferry, Hamilton et al. 2000, Li, Yu et al. 2000), with ERCC1 expression negatively 
correlating with treatment outcome in various cancer types (Metzger, Leichman et al. 1998, 
Olaussen, Dunant et al. 2006, Bellmunt, Paz-Ares et al. 2007, Handra-Luca, Hernandez et al. 
2007). Thus, the expression of ERCC1 could possibly indicate the functionality of NER 
machinery in cisplatin-treated patients, although an effective way to measure DNA repair 
activity in these tumours is by far lacking. Nonetheless, the potential of ERCC1 as a 
biomarker candidate has been considered for the selection of NSCLC patients in cisplatin-
containing trials (Olaussen 2009). 
In some cases, inter-strand crosslinking by cisplatin induces double-strand break. This 
lesion is commonly resolved by HR mechanisms (Dudás and Chovanec 2004). Breast 
cancer 1, early onset (BRCA1) and breast cancer 2, early onset (BRCA2) proteins are two 
key components of the HR machinery that mediate strand invasion, a crucial step in HR 
repair (Venkitaraman 2002). Both BRCA1 and BRCA2 genes are considered as tumour-
suppressor genes, as loss-of-function mutations are often detected along these genes in 
multiple tumour types, especially breast and ovarian cancers (Ford, Easton et al. 1998, 
Welcsh and King 2001, Yoshida and Miki 2004). Deficiencies of BRCA1 and BRCA2 
impair DNA repair mechanism, thus increase risk of genetic aberrations and tumourigenesis 
(Venkitaraman 2002, Evers and Jonkers 2006). However, in line with general viewpoint, 
lack of BRCA-dependent DNA-repair machinery due to inherent mutations leads to better 
prognosis in cisplatin-treated tumours (Ben David, Chetrit et al. 2002, Farmer, McCabe et al. 
2005, Chetrit, Hirsh-Yechezkel et al. 2008). More recently, it is reported that a secondary 
mutation of BRCA1/2, that restores wild-type BRCA1/2 reading frame and their DNA repair 
functions, induces acquired resistance to cisplatin in tumour cells (Sakai, Swisher et al. 2008, 
Wang and Figg 2008, Dhillon, Swisher et al. 2011). Taken together, these findings suggest 




1.3.3.3 Cisplatin resistance: Interruption of cell death machinery 
Interruption of cell death machinery is another class of mechanisms that leads to cisplatin 
resistance. Abnormal regulations of key components along the cell death pathway allow the 
tumour cells to elude the cytotoxic potential of chemotherapy and gain survival advantage 
(Lowe and Lin 2000). In the case of cisplatin resistance, DNA damage beyond repair leads 
to activation of pro-apoptotic signalling (Gonzalez, Fuertes et al. 2001). Several genetic and 
epigenetic alterations within the apoptotic pathway have been associated with cisplatin 
resistance. One of the most established alterations involves the inactivation of p53 function 
(Vousden and Lane 2007). It has been documented that somatic mutation of TP53 is 
detected in approximately 50% of all human cancers (Olivier, Hollstein et al. 2010), while 
in other tumours p53 pathway is commonly inactivated by alternative mechanisms (Leach, 
Tokino et al. 1993, Liggett and Sidransky 1998, Esteller, Tortola et al. 2000, Esteller, 
Cordon-Cardo et al. 2001, Manfredi 2010). The role of p53 in the apoptotic pathway is 
described in Chapter 1.3.2.3. Deactivation of p53 pathway impairs the transactivation of 
apoptotic genes, which include BAX, thus prevent the inhibition of pro-survival Bcl-2 by 
BAX in resistant phenotypes (Perego, Giarola et al. 1996). Several in vitro studies have 
highlighted the role of p53 in determining response to cisplatin, with defects in p53 
signalling consistently induce cisplatin resistance (Fan, el-Deiry et al. 1994, Perego, Giarola 
et al. 1996, O'Connor, Jackman et al. 1997, Branch, Masson et al. 2000). Clinical data have 
also suggested that TP53 mutational status negatively correlates with treatment outcome of 
cisplatin-based regimes in breast, ovarian, and head and neck cancers (Righetti, Della Torre 
et al. 1996, Shiga, Heath et al. 1999, Gadducci, Cosio et al. 2002, Perrone, Bossi et al. 2010). 
Furthermore, the pro-apoptotic activity of wild-type p53 in cervical cancer is shown to be 
abrogated by human papillomavirus (HPV) and thus causes platinum resistance (Kessis, 
Slebos et al. 1993). Interestingly, p53 function is rarely impaired in testicular germ cell 
tumours that are extremely sensitive to cisplatin (Peng, Hogg et al. 1993, Raghavan 2003), 
suggesting a strong implication of p53 activity in predicting cisplatin resistance. 
The induction of cellular apoptosis can be regulated by p53-dependent and –independent 
mechanisms (Zamble, Jacks et al. 1998). Various component of the apoptotic pathway, as 
illustrated in Figure 1.3, are commonly dysregulated in cisplatin-resistant phenotypes. To 
begin, activations of critical caspases that mediate apoptosis, caspase 3, 8 and 9, are found 
to be attenuated in cisplatin-resistant cells (Henkels and Turchi 1999, Blanc, Deveraux et al. 
2000). This abrogation of apoptosis in the resistant phenotypes could be regulated via 
mutations or altered expression of the pro-survival Bcl-2 family members and XIAP (Reed 
1995, Beale, Rogers et al. 2000, Asselin, Mills et al. 2001). In line with this concept, 
overexpression of Bcl-2, together with the increase in GSH, has been shown to result in 
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resistance to cisplatin (Hockenbery, Oltvai et al. 1993, Chiao, Carothers et al. 1995). 
Similarly, increased expression of Bcl-xl and reduced levels of Bad are observed in resistant 
tumour cells (Minn, Rudin et al. 1995, Hayakawa, Ohmichi et al. 2000). Lastly, the 
inhibition of caspase 3 and 8 may be partially related to the down-regulation of FAS in 
ovarian cancer cells (Mansouri, Zhang et al. 2003), whereas up-regulation of Fas re-
sensitizes small cell lung cancer cells to cisplatin (Wu, Wang et al. 2010). 
 
1.3.3.4 Cisplatin resistance: Alteration of signal transduction machinery 
Till date, the regulation of signalling pathways by cisplatin is yet to be fully deciphered. 
Furthermore, contrasting findings have been reported on the relative contribution of these 
signalling cascades on the cytotoxicity of cisplatin.  The amplification of a transmembrane 
receptor tyrosine kinase, human growth factor receptor 2 (HER2), is associated with poor 
response of breast and ovarian tumours to cisplatin treatment (Slamon, Godolphin et al. 
1989, Hengstler, Lange et al. 1999). Under in vitro conditions, overexpressing HER2 
reduces cisplatin potency (Tsai, Yu et al. 1995), while suppressing this receptor increases 
cisplatin cytotoxicity (Pietras, Fendly et al. 1994). 
The HER2 protein is extensively similar to the human epidermal growth factor receptor 
(EGFR), which will be discussed later in Chapter 1.4 (Bargmann, Hung et al. 1986, 
Yamamoto, Ikawa et al. 1986). The activation of HER2/EGFR in cisplatin-resistant cells 
propagates the activation of SHC/Grb2/SOS/Ras/MAPK and PI3K/Akt pathways (Hung and 
Lau 1999). The PI3K/Akt signalling is widely considered as a pro-survival pathway (Datta, 
Brunet et al. 1999). Some of these Akt-induced pro-survival signals involve the inactivation 
of Bad (Hayakawa, Ohmichi et al. 2000), stabilization of XIAP (Fraser, Leung et al. 2003, 
Dan, Sun et al. 2004), and induction of Smac release from mitochondria (Fraser, Leung et al. 
2003). These events lead to the attenuation of cisplatin-mediated anti-proliferative effects. 
Furthermore, Akt is shown to promote MDM2 phosphorylation and nuclear translocation, 
which then lead to degradation of p53 and abrogation of its activities (Mayo and Donner 
2001, Mayo and Donner 2002, Ogawara, Kishishita et al. 2002). Taken together, these 
findings provide possible insights to how Akt attenuate the cell death pathway, but the 
precise mechanism by which Akt mediates cisplatin resistance remains unclear. 
As discussed in Chapter 1.3.1.5, members of the MAPK sub-families (Erk, JNK, p38) are 
closely associated with the mode of action of cisplatin. Early studies have demonstrated that 
tumours with RAS mutation or amplification are more resistant to cisplatin (van 't Veer, 
Hermens et al. 1988, Fan, Banerjee et al. 1997, Dempke, Voigt et al. 2000). Subsequently, 
cisplatin-induced activations of Erk and JNK signal for cellular protection in cisplatin-
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resistant cells (Potapova, Haghighi et al. 1997, Persons, Yazlovitskaya et al. 1999, Cui, 
Yazlovitskaya et al. 2000, Levresse, Marek et al. 2002). Cross-talk between MAPK 
signalling with other pathways could also regulate cisplatin resistance. In a study on 
melanoma cell lines, Li and Melton showed that activation of MAPK pathway by cisplatin 
up-regulates ERCC1 expression and induces chemoresistance (Li and Melton 2012). 
Moreover, MAPK activation induces up-regulation of several transcription factors, such as 
c-Myc, c-Fos and c-Jun (Deng and Karin 1994, Robinson and Cobb 1997), which are 
believed to be responsible for reduced sensitivity to cisplatin. For instance, both c-Fos and 
c-Jun induce ERCC1 (Li, Gardner et al. 1998, Li, Zhang et al. 1999), a key component of 
DNA repair mechanism. Furthermore, antisense silencing of c-Jun reverses cisplatin 
resistance in ovarian cancer cell lines (Pan, Yao et al. 2002). These exemplify some 
mechanisms of cisplatin resistance that are regulated by MAPK signalling. 
However, it is important to note that the cytotoxic effects of HER2, PI3K and MAPK 
pathways remain controversial due to contradicting findings. Firstly, introduction of HER2 
increased cisplatin cytotoxicity in breast cancer cell lines (Arteaga, Winnier et al. 1994). 
Next, the cisplatin-induced p38 MAPK activity has been linked to cisplatin sensitivity 
(Hernández Losa, Parada Cobo et al. 2003, Mansouri, Ridgway et al. 2003). Furthermore, 
inhibition of Erk signalling reduces cisplatin sensitivity in melanoma and ovarian cell lines 
(Mandic, Viktorsson et al. 2001, Yeh, Chuang et al. 2002), whereas JNK activation 
contributes to cisplatin-induced cell death (Zanke, Boudreau et al. 1996, Sánchez-Perez, 
Murguía et al. 1998, Mansouri, Ridgway et al. 2003). Lastly, JNK and its upstream kinase, 
MAP/Erk kinase kinase 1 (MEKK1), stabilizes and activates p53 through phosphosrylation 
of p53 (Fuchs, Adler et al. 1998). The loss-of-function defect in MEKK1 could lead to 
failure in p53 activation and thus contributes to cisplatin resistance in ovarian 
adenocarcinoma cell lines (Gebauer, Mirakhur et al. 2000). Thus far, the understanding of 
signal transduction pathways could only provide partial explanation for their influence on 
the modulation of cisplatin resistance.  Studies on the molecular cross-talk involving PI3K, 
MAPK, p53 and other relevant proteins could provide better insights on the key regulators 







1.4 Molecular targeted therapies in lung cancer 
At present, much effort has been focused on the development of personalized therapy by 
defining the biology and molecular features of respective tumour cells. These strategies aim 
to achieve promotion of apoptosis, inhibition of cell cycle, anti-angiogenesis, inhibition of 
cell proliferation, and inhibition of multi-drug resistance in tumours cells (Abidin, Garassino 
et al. 2010). Several molecular targeting therapies have been proposed in NSCLC, which 
include histone deacetylase (HDAC) inhibitors (Neal and Sequist 2012), matrix 
metalloproteinase (MMP) inhibitors (Bissett, O'Byrne et al. 2005, Leighl, Paz-Ares et al. 
2005), vascular endothelial growth factor receptor (VEGFR) antibody (Sandler, Gray et al. 
2006), proteosome inhibitors (Fanucchi, Fossella et al. 2006, Davies, Lara et al. 2007), and 
immunoconjugates (Elias, Hirschowitz et al. 1990, Goodman, Hellström et al. 1990, Ross, 
Hart et al. 2006). The mode-of-actions of these therapeutic agents have been explicitly 
studied by with promising results in trials involving these inhibitors. 
Over the past decade, the concept of oncogene addiction has been proposed. It is now well-
understood that tumourigenesis is a multi-step process in which mutations in key cellular 
genes lead to alteration in cellular processes that equip the tumour cells for malignant 
transformation. These biological processes, which include sustained proliferation, evasion 
of growth suppression, inhibition of cell death, unrestrictive replication, activation of 
angiogenesis, induction of invasion and metastasis, occurrence of genomic instability, 
acquisition of tumour-promoting inflammation, reconstruction of cellular metabolism, and 
evasion of immune surveillance, are now regarded as the hallmarks of cancer (Hanahan and 
Weinberg 2000, Hanahan and Weinberg 2011). These features of cancer cells are initiated 
by the progressive accumulation of genetic aberrations and epigenetic abnormalities within 
the tumour cells. Oncogenes and tumour suppressor genes that carry highly diverse 
biochemical functions are commonly mutated and abnormally regulated in many cancer cell 
types. Characterization of these mutations has led to the observations that specific 
abrogation of biochemical functions of particular mutated genes is sufficient to improve 
treatment outcome (Colomer, Lupu et al. 1994, Chin, Tam et al. 1999, Jackson, Willis et al. 
2001, Moody, Sarkisian et al. 2002, Moody, Perez et al. 2005). The apparent dependency of 
certain cancer subsets on one or few genes for the maintenance of tumour malignancy is 
termed “oncogene addiction” (Weinstein 2002).   
Intensive studies have revealed that malignant carcinoma of the lung displayed prominent 
mutations in multiple oncogenes, which then resulted in aberrant induction of pro-survival 
signals. Several driver mutations, which include EGFR mutation, KRAS mutation, EML4-
ALK fusion, HER2 mutation, BRAF mutation, PIK3CA mutation, AKT1 mutation, MAP2K1 
mutation and ROS1 fusions, are commonly detected in lung adenocarcinoma (Pao and 
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Hutchinson 2012) (Figure1.8). Targeted therapies involving kinase inhibitors customized to 
the genetic mutations of individual tumours have led to superior treatment outcome 
compared to conventional chemotherapy. Several molecular targeting agents that have 




Figure 1.8: Distribution of clinically relevant driver mutations in lung adenocarcinoma 
and several clinically available targeted therapies.  
In recent years, lung cancer has established as a model for investigation on the “oncogene 
addiction” concept due to the high frequency of genetic mutations being identified. These 
mutations include: EGFR, HER2, KRAS, ALK, BRAF, PIK3CA, AKT1, ROS1, NRAS and 
MAP2K1 (A). The recently identified kinesin family member 5B-ret proto-oncogene 
(KIF5B-RET) is boxed (Kohno, Ichikawa et al. 2012, Takeuchi, Soda et al. 2012). Some of 
the clinically tested targeted therapies that inhibit the aberration activation of oncogenic 







1.4.1 EGFR and HER2 mutations 
The EGFR is a transmembrane receptor tyrosine kinase (RTK) that belongs to the 
HER/ErbB protein family. The EGFR pathway is a crucial cellular signalling mechanism 
that regulates growth, survival proliferation as well as differentiation in human cells (Hackel, 
Zwick et al. 1999). It has been well-established that the EGFR network is triggered 
following the binding to EGF-like growth factors, such as EGF and transforming growth 
factor α (TGF-α), which leads to dimerization and autophosphorylation of the receptor 
(Yarden and Sliwkowski 2001). Multiple tyrosine residues found on the cytoplasmic-bound 
C-terminal domain of EGFR have been identified as autophosphorylation sites. The 
autophosphorylation of EGFR trigger the downstream pathways through activation of the 
signalling cascade (Burgess, Cho et al. 2003, Garrett, McKern et al. 2003).  The main 
signalling transduction cascades of EGFR include the MAPK/Ras/Raf/Erk, PI3K/Akt and 
Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathways (Figure 
1.9). 
Mutation of EGFR is a common aberration in lung cancer and is detected in almost a quarter 
of all diagnosed patients (Cheng, Alexander et al. 2012, Pao and Hutchinson 2012). When 
EGFR is mutated, it often leads to ligand independent receptor homodimerization or ligand-
dependent signal amplification, and subsequently enhances downstream signalling of EGFR 
(Irmer, Funk et al. 2007). It was soon discovered that tumour cells with mutated EGFR are 
susceptible to tyrosine kinase inhibitors (TKIs), thus these tumours are deemed as 
oncogene-addicted (Heymach, Nilsson et al. 2006, Irmer, Funk et al. 2007). TKIs, such as 
gefitinib and erlotinib that targets the cytoplasmic autophosphorylation sites of EGFR, have 
achieved clinical successes in treatment of NSCLC patients with improved response and 
prolonged survival (Paez, Jänne et al. 2004, Tsao, Sakurada et al. 2005). Antibodies that 
target the ligand-binding region of EGFR, such as Cetuximab, have been tested as well. 
However, both FLEX (First-Line Erbitux in Lung Cancer) and BMS-099 (Bristol-Myers 
Squibb 099) studies have shown unsatisfactory clinical benefit for the addition of 
Cetuximab to conventional chemotherapy (Pirker, Pereira et al. 2009, Lynch, Patel et al. 
2010). 
HER2 is another member of the HER/ErbB RTK family with similar function as EGFR. 
Unlike EGFR, HER2 mutation is detected in less than 5% of NSCLC cases (Stephens, 
Hunter et al. 2004, Cheng, Alexander et al. 2012). Both the TKI lapatinib and HER2 
antibody trastuzumab have been applied on NSCLC patients (Cappuzzo, Bemis et al. 2006, 




1.4.2 RAS and BRAF mutations 
The mutation of RAS gene is the second most commonly detected aberration in lung cancer 
apart from TP53.  Approximately 25% of all lung adenocarcinoma cases harbour somatic 
mutations on the KRAS gene, with a further 1% with NRAS mutation (Cheng, Alexander et 
al. 2012, Ohashi, Sequist et al. 2013). The GTPase activation protein, Ras, is a downstream 
effector of EGFR. Through conversion of guanine triphosphates (GTP) to guanine 
diphosphate (GDP), the Ras protein recruits and stimulates the Raf/MEK/Erk pathway 
(Buday and Downward 1993, Huang, Marshall et al. 1993). The serine/threonine kinase, Raf, 
is the direct target of Ras. Activated Ras switches on the signalling of Raf, which activates 
mitogen-activated protein kinase kinases (MAP2K or MEK) that phosphorylate both 
extracellular signal-regulated kinases 1 and 2 (Erk1/2) (Figure 1.9). 
Ras is inactivated upon binding of GDP, but mutations in Ras prevent the GDP-mediated 
inhibition, thus lead to the constitutive activation of the MAPK signalling (Bos 1989, 
Watanabe, Nobuta et al. 1996). Due to the frequency of RAS mutation in all human cancers, 
much effort has been invested on the development of specific inhibitors for the Ras protein. 
However, this target is by far undruggable as most of the drugs designed have failed to shut 
down its signalling, probably due to its high affinity to GTP/GDP and the absence of known 
allosteric sites (Downward 2003). More importantly, as Ras is a downstream effector of 
EGFR, constitutive activation of mutant Ras induces drug resistance to EGFR inhibitors 
(O'Byrne, Gatzemeier et al. 2011, Misale, Yaeger et al. 2012). Recently, a research group 
has synthesized a small molecule that is claimed to inhibit Kras allosterically through 
reducing GTP affinity and interaction with its effector (Ostrem, Peters et al. 2013). However, 
the clinical efficacy of this molecule is yet to be determined. Current clinical approach has 
focused on targeting downstream kinases of Ras for treatment of tumours with mutant Ras 
(Downward 2003). Thus far, several inhibitors of MEK have shown promising effect in 
early trials (Chen and Sweet-Cordero 2013, Jänne, Shaw et al. 2013).  
Mutation of BRAF gene in lung cancer is rare (1-4%) as compared to that of melanoma 
(Davies, Bignell et al. 2002, Naoki, Chen et al. 2002, Paik, Arcila et al. 2011). Unlike 
melanoma tumour, BRAF mutation in lung cancer does not predominantly occur at valine 
600 (V600) residue. In fact, several BRAF mutated sites have been identified within the 
kinase domain (Paik, Arcila et al. 2011). Similar to RAS mutation, mutant B-Raf 
constitutively stimulates the P44/42 MAPK signalling. A B-Raf enzyme inhibitor, 
vemurafenib, has shown dramatic response in a BRAF V600E-mutant lung adenocarcinoma 





Figure 1.9: Overview of the activation and pharmacologic inhibition of EGFR 
signalling pathway in lung cancer.  
EGFR/HER2 is activated by EGF-like growth factors that results in autophosphorylation of 
key tyrosine residues. The phosphorylated sites function as docking regions for recruitment 
of downstream kinases through their Src homology 2 (SH2) domains. Downstream 
signalling cascades for EGFR/HER2 include MAPK/Ras/Raf/Erk, PI3K/Akt and Janus 
kinase/signal transducer and activator of transcription 3 (JAK/STAT) pathways. Several 
clinically tested molecular targeting agents are shown: EGFR inhibitors (gefitinib, erlotinib, 
afatinib, cetuximab), HER2 inhibitors (trastuzumab, lapatinib), B-Raf inhibitor 
(Vemurafenib), MEK inhibitors (PD0325901, selumetinib, trametinib), PI3K inhibitors 
(GDC0941, BKM120), and Akt inhibitor (MK2206). Red indicates FDA-approved agents. 






1.4.3 PIK3CA mutation 
EGFR signalling also promotes cell survival through the activation of PI3K/Akt pathway 
(Henson and Gibson 2006). Upon its activation, cytoplasmic tail of EGFR/HER2 recruits 
PI3K to its SH2 domains. Activated PI3K phosphorylates phosphatidylinositol (4,5)-
biphosphate (PIP2) to phosphatidylinositol (3,4,5)-triphosphate (PIP3), which then activates 
Akt family members (Bos 1995). Akt promotes cell survival through activation of NF-κB, 
glycogen synthase kinase 3 (GSK3) and mammalian target of rapamycin (mTOR). PI3K is 
also known to activate Ras, leading to the activation of p44/42 MAPK signalling (Hennessy, 
Smith et al. 2005) (Figure 1.9). 
Somatic mutation in PIK3CA has been detected in 1-3% of NSCLC patients (Samuels, 
Wang et al. 2004, Kawano, Sasaki et al. 2006, Cheng, Alexander et al. 2012). These 
mutations often occur at two “hotspots” within exon 9 and exon 20 that encode for the 
helical domain and kinase domain respectively. Tumour cells with mutated PIK3CA show 
aberrant activation of the PI3K/Akt/mTOR signalling and are less sensitive to 
chemotherapies (Hennessy, Smith et al. 2005). Recently, mutations on PIK3CA have been 
shown to predict treatment response to PI3K/Akt/mTOR inhibitors (Janku, Wheler et al. 
2012). Several trials are in progress to investigate the efficacy of Akt inhibitor (MK2206) 
and PI3K inhibitors (GDC0941, BKM120) in NSCLC. 
 
1.4.4 EML4-ALK fusion 
The fusion of echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic 
lymphoma kinase (ALK) is found in approximately 3-7% of all lung cancer cases (Wong, 
Leung et al. 2009, Kwak, Bang et al. 2010, Cheng, Alexander et al. 2012). Although 
multiple variants of EML4-ALK fusions have been described (Choi, Takeuchi et al. 2008), 
the fusion of EML4 consistently leads to the ligand-independent oligomerization of ALK 
and constitutive activation of its kinase activity, thus leading to cancer formation (Choi, 
Takeuchi et al. 2008).  
Upon the identification of this aberration, the development of clinically-ready ALK 
inhibitor, crizotinib, is rapid and has achieved improvement in progress-free survival  in 
some lung cancer patients (Kwak, Bang et al. 2010). The status of ALK fusion is detected by 
fluorescence in situ hybridization (FISH) or immunohistochemistry (IHC) (Paik, Choe et al. 
2011, Yi, Boland et al. 2011). Currently, FDA has approved the usage of crizotinib as 
standard first-line therapy for advanced NSCLC patients harbouring ALK rearrangement 
(Kwak, Bang et al. 2010, Shaw, Yeap et al. 2011).. 
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1.4.5 Lack of driver mutations in lung SCC 
The application and efficacy of molecular targeted therapies in NSCLC patients has been 
limited to lung adenocarcinoma tumours. Despite being identified as one of the most 
representative tumour type for investigation of oncogenic dependency, the spread of somatic 
mutations in NSCLC are unevenly distributed across lung adenocarcinoma and lung SCC  
(Naoki, Chen et al. 2002). With the exception of PIK3CA mutation (Kawano, Sasaki et al. 
2006), genetic aberrations in EGFR, Kras, B-Raf and EML4-ALK are more commonly 
detected in lung adenocarcinoma tumours (Brose, Volpe et al. 2002, Pao, Miller et al. 2004, 
Boland, Erdogan et al. 2009, Paik, Arcila et al. 2011).  
It is now well-established that lung SCC is lacking of clinically relevant oncogenic driver 
mutations (Rekhtman, Paik et al. 2012). The recently published report by The Cancer 
Genome Atlas (TCGA) Network has attempted to investigate the alterations of genomic 
landscape in this disease (Network 2012). Despite the high mutational rate, EGFR, KRAS 
mutations and ALK fusions are rarely detected among the 178 lung SCC cases. Therefore, 
the FDA-approved EGFR inhibitors (gefitinib and erlotinib) and ALK inhibitor (Crizotinib) 
that were developed for lung adenocarcinoma are largely ineffective against lung SCC 
(Boland, Erdogan et al. 2009, Camidge, Hirsch et al. 2011, Rekhtman, Paik et al. 2012). The 
more comprehensive platinum-based chemotherapy, used in combination with other 
chemotherapeutic agents, remains as the first-line treatment for patients diagnosed with lung 













1.5 Histones, HDACs and HDAC inhibitors in cancer 
The rapid advancement in understanding of tumourigenesis have revealed the requirements 
for constitutive activation of oncogenes and functional inactivation of tumour suppressor 
genes for development of malignancy (Hanahan and Weinberg 2011). The activation or 
repression of transcription is partly associated with epigenetic regulation and chromatin 
remodelling. Aberrant acetylation of histone tails has been strongly associated with 
alteration of chromatin structure and abnormal transcriptomic regulations in tumour cells 
(Jacobson and Pillus 1999). Subsequently, several mutations that affect activity of HATs are 
detected in malignant cells, while HDACs are reported to be overexpressed or aberrantly 
recruited by onco-proteins (Minucci and Pelicci 2006). These lead to inappropriate 
regulations of a number of well-characterized cellular oncogenes and tumour suppressor 
genes that favour tumourigenesis (Hess-Stumpp 2005, Glozak and Seto 2007). 
Understanding the link between histones, HDACs and the transcriptomic expressions has 
provided opportunities for therapeutic intervention of tumour cells. 
 
1.5.1 Histones 
Chromatin is composed of DNA and proteins at ratio of 1:1. Histones are highly alkaline 
chromosomal proteins that form the building blocks of chromatin. Coiled DNA winds 
around histones to form nucleosomes, which bundle to form chromatin, and eventually 
condensed to form the compact chromosome (Ura, Hayes et al. 1995, Kornberg and Lorch 
1999). Chromatin architecture can be modified by chromatin remodelling through post-
translational modifications of histone tails that relocate nucleosomes and changes 
nucleosome structure. To date, five major histone families are identified: the linker histones, 
H1/H5; and the core histones, H2A, H2B, H3 and H4 (Kornberg and Lorch 1999). Two of 
each of the core histone interact and form the octameric nucleosome core. The superhelical 
DNA winds around this octameric structure and is stabilized by both protein-protein 
interactions between the histones as well as the electrostatic attraction of positively-charged 
lysine residues on histones and the negatively-charged phosphates backbone of DNA (Luger, 
Mäder et al. 1997, Mizzen and Allis 1998).  The linker histone binds the nucleosome at both 
the entry and exit sites of the DNA, thus increasing the stability of the histone-DNA 
complex (Pruss, Bartholomew et al. 1996). 
The assembly and disassembly of nucleosome is mainly regulated by post-translational 
modifications of histones. Modifications of histones include acetylation, phosphorylation, 
methylation, ubiquitination, and sumoylation, which ultimately determine the chromatin 
structure as the assembly of euchromatin (relaxed chromatin) and heterochromatin 
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(condensed chromatin) is influenced by the degree of interaction between DNA and histones. 
The transition between euchromatin and heterochromatin is determined by the extent of 
acetylation and methylation on histone tails (Casas-Delucchi, van Bemmel et al. 2012). 
Furthermore, it was reported that certain combinations of modifications are consistently 
observed, thus postulating the presence of histone codes that directly affect gene 
transcription through epigenetic regulatory system (Strahl and Allis 2000, Jenuwein and 
Allis 2001). 
Among these modifications, acetylation is probably the most extensively studied mechanism 
(Ura, Kurumizaka et al. 1997). Histone hyperacetylation leads to unfolding of the 
nucleosome core complex (Oliva, Bazett-Jones et al. 1990, Struhl 1998, Annunziato and 
Hansen 2000); whereas histone hypoacetylation strengthens histone tail-DNA interactions 
(Casas-Delucchi, van Bemmel et al. 2012) (Figure 1.10 A). Histone acetylations modulate 
transcriptional activity by determining the accessibility of DNA template to the transcription 
machinery, which begins with the binding of transcription factor II D (TFIID) and TATA 
box-binding protein (TBP) to core promoter regions (Mizzen and Allis 1998). Taken 
together, acetylation of histones facilitates the promoter binding of TFIID and TBP, as well 
as the recruitment of other transcription factors, activators and co-activators, thus initiating 
transcription. 
 
1.5.2 Histone acetyl-transferases (HATs) 
Acetylation of histone tails is regulated in opposing manner by HATs and HDACs. Till date, 
about 30 HATs that are grouped into 5 different families have been identified (Carrozza, 
Utley et al. 2003). Tip60, p300, and cyclin-AMP-response-element binding protein (CBP) 
are among the extensively studied human HATs. These enzymes induce acetylation of the ε-
NH2 group on the lysine residues along the histone tails by utilizing acetyl-Co as a co-factor 
(Marmorstein and Roth 2001). HATs are also known to bind to transcriptional co-activators, 
such as p300/CBP-associated factor (PCAF) (Schiltz, Mizzen et al. 1999). Both HATs and 
PCAF are known to play a critical role in transcriptional control by relieving the repressive 
effects on chromatin through acetylation of histone tails (Kundu, Palhan et al. 2000, 
Marmorstein and Roth 2001). The addition of an acetyl-group removes the positive charge 
on the histones and reduces its interaction with the negatively charged DNA (Figure 1.10 A). 
This unwinds the coiled DNA and allows access for transcription machinery, and eventually 
triggers transcriptional activation. 
Apart from histones, HATs also acetylate a wide range of non-histone proteins (Glozak, 
Sengupta et al. 2005). The transactivation of p53 through acetylation by HATs (CBP/p300, 
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PCAF, Tip60) has been discussed earlier in Chapter 1.3.2.2. Furthermore, HATs regulate 
the acetylation of HMG proteins (Munshi, Merika et al. 1998), STAT3 (Wang, Cherukuri et 
al. 2005), c-Myc (Patel, Du et al. 2004), GATA (Boyes, Byfield et al. 1998),  and NF-κB 
(Chen Lf, Fischle et al. 2001). In general, HATs play a significant role in mediating the 
cellular processes and functions by affecting a wide range of substrates. 
 
1.5.3 Histone deacetylases (HDACs) 
HDACs are enzyme complexes that are responsible for the specific deacetylation of histones.  
This class of enzyme removes the acetyl-group from the lysine residues on histone tails and 
represses gene transcription by various mechanisms. Firstly, the condensed structure of 
heterochromatin prevents access of the transcriptional machinery to the DNA strands (Struhl 
1998). Secondly, deacetylation of specific lysine residues promotes its recognition by 
histone methy-transferases (Martin and Zhang 2005). Methylated lysine residues recruit 
chromodomain proteins that facilitate the assembly of heterochromatin through recognition 
of trimethylated lysine 9 of histone H3 (Lachner, O'Carroll et al. 2001, Nakayama, Rice et al. 
2001). These mechanisms collectively reduce transcriptional activity and increase 
transcriptional silencing (Figure 1.10 A). 
Till date, 17 genes have been identified to encode for four distinct classes of HDACs (Gray 
and Ekström 2001, de Ruijter, van Gennip et al. 2003). Class I (HDAC1, 2, 3, 8) and class II 
(HDAC4, 5, 6, 7, 9, 10) are evolutionarily related and universally induced Zn-catalyzed 
hydrolysis of the acetyl-lysine amide bond. Class IV HDAC (HDAC11) is also Zn-
dependent but is phylogenetically different from both class I and II enzymes (de Ruijter, van 
Gennip et al. 2003).  Class III HDAC of the sirtuin (SirT) family is distinctly different from 
the other classes as it lacks the Zn-dependent enzymatic mechanism and is evolutionarily 
unrelated (Blander and Guarente 2004, North and Verdin 2004). Instead, lysine 
deacetylation activity of sirtuins is NAD-dependent. HDAC1, 2, and 3 are mostly nuclear-
bound, while the other HDACs are indentified at both nucleus and cytoplasm (Gray and 
Ekström 2001).  
The functions of each HDAC, other than the deacetylation of histone tails, have been 
comprehensively characterized. Apart from histones, HDACs are found to interact and 
deacetylate a wide range of non histone proteins (Glozak, Sengupta et al. 2005). The closely 
related HDAC1 and HDAC2 are found as key components of the transcriptional-repression 
SIN3-HDAC complex and the nucleosome-remodelling NuRD-Mi2-NRD complex 
(Khochbin, Verdel et al. 2001, Yang and Seto 2003). The transcriptional repressing effects 
of class I HDACs are partly regulated by the co-activation of nuclear-receptor corepressor 
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(NCOR) and silencing mediator for retinoid and thyrold-hormone receptors (SMRT) (Li, 
Wang et al. 2000, Guenther, Barak et al. 2001, Khochbin, Verdel et al. 2001). Individually, 
HDAC3 is shown to affect stability and DNA-binding ability of NF-κB by deacetylating its 
RelA subunit (Kiernan, Brès et al. 2003), while HDAC8 has been reported to protect 
telomere degradation and play a part in tumourigenesis (Lee, Sengupta et al. 2006). The 
transcription factor GATA-2 is repressed by both HDAC3 and HDAC5 (Ozawa, Towatari et 
al. 2001), whereas GATA-1 interacts with HDAC3, 4, and 5 (Watamoto, Towatari et al. 
2003). Moreover, several class I HDACs are able to repress transactivation of p53 signalling 
by deacetylating the p53 protein (Luo, Su et al. 2000, Ito, Kawaguchi et al. 2002, Zeng, 
Xiao et al. 2006, Karagianni and Wong 2007).  
Class II HDACs are characterized by their ability to shuttle between the cytoplasm and 
nucleus. These HDACs are not involved in the SIN3-HDAC and NuRD-Mi2-NRD 
complexes (Khochbin, Verdel et al. 2001, Yang and Seto 2003), but mediate transcriptional 
repression through binding to transcription factors, such as myocyte enhancer factor 2 
(MEF2) and members of the Runt-related transcription factor (Runx) family (Lu, McKinsey 
et al. 2000, Lu, McKinsey et al. 2000, Zhang, McKinsey et al. 2002). Furthermore, several 
cytoplasmic interactive partners of class II HDACs have been illustrated, which include 14-
3-3 (McKinsey, Zhang et al. 2000), tubulin (Hubbert, Guardiola et al. 2002),  and Hsp90 
(Kovacs, Murphy et al. 2005).  
The class III HDACs, commonly referred to as the sirtuins, have been implicated in aging, 
transcription, apoptosis and inflammation (Donmez and Guarente 2010, Roth and Chen 
2013). The knowledge on sirtuins is by far limited. However, it has been reported that 
sirtuins induce p53 deacetylation at the C-terminus and inhibit p53-mediated functions 
(Vaziri, Dessain et al. 2001, Haigis and Guarente 2006). Lastly, little is known about the 
class IV HDAC, despite being reported to be highly expressed in several carcinomas when 
compared to healthy tissues (Deubzer, Schier et al. 2013).  
Abnormal expressions of several HDACs have been reported to be associated with 
prognosis in various cancers. In NSCLC, low expression of class II HDACs genes, such as 
HDAC5 and HDAC10, has been correlated with poor prognosis (Osada, Tatematsu et al. 
2004). The authors postulate that class II HDACs may repress critical oncogenes, and that 
low expression of these HDACs may favour the malignant progression of lung tumours. On 
the contrary, high expression of HDAC1 has been linked with poor prognosis in patients 
with lung adenocarcinoma (Minamiya, Ono et al. 2011). However, the correlation of 





Figure 1.10: Regulation of chromatin structure cellular determines transcriptional 
activity and cellular processes.  
A, Histones is the building block for formation of nucleosome. DNA (black line) winds 
around the octmeric histones. Condensed heterochromatin recruits methyl-binding proteins 
(MECP2) and HDACs that maintains its closed-chromatin configuration and transcriptional 
repression. Post-translational modifications of histone tails by acetylation (Ac), methylation 
(Me) and phosphorylation (P) alter the nucleosomal architecture. HATs induce histone 
acetylation that relaxes chromatin and promotes transcriptional activation. B, HDAC 
inhibitors inhibit enzymatic activity of HDACs, thus causing hyper-acetylation of histones. 
This represses DNA damage repair, angiogenesis, metastasis and invasion; while increases 
cell differentiation, cell growth arrest and cell death. [Adapted from (Johnstone 2002)] 
 
1.5.4  Histone deacetylase inhibitors 
As summarized in the previous chapter, HATs and HDACs play crucial roles in biological 
functions through modulation of histones and non-histones proteins. Apart from directly 
influencing chromatin remodelling, HATs and HDACs modulate cellular processes by 
affecting the DNA-binding affinity, protein stability and protein-protein interaction of non-
histone proteins, thereby indirectly influences transcriptional activity (Glozak, Sengupta et 
al. 2005). Since imbalanced acetylation of histone and non-histone proteins is common 






These expanding understandings on epigenetic control of gene expression in malignant cells 
have provided new targets for cancer therapy. For instance, reversing low histone 
acetylation has been proposed as one possible approach for epigenetic cancer therapy 
(Dawson and Kouzarides 2012). However, pharmacologic modulators of HATs are limited, 
with the few available HAT inhibitors and enhancers limited to in vitro investigations (Lau, 
Kundu et al. 2000, Mantelingu, Kishore et al. 2007). On the contrary, HDAC inhibitors 
discovered at early stages has demonstrated inhibitory effects on HDACs activity (Riggs, 
Whittaker et al. 1977, Novogrodsky, Dvir et al. 1983, Yoshida, Kijima et al. 1990). 
Subsequently, pronounced anti-neoplastic effect was observed in trichostatin-A (TSA), a 
hydroxamic acid class HDAC inhibitor (Vigushin, Ali et al. 2001). This has generated 
interest in the attempt to identify novel molecules for specific targeting of HDACs. 
Crystallographic analysis indicates that HDAC inhibitors block the zinc-containing catalytic 
site of HDACs, thereby inhibiting the enzymatic activity of these compounds (Finnin, 
Donigian et al. 1999). To date, five classes of HDAC inhibitors with distinctive structures 
have been developed, which include: short-chain fatty acids like butyric acid, hydroxamic 
acids, electrophilic ketones, cyclic tetrapeptides, and benzamides (Johnstone 2002). 
Over the past 30 years, advances in development of HDAC inhibitors have been made. The 
short chain fatty acids like butyric acid compounds, such as valproic acid and 
phenylbutyrate, are among the first HDAC inhibitors to be identified (Riggs, Whittaker et al. 
1977, Novogrodsky, Dvir et al. 1983). This class of HDAC is considered as the least potent 
among all the HDAC inhibitors with short plasma half-life and optimal cytotoxic 
concentrations at millimolar range (Novogrodsky, Dvir et al. 1983, Phiel, Zhang et al. 2001). 
Hydroxamic acids, such as TSA and SAHA, were identified in the 1990s. These compounds 
are now characterized as the most potent class of HDAC inhibitors with improved half-lives, 
optimal growth inhibition concentration at micromolar range, and specific inhibition of both 
class I and II HDACs at nanomolar concentrations (Richon, Webb et al. 1996, Kelly and 
Marks 2005).  As the zinc-binding hydroxamic group is deemed responsible for the short 
half-lives, elextrophilic ketones were developed. However, these HDAC inhibitors only 
possess modest anti-proliferative effect with poor in vivo pharmacokinetic parameters (Frey, 
Wada et al. 2002, Wada, Frey et al. 2003). The final classes of HDAC inhibitors, 
benzamides and cyclic tetrapeptides, have shown potent HDAC inhibitory activities 
(Furumai, Matsuyama et al. 2002, Kraker, Mizzen et al. 2003). 
As described, sirtuins are Zn-independent, NAD-dependent class III HDACs (Imai, 
Armstrong et al. 2000). Thus, pan-HDAC inhibitors that almost certainly target on Zn-
dependent catalytic sites are ineffective against sirtuins. Development of sirtuin inhibitors is 
thus based on inhibition of NAD-catalytic activity (Grozinger, Chao et al. 2001), which 
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include sirtinol, cambinol, suramin, salermide and tenovin (Villalba and Alcaín 2012). 
Recently, the potential of sirtuin inhibitors as anti-cancer therapies has been investigated 
(Ford, Jiang et al. 2005, Lara, Mai et al. 2009). Interestingly, sirtuin inhibitors have been 
established as a potent activator of p53 functions through acetylating the p53 proteins 
(Vaziri, Dessain et al. 2001, Lain, Hollick et al. 2008). 
 
1.5.4.1 Mechanism-of-action of HDAC inhibitors 
Although HDACs play a crucial role in regulation of gene expression, HDAC inhibitors do 
not seem to be able to induce global transcriptional regulation. Instead, studies have 
reported that only about 2 - 10% of genes are affected by treatment of HDAC inhibitors 
(Van Lint, Emiliani et al. 1996, Mariadason, Corner et al. 2000, Peart, Smyth et al. 2005). It 
was then observed that HDAC inhibitors trigger the activation of a common set of genes, 
thus suggesting that these compounds have specific selectivity towards particular loci. 
Moreover, genes regulating cell proliferation and survival are the most affected by HDAC 
inhibitors, while many tumour cells display sensitivity to a wide range of HDAC inhibitors 
(Schrump 2009). More importantly, several HDAC inhibitors have been reported to 
sensitize both chemotherapy and molecular targeted therapy in drug-resistant cancer cells 
(Sharma, Lee et al. 2010, Bangert, Häcker et al. 2011, Chen, Chen et al. 2013). These 
prompted the exploration of the anti-neoplastic mechanisms of HDAC inhibitors in 
malignant cells. Several mechanisms of HDAC inhibitors have been proposed. These 
mechanisms often lead to reduced DNA damage repair, increased cell growth arrest and 
senescence, increased cell death, induction of differentiation, and inhibition of angiogenesis, 
metastasis and invasion (Figure 1.10 B).  
HDAC inhibitors could induce DNA damage as indicated by the accumulation of activated 
H2AX, especially after exposure to irradiation or cytotoxic agents (Karagiannis, 
Harikrishnan et al. 2007, Wilson, Holson et al. 2011, Wilson, Lalani et al. 2012). This is 
achieved through the attenuation of DNA damage repair mechanisms, as HDAC inhibitors 
have been shown to reduce the expression of genes involved in HR and non-homologous 
end joining (NHEJ) DNA repair pathways (Munshi, Kurland et al. 2005, Adimoolam, 
Sirisawad et al. 2007, Chen, Wang et al. 2007, Kachhap, Rosmus et al. 2010). Furthermore, 
it was reported that DNA damage induces by vorinostat could be effectively repaired by 
normal cells but not malignant cells (Lee, Choy et al. 2010).  
Like other anti-cancer agents, HDAC inhibitors induce both cell senescence and cell death 
in tumour cells. Several HDAC inhibitors can induce both G1 and G2 cell cycle arrest with 
depletion of cells progressing into S phase, probably through expression of p21 in both p53-
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dependent and –independent manners (Richon, Sandhoff et al. 2000, Ju and Muller 2003, 
Gui, Ngo et al. 2004). Other potential growth inhibitory mechanisms include up-regulation 
of Gadd45 gene and activation of transforming growth factor beta (TGF-β) pathway that 
induce cell cycle arrest (Chen, Clark et al. 2002, Halder, Cho et al. 2011). Furthermore, 
HDAC inhibitors trigger both intrinsic and extrinsic apoptotic pathway. Several studies have 
demonstrated the transcriptional activation of extrinsic apoptosis through up-regulation of 
death receptors and their ligands, such as Fas, FasL, TRAIL and TNF-α (Imai, Adachi et al. 
2003, Nebbioso, Clarke et al. 2005, Sutheesophon, Nishimura et al. 2005, Huang, Scruggs et 
al. 2013). The induction of mitochondrial death pathway is determined through direct 
transcriptiomic regulation of Bcl-2 family members and accumulation of intracellular 
reactive oxygen species (ROS). The expressions of various pro-apoptotic markers, such as 
Bim, Bak and caspase 9, are increased by HDAC inhibitors (Moore, Barbi et al. 2004, 
Zhang, Gillespie et al. 2004). On the contrary, HDAC inhibitors attenuate the expression 
and activity of several anti-apoptotic markers that include Bcl-2, Bcl-xl, Bcl-w, and XIAP 
(Moore, Barbi et al. 2004, Zhang, Gillespie et al. 2004, Rosato, Maggio et al. 2006). 
Moreover, elevated levels of ROS are detected in cells treated with HDAC inhibitors (Ruefli, 
Ausserlechner et al. 2001). As ROS is a negative indicator of mitochondria membrane 
potential (Jing, Cai et al. 2007), intrinsic apoptosis may be triggered by accumulation of 
ROS in HDAC inhibitors-treated cells (Ruefli, Ausserlechner et al. 2001, Rosato, Almenara 
et al. 2003). The detailed mechanism of this phenomenon is still unclear. However, 
increased expression of thioredoxin-binding protein-2 (TBP-2), a positive regulator of 
oxidative stress, has been reported in vorinostat (suberanilohydroxamic acid; SAHA)-
treated cells (Butler, Zhou et al. 2002). 
Interestingly, HDAC inhibitors also possess anti-angiogenic and anti-invasive properties 
both in vitro and in vivo. HDAC inhibitors block angiogenesis by decreasing the expression 
of pro-angiogenic genes, such as vascular endothelial growth factor (VEGF) and hypoxia-
inducible factor 1α (HIF1α) (Deroanne, Bonjean et al. 2002, Sasakawa, Naoe et al. 2003). 
Furthermore, HDAC inhibitors exhibit mesenchymal-epithelial transition (MET) by 
suppression of MMPs (Kim, Ahn et al. 2004), a mesenchymal marker, and up-regulation of 
epithelial markers such as E-cadherin and tissue inhibitor of metalloproteinases (TIMPs) 
(Thelen, Schweyer et al. 2004, Witta, Gemmill et al. 2006, Nasu, Nishida et al. 2008). 
Back then in 1990s, vorinostat was first observed to induce differentiation of murine 
erythroleukemia cells, and subsequently cell cycle arrest and apoptosis (Richon, Webb et al. 
1996). It is now clear that different classes of HDAC inhibitors are able to induce cellular 
differentiation that is characterized by reduced proliferation, alteration of morphology, and 
accumulation of transcription factors (Werling, Siehler et al. 2001, Svechnikova, Almqvist 
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et al. 2008). The mechanisms in which cellular differentiation occur have not been fully 
deciphered, but it could be partly dependent on retinoic acid (RA) and retinoic acid receptor 
α (RARα) (Côté, Rosenauer et al. 2002). Cell growth arrest induced by low doses of HDAC 
inhibitors facilitates the occurrence of cell differentiation. In cases whereby high doses of 
HDAC inhibitors are used, induction of apoptosis usually precedes cell differentiation 
(Marks, Richon et al. 2000). 
 
1.5.4.2 Clinical limitations of HDAC inhibitors 
The promises of HDAC inhibitors both in vitro and in xenograft models have allowed this 
class of agents to progress into clinical settings. The adverse side effects of HDAC 
inhibitors and the development of resistance mechanisms have been detailed over the years. 
Despite the differences in chemical structures and specificities, all classes of HDAC 
inhibitors seemingly produce comparable toxicity profiles that are varied from those 
observed in conventional chemotherapies (Kelly, O'Connor et al. 2002). The common 
adverse events include nausea and vomiting (Sandor, Bakke et al. 2002), fatigue (Kummar, 
Gutierrez et al. 2007), thrombocytopenia, anemia (Giles, Fischer et al. 2006, Ellis, Pan et al. 
2008), cardiac toxicity such as CT prolongation (Strevel, Ing et al. 2007), liver toxicities 
(Garcia-Manero, Assouline et al. 2008), and in some cases neurotoxicity (Ryan, Headlee et 
al. 2005). These adverse side effects have significantly affected the clinical usage of HDAC 
inhibitors as a monotherapy. 
Similar to other anti-cancer agents, resistance to HDAC inhibitors have been reported. The 
resistance mechanisms of HDAC inhibitors effectively counteract the mechanism-of-action. 
In certain cell type, it has been reported that increased activity of Chk1, a component of the 
G2 checkpoint, is associated with resistance to HDAC inhibitors (Lee, Choy et al. 2011). 
However, clinical correlation is lacking to support most of these claims. Furthermore, 
inhibition of apoptotic pathways also leads to resistance to HDAC inhibitors. Increased 
levels of anti-oxidant genes, such as thioredoxin, superoxide dismutase 2 and glutathione 
reductase, as well as the anti-apoptotic Bcl-2 are detected in tumours with resistance to 
HDAC inhibitors (Marks 2006, Garcia-Manero, Yang et al. 2008, Shao, Growney et al. 
2010). These changes either inhibit the accumulation of intracellular ROS or inhibit the 
formation of MAC, thus abrogating the induction of apoptosis. Lastly, several studies have 
revealed that certain HDAC inhibitors, such as romidepsin, are prone to drug efflux 
mechanisms that are mediated by P-glycoprotein (Peart, Tainton et al. 2003). Increased 
expression of MDR1 gene, which encodes for P-glycoprotein, has been found in peripheral 
blood mononuclear cells of patients receiving romidepsin treatment (Robey, Zhan et al. 
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2006). This is postulated as a possible self-induced mechanism of resistance to HDAC 
inhibitors in certain tumours.  
Lastly, it has been discussed earlier that repressive effects of histone deacetylation promotes 
histone and DNA methylation. The concurrent induction of both acetylation and 
methylation further facilitates the formation of heterochromatin (Casas-Delucchi, van 
Bemmel et al. 2012). Importantly, DNA methylation seemingly possesses stronger 
repressive effects that histone deacetylation (Fuks, Burgers et al. 2000). In these cases, using 
HDAC inhibitors as a single agent is insufficient to restore gene transcription. The addition 
of a demethylating agent, such as 5-azacitidine, has successfully increased gene expression 
significantly in pre-clinical studies (Cameron, Bachman et al. 1999). Clinical evaluation of 
such drug combinations has yielded tolerable safety profiles (Garcia-Manero, Kantarjian et 
al. 2006, Gore, Baylin et al. 2006, Soriano, Yang et al. 2007). 
Taken together, effects of HDAC inhibitors in the clinical settings have been restricted by 
the presence of adverse side effect and development of drug resistance. These are 
presumably due to the usage of high doses of HDAC inhibitors, resulting in cellular toxicity. 
As reviewed by Azad et. al., induction of cell death may not be the optimal clinical benefit 
for cancer patients (Azad, Zahnow et al. 2013). Therefore, selecting the right doses of 
HDAC inhibitors is a crucial determinant for the optimal specificity of these agents.  
 
1.5.4.3 Clinical trials of HDAC inhibitors in lung cancer 
Given the above mentioned limitations, HDAC inhibitors could still be potent anti-cancer 
agents if used with the optimal doses, timing and combinations (Azad, Zahnow et al. 2013). 
Various candidates from the five classes of HDAC inhibitors have been tested in the clinical 
setting. Recently, vorinostat and romidepsin have been approved by the FDA for the 
treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) 
(Mann, Johnson et al. 2007, Piekarz, Frye et al. 2009). More recently, romidepsin has 
gained FDA approval for the treatment of peripheral T-cell lymphoma (PTCL) (Piekarz, 
Frye et al. 2011). However, the utility of HDAC inhibitors in solid tumours is less 
established. Trials on HDAC inhibitors have not revealed superior progress in advanced 
solid malignancies (Bradley, Rathkopf et al. 2009, Ramalingam, Belani et al. 2009, Mackay, 
Hirte et al. 2010), largely due to the poor bioavailability and potency (Elaut, Rogiers et al. 
2007). 
The clinical report of HDAC inhibitors as a monotherapy on NSCLC has by far been limited. 
An initial report by Ramalingam et. al. has first investigated the clinical efficacy of 
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vorinostat, in combination with carboplatin and paclitaxel, in advanced solid tumours. They 
observed encouraging anti-tumour response among NSCLC patients in this phase I study 
(Ramalingam, Parise et al. 2007). A follow-up randomized phase II trial on the same 
combination treatment has shown improved progression-free-survival and overall survival 
in NSCLC cases (Ramalingam, Maitland et al. 2010). However, a subsequent Phase III trial 
was discontinued prematurely due to unsatisfactory clinical response and lack of 
improvement in survival rates (Belani, Ramalingam et al. 2009).  
Current therapeutic intervention has attempted to derive the efficacy of HDAC inhibitors 
with TKIs in lung cancer. A randomized phase II trial on entinostat, a specific inhibitor of 
class I HDACs, and erlotinib in NSCLC has been completed recently (Witta, Jotte et al. 
2012). Disappointingly, this combination regime has again failed to offer additional efficacy 
as compared to using erlotinib alone. These setbacks in the approach to combine HDAC 
inhibition with conventional chemotherapy or molecular targeted therapy have restricted the 
development of HDAC inhibitors in clinical setting for NSCLC patients.  
 
1.5.5 Belinostat 
Belinostat (PXD101) is a hydroxamic acid type HDAC inhibitor. Similar to other HDAC 
inhibitors, belinostat has demonstrated strong anti-neoplastic activity in several cancer types 
by inhibiting cell proliferation, promoting cellular differentiation, blocking angiogenesis and 
invasion, and triggering apoptosis in several preclinical studies (Plumb, Finn et al. 2003, 
Qian, LaRochelle et al. 2006, Lin, Lin et al. 2013). The commonly reported adverse events 
such as fatigue, diarrhoea, and the more life-threatening cardiac, hematologic and 
neurologic toxicities are posed to be major obstacles for the progression of HDAC inhibitors 
in clinic. However, when compared to other HDAC inhibitors, belinostat seemingly 
produces tolerable adverse effects while haematological toxicity is rare (Gimsing, Hansen et 
al. 2008, Steele, Plumb et al. 2008, Ramalingam, Belani et al. 2009, Yeo, Chung et al. 2012).  
The cytotoxicity of belinostat has been investigated in several tumour cell lines that include 
hepatocellular carcinoma, leukemia, head and neck SCC (HNSCC), ovarian cancer, colon 
cancer, thyroid cancer and pancreatic cancer (Qian, LaRochelle et al. 2006, Buckley, Yoon 
et al. 2007, Duan, Friedman et al. 2007, Dai, Chen et al. 2008, Fazzone, Wilson et al. 2009, 
Ma, Sung et al. 2010, Chan, Zheng et al. 2013, Chien, Lee et al. 2013). In addition, 
belinostat has displayed strong anti-neoplastic effects in several drug resistant tumour cells, 
emphasizing its chemosensitizing properties (Fazzone, Wilson et al. 2009).  
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Belinostat has progressed to late stage clinical development with multiple haematologic and 
solid malignancies being investigated. The maximum tolerated dose of belinostat in 
combination with other chemotherapies has been tested in a recently completed trial 
(ClinicalTrials.gov Identifier NCT01310244). The efficacy of belinostat has been evaluated 
in myeloma, lymphoma (Gimsing, Hansen et al. 2008), mesothelioma (Ramalingam, Belani 
et al. 2009), thymic epithelial carcinoma (Giaccone, Rajan et al. 2011) and ovarian cancer 
(Mackay, Hirte et al. 2010). Despite the mixed outcome obtained from these clinical 





















1.6  Objectives 
Historically, therapeutic approaches in the field of tumour biology have primarily focused 
on chemotherapy but recent specific pathway-targeted treatment regimens have proven 
advantageous.  However, treatment options for lung SCC patients have been severely 
limited to conventional chemotherapies due to lack of oncogenic driver mutations in this 
disease. Unlike lung adenocarcinoma, whereby EGFR and KRAS mutations are common, 
the rarity of genetic aberrations restricts a majority of the targeted therapeutic approaches. 
The first aim of this thesis is to characterize the mutational landscape of lung SCC and 
verify representative cell lines as study models for this cancer type through a combination of 
genomic and proteomic approaches (Chapter 3).  
The emergence of chemoresistance in lung SCC patients has led to paucity in treatment 
regime. While most current efforts have focused on identifying individualized treatment 
regimes for drug-resistant tumours, it was hypothesized that combination of appropriate 
chemotherapeutic agents with specific targeting of oncogenic pathways offers a powerful 
approach to circumvent the drug-resistance mechanisms in treatment of cancer. In the 
second part of the thesis, the mechanisms of cisplatin resistance in lung SCC cell lines were 
exploited. In view of the lack of targetable driver oncogenes in this disease, strategies that 
counteract drug resistance could enhance treatment outcome (Chapter 4).  
As outlined in previous chapters, multiple mechanisms-of-action of HDAC inhibitors have 
been described in pre-clinical studies which include cell death, cell growth arrest, cell 
differentiation and anti-angiogenesis. However, the genotoxic and cytotoxic stresses exerted 
on mammalian cells by high doses of HDAC inhibitors often result in immediate induction 
of cell death and possibly preclude the clinically-important cellular differentiation and 
reprogramming. Therefore, these cytotoxic effects of HDAC inhibitors at high doses may 
result to the lack of therapeutic efficacy in most solid tumours as well as adverse side effects. 
It was postulated that when administered at suitable doses, HDAC inhibitors could 
effectively alter the tumour biology in clinically-relevant manner. In the next parts of the 
thesis, the chemosensitizing effect (Chapter 4) and synergistic cytotoxicity (Chapter 5) of 




CHAPTER 2  MATERIALS AND METHODS 
2.1 Materials 
2.1.1 General chemicals and reagents 
Chemicals/Reagents Supplier Place of origin 
Acetic acid Merck Darmstadt, Germany 
β-estradiol Sigma Aldrich MO, USA 
Bovine serum albumin Sigma Aldrich MO, USA 
Dimethyl sulfoxide (DMSO) Sigma Aldrich MO, USA 
Dulbucco’s Modified Eagle’s Medium 
(DMEM) 
Life Technologies CA, USA 
Eagle's Minimum Essential Medium 
(EMEM) 
Life Technologies CA, USA 
Epidermal Growth Factor (EGF) Sigma Aldrich MO, USA 
Ethanol Merck Darmstadt, Germany 
Ethanolamine Sigma Aldrich MO, USA 
Ethylenedinitrilo tetraacetic acid (EDTA) Sigma Aldrich MO, USA 




Gene Print® 10 system Promega WI, USA 
Glycine  Bio-Rad CA, USA 
HEPES Sigma Aldrich MO, USA 
Hydrochloric acid (HCl) Merck Darmstadt, Germany 
Hydrocortisone Sigma Aldrich MO, USA 
Insulin Sigma Aldrich MO, USA 
Isopropanol Merck Darmstadt, Germany 
Leibovitz's L-15 medium Life Technologies CA, USA 
L-glutamine Life Technologies CA, USA 
McCoy’s 5 medium Life Technologies CA, USA 
Methanol Merck Darmstadt, Germany 
Penicillin-Streptomycin Life Technologies CA, USA 
Phosphate buffer saline (PBS) CSI Singapore 
Phosphorylethanolamine Sigma Aldrich MO, USA 
RPMI-1640 medium Life Technologies CA, USA 
Sodium pyruvate Sigma Aldrich MO, USA 
Sodium selenite Sigma Aldrich MO, USA 
Transferrin Sigma Aldrich MO, USA 
Triiodothyronine  Sigma Aldrich MO, USA 
Tris base Sigma Aldrich MO, USA 
Trypan blue dye Sigma Aldrich MO, USA 
Trypsin-EDTA Life Technologies CA, USA 
β-mercaptoethanol (β-ME) Merck Darmstadt, Germany 
 




Drugs Supplier Place of origin 
Belinostat (PXD101) Selleck Chemicals TX, USA 
Cetuximab Merck Darmstadt, Germany 
Cisplatin (CDDP) Pfizer NY, USA 
GDC0879 Selleck Chemicals TX, USA 
Nutlin-3a Selleck Chemicals TX, USA 
PD-0325901 Selleck Chemicals TX, USA 
RDEA119 Selleck Chemicals TX, USA 
Tenovin-6 p53Lab Singapore 
Trametinib (GSK1120212) Selleck Chemicals TX, USA 
 
Table 2.2: List of drugs. 
 
2.2 Mammalian cell culture 
2.2.1 Preparation of media 
Medium Supplements 
RPMI 1640 





DMEM 10% FBS, 4mM L-glutamine 
ACL-4 
10% FBS, 2mM L-glutamine, 100μg/mL streptomycin and 100U/mL 
penicillin, 0.02mg/mL Insulin, 0.01mg/mL transferrin, 25nM sodium 
selenite, 50nM hydrocortisone, 1ng/mL EGF, 0.01mM ethanolamine, 
0.01mM phosphorylethanolamine, 100pM triiodothyronine, 0.5% (w/v) 
BSA, 10mL HEPES, 0.5mM sodium pyruvate 
HITES 
5% FBS, 2mM L-glutamine, 100μg/mL streptomycin and 100U/mL 
penicillin, 0.005mg/mL Insulin, 0.01mg/mL transferrin, 30nM sodium 
selenite, 10nM hydrocortisone, 10nM beta-estradiol  
 








2.2.2 Mammalian cell lines 
All lung squamous cell carcinoma cells (H226, H520, H596, H1869, H2066, H2170, Calu-1, 
ChaGo-k-1, SK-MES-1, and SW900) and normal fibroblast cells (MRC-5, IMR-90, and 
WI-38) were purchased from American Type Culture Collection (ATCC; Rockville, MD). 
HEK293T cells were kindly provided by Prof Jean-Paul Thiery (Cancer Science Institute, 
Singapore). 
 
2.2.3 Cell culture maintenance 
Lung squamous cell carcinoma lines H226, H2170, H520, H596, ChaGo-k-1 were cultured 
in RMPI 1640, Calu-1 in McCoy’s 5a, SK-MES-1 in DMEM, SW900 in Leibovitz’, H1869 
in ACL-4 and H2066 in HITES medium. Lung normal fibroblast cells MRC-5, IMR-90 and 
WI-38 were cultured in EMEM medium. HEK293T cells were cultured in DMEM. All 
medium were enriched with additional supplements as described in Chapter 2.2.1. FBS used 
was heat-inactivated at 56°C to destroy heat-sensitive complement proteins. All cell lines, 
except for SW900, were cultured and maintained at 37°C in a humidified incubator of 5% 
CO2. SW900 cells were cultured and maintained at 37°C in a humidified incubator without 
CO2. All cell lines are adherent in nature. During subculturing, cell lines were rinsed with 1 
x PBS (137mM NaCl, 2.7mM KCl, 4.3mM NaH2PO4, 1.4mM KH2PO4 pH7.4), trypsinized 
with 0.05% trypsin-EDTA solution and split into new culture flask with an appropriate split 
ratio. Cell lines were maintained at below 90% confluency.  
 
2.2.4 Cryopreservation of cell lines 
Cryopreservation was performed to maintain the primary stocks for individual cell lines. 
Upon trypsinization with 0.05% trypsin-EDTA solution, cell suspensions were pelleted by 
centrifugation at 800 rpm for 3 minutes. Cell pellets were resuspended in sterile-filtered 
freezing medium (90% FBS, 10% DMSO) and placed into sterile cryovials at a maximum 
density of 1 x 106 cells/mL. The cells were allowed to freeze gradually in cryo-freezing 
containers filled with isopropanol (at a rate of 1°C/min) in -80°C freezers. For long term 
preservation, frozen cells were stored in liquid nitrogen. Subculturing of cryopreserved cells 
required quick thawing that was facilitated with 37°C water bath. The thawed cell lines were 
then mixed in pre-warmed complete medium and centrifuged at 800 rpm for 3 minutes to 




2.2.5 Trypan blue cell counting and seeding density 
Upon trypsinization, single cell suspension was obtained from resuspension in complete 
medium with gentle pipetting. The cell suspension was mixed with equal volume of Trypan 
blue dye (1:1 ratio) and transferred to a hemocytometer. The viable cells (bright cells, as 
Trypan blue dye diffuses into dead cells) located at the 4 squares at the corner of the 
indicated area were counted. As each corner square has a dimension of 0.1mm3 (or 0.1μL) 
(1mm x 1mm x 0.1mm), total cell count in the cell suspension was estimated with the 
following formula: 
Cells/mL = [(counts in 4 corner squares)/4] x (dilution factor) x 104 
Cell lines were seeded in 10cm2 dish, 6-well plate, 24-well plate and 96-well plate 
depending on the nature of the experiment. Seeding density was determined by the growth 
rate and cell size of each cell line. For a rough estimate, 1 x 106 cells were seeded in 10cm2 
dish; 1 - 1.5 x 105 cells for 6-well plate; 2 - 2.5 x 104 cells for 24-well plate; and 3 - 5 x 103 
cells for 96-well plate. 
 
2.2.6 Cell line authentication 
All SCC cell lines were authenticated using GenePrint® 10 System according to 
manufacturer’s protocol. The gDNA for the cells lines was extracted as described in Chapter 
2.7.3.1. Briefly, 10ng of template DNA was diluted in nuclease-free water to a final volume 
of 15μL. 5μL each of Master Mix and Primer Pair Mix was added to each sample. A 
positive amplification control (2800M Control DNA) was added to the list of samples. 
Thermal cycling was performed on MyCycler PCR thermal cycle (Bio-Rad; CA, USA) 
according to the manufacturer’s protocol for amplification of template DNA. The efficiency 
of the amplification was determined by agarose gel electrophoresis (Chapter 2.7.7). After 
PCR amplification, 1μL of each sample was mixed with Internal Lane Standard 600 in Hi-
DiTM formamide and subjected to denaturation at 95°C for 3 minutes in a thermal cycler. 
The denatured samples were placed on ice immediately after heating. Detection of amplified 
fragments was carried out using the ABI PRISM® 3100 Genetic Analyser (Life 
Technologies; CA, USA) by Centre for Translational Research and Diagnostics (CTRAD; 
CSI, Singapore). Data for the Gene Print® 10 Panels were imported and analysed with 




2.3 Transient gene silencing 
2.3.1 Chemicals and reagents 
Chemicals/Reagents Supplier Place of origin 
JetPRIME buffer Polyplus Transfection Illkirch, France 
JetPRIME reagent Polyplus Transfection Illkirch, France 
 
Table 2.4: List of chemicals and reagents used in siRNA-mediated knockdown. 
 
2.3.2 siRNA sequence 
All small-interfering RNAs were obtained from Qiagen (Hilden, Germany). 
siRNA Sequence 
Allstar Negative control NA 
MAP2K1I  (MEK1) 5'-GUGAAUAAAUGCUUAAUAATT-3' 
MAP2K2 (MEK2) 5'-GCAUUUGCAUGGAACACAUTT-3' 
MAPK1 (Erk1) 5'-CGUCUAAUAUAUAAAUAUATT-3' 
MAPK2 (Erk2) 5'-GUUCGAGUAGCUAUCAAGATT-3' 
SOS1 5’-GGAGGUCCUAGGUUAUAAATT-3’ 
SOS2 5’-UCAUUAUCGUAGUACUCUATT-3’  
TP53 5’-GGAAAUUUGCGUGUGGAGUTT-3’ 
 
Table 2.5: List siRNA sequences used in siRNA-mediated knockdown. 
 
2.3.3 siRNA transfection 
Respective cell lines were seeded at the optimized density in 6-well plate. Transfection was 
conducted when cells reached 30-50% confluency. Both target and scrambled siRNA (50nM 
for each siRNA) was diluted in 200μL JetPRIME buffer and mixed thoroughly by vortexing. 
4μL of JetPRIME reagent was added to the siRNA mixture for each reaction well, mixed 
thoroughly by vortexing, and incubated for 15 minutes at room temperature. The siRNA-
JetPRIME complexes were then added to the cells for gene delivery. The complexes were 
removed from the cells after 24 hours of siRNA delivery and fresh complete media were 
added to each well. Knockdown efficiency was determined 48 hours after transfection by 
Western blotting. In particular experiments, the transfected cells were re-plated for cell 




2.4 Stable gene silencing 
2.4.1 Reagents and kits 
Chemicals/Reagents/Kits Supplier Place of origin 
FuGENE HD Promega WI, USA 
MISSION® lentiviral packaging mix Sigma Aldrich MO, USA 
OptiMEM  Invitrogen CA,USA 




Polybrene Sigma Aldrich MO, USA 
Puromycin Sigma Aldrich MO, USA 
 
Table 2.6: List of chemicals and reagents used in lentiviral packaging and tranduction. 
 
2.4.2 Plasmids and lentiviral strains 
All vectors used in this study contained the pLKO.1-puro backbone. Luciferase shRNA 
plasmid was kindly provided by Prof Jean-Paul Thiery (Cancer Science Institute, Singapore). 
Lentiviral particles for transduction of GFP (pLKO.1-puro-CMV-TurboGFP; 2.7 X 107 
TU/mL) and non-targeting shRNA (pLKO.1-puro-CMV-shNT; 2.7 x 107 TU/mL) were 
obtained from Sigma Aldrich (MO, USA). Two lentiviral strains transducing TP53 shRNAs 
(sh55 and sh56) were kindly provided by Sir Prof David P. Lane and Dr Cheok Chit Fang 
(p53Lab, A*Star, Singapore). All viral work was conducted within the viral facilities 
provided by Cancer Science Institute of Singapore. 
 
2.4.3 Lentiviral packaging 
HEK293T cells were seeded at 1 x 106 cells in each 10cm2 dish and cultured over night in 
DMEM media. On day of transfection, the packaging cells should reach 70% confluency. 
Briefly, 18µl of Fugene HD was mixed in 582µL of serum-free OptiMEM media and 
incubated for 5 minutes at room temperature. 3µg of shRNA transfer vector and 30µL (3µg 
of plasmids) of Lentiviral Packaging Mix was then added to the diluted FuGENE HD 
solution (1μg DNA: 3μL FuGENE). The Lentiviral Packaging Mix contains 2 plasmids: one 
that encodes for viral packaging genes and one for viral envelope gene. The vector and 
transfection reagent were then mixed evenly by gentle vortexing, and allowed to incubate 
for 15 minutes at room temperature. The DNA-FuGENE complexes were then added 
dropwise to each dish of cells and incubated overnight at 37°C in tissue culture incubator. 
At 16 hours post-infection, media was removed from the transfected cells gently without 
disturbing the cells. 5μL of pre-warmed DMEM media was added to each dish.  Cells were 
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incubated for an additional 24 hours at 37°C in tissue culture incubator. The medium 
supernatant, which contained virus, was removed gently and placed in sterile 15mL Falcon 
tube. Again, 5mL of pre-warmed DMEM media was added to each dish and incubated 
overnight at 37°C in tissue culture incubator. The collection procedure was repeated to 
collect a second set of supernatant. Both sets of viral-containing supernatant were filtered 
with 0.45μm filter, aliquoted into eppendorf tube, tightly sealed and kept at -80°C. Viral 
titer was determined by ZeptoMetrix HIV p24 Antigen ELISA kit according to 
manufacturer’s protocol. 
 
2.4.4 Determining the multiplicity of infection (MOI) 
Infection efficiency of each cell line was first determined by lentiviral transduction with 
TurboGFP Control transduction particles, which contains a gene encoding for TurboGFP 
under the control of Cytomegalovirus (CMV) promoter. Briefly, 3 - 5 x 103 cells were 
seeded into each well in a 96-well plate and cultured overnight at 37°C in tissue culture 
incubator. Triplicate wells were needed for each lentiviral construct to be used. The next day, 
media were removed from each well, and each well was added with 50μL of transduction 
mixture containing a range of serial diluted TurboGFP viral particles and incubated 
overnight for 20 hours at 37°C in tissue culture incubator. The media containing the 
lentiviral particles were removed and 200μL of fresh pre-warmed complete media were 
added to each well. The cells reached 90 - 100% confluency 48 hours after viral 
transduction. The infection efficiency was estimated by observation of the GFP expressing 
cells or cell proliferation assay (described in Chapter 2.9.2) with puromycin treatment. 
 
2.4.5 Transduction of target shRNA 
Cells were seeded at 1 - 1.5 x 105 cells per well of 6-well plate and cultured overnight at 
37°C in tissue culture incubator. On day of transduction, the packaging cell should reach 30% 
confluency. Briefly, each well was added with 1mL of transduction mixture diluted viral 
particles. The desired amount of viral particles was determined with the following formula: 
(No. of cells/well) x (estimated MOI) = Amount of viral particles needed (TU) 
The cells were incubated for 20 hours at 37°C in tissue culture incubator. The media 
containing the lentiviral particles were removed and 2mL of fresh pre-warmed complete 
media were added to each well for overnight incubation. A pool of cells containing both 
infected and non-infected populations was obtained. 
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2.4.6 Selection, maintenance and expansion of infected clones 
Lethal doses of Puromycin to each cell line were determined prior to selection of infected 
clones. The infected cells should reach 80 - 100% confluency at 48 hours post-infection. 
The supernatants in each well were aspirated and replaced with 2mL of pre-warmed 
complete media with 5μg/mL (~100% cytotoxic dose for non-infected cells) of Puromycin 
and incubated overnight at 37°C in tissue culture incubator. The cells were selected 24 hours 
after antibiotic selection and were maintained under selection pressure until 100% 
confluency. The knockdown cells were expanded, validated with Real time polymerase 
chain reaction and Western blotting, and cryopreserved. 
 
2.5 Overexpressing gene-of-interest 
2.5.1 Chemicals and reagents 
Chemicals/Reagents Supplier Place of origin 
FuGENE HD Promega WI, USA 
Neomycin (G418) Sigma Aldrich MO, USA 
OptiMEM  Invitrogen CA,USA 
 
Table 2.7: Chemicals and reagents used in plasmid transfection and clonal selection. 
 
2.5.2 Plasmids 
Both p53 mutant wild-type overexpression plasmids were generated in this study using 
pcDNA3.1 vector with Geneticin resistant (neo) (Described in detail in Chapter 2.6), namely 
the pcDNA-p53wt and pcDNA-p53R158G plasmids. (The first letter of R158G represents 
the amino acid residues present in the wild-type molecule, while the last letter represents the 
modified amino acid in the mutated molecule. The number represents the position of the 
amino acid residue counting from the N terminus. This nomenclature will be used 
throughout this thesis.) 
 
2.5.3 Plasmids transfection 
Cells were seeded in 24 well plate and 6-well plate and cultured overnight at 37°C in 
complete media. On day of transfection, the cells should reach 30% confluency. Conditions 
of transfection complexes were listed in Table 2.8. Briefly, Fugene HD was mixed with 
serum-free OptiMEM media and incubated for 5 minutes at room temperature. Plasmids 
containing the gene-of-interest were added to the diluted FuGENE HD solution (1μg DNA: 
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3μL FuGENE), mixed evenly by gentle vortexing, and allowed to incubate for 15 minutes at 
room temperature. The DNA-FuGENE complex was then added dropwise to each well of 
cells and incubated overnight at 37°C in tissue culture incubator. At 16 hours post-infection, 
media was removed from the transfected cells gently. Pre-warmed fresh media were added 
to each well. Cells were ready for analysis 48 hours post-transfection. 
 
 24-well plate 6-well plate 
Medium (mL/well) 0.5 2 
No. of cells/well 2.5 x 104 1 x 106 
OptiMEM (mL/well) 0.1 0.5 
FuGENE HD (μL/well) 0.75 3 
DNA construct (μL/well) 0.25 1 
 
Table 2.8: Preparation of master mix for plasmid transfection in 24- and 6-well plates. 
 
2.5.4 Selection of transformants 
Lethal doses of neomycin (G418) to each cell line were determined prior to selection of 
stable clones. The transfected cells should reach 80 - 100% confluency at 48 hours post-
infection. The cells were trypsinized, resuspended in complete media and re-plated in 10cm2 
dish. Neomycin at 250μg/mL (~100% cytotoxic for non-infected cells) was added to each 
dish and cell lines were culture at at 37°C in tissue culture incubator. Culture supernatants 
were replaced with fresh media containing neomycin every 3 days until 100% confluency. 
The selected clones were expanded, validated with Western blotting, and cryopreserved. 
 
2.5.5 Generation of single cell colony 
The validated cells with overexpression of target proteins were serial diluted with complete 
media and neomycin (250μg/mL) to 10 cells/mL. 100μL of cells were seeded into each well 
of 96-well plate and culture at at 37°C in tissue culture incubator. Formation of single cell 
colonies was monitored over time. Culture supernatants in each well were replaced with 
fresh media containing neomycin every 3 days until obvious colonies were observed. The 
colonies were trypsinized, resuspended and re-plated in 24 well plates, followed by 6 well 
plates and 10 cm2 dishes. The overexpressing clones were validated with Real time 




2.6 Molecular cloning 
2.6.1 Chemical, reagents and kits 
Chemicals/Reagents/Kits Supplier Place of origin 
Ampicillin  Sigma Aldrich MO, USA 
Luria-Bertani (LB) agar CSI Singapore 
Luria-Bertani (LB) broth CSI Singapore 
OneShot® TOP10 competent cells  Life Technologies CA, USA 
QIAquick Plasmid Midi Preps kit Qiagen Hilden, Germany 
S.O.C medium Life Technologies CA, USA 
 
Table 2.9: List of chemicals and reagents used in DNA cloning. 
 
2.6.2 Competent cells and plasmids 
One Shot® TOP10 E. coli competent cells that allowed for high-efficiency cloning of high-
copy number plasmids were obtained from Invitrogen (CA, USA). The backbone plasmid, 
pcDNA3.1 vector, was kindly provided by Dr John Low and Dr Hsieh Wen-Son.  
 
2.6.3 Primer design 
Primers were designed to include the length of the coding region of the gene-of-interest, 
TP53, by beginning at the start codon (ATG) and ending at the stop codon (TGA). A 
sequence encoding for hemagglutinin (HA)-tag was included at the 5’-end right next to the 
start codon. A Kozak consensus sequence (GCCGCCCC) was included to facilitate the 
initiation of translation (Kozak 1987). A HindIII restriction site was added to the 5’ end and 
an EcoRI restriction site was added to the 3’ end. The primer designs are listed below:  
 








3’ Primer: (5’3’): 
 
CCGAATTCTCAGTCTGAGTCAGGCCCTTCTGTC 
          





2.6.4 Cloning of pcDNA-TP53R158G and pcDNA-TP53wt plasmids 
The primers mentioned in Chapter 2.6.3 were specifically designed for amplification of the 
open-reading frame (ORF) of TP53 gene, and was flanked with two restriction digestion 
sites with a HA-tag sequence at the 5’ primer. The mutant (R158G) and wild-type sequences 
were cloned from H2170 and MRC5 cells respectively by polymerase chain reaction (PCR) 
using the cDNA extracted from these two cell lines. Restriction digestion was performed on 
pcDNA3.1 empty vector (EV) and the amplified inserts to expose the ligation site. Both 
digested vectors and inserts were purified from gel electrophoresis as described in Chapter 
2.7.7, and ligated to form expression vectors as described in 2.7.6.  
 
2.6.5 Transformation of chemically competent cells 
Chemically competent One Shot® TOP10 cells were transformed based on the 
manufacturer’s protocol with slight modifications. Briefly, One Shot competent cells were 
thawed on ice (one vial of One Shot® cells was used for each transformation). Immediately 
upon thawing, all the ligation mix from Chapter 2.6.4 was added into the competent cells, 
mixed by gentle tapping and incubated on ice for 30 minutes. Subsequently, the competent 
cells were heat-shocked in a 37°C water bath for 45 seconds without shaking. Immediately 
after heat-shock, removed the cells from the water bath and placed on ice for 2 minutes. 
250μL of pre-warmed S.O.C. medium was added into each vial of competent cells. 
Competent cells were allowed to recover at 37°C for 2 hours with shaking at 200 rpm in 
Thermo Twister Orbital Shaker (Quantifoil Instruments; Jena, Germany). During this 
incubation, the selection plates (10mL of LB agar in each petri dish, supplemented with 
100μg/mL ampicillin) were warmed in 37°C incubator. The transformed competent cells 
(300μL) were streaked on two individual selection plates with different volumes to increase 
chances of obtaining single colonies (100 and 200μL). The plates were allowed to dry and 
incubated at 37°C overnight in an inverted position.  
 
2.6.6 Expansion of E. coli culture 
20 hours after transformation, successfully transformed cells formed colonies on selection 
plates. Well-spaced single colonies were picked and placed into 2mL of starter culture (LB 
broth supplemented with 100μg/mL ampicillin). The selected colonies were grown in starter 
culture for 16 hours at 37°C with shaking at 200 rpm. The competent cells were collected 




2.6.7 Plasmid extraction 
Plasmid DNA was extracted and purified from the expanded E. coli culture in Chapter 2.6.6 
using the QIAquick Plasmid Midi Preps kit according to manufacturer’s protocol. Briefly, 
the competent cells were harvest by centrifugation at 6000 g for 15 minutes at 4°C. The 
bacteria pellet was resuspended in Buffer P1 and incubated with same volume of Buffer P2 
at room temperature for 5 minutes. Next, same volume of pre-chilled Buffer P3 was added 
and the suspension was mixed thoroughly before incubation at 4°C for 15 minutes. The 
mixed suspension was then centrifuged at 20,000 g at 4°C for 30 minutes. The supernatant 
was collected and again centrifuged at 20,000 g at 4°C for 15 minutes to clear all bacteria 
debris. The supernatant (containing the plasmid DNA) was allowed to pass through the 
QIAGEN-tip 100 that has been equilibrated with Buffer QBT by gravity flow. The plasmid 
DNA was captured by the resin in the QIAGEN-tip, and the resin was washed twice with 
Buffer QC by gravity flow. The plasmid was eluted with Buffer QF and precipitated by 
addition of isopropanol (at 0.7 x volume of the eluted DNA). The plasmid DNA was 
pelleted at 15,000 g at 4°C for 30 minutes. The supernatant was decanted carefully and the 
pellet was washed at room temperature with 70% ethanol. The DNA pellet was pelleted 
again by centrifugation at 15,000 g at 4°C for 10 minutes. Ethanol was removed completely 
and the pellet was air-dried for 10 minutes at room temperature. Plasmid DNA was 
dissolved in TE buffer (10mM Tris-Cl, 1mM EDTA, pH 7.5). Concentration and purity of 
the purified plasmid were determined by NanoDrop as described in 2.7.3.3. Integrity of the 











2.7 Molecular biology 
2.7.1 Chemical, reagents and kits 
Chemicals/Reagents/Kits Supplier Place of origin 
100bp DNA ladder Thermo Fisher MA, USA 
10x PCR Buffer II  Life Technologies CA, USA 
1kb DNA ladder Thermo Fisher MA, USA 
Agarose powder Bio-Rad CA,USA 
ApplauseTM WT-Amp ST RNA 
Amplification System 
NuGEN Technologies CA, USA 
Blue/Orange 6x loading dye Thermo Fisher MA, USA 
DNase I kit Qiagen Hilden, Germany 
dNTPs  
(2.5mM each of dATP, dGTP, dCTP, dTTP)  
Life Technologies CA, USA 
EcoRI Resctiction Enzyme New England Biolabs MA, USA 
Ethidium bromide (EtBr) Bio-Rad CA,USA 
GoTaq® DNA polymerase Promega WI, USA 
HindIII Restriction Enzyme New England Biolabs MA, USA 
Human GeneChip Gene 1.0ST array Affymetrix CA, USA 
MgCl2  Life Technologies CA, USA 
MiniElute Reaction Cleanup Kit Qiagen Hilden, Germany 
NEB Buffer II New England Biolabs MA, USA 
QIAquick Gel Extraction kit Qiagen Hilden, Germany 
QIAquick PCR Purifiction kit Qiagen Hilden, Germany 
QIAshredder homogenizer Qiagen Hilden, Germany 
Random Hexamer primer  Life Technologies CA, USA 
Reverse transcriptase MuLV  Life Technologies CA, USA 
RNase Inhibitor Life Technologies CA, USA 
RNeasy Mini kit Qiagen Hilden, Germany 
Takara DNA Ligation kit Takara Bio Inc. Shiga, Japan 
Wizard® SV Genomic DNA Purification 
System 
Promega WI, USA 
 
Table 2.10: List of chemicals and reagents used in RT-PCR, qPCR, agarose gel 






























               CATACGATGTTCCAGATTACGCTA 
              TGGAGGAGCCGCAGTCAGATCCTA 61 35 
Reverse: CCGAATTCTCAGTCTGAGTCAGGC 
               CCTTCTGTC 
 
Table 2.11: List of primers used in RT-PCR. The annealing temperature and cycle 
number used for each primer pair were shown. 
 


























2.7.3 Extraction of nucleic acid 
2.7.3.1  Genomic DNA extraction 
Extraction of genomic DNA (gDNA) from mammalian cell lines was conducted using 
Wizard® SV Genomic DNA Purification System according to manufacturer’s protocol. 
Briefly, a maximum of 5 x 106 cells was disrupted in Wizard® SV Lysis Buffer. The 
suspensions containing the lysed cells were transferred to individual Wizard® SV 
Minicolumn Assembly and centrifuged at 14,000 rpm for 3 minutes until all liquid flowed 
through. Discard the liquid in the collection tube and washed the column 4 x 650μL with 
Column Wash Solution (diluted with 95% ethanol). After washing, the collection tubes were 
emptied and the columns were centrifuged at 14,000 rpm for another 2 minutes to dry the 
binding matrix. 250μL of nuclease-free water was added to each column and allowed to 
incubate at room temperature for 2 minutes. The columns were centrifuged at 14,000 rpm 
for 1 minute in clean eppendorf tubes to elute the DNA. The extracted gDNAs were stored 
at -80°C. Concentration and purity of the purified RNAs were determined by NanoDrop as 
described in Chapter 2.7.3.3.  
 
2.7.3.2 RNA extraction 
Extraction of total RNA from mammalian cell lines was conducted using RNeasy® Mini kit 
according to manufacturer’s protocol. Briefly, a maximum of 1 x 107 cells was disrupted in 
lysis buffer RLT (containing 1% β-ME) by homogenization using needle and syringe or 
QIAshredder homogenizer. Equal volume of 70% ethanol was added to the homogenized 
lysate, mixed well and transferred to RNeasy Mini Spin columns for binding of RNA to the 
RNeasy membrane through centrifugation at full speed. The membrane of each column was 
washed once with RW1 buffer, treated with DNase I for 30 minutes for removal of DNA, 
and washed twice with buffer RPE. Purified RNA was eluted with 30 - 50μL of nuclease-
free water. Concentration and purity of the purified RNAs were determined by NanoDrop as 
described in Chapter 2.7.3.3. 
 
2.7.3.3 Nanodrop quantification 
The concentration of total DNA and RNA were quantified by the NanoDropTM 
Spectrophotometer (Thermo Scientific). The absorbance range was from 220nm to 750nm. 
To begin with, 1.5μL of total RNA/DNA was aspirated and placed onto the measurement 
pedestal. Ratios of absorbance measured at 260nm and 280nm (A260/280) were determined 
to assess purity of RNA/DNA. RNA with A260/A280 ratio within 1.8 to 2 is considered as 
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satisfactory quality; whereas DNA with A260/A280 ratio above 2 is considered as 
satisfactory quality. The concentrations (ng/μL) of DNA/RNA were estimated. 
 
2.7.4 Reverse-transcription polymerase chain reaction (RT-PCR) 
2.7.4.1 Reverse transcription 
Total RNA extracted was reverse transcribed to complementary DNA (cDNA) strands by 
RT-PCR. For each RNA sample, 1μg of RNA was diluted to a final volume of 3μL with 
nuclease-free water. Diluted RNA was denatured at 90°C for 5 minutes to expose the 
secondary and tertiary structures for proper binding of reverse transcriptase. Heated RNA 
was cooled on ice immediately. 17μL of RT master mix (Table 2.13) was added to each 
sample (total reaction volume per 1μg RNA = 20μL). Reverse transcriptase was activated at 
23°C for 10 minutes, cDNA synthesis was performed at 42°C for 1 hour, and reverse 
transcriptase was inactivated at 99°C for 5 minutes. The synthesized cDNA was stored at -
20°C. 
Reagents Volume for 1 reaction 
RNA + nuclease-free water (μL) 3 
dNTPs (μL) 8 
10x PCR Buffer II (μL) 2 
MgCl2 (μL) 4 
Random Hexamer primer (μL) 1 
RNase Inhibitor (20U/μL) (μL) 1 
Reverse transcriptase MuLV (50U/μL) (μL) 1 
Total volume (μL) 20 
 
Table 2.13: Preparation of master mix for reverse transcription. 
 
2.7.4.2 Polymerase chain reaction (PCR) 
All PCR reactions in this study were carried out with GoTaq® DNA polymerase and 
respective primers (Table 2.11) unless specified otherwise. PCR was performed using 
MyCycler PCR thermal cycle (Bio-Rad; CA, USA). In most cases, 50μL reaction mix 
[100ng cDNA template, 1.5nM MgCl2, 0.2mM each of dNTPs (dATP, dGTP, dCTP, dTTP), 
1.25 unit of GoTaq® polymerase, 0.6μM of each primers, and 1 x reaction buffer] was 
prepared for each PCR amplification. The setup configuration for PCR: initial denaturation 
step of 95°C for 10 minutes; followed by 25 - 35 cycles of DNA denaturation at 94°C for 30 
sec, primer annealing at indicated temperature for 30 sec, and DNA elongation at 72°C for 
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30 sec – 2 minutes (depending on size of PCR product, approximately 1 min/kb); and ended 
with DNA extension step at 72°C for 10 minutes. The PCR products could then be stored at 
4°C. The efficacy of the PCR was determined by agarose gel electrophoresis as described in 
2.7.7.1. In cases whereby the PCR products were subjected to DNA sequencing or cloning, 
PCR purification was performed using QIAquick PCR Purification kit according to 
manufacturer’s protocol. Concentration and purity of the purified PCR were determined by 
NanoDrop as described in Chapter 2.7.3.3. 
 
2.7.5 Restriction enzyme (RE) digestion and DNA ligation 
DNA digestion was performed with appropriate REs in their corresponding buffers 
according to the manufacturer’s protocol. As both HindIII and EcoRI REs share the same 
working buffer (NEB Buffer II), the one-step digestion was performed. The PCR products 
and pcDNA3.1 vector were subjected to restriction digestion by incubating the DNA-
enzyme mixtures at 37°C in a heat block for 2 hours. The restriction profile was analysed by 
DNA gel electrophoresis (Chapter 2.7.7.1). The bands indicating the linearized vectors and 
the digested inserts were excised and purified by gel extraction (Chapter 2.7.7.2). After 
purification, the open-end pcDNA3.1 vectors and inserts were mixed with Takara DNA 
ligase master mix for 15 minutes at room temperature. Ligation was completed at the end of 
incubation. 
 
2.7.6 Agarose gel electrophoresis 
2.7.6.1 Gel migration 
Agarose gel electrophoresis was performed to analyse PCR product/digested DNA/ligated 
DNA. In most cases, 1 - 2% (w/v) agarose gel was prepared in 100mL of TAE buffer 
(40mM Tris, 20mM acetate acid, 1mM EDTA, pH7.8) and stained with EtBr at 1: 50 
dilution. The product-of-interest was aliquoted and mixed with blue/orange 6x loading dye 
to a maximum volume of 25μL per well. 6μL of 1kb or 100bp DNA ladder was used as 
indicator for estimation of band sizes. Electrophoresis was carried out by gel migration in 1 
x TAE buffer at 100 V for 30 minutes. DNA bands were visualized under a ultra-violet (UV) 




2.7.6.2 Gel extraction 
After gel electrophoresis, DNA fragments of interest (for DNA sequencing or DNA ligation) 
were excised carefully from agarose gel using clean scalpels. Low UV light (366nm) was 
used to facilitate the visualization of DNA fragments. High UV wavelength and prolonged 
exposure to UV were avoided to prevent fragmentation of the desired DNA. The excised 
agarose gels were subjected to DNA extraction using the QIAquick Gel Extraction kit as 
described in the manufacturer’s protocol. Briefly, the excised gel was mixed with 3 volumes 
of Buffer QX1 and incubated at 50°C until the gel was completely dissolved. Next, 1 gel 
volume of isopropanol was added to the sample, mixed by inverting the tube, and all sample 
was loaded to the QIAquick spin column. The DNA fragment was bound to the resin by 
centrifugation at 14,000 rpm for 1 minute. The flow-through was discarded from the 
collection tube, and the resin was washed once each with Buffer QX1and Buffer PE. The 
resin was cleared by centrifugation at 14,000 rpm for 1 minute. The purified DNA was 
eluted with 20 - 30μL of Elution Buffer. 
 
2.7.7 Real-time quantitative polymerase chain reaction (qPCR) 
2.7.7.1 qPCR setup 
Real time qPCR was conducted by using the Taqman® Gene Expression Assay System 
(Applied Biosystem; CA, USA). 10ng of cDNA template was used per reaction. qPCR 
reaction mix was prepared as shown in Table 2.14. 11μL of reaction mix and 9μL of diluted 
cDNA template were added into each of the assigned wells in the MicroAmp® Optical 96-
well Reaction Plate (Applied Biosystem; CA, USA). Each reaction was performed in 
triplicates. Nuclease-free water was added instead of the cDNA template as no-template 
control. Passive reference ROX dye present in the Taqman® master mix serves as an 
internal fluorescence reference by which the reporter dye signal was normalized against 
during data analysis. Real-time qPCR was performed using ABI Prism 7500 Real time PCR 
System (Applied Biosystem; CA, USA). The amplification begins with an initial 
denaturation step at 95°C for 10 minutes, followed by PCR cycling for 40 cycles comprising 
of DNA denaturation at 94°C for 15 sec and primer annealing at 60°C for 1 minute, and a 






Reagents Volume for 1 reaction 
cDNA template (μL) 0.2 
Nuclease free water (μL) 8.8 
2 x Tagman® Universal PCR master mix (μL) 10 
20 x primer mix (μL) 1 
Total volume (μL) 20 
 
Table 2.14: Preparation of master mix for real time qPCR. 
 
2.7.7.2 Configuration of qPCR data analysis 
The real time qPCR data on gene expression quantification was exported from the Applied 
Biosystem Standard 7500 software and was interpreted as relative quantification (RQ). The 
amplification was expressed as fluorescence intensity that was depicted by the amplification 
curve generated by the system. Baseline value was set at initial cycle where amplification of 
signal was first detected. The threshold cycle (Ct) values for each sample on respective 
target gene were determined as the point of intersection between the amplified curve and the 
indicated threshold. The average Ct values for the triplicates were normalized against the 
endogenous reference gene (GAPDH), which was represented by δCt. The δCt values from 
each sample were compared against a calibrator, usually the control group, to obtain δδCt 
values. The RQ values for the changes in gene expression were calculated based on the δδCt 
values. The formula for the above mentioned calculation was shown: 
δCtsample = Ctsample – CtGAPDH  
      δδCt = δCttarget – δCtcalibrator 













2.7.8 Gene expression profiling by Microaary 
2.7.8.1 Microarray 
Cells were seeded in 10cm2 dishes and cultured overnight at 37°C in a tissue culture 
incubator. Drug treatment was performed the subsequent day. Cells were harvested for total 
RNA purification after 8 hours drug treatment with RNeasy Mini Kit as described in 
Chapter 2.7.3.2. The RNA purity was checked with NanoDrop (Chapter 2.7.3.3) while the 
RNA integrity was determined with the RNA 6000 Nano LabChip Bioanalyser (Agilent; 
CA, USA). The RNA Integrity Number (RIN) for each sample was ensured to be above 9.2 
(Good quality). The RNAs that passed quality control tests were subjected to reverse 
transcription and amplification using ApplauseTM WT-Amp ST RNA Amplification System 
according to manufacturer’s protocol. 150ng of RNA was required for each sample in 
duplicates. As an overview, first strand cDNA was generated based on the RNA, which was 
followed by generation of DNA/RNA heteroduplex double-strand cDNA, SPIA 
amplification, and post-amplification modification. SPIA amplication is a linear isothermal 
DNA amplification procedure developed by NuGEN that generates multiple single strands 
cDNA. The post-SPIA modification allows for annealing of random priers onto the single 
strand cDNA and extension of second strand cDNA. The amplified cDNAs were purified 
using Qiagen’s MiniElute Reaction Cleanup Kit according to manufacturer’s protocol. 
Briefly, each cDNA sample was mixed well with 300μL of ERC buffer and bound to 
MiniElute spin column by centrifugation for 1 minute at 14,000 rpm. The columns were 
washed once with Buffer PE, centrifuged at full speed to remove residual buffer, and eluted 
with 15μL of nuclease-free water with centrifugation for 1 minute at 14,000 rpm. Yield and 
purity of each cDNA sample were determined with Nanodrop (Chapter 2.7.3.3). Each 
sample was then labelled with biotin in preparation for hybridization on microarray 
GeneChip according to WT-Amp ST Targeting Labeling Protocol. Briefly, 2.5μg of purified 
SPIA cDNA was diluted in nuclease-free water, fragmented with the provided 
Fragmentation enzymes and labelled with Encore Biotin Module. The purified and labelled 
cDNAs were then processed and hybridized onto Human GeneChip Gene 1.0ST array for 
gene expression profiling. In brief, each cDNA sample was mixed at room temperature with 
the hybridization cocktail. The mixture was denatured at 99°C for 2 minutes and heated for 
45°C in a heat block for 5 minutes. Prior to loading, all samples were centrifuged at 14,000 
rpm speed for 1 minute.  90μL of each hybridization mixture was loaded into single array 
chip and hybridized for 18 hours at 60 rpm in a GeneChip Hybridization Oven 640 
(Affymetrix; CA, USA). The arrays were washed using GeneChip Fluidics station 450 
(Affymetrix; CA, USA) using fluidic protocol FS450_0001 and scanned using GeneChip 
Scanner 3000 7G (Affymetrix; CA, USA) according to manufacturer's instructions.  
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2.7.8.2 Transcriptomic analysis 
Thirty-two microarray data, including duplicates for both treated and untreated samples, 
were obtained in .CEL format. The CEL files were imported into GeneSpring Software V12 
(Agilent; CA, USA) for data normalization and identification of differentially expressed 
mRNAs of interest. The gene sets with absolute fold change > 1.5 across the comparison 
groups were denoted as commonly altered genes (Appendix 1 and 2). Pathway analysis was 
conducted with the publicly available Database for Annotation, Visualisation and Integrated 
Discovery (DAVID) Bioinformatics Resources 6.7 Software (Huang, Sherman et al. 2009) 
and mapped to the Kyoto Encyclopedia of Genes and Genomes (KEGG) database for 
pathway analysis. 
 
2.7.9 DNA sequencing 
Purified plasmids or PCR products were sent to Integrated DNA Technologies (IDT; 
Singapore) for Sanger sequencing with the indicated primers. The FASTA file was analysed 
for nucleotide changes. The obtained sequence was aligned and search in the human genome 
















2.8 Protein expression analysis 
2.8.1 Chemicals reagents and kits 
Chemicals/Reagents/Kits Supplier Place of origin 
30% Acrylamide-Bis Solution Bio-Rad CA, USA 
Amersham ECL Prime Chemiluminescent reagent GE Healthcare Little Chalfont, UK 
Ammonium Persulfate (APS) Bio-Rad CA, USA 
Bicinchoninic Acid (BCA) Protein Assay kit Pierce Biotech IL, USA 
Blocking-grade Skim milk powder Bio-Rad CA, USA 
Bromophenol blue Bio-Rad CA, USA 
Cell LyticTM Buffer Sigma Aldrich MO, USA 
Glycerol Sigma Aldrich MO, USA 
Nuclear extraction kit Active Motif CA, USA 
PhosSTOP phosphatase inhibitor cocktail Roche Penzberg, Germany 
Pre-stained protein ladder Thermo Fisher MA, USA 
Protease inhibitor cocktail Roche Penzberg, Germany 
Proteome Profiler MAPK-array R&D System MN, USA 
PVDF Membrane Bio-Rad CA, USA 
Tetramethylethylenediamine (TEMED) Bio-Rad CA, USA 
Tween-20 Sigma Aldrich MO, USA 
Western blot stripping buffer Thermo Fisher MA, USA 
X-Ray film AGFA Healthcare Mortsel, Belgium 
 
Table 2.15: List of chemicals, reagents and kits for protein studies. 
 
2.8.2 Antibodies for Western blotting 
Antibody Target Supplier Dilution 
Acetyl-CBP (Lys1535)/p300 Rabbit Cell Signalling 1:2000 
Acetyl-Histone H3 (Lys23) Rabbit Cell Signalling 1:10000 
Acetyl-Histone H3 (Lys9/Lys14) Rabbit Cell Signalling 1:10000 
Acetyl-Histone H4 Rabbit Millipore 1:10000 
Acetyl-p53 (Lys379) Rabbit Cell Signalling 1:1000 
acetyl-p53 (Lys382) Rabbit Cell Signalling 1:2000 
BAD Rabbit Cell Signalling 1:2000 
BAK Rabbit Cell Signalling 1:2000 
BAX Rabbit Cell Signalling 1:5000 
Bcl-2 Rabbit Cell Signalling 1:2000 
Bcl-w Rabbit Cell Signalling 1:2000 
Bcl-xl Rabbit Cell Signalling 1:2000 
Bid Rabbit Cell Signalling 1:2000 
Bim Rabbit Cell Signalling 1:2000 
Caspase-3 Rabbit Cell Signalling 1:1000 
Caspase-4 Rabbit Cell Signalling 1:2000 
Caspase-7 Rabbit Cell Signalling 1:2000 
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Caspase-8 Mouse Cell Signalling 1:2000 
Caspase-9 Rabbit Cell Signalling 1:2000 
EGFR Rabbit Cell Signalling 1:2000 
HA-tag Rabbit Cell Signalling 1:2000 
HDAC1 Mouse Cell Signalling 1:2000 
HDAC2 Mouse Cell Signalling 1:2000 
HDAC3 Mouse Cell Signalling 1:2000 
HDAC4 (D15C3) Rabbit Cell Signalling 1:2000 
HDAC6 (D2E5) Rabbit Cell Signalling 1:2000 
HRP-conjugated β-actin - Cell Signalling 1:5000 
p21 Waf/Cip 1 Rabbit Cell Signalling 1:2000 
PARP Rabbit Cell Signalling 1:2000 
Phospho-B-Raf (Ser445) Rabbit Cell Signalling 1:2000 
Phospho-Erk 1/2 (T202/Y204) Rabbit Cell Signalling 1:2000 
Phospho-HDAC3 (Ser424) Rabbit Cell Signalling 1:2000 
Phospho-MDM2 (Ser166) Rabbit Cell Signalling 1:2000 
Phospho-MEK1/2 (Ser217/221) Rabbit Cell Signalling 1:2000 
Phospho-MSK1 (Ser360) Rabbit Cell Signalling 1:2000 
Phospho-p38 (T180/Y182) Rabbit Cell Signalling 1:2000 
Phospho-p53 (ser15) Mouse Cell Signalling 1:2000 
Phospho-Sirt1 (Ser27) Rabbit Cell Signalling 1:2000 
PUMA Rabbit Cell Signalling 1:2000 
SOS1 Rabbit Cell Signalling 1:1000 
SOS2 Rabbit abcam 1:1000 
Survivin Rabbit Cell Signalling 1:2000 
TATA box binding protein (TBP) Mouse Abcam 1:3000 
Total Erk Rabbit Cell Signalling 1:5000 
Total H4 Rabbit Cell Signalling 1:5000 
Total Histone H3 Rabbit Cell Signalling 1:10000 
Total MEK1/2 Rabbit Cell Signalling 1:1000 
Total MSK1 Rabbit Cell Signalling 1:1000 
Total p38 Rabbit Cell Signalling 1:2000 
Total p53 Rabbit Cell Signalling 1:2000 
Total p53 Mouse Santa Cruz 1:5000 
Total Sirt1 Rabbit Cell Signalling 1:2000 
XIAP Rabbit Cell Signalling 1:2000 
α-tubulin Mouse Santa Cruz 1:5000 
HRP-conjugated Anti-Mouse IgG Secondary Cell Signalling 1:2000 
HRP-conjugated Anti-Rabbit IgG Secondary Cell Signalling 1:2000 
 




2.8.3 Total protein extraction 
For preparation of protein lysates, all cells (from treated/untreated groups) were collected. 
The culture supernatant from each treatment group was aspirated and placed in collection 
tubes. The attached cells were washed once with 1 x PBS (PBS was collected as well), 
trypsinized from their respective culture plates and placed in the same collection tubes as 
their culture supernatant. Cells were centrifuged at 1000 rpm for 5 minutes at room 
temperature. The obtained pellets were rinsed once with ice-cold 1 x PBS and pelleted again 
by centrifugation at 1000 rpm for 5 minutes at room temperature. The supernatant was 
removed, and appropriate amount (dependent on the size of the pellet) of lysis buffer [Cell 
LyticTM Buffer (50mM NaCl, 0.41% bicine, 2% EDTA) supplemented with complete 
protease inhibitor cocktail and PhosSTOP phosphatase inhibitor cocktail] was added. Cell 
lysis was completed with sonication on ice at 5W for 10 sec twice. Lysates were then 
centrifuged for 20 minutes at 14,000 rpm to remove cell debris. Protein concentration was 
determined by BCA protein assay as described in Chapter 2.8.5. The supernatants were 
collected and aliquoted for storage at -80°C.  
 
2.8.4 Nuclear and cytosolic extraction 
Separation of cuclear and cytosolic fractions was perfoemd using Active Motif Nuclear 
Extraction kit according to the manufacturer’s protocol with minor modifications. All cells 
were collected as described in Chapter 2.8.3. Cells were centrifuged at 1000 rpm for 5 
minutes at room temperature. The obtained pellets were rinsed once with ice-cold 
PBS/phosphatase inhibitor mix provided by manufacturer and centrifuged at 1000 rpm for 5 
minutes at room temperature. The cell pellets were then resuspended in 1 x Hypotonic 
Buffer and incubated on ice for 10 minutes. Next, detergent was added to each sample and 
the suspension was vortexed for 10 seconds. The cell suspensions were then centrifuged at 
14,000 rpm for 30 seconds at 4°C. After this step, the nuclei were pelleted while the 
supernatants (cytoplasmic fractions) were collected. The cell pellets (nuclear fractions) were 
resuspended in Complete Lysis Buffer, vortexed for 10 sec at maximum speed, and 
incubated on ice for 30 minutes on a rocking platform at 150 rpm. After incubation, the cell 
suspensions were vortexed for 30 sec at maximum speed and centrifuged at 14,000 rpm for 
10 minutes at 4°C. The supernatants (nuclear fractions) were collected. Both nuclear and 
cytoplasmic fractions were sonicated on ice at 5W for 10 seconds twice. Protein 
concentration was determined by BCA protein assay as described in Chapter 2.8.5. The 
supernatants were aliquoted for storage at -80°C. 
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2.8.5 Quantification and preparation of protein lysates 
BCA protein assay was performed to determine the concentration of the obtained protein 
lysates according to manufacturer’s protocol. 5μL of each sample was used for 
quantification. A range of BSA concentration (2mg/mL, 1.5mg/mL, 1mg/mL, 0.75mg/mL, 
0.5mg/mL, 0.25mg/mL and 0.125mg/mL) was used as reference standards. All samples and 
standards were placed in 96-well plates. 200μL of BCA working reagent (1: 50 dilution for 
buffer A: buffer B) was added to each sample and standard. The mixture was incubated at 
37°C for 30 minutes and absorbance was measured at 562nm with Infinite200 Pro 96-well 
plate reader (Tecan; Switzerland). Preparation of samples for SDS-PAGE Western blotting 
was completed by heat denaturation and β-ME reduction.  The quantified lysates were 
mixed with SDS loading buffer [final concentration: 62.5mM Tris-HCl (pH7.4), 10% 
glycerol, 2.5% SDS, 0.01% bromophenol blue, 5% β-ME]. Lysates were then denatured at 
95°C for 5 minutes. The samples were stored at -20°C. 
 
2.8.6 Sodium dodecyl sulphate-Polyacrylamide gel electrophoresis (SDS-PAGE) 
The prepared protein lysates in Chapter 2.8.7 were resolved in acrylamide gels using the 
SDS-PAGE Mini-Protein II system (Bio-Rad; CA, USA). Acrylamide gels were casted in 
two layers (stacking and resolving layers) at various percentage of acrylamide (Table 2.17) 
for separation of various protein sizes. The gels were assembled into the Mini-Protein II gel 
tank. The tank was filled up with SDS-PAGE running buffer (25mM Tris, 192mM glycine, 
0.1% SDS). Protein samples and pre-stained protein ladder were then loaded into respective 
wells. Gel electrophoresis was conducted at a constant voltage of 80V (for the first 20 
minutes while proteins were at stacking gel) and subsequently increased to 100V for protein 
separation in resolving gel for approximately 2 hours. 
 Resolving Gel (%) 
Stacking 
Gel (%) 
Component 6% 8% 10% 12% 15% 5% 
Water (mL) 5.3 4.65 4 3.3 2.3 5.7 
30% Acrylamide/Bis (mL) 2 2.65 3.3 4 5 1.7 
1.5 M Tris-HCl, pH 8.8 (mL) 2.5 2.5 2.5 2.5 2.5 - 
0.5 M Tris-HCl, pH 6.8 (mL) - - - - - 2.5 
10% SDS (μL) 100 100 100 100 100 100 
10% APS (μL) 100 100 100 100 100 50 
TEMED (μL) 8 6 4 4 4 10 
Total volume (mL) 10 10 10 10 10 10 
 
Table 2.17: Preparation of stacking and resolving gels for SDS-PAGE. 
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2.8.7 Western blotting 
After SDS-PAGE, the resolved proteins were transferred onto methanol-activated 6cm x 
8cm PVDF membrane using Bio-Rad wet transfer system. The resolved gels were 
assembled with the PVDF membrane and filter papers. Prior to eletro-transfer, the gels, 
PVDF membranes and filter papers were pre-wet with Towbin transfer buffer [25mM Tris, 
192mM glycine, 20% (v/v) methanol) for 15 minutes. Wet transfer was performed at 80V 
for 2 hours. After completion of electro-transfer, the PVDF membranes were blocked with 5% 
skim milk diluted in 1 x PBS/TBS with 0.1% Tween-20 (PBS-T/TBS-T) at room 
temperature for 1 hour. Primary antibodies (Table 2.16) were then probed on the PVDF 
membrane for 1 hour at room temperature or overnight at 4°C depending on the optimal 
incubation time for individual antibodies. Tris-buffered saline (TBS) (50mM Tris-Cl, 
150mM NaCl, pH7.4) was used when probing for protein targets containing phosphate 
group. After primary antibody incubation, membranes were washed 5 x 10 minutes with 
PBS-T/TBS-T and probed with secondary antibodies (Table 2.16) in 5% milk/PBS-T/TBS-
T for 1 - 2 hours at room temperature. After secondary antibody incubation, membranes 
were again washed 5 x 10 minutes with PBS-T/TBS-T. Chemiluminescence detection of 
immunoblotted proteins was carried out with Amersham ECL Prime Western Blotting 
Chemiluminescent reagents and exposed with X-Ray film. After immuno-detection, 
membranes were stripped gently in Stripping Buffer for 10 minutes with mild shaking. The 
stripped membranes were washed with PBS-T/TBS-T, blocked with 5% milk/PBS-T/TBS-T 
and reprobed with primary antibodies if necessary. 
 
2.8.8  Phospho-kinase array analysis 
2.8.8.1 Target capturing and chemiluminescence detection 
The Proteome Profiler MAPK-array was obtained from R&D Systems and the experiment 
was performed according to the manufacturer’s instructions. Briefly, whole cell lysate from 
cells treated with cisplatin or untreated control were collected after 48 hours of drug 
incubation and quantified using BCA protein assay as described in Chapter 2.8.3. Briefly, 
the Proteome Profiler Phospho-MAPK membranes that are spotted with capture and control 
antibodies in duplicate were blocked with Array Buffer 1 for 1 hour. 250μg of protein 
lysates were then diluted in Array Buffer 1 to a final volume of 2mL and incubated on the 
blocked Proteome Profiler Phospho-MAPK membranes overnight at 4°C. Subsequent day, 
the membranes were washed 3 x 10 minutes with washing buffer provided. Next, the 
membranes were probed with 1mL of Detection Antibody Cocktail diluted in Array Buffer 
2 for 2 hours at room temperature on a rocking platform. After incubation, the membranes 
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were washed 3 x 10 minutes with washing buffer provided. After washing, residual buffers 
were carefully removed for the membranes. The membranes were then incubated with 1mL 
of Streptavidin-HRP diluted in Array Buffer 2 for 30 minutes at room temperature on a 
rocking platform. Washed the membranes 3 x 10 minutes with washing buffer and removed 
the residual buffers before immuno-detection was carried out with Amersham ECL Prime 
Western Blotting Chemiluminescent reagents and exposed with X-Ray film. Multiple films 
with varied exposure time were developed to obtain the optimal signals of phosphorylated 
protein on each antibody spot.  
 
2.8.8.2 Densitometric analysis 
ImageJ Software (http://rsb.info.nih.gov.libproxy1.nus.edu.sg/ij/; v.1.45s, NIH) was utilised 
for densitometric analysis. Briefly, the developed films were scanned and the images were 
imported into ImageJ. Pixel density of each spot was measured using the <Analyse Gel  
lane> function. Background signal (in pixels) was obtained from the negative control spot. 
Signals generated from the positive control spots were used for normalization. In summary, 
densitometric analysis of each spot was performed by subtraction of background density 
signal and normalization with corresponding positive controls. Fold change was obtained by 







2.9 Cell-based assays 
2.9.1 Reagents and kits 
Chemicals/Reagents/Kits Supplier Place of origin 
3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) 




Promega WI, USA 
4’,6-diamidino-2-phenylindole (DAPI) dye Invitrogen CA,USA 
Annexin-V binding buffer Life Technologies CA, USA 
Annexin-V-Allophycocyanin (APC) antibody Life Technologies CA, USA 
BactoTM agar Becton Dickinson  NJ, USA 
Caspase-Glo® 3/7 kit Promega WI, USA 
Caspase-Glo® 8 kit Promega WI, USA 
Caspase-Glo® 9 kit Promega WI, USA 
Hoechst 33342 dye Becton Dickinson (BD) NJ, USA 
Paraformaldehyde Sigma Aldrich MO,USA 
Prolong Gold Antifade Reagent with 4’,6-
diamidino-2-phenylindole (DAPI) 
Invitrogen CA,USA 
Propidium iodide (PI) Becton Dickinson (BD) NJ, USA 
Triton X-100 Sigma Aldrich MO,USA 
 
Table 2.18: List of chemicals, reagents and kits used in cell-based assays. 
 
2.9.2 MTS cell proliferation assay 
Cell viability was estimated by CellTiter 96® AQueous One Solution cell proliferation assay 
(MTS) that measures mitochondrial dehydrogenase activity according to manufacturer’s 
protocol with minor modifications. Briefly, cell lines in 100μL of complete media were 
seeded into 96-well plate, co-incubated with 100μL of media containing drugs at various 
concentrations (0.01 - 100μM), and cultured at 37°C in tissue culture incubator for 72 hours. 
The cells reached 80 - 100% confluency on day of assay. 20μL of MTS solution was added 
to each well and incubated at 37°C for 2 - 4 hours at a humidified, 5% CO2 atmosphere. 
Absorbance at 490nm was measured with Infinite200 Pro 96-well plate reader (Tecan; 
Switzerland). The half-maximum inhibitory concentration (IC50) was calculated by 




2.9.3 Anchorange-independent soft agar assay 
2.9.3.1  Colony forming assay 
Anchorage-independent soft agar assay was performed on 24-well plate. Layers of soft agar 
(0.6% bottom layer; 0.36% middle layer) were formed by mixing complete culture media 
with 3% BactoTM agar. BactoTM agar was liquefied by heating with microwave oven. Media 
were pre-warmed to 40°C in a water bath. The mixture of agar and media was equilibrated 
to 40°C while being monitored to prevent solidification. Briefly, each well of 24-well plates 
were first layered with 600μL of 0.6% agar layer (3mL of BactoTM agar in 12mL of 
complete media per plate) and allowed to solidify for roughly 15 minutes at room 
temperature. The second layer comprised of an agar mixture and cell mixture. The agar 
mixture (1.8mL of BactoTM agar in 11.7mL of complete media per plate) was prepared, 
equilibrated to 40°C and mixed with 1.5mL of cell mixture. 500μL of the final agar mixture 
was added onto the bottom layer. Each well contained approximately 5,000 to 10,000 cells 
depending on the number and size of colony formed. The second layer was allowed to 
solidify for roughly 30 minutes at room temperature. The top layer comprised of complete 
media containing drugs at a range of concentrations (0.001 - 10μM). Each treatment group 
was conducted in duplicates. The colonies were allowed to form for 2 - 4 weeks depending 
on the growth rate. Colonies were stained by adding 40μL of MTT solutions (5mg/mL in 
PBS) to each and incubated at 37°C for 4 hours. The extent of anchorage-independent 
growth was imaged with Epson Perfection V330 Photo scanner.  
 
2.9.3.2 Colony counting and data analysis 
The scanned images from Chapter 2.9.3.1 were analysed using ImageJ Software. Individual 
images were cropped into similar sizes and processed simultaneously. Colonies were 
identified as particles with the <Find Edges> function. The number of particles for 
individual image was counted with the <Find Particles> function. Values from duplicates 
were averaged and IC50 was calculated by GraphPad Prism software (GraphPad Software; 
CA, USA) based on curve fitting concept. 
 
2.9.4 Combination Index (CI) and Dose Reduction Index (DRI) 
Combination index (CI) values for multiple drug interactions was determined by CalcuSyn 
Software (Biosoft, UK) based on the median-effect equation and CI algorithms (Chou and 
Talalay 1984, Chou 2010). The CI values provide quantitative definition for the nature of 
drug interaction: synergism (CI < 0.8), additive effect (0.8 < CI < 1.2), and antagonism (CI > 
 80 
 
1.2). Dose Reduction Index (DRI) measures the fold reduced of each drug in a synergistic 
combination when compared with the dose of each individual drug. The reduced DRI 
implicates for increased effect of individual drugs in the combination: DRI = 1 indicates no 





Antibody Target Supplier Dilution 
Acetyl-lysine Rabbit Cell Signalling 1:1000 
Acetyl-p53 (Lys382) Rabbit Cell Signalling 1:500 
Phospho-Erk1/2 (T202/Y204) Rabbit Cell Signalling 1:1000 
Phospho-p53 (Ser15) Rabbit Cell Signalling 1:1000 
Total p53 Mouse Santa Cruz 1:1000 
Alexa Fluor Chicken Anti-Rabbit 488 Secondary Invitrogen CA,USA 
Alexa Fluor Chicken Anti-Mouse 488 Secondary Invitrogen CA,USA 
Alexa Fluor Chicken Anti-Mouse 594 Secondary Invitrogen CA,USA 
 
Table 2.19: List of antibodies used in immunofluorescence staining.  
 
2.9.5.2 Immunofluorescence staining 
Immunofluorescence staining on cultured cells was performed either on glass coverslips in 
6-well plate or directly on Corning® black-walled, clear-bottomed 96-well plates. Briefly, 1 
x 105 cells (in 6-well plate) or 5 x 103 cells (in 96-well plate) were seeded and cultured at 
37°C in tissue culture incubator overnight. Media containing drugs were added on the 
subsequent day and cultured at 37°C in tissue culture incubator for 48 hours. The cells 
reached 70 - 80% confluency on day of assay. The cells were gently rinsed once with 1 x 
PBS and fixed with 4% (w/v) paraformaldehyde for 30 minutes in room temperature on a 
rocking platform. After fixation, the cells were washed 3 x 10 minutes with PBS to 
completely remove residual paraformaldehyde. Next, fixed cells were blocked with blocking 
buffer [5% (w/v) BSA in PBS with 0.3% (v/v) Triton X-100] for 1 hour in room 
temperature on a rocking platform, washed 3 x 10 minutes with PBS, and incubated with 
primary antibody (Table 2.19) in the dark at 4°C overnight on a rocking platform. The 
volumes of antibody added have to cover the entire well. After incubation, the cells were 
again washed 3 x 10 minutes with PBS, and incubated with secondary antibody (Table 2.19) 
in the dark at 4°C overnight on a rocking platform. At the end of secondary antibody 
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incubation, Hoechst 33342 or DAPI (to a final dilution of 1:5000) dye was added to 
counterstain cell nuclei for 15 minutes at room temperature on a rocking platform. The cells 
were then washed 3 x 10 minutes with PBS. Cells seed on 96-well plate were covered in 
200μL of PBS, sealed with sealing mats and were ready for imaging. Cells seeded on 
coverslips were rinsed once in deionised water to remove salt residues, air dried in the dark, 
and mounted with 20μL of Prolong Gold anti-fade reagent. The anti-fade reagents were 
allowed to dry overnight at 4°C before being sealed with nail polish and were now ready for 
imaging. 
 
2.9.5.3 Fluorescence and confocal microscopy 
Fluorescence imaging was conducted with AxioPlan 2 imaging fluorescence microscope 
(Carl Zeiss; Oberkochen, Germany) at 1000 x magnification. Confocal images were 
captured with A1R Confocal (Nikon; Tokyo, Japan) at 1000 x magnification. High content 
imaging was carried out with ImageXpress Unltra confocal system (Molecular Devices; CA, 
USA) at 400 x magnification. 
 
2.9.5.4 High-content imaging analysis 
For high content screening, cells were seeded in black-walled 96-well plates in duplicates. 
All images for the same experiment were acquired in 4 - 8 adjacent fields. High-content 
analysis was performed with ImageJ Software for separation of nuclear and cytoplasmic 
signals as previously described (Chua, Sim et al. 2012). Briefly, the cell nuclei were 
identified and segmented according to the Hoechst 33342 staining. Nuclear signals were 
measured by determining the signal intensity within the segmented area. Cytoplasmic 
signals were measure by subtracting the total signal with the obtained nuclear signal.  
 
2.9.6 Fluorescence-activated cell sorting (FACS) on apoptosis 
FACS analysis was performed to detect the extent of apoptosis induced by drug treatment. 
APC conjugated Annexin-V antibody was stained for identification of the 
phosphatidylserine (PS) on the outer membrane surface of the apoptotic cells, while PI was 
stained for detection of dead cells with permeabilized membrane. Annexin-V/PI staining 
was carried out according to manufacturer’s protocol with slight modifications. Briefly, 1 - 
1.5 x 105 cells were seeded in 6-well plates and drug treated for 48 hours at 37°C in tissue 
culture incubator. On day of assay, all cells were harvested and cell pellets were obtained 
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through centrifugation at 1000 rpm for 5 minutes at room temperature. The cell pellets were 
washed once with 1mL of Annexin-V binding buffer, centrifuged again at 1000 rpm for 5 
minutes at room temperature. The supernatants were removed and the cell pellets were 
resuspended in 100μL 1 x Annexin-V binding buffer. For each sample, 3μL of Annexin-V-
APC and 1μL of PI dye were added, mixed well by vortexing, and incubated in the dark for 
15 minutes at room temperature. After incubation, 400μL of Annexin-V binding buffer was 
added into each sample. The staining profile was analysed by flow cytometry using LSR II 
Flow Cytometer (BD; NJ, USA) within 1 hour after staining. 
 
2.9.7 Caspase activity assay 
The activity of caspase 3/7, 8 and 9 was measured with Caspase-Glo® kits according to 
manufacturer’s protocol. Activation of caspases was determined using luminogenic 
substrates that are synthetic oligopeptides that contain the tetrapeptide sequence DEVD at 
N-terminus. DEVD are substrates of luciferase. Release of DEVD from the oligopeptides by 
caspases cleavages results for luciferase activity. Briefly, 3 - 5 x 103 cells were seeded in 
white-walled 96-well plate and cultured at 37°C in tissue culture incubator overnight. Drug 
treatment was performed 24 hours after seeding and incubated at 37°C in tissue culture 
incubator for 72 hours. At the end of incubation, 100μL of Caspase-Glo® reagents that 
contain lysis buffer, luminogenic substrates and luciferase and luciferase were added into 
each well and incubated at room temperature for 30 minutes at a rocking platform set at 200 
rpm. The luminescence signal of each sample was measured at 1 sec interval with 
Infinite200 Pro 96-well plate reader (Tecan; Switzerland). Caspase activity was normalized 









2.10 Luciferase assay 
2.10.1 Reagents and kits 
Reagents/Kits Supplier Place of origin 
Cignal p53 reporter (Luc) kit Qiagen Hilden, Germany 
Dual-Luciferase Reporter Assay System Promega WI, USA 
 
Table 2.20: List of reagents and kits used in luciferase reporter assay. 
 
2.10.1 Promoter constructs 
The p53-responsive firefly luciferase construct, non-inducible firefly luciferase construct 
(negative control), constitutively expressing CMV-GFP construct, constitutively expressing 
CMV-firefly construct (positive control), and the constitutively expressing CMV-Renilla 
construct were obtained from Qiagen (Hilden, Germany). The CMV-Renilla construct was 
used as normalization construct for each sample.  
 
2.10.2 Luciferase Promoter assay 
Cells were seeded in 24-well plate and cultured overnight at 37°C in complete media. On 
day of transfection, the cells should reach 30% confluency. Transfection procedures were 
described in Chapter 2.5.3. Drug treatments were performed 24 hours after transfection and 
cells were incubated at 37°C in incubator for 24, 48 and 72 hours. All cells were collected 
for the assay. Briefly, the culture supernatant from each treatment group was aspirated and 
placed in collection tubes. Cells were washed once with 1 x PBS (PBS was collected as 
well), trypsinized, and collected in the same collection tubes. The cells were centrifuged at 
1000 rpm for 5 minutes at room temperature, rinsed once with ice-cold 1 x PBS and pelleted 
again by centrifugation at 1000 rpm for 5 minutes at room temperature. The supernatant was 
removed, lysed with 200μL of Passive Lysis Buffer (PLB) and incubated for 15 minutes on 
a rocking platform. After incubation, the samples were centrifuged at 14,000 rpm for 30 sec 
at 4°C and supernatants were collected for the assay. Firefly and Renilla luciferase activities 
were measured according to manufacturer’s protocol. 20μL of each of the sample was added 
to luminometer tubes that contained 100μL of LARII solution (containing substrates for 
firefly luciferase) and mixed by gentle tapping. The firefly luminescence signals were 
recorded in a luminometer (Berthold Technologies; Bad Wildbad, Germany) with 10 sec 
interval. Next, 100μL of Stop & Glo® Reagent was added to each sample, tapped to mix, 
and the Renilla luminescence signals were recorded. For data analysis, the Firefly luciferase 
signal from each sample was normalized with corresponding Renilla signal. 
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2.11 Clinicopathological analysis 
2.11.1 Clinical samples 
Head and neck SCC tissues were obtained from 33 cases diagnosed with the disease. The 
formalin-fixed, paraffin-embedded (FFPE) tissues were retrieved from the tissue repository 
of National University Hospital (NUH), Singapore. Tissue sections were provided by Dr 
Nga Min En from the Department of Pathology, NUH, and stored at 4°C prior to staining. 
 
2.11.2 Ethical approval 
The use of these head and neck SCC samples has been approved by the NUHS Institutional 
Review Board (IRB). The protocol for the study has been drafted by A/P Goh Boon Cher 
and Kong Li Ren under the title “Evaluation of Platinum-resistance Pathways in Squamous 
Cell Carcinoma of the Head and Neck”, and has been approved by the Domain-specific 
Review Board (DSRB) of National Healthcare Group (NHG).  
 
2.11.3 Chemicals, reagents and kits 
Chemicals/Reagents/Kits Supplier Place of origin 
Ammonium hydroxide Merck 
Darmstadt, 
Germany 
Canada Balsam Sigma Aldrich MO,USA 
Dako Antibody Diluent DakoCytomation CA, USA 
Dako EnVisionTM+ System-HRP (DAB) Kit 
(Peroxidase Block, Labelled polymer-HRP 
anti-Rabbit, DAB+ Substrate Buffer, DAB+ 
chromogen) 
DakoCytomation CA, USA 
Dako Target Retrieval Solution, Citrate pH 6.0 DakoCytomation CA, USA 
Histo-Clear II Agar Scientific Essex, UK 
Mayer’s Haematoxylin Sigma Aldrich MO,USA 
 
Table 2.21: List of chemical, reagents and kits used in IHC staining. 
  
2.11.4 Antibodies 
Antibody Target Supplier Dilution 
Phospho-Erk1/2 (T202/Y204) Rabbit Cell Signalling 1:1000 
 
Table 2.22: List of antibodies used in IHC staining.  
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2.11.5 Immunohistochemistry (IHC) staining 
IHC staining was performed according to the Dako CytomationTM IHC Methods that applied 
diaminobenzidine (DAB) substrate-chromogen system.  Prior to staining, tissue slides were 
warmed at 40°C for 10 minutes on a heat block and deparaffinized in Histo-Clear II solution 
for 3 x 5 minutes. After complete removal of paraffin, the slides were rehydrated in 
descending grades of ethanol (twice each of 100%, 90%, and 75%, 3 minutes each) and 
placed in deionised water for 5 minutes at room temperature. Antigen retrieval was 
performed on the tissue slides to retrieve epitopes that were cross-linked during formalin 
fixation by using Dako Target Retrieval Solution according to manufacturer’s protocol. 
Briefly, the rehydrated slides were placed into the processing chamber, which was then 
located in the assigned Retriever. The Retriever was filled with Target Retrieval Solution 
until all slides were thoroughly covered. Pressure-induced antigen retrieval was performed 
at 98°C for 20 minutes. The slides were allowed to cool in the Retriever for 15 minutes 
under running water before being removed from the chamber and placed into deionised 
water. Next, the slides were tapped off excess buffer and wiped around the samples with 
Kimwipe to removed remaining liquid. The samples were treated with 3 - 5 drops of Dako 
Peroxidase Block (3% hydrogen peroxide) for 10 minutes to remove endogenous peroxidase 
activity. After blocking, the slides were tapped, wiped as before, washed 3 x 5 minutes with 
1 x TBS and incubated with primary antibody (diluted in Antibody Diluent) overnight at 
4°C. The next day, the slides were washed 3 x 5 minutes with 1 x TBS, wiped as before and 
incubated with several drops of Labeled polymer-HRP anti-Rabbit for 30 minutes at room 
temperature. Subsequently, the slides were washed 3 x 5 minutes with 1 x TBS and wiped 
as before. Sufficient DAB+ substrate-chromogen solution (20μL chromogen: 1mL buffer) 
was added to each slide to cover the sample and incubated for 5 – 15 minutes until optimal 
signal was developed. The reaction was inhibited by dipping the slides into deionised water. 
Next, the slides were counterstained with Mayer’s Hematoxylin dye for 10 sec with mild 
agitation, rinsed in flowing water immediately and dipped 10 x in 1% ammonium hydroxide 
solution to blue nuclei. Lastly, the slides were rinsed in deionised water, dehydrated in 
ascending grades of ethanol (2 minutes each of 75%, 90% and 100%), cleared with 3 x 2 
minutes Histo-Clear II solution, and mounted with coverslips with Canada Balsam. The 
slides were allowed to dry overnight at room temperature in the fume hood.  
 
2.11.6 Scoring 
Scoring of the TMAs was performed by a pathologist (Dr Nga Min En) in a blinded manner 
with respect to the details of clinical data. Here, the German semi-quantification scoring 
system as reported in previous studies was adopted based on the staining intensity and area 
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extent (Cheng, Wu et al. 2007, Koo, Kok et al. 2009). Each tissue was scored according to 
the region stain (nuclear/cytosol), staining intensity (0, negative; 1, weak; 2, moderate; and 
3, strong) and the fraction of stained tumour cells (0 - 100%). The final immunoreactive 
score was determined by multiplying the intensity score with the fraction stained (0 - 300). 
For clinicopathological analyses, samples were separated based on the immunoreactive 
score. Survival outcomes were defined by overall progression-free survival. 
 
2.12 Next Generation Sequencing (NGS) of lung SCC samples 
2.12.1 Clinical samples 
Lung SCC tissues were obtained from 45 cases diagnosed with the disease. The formalin-
fixed, paraffin-embedded (FFPE) tissues were retrieved from the tissue repository of 
National University Hospital (NUH), Singapore. Tissue sections were prepared by Dr Pang 
Yin-Huei from the Department of Pathology, NUH, and stored at 4°C prior to staining.  
 
2.12.2 Ethical approval 
The use of these lung SCC samples has been approved by the NUHS Institutional Review 
Board (IRB). The protocol for the study has been provided by A/P Ross Soo (NUH). 
 
2.12.3 Reagents 
Chemicals/Reagents Supplier Place of origin 




GeneRead Adapter I 1-plex Qiagen Hilden, Germany 
GeneRead DNA Amplification Kit Qiagen Hilden, Germany 
GeneRead DNAseq Gene Human Lung 
Panel 
Qiagen Hilden, Germany 
GeneRead DNAseq Library Quant Array Qiagen Hilden, Germany 
GeneRead Size Selection Kit Qiagen Hilden, Germany 
QIAamp® DNA FFPE Tissue Kit Qiagen Hilden, Germany 





Table 2.23: List of chemicals, reagents and kits used in library preparation for NGS.  
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2.12.4 Primers for Indexing 
Universal Forward 5’ Primer: 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC*T 
 
Index ID Index Index ID Index Index ID Index 
MP_01 CGTGAT MP_16 GGACGG MP_31 ATCGTG 
MP_02 ACATCG MP_17 CTCTAC MP_32 TGAGTG 
MP_03 GCCTAA MP_18 GCGGAC MP_33 CGCCTG 
MP_04 TGGTCA MP_19 TTTCAC MP_34 GCCATG 
MP_05 CACTGT MP_20 GGCCAC MP_35 AAAATG 
MP_06 ATTGGC MP_21 CGAAAC MP_36 TGTTGG 
MP_07 GATCTG MP_22 CGTACG MP_37 ATTCCG 
MP_08 TCAAGT MP_23 CCACTC MP_38 AGCTAG 
MP_09 CTGATC MP_24 GCTACC MP_39 GTATAG 
MP_10 AAGCTA MP_25 ATCAGT MP_40 TCTGAG 
MP_11 GTAGCC MP_26 GCTCAT MP_41 GTCGTC 
MP_12 TACAAG MP_27 AGGAAT MP_42 CGATTA 
MP_13 TTGACT MP_28 CTTTTG MP_43 GCTGTA 
MP_14 GGAACT MP_29 TAGTTG MP_44 ATTATA 
MP_15 TGACAT MP_30 CCGGTG MP_45 GAATGA 
 
Table 2.24: List of indexes used for multiplexing of libraries for NGS.  
The reverse primers with unique indexes were provided by Dr Ong Qi Rui (Qiagen; Hilden, 
Germany). 
 
2.12.5 Genomic DNA (gDNA) extraction from FFPE samples 
For better yield, 5 x 10μm of each sample were pooled into 1.5mL eppendorf tube. 
Extraction of gDNA from tissue sample was carried out using QIAamp® DNA FFPE Tissue 
Kit according to manufacturer’s protocol. Briefly, 1mL of xylene was added to each sample 
and vortex vigorously for 10 sec to deparaffinize the sample. The xylene solution was 
centrifuged at 14,000 rpm for 2 minutes at room temperature. The supernatant containing 
the dissolved paraffin was removed. The pellet (tissue) was resuspended with 1mL of 100% 
ethanol for extraction of residual xylene from sample. Again, the solution was centrifuged at 
14,000 rpm for 2 minutes at room temperature and all liquid are removed carefully. The 
samples were allowed to air-dry at room temperature for 10 minutes to evaporate all residual 
ethanol. The dried pellet was resuspended in Buffer ATL containing 20μL of proteinase K 
and incubated on a heat block at 56°C for 3 hours until the sample was fully dissolved. The 
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sample was further heated at 90°C for 1 hour to reverse formaldehyde modification of 
gDNA. The gDNA was precipitated by mixing the sample with Buffer AL and ethanol. All 
samples were then loaded onto QIAamp MinElute column. The gDNA was bound to the 
resin through centrifugation at 8000 rpm for 1 minute at room temperarture, washed once 
each with Buffer AW1 and AW2 with the same centrifugation condition. The column was 
centrifuged at 14,000 rpm to dry the membrane completely. The gDNA was eluted with 
50μL of Buffer ATE. Quality control was conducted on the extracted gDNA. Concentration 
and purity of the purified PCR were determined by NanoDrop as described in Chapter 
2.7.3.3. All samples achieved A260:A230 > 1.7, A260:A280 > 1.8, and concentration > 4ng/μL 
and were progressed to library construction. 
 
2.12.6 Library construction 
The GeneRead DNAseq Gene Human Lung Panel provides overlapping primer sets across 
the exonic regions of multiple genes. This allows for wide coverage of the sequencing reads 
that could align to the target genes. The primer sets were split into 4 groups to ensure for 
uniform coverage. Targeted exon enrichment and library construction was performed 
according to manufacturer’s protocol. Briefly, each sample was diluted to 4ng/μL and 20ng 
was mixed with each of the 4 x primer sets. PCR amplification was conducted in the 
MyCycler thermal cycler. Upon completion of PCR, all 4 sets of PCR products from the 
same sample were pooled and purified with QIAquick PCR Purification kit according to 
manufacturer’s protocol. Next, library was constructed for each sample by adding both Start 
and End adaptors (60bp each) to the PCR fragments (~150bp) through end-repair and 
adaptor ligation steps. Subsequently, two size selection steps were conducted to remove the 
small and large fragments. The smaller fragments (< 280bp) were removed by GeneRead 
Size Selection kit by binding of large fragments to the MinElute spin column and allowed 
the smaller fragments to be washed off. The selected fragments were eluted in 90μL of 
Elution Buffer. The larger fragments (> 280bp) were then removed by AMPure XP Beads 
according to manufacturer’s protocol. Briefly, 72μL (0.8 x of initial volume) of AMPure XP 
Beads was added to the eluted solution and incubated for 5 minutes at room temperature. 
The suspension mix was then placed on a magnetic rack to separate the beads from the 
supernatant. In the 1st bead selection process, the supernatant was transferred to a fresh tube 
and the beads that contained the larger fragments were discarded. Next, 27μL (0.3 x of 
initial volume) of AMPure Beads was added to the supernatant, allowed to incubate for 5 
minutes at room temperature, and placed on magnetic rack again. In the 2nd bead selection 
process, the supernatant was discarded while the beads that contained the DNA targets were 
collected. Each pellet (with the beads) was rinsed 2 x 200μL freshly-prepared 80% ethanol 
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in the magnetic stand. The ethanol was carefully removed from each sample without 
disturbing the pellet. Upon air-dried of residual ethanol, the DNA target was eluted from 
beads by pipetting with 19μL of nuclease-free water, placed on magnetic rack until solution 
was clear, and transferred to a new tube. The size-selected libraries were proceeded on with 
DNA amplification and multiplexing. 
 
2.12.7 Library amplification and multiplexing 
Barcoding of the constructed libraries was performed during DNA amplification with slight 
modifications from GeneRead DNA Amplification Kit to include the designed primers for 
sample barcoding. Each sample was mixed with a universal forward primer and an 
individual reverse primer. Each reverse primer contains conservative sequence that is 
complimentary to the adapter and a short region of unique indexing sequence for the 
purpose of sample identification (Table 2.24). Briefly, the size-selected libraries (17μL) 
were mixed with DNA Amplification cocktail containing HiFi HotStar DNA Master Mix, 
universal forward primer (0.3μM) and index reverse primer (0.3μM). The setup 
configuration for PCR: initial denaturation step of 98°C for 2 minutes; followed by 9 cycles 
of DNA denaturation at 98°C for 20 sec, primer annealing 60°C for 30 sec, and DNA 
elongation at 72°C for 30 sec; and ended with DNA extension step at 72°C for 1 minute. 
PCR purification was performed using QIAquick PCR Purification kit according to 
manufacturer’s protocol.  
 
2.12.8 Quality controls for libraries and NGS Run 
NGS for this study was carried out on HiSeq 2000 System (Illumina; CA, USA). Prior to 
NGS run, several quality check procedures were conducted on the purified and size-selected 
samples. The sizes of target gene fragments were determined using Agilent 2100 
Bioanalyser (Agilent; CA, USA) and QIAxel Advanced System (Qiagen; Hilden, Germany). 
A clean fragment of ~276bp was detected for each sample (150bp of amplified fragment; 
60bp of Start adaptor; 60bp of End adaptor; and 6bp of barcode). To ensure for highly 
accurate quantification of the libraries, qPCR was carried out with GeneRead DNAseq 
Library Quant Array according to manufacturer’s protocol. A standard curve was generated 
using the sequential diluted DNA standards provided and the DNA molecules with adaptors 
at both ends were specifically were quantified based on the standard curve. The libraries that 
passed quality check were sent to Macrogen Inc. (Seoul, Korea) for NGS run. Sequencing 
reads were decoded based on the indexes displayed in Table 2.24. 
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2.13 Statistical analysis 
All experiments were carried out 3 times unless stated otherwise. Results were expressed as 
mean ± SD. Statistical analysis for comparison between two groups was conducted using 
unpaired Student’s t-test; while analysis for comparison of multiple groups was conducted 
using one-way-analysis of variance (ANOVA) and followed by Post-hoc Bonferroni test.  
Chi-square test was performed to test the statistical difference of clinical outcomes between 
groups with different immunoreactive scores (high and low).The confidence intervals were 










CHAPTER 3 Evaluating lung SCC cell lines as tumour models by 
comparison of genetic aberrations, drug sensitivities and 
transcriptome profiles 
A common challenge to effectively reproduce treatment efficacy of adenocarcinoma in lung 
SCC is the identification of oncogenic driver mutation. According to TCGA Research 
Network, lung SCC has an average of 8.1 mutations per megabase, which is higher than 
rates reported for acute myelogenous leukemia, breast cancer, ovarian cancer, glioblastoma 
and colorectal cancer (Network 2012). Despite so, no common oncogene driver mutations 
have been clearly identified in lung SCC to guide therapy. Hence, platinum-based 
chemotherapy remains as the established standard-of-care treatment for lung SCCs either as 
a single therapy or in combination with  other chemotherapeutic agents or radiotherapy 
(Wang and Lippard 2005). Despite so, intra-tumour heterogeneity and drug resistance have 
limited the potency of cisplatin-based chemotherapies. 
In this chapter, a panel of tumour-derived lung SCC cell lines was being analysed, using 
several genomic and proteomic-based technologies, to characterize the molecular profile of 
this disease. These profiles were validated against a panel of human SCC samples to 
determine their clinical relevance. Secondly, the in vitro sensitivities of cisplatin, one of the 
most commonly used platinum-based chemotherapy, was determined within this panel of 
cell lines that may be contributed by the phenotypic and functional heterogeneity in cancer 
cells. Thirdly, pathways associated with platinum resistance were identified by investigating 
the transcriptomic profiling of these study models. Lastly, through molecular dissection of 
the mechanism of synergistic cytotoxicity of cisplatin and belinostat, therapeutic potential of 










3.1  Global mutational landscape of lung SCC  
3.1.1 Lack of driver oncogenic mutations in lung SCC  
As described in Chapter 1.4, EGFR mutation, RAS mutation, EML4-ALK fusion, HER2 
(ERBB2) mutation, BRAF mutation, PIK3CA mutation, and AKT1 mutation are common 
driver mutations in NSCLC (Pao and Hutchinson 2012). Moreover, abnormal activation of 
mTOR signalling appears to be frequently observed in human cancer (Schmelzle and Hall 
2000), whereas STK11 (serine/threonine kinase 11), negative regulator or mTOR signalling, 
is often inactivated in lung tumours. Furthermore, loss-of-function mutations in key tumour 
suppressor genes, such as TP53, PTEN (Phosphatase and tensin homolog), RB1 and 
CDKN2A, usually precede malignant transformation of lung cancer (Horowitz, Park et al. 
1990, Marsit, Zheng et al. 2005, Andujar, Wang et al. 2010). Somatic mutations in PTEN, 
CDKN2A and RB1 result in aberrant activation of Akt/PKB pathway, inactivation of p53 
and dysregulation of cell cycle checkpoint respectively (Murphree and Benedict 1984, 
Pacifico and Leone 2007, Song, Salmena et al. 2012). Alterations of activities of these genes 
via mutations are found to often lead to oncogenic processes. NGS was performed on 45 
lung SCC specimens obtained from patients presenting at the National University Hospital 
from 1989 to 2008.  The multiplexed PCR-based assay, Human Lung Cancer GeneRead 
DNAseq Gene Panel, was used for targeted enrichment of the coding and untranslated 
region (UTR) of several commonly mutated genes in lung cancer.  
Detailed processing and barcoding of amplified DNA products were previously described in 
Chapter 2.12 and NGS was performed using the Illumina platform. Sequencing reads were 
first analysed with GeneRead Targeted Exon Enrichment Panel Data Analysis. A 
preliminary alignment was then performed using the entire read set and Quality Filter was 
subsequently applied to remove sequencing reads with an untrimmed length of less than 
45bp. The mean of total number of reads mapped (11,447,300) and median depth of 
coverage (94.75%) for each sample was generated after Quality Filter (Data not shown). 
Final sequencing reads were subjected to variant calling by using Genome Analysis Toolkit 
(GATK; http://www.broadinstitute.org/gatk/) from Broad Institute (MA; USA). The results 
generated displayed a variety of DNA alterations among the 15 genes tested with a mean of 
56.3 SNPs and 8.62 insertions/deletions per tumour for each sample (Data not shown). The 
list of SNPs/ insertions/deletions was then compared with the Catalogue of Somatic 
Mutations in Cancer (COSMIC) Database (Wellcome Trust Sanger Institute; 
http://www.sanger.ac.uk/cosmic). COSMIC mutations identified in the sequencing reads 
were clustered and aligned with respective samples. Heat maps were generated by first 
sorting the obtained gene lists according to the number of mutation hits detected across 
individual samples (highest to lowest from top to bottom) and subsequently by the number 
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of mutations detected in each gene in all samples (highest to lowest from right to left) 
(Figure 3.1 A). After filtering, each lung SCC specimen had a mean of 7.87 COSMIC 
mutations (Taken as average of all samples in Figure 3.1 A; values not shown). Among the 
15 genes investigated, ALK mutation was detected in all specimens, while high mutational 
frequencies were observed in TP53 (71.11%), CDKN2A (80%) and EGFR (80%) across all 
samples (Figure 3.1 B). Next, HRAS mutation was detected in roughly a quarter of the 
samples (26.67%), while mutations of PTEN (15.56%), RB1 (15.56%), STK11 (13.33%), 
PIK3CA (13.33%), BRAF (11.11%) and NRAS (11.11%) were also detected (Figure 3.1 B). 
To investigate the significance of these somatic DNA alterations on the disease, the sum of 
each mutation in all specimens was determined. Among these 15 genes, ALK (76), TP53 
(75), CDKN2A (70) and EGFR (64) had the highest number of mutational hits across all 
samples (obtained by summation of mutational hits in all samples for each gene) (Figure 3.1 
C). Next, the mutation hits based on the COSMIC ID of each individual mutation were 
clustered. Among the 76 mutational hits in ALK gene, 8 different COSMIC mutations were 
identified (Figure 3.1 D). Likewise for CDKN2A and EGFR, 16 and 21 COSMIC mutations 
were identified respectively (Figure 3.1 D). These results indicate the presence of recurring 
mutations within each gene across all samples. However, among the 75 mutational hits of 
TP53, a total of 65 individual variants were identified based on their COSMIC IDs. As the 
weightage of each variant could possibly reflect the significance of a specific mutation in 
lung SCC, 14 variants that were identified in more than 3 specimens were identified (5% of 
total samples). The identity and details of each variant is shown in Table 3.1.  
Further analysis led to the identification of a CDKN2A variant with intronic substitution 
(COSM14251) in all samples (Table 3.1). However, the impact of this intronic substitution 
has yet to be characterized. Next, a missense mutation from lysine (K) to arginine (R) was 
identified at AA position 1491 of ALK gene in 40 out of 45 specimens (88.89%) at a mean 
of 77.3% in each sample harbouring this mutation (Table 3.1). The high frequency of this 
SNP across all samples suggested that it could be a germ-line polymorphism instead of 
somatic mutation. However this could not be verified as adjacent normal tissues were not 
available for the study. Two common mutations were detected in the EGFR gene in 18 and 
26 specimens, however both were silent mutations and did not affect the phenotype of 
translated EGFR protein. The remaining COSMIC mutations in ALK, HRAS, PTEN and RB1 
were either found within the untranslated intronic region or silent mutations (Table 3.1); 




The mutational landscape of lung SCC tumors has been previously characterized by The 
Cancer Genome Atlas (TCGA) group (Network 2012). To look for oncogenic mutations in 
SCC tumours among Asian patients that would be responsive to molecular targeting, the 
mutated driver oncogenes that were frequently found in NSCLC were investigated: EGFR, 
KRAS, NRAS, HRAS, ALK, ERBB2, BRAF, PIK3CA, and AKT1; as well as the commonly 
altered tumour-suppressor genes: TP53, CDKN2A, PTEN and RB1 (Figure 3.1 E).  
Consistent with the findings by TCGA, common mutations to driver oncogenes in lung 
adenocarcinoma were rarely found in these SCC tumors. Despite observing EGFR mutation 
in 82% of all samples (37/45), these alterations were almost codon silent event exclusively 
(30/37). All detected TP53 mutations (31/45 of all samples) were non-synonymous 
alterations, suggesting loss-of-function. Moreover, non-synonymous mutations in ERBB2, 
KRAS, BRAF, AKT1 and PIK3CA were rare (< 10%). These observations concluded the lack 
of oncogenic driver mutations in lung SCC tumours. 
Collectively, these observations concluded the lack of oncogenic driver mutations in lung 
SCC tumours. An ALK A1491R mutation was consistently detected in 88.89% of all 












Figure 3.1: Mutated genes in lung SCC. 
A, Heat map was generated based on the somatic mutations identified in each tumour 
specimen. The mutations were determined by variant calling through GATK and comparing 
the NGS sequencing reads to the COSMIC Database. Genes covered by GeneRead Lung 
Panel were listed horizontally according to the number of mutational hits detected in each 





highest overall number of mutations plotted at the top. B, frequency and percentage of gene 
mutation in all samples were determined. Sum of the mutational hits (C) and number of 
somatic variants (D) in each gene were shown. E, Lack of significantly altered genes in lung 
squamous cell carcinoma (SCC) tumors. Exome sequencing after targeted enrichment 
identified significant mutations (P < 0.01) within a panel of 45 lung SCC specimens. 
Percentage of samples with mutation(s) detected by automated calling was displayed on the 
right. Genes were listed vertically according to the percentage of mutation with the highest 
number at the top. Samples were displayed horizontally according to the number of 
mutations detected with the highest frequency on the left. Types of mutations were indicated: 
synonymous (syn), non-synonymous (non-syn), missense, nonsense, frame shift and splice 
site.   
 
 








COSM1130802 c.4472A>G Sub p.K1491R Sub - Missense 40 88.89 
COSM148825 c.2535T>C Sub p.G845G Sub - CS 18 40.00 
COSM148824 c.3036G>A Sub p.T1012T Sub - CS 11 24.44 
COSM1407683 c.784T>C Sub p.Y262H Sub - Missense 3 6.67 
TP53 
COSM45292 c.1057G>A Sub p.A353T Sub - Missense 3 6.67 
COSM99602 c.743G>A Sub p.R248Q Sub - Missense 3 6.67 
CDKN2A 
COSM14251 c.471+29G>C Sub - intronic - Unknown 45 100.00 
COSM14252 c.471+69C>T Sub - intronic - Unknown 11 24.44 
EGFR 
COSM1451600 c.2361G>A Sub p.Q787Q Sub - CS 18 40.00 
COSM42978 c.474C>T Sub p.N158N Sub - CS 26 57.78 
HRAS COSM249860 c.81T>C Sub p.H27H Sub - CS 11 24.44 
PTEN COSM5915 c.1-9C>G Sub - intronic - Unknown 4 8.89 
RB1 COSM147687 c.2664-10T>A Sub - intronic - Unknown 6 13.33 
STK11 COSM21360 c.1062C>G Sub p.F354L Sub - Missense 4 8.89 
 
Table 3.1: COSMIC mutations detected in > 5% of lung SCC. 
Among the genes investigated using NGS, several specific somatic mutations were 
frequently detected in more than 5% of the tumours (at least 3 out of the 45 samples): ALK 
(4), TP53 (2), CDKN2A (2), EGFR (2), HRAS (1), PTEN (1), RB1 (1), and STK11 (1). The 
COSMIC IDs, coding sequence (CDS) mutations, amino acid (AA) mutations (Sub – 
substitution mutation; CS – coding silent mutation) for each mutation were shown. The 







3.1.2 TP53 mutations in lung SCC occur predominantly within DNA-binding 
domain 
Inactivation of p53 pathway is a commonly observed phenomenon in multiple cancer types 
(Olivier, Hollstein et al. 2010). Several mechanisms have been previously reported to 
abrogate p53 function which includes loss-of-function mutations of TP53 and CDKN2A 
genes (Bates, Phillips et al. 1998, Olivier, Hollstein et al. 2010). From the NGS analysis, 
both genes were found mutated in 71.11% (TP53) and 80% (CDKN2A) of all samples 
(Figure 3.1 B). Majority of the COSMIC mutations on CDKN2A was detected at 2 sites 
(Table 3.1), resulting in intronic substitution and there is no report on their effects on the 
coding region. On the contrary, 65 different COSMIC mutations were identified from the 75 
mutational count of TP53 gene in all samples. The effects of these somatic mutations on 
affecting the translated p53 protein were next analysed. 
Among the 65 COSMIC mutations, 5 intronic substitutions, 1 frameshift deletion, 6 
nonsense mutations, 10 codon silent substitutions, and 43 missense mutations were 
identified (Table 3.2). Both frameshift deletion and nonsense mutations resulted in 
premature termination of protein translation. While the effect of the intronic substitutions 
was unknown, codon silent substitutions did not affect the AA sequence of the translated 
protein. As p53 functions correspond to the roles of the four main domains (Chapter 1.3.2), 
the impact of these AA changes was predicted by noting the sites of mutations. Among the 
43 somatic variants with missense mutation, majority of the AA alterations were detected 
within the DBD (31), with several cases in the proline-rich domain (7) and oligomerization 
domain (4), as well as one mutation that was located outside the four main domains (Table 
3.2). To identify the common “hotspot” of p53 mutation, the frequency of these missence 
mutations in terms of translated AA residues was determined. While most AA alterations 
were unique to only one case, 4 residues (G152, R158, M246, and R249) were mutated 
twice while mutations on R248 were detected on 6 occasions (Table 3.2). 
Despite the absence of dominant somatic mutation in TP53, 31 out of the 65 mutations 
(47.69%) occurred within the DBD. AA alterations at R248 residue were detected in 6 cases 
while AA alternations at G152, R158, M246, and R249 were detected twice each (Table 
3.2). These suggested that a large proportion of TP53 mutations occurred along the DBD 















COSM11496 c.476C>A Sub p.A159D Sub - Missense DBD 1 2.22 
COSM116690 c.184G>A Sub p.E62K Sub - Missense Proline-rich 1 2.22 
COSM1189383 c.463C>G Sub p.R155G Sub - Missense DBD 1 2.22 
COSM126981 c.880G>T Sub p.E294* Sub - Nonsense - 1 2.22 
COSM1386800 c.146G>A Sub p.R49H Sub - Missense - 1 2.22 
COSM1610837 c.454G>C Sub p.G152R Sub - Missense DBD 1 2.22 
COSM1645282 c.455C>T Sub p.P152L Sub - Missense DBD 1 2.22 
COSM1649381 c.488A>G Sub p.Y163C Sub - Missense DBD 1 2.22 
COSM18569 c.216delC Deletion p.V73fs*50 
Deletion - 
Frameshift 
- 2 4.44 
COSM216410 c.797G>A Sub p.G266E Sub - Missense DBD 1 2.22 
COSM307329 c.1020G>A Sub p.M340I Sub - Missense Oligo 1 2.22 
COSM308309 c.299A>G Sub p.H100R Sub - Missense Proline-rich 1 2.22 
COSM43555 c.736A>G Sub p.M246V Sub - Missense DBD 1 2.22 
COSM43615 c.473G>C Sub p.R158P Sub - Missense DBD 1 2.22 
COSM43629 c.745A>T Sub p.R249W Sub - Missense DBD 1 2.22 
COSM43632 c.493C>T Sub p.Q165* Sub - Nonsense DBD 1 2.22 
COSM43650 c.638G>T Sub p.R213L Sub - Missense DBD 1 2.22 
COSM43688 c.265C>T Sub p.P89S Sub - Missense Proline-rich 1 2.22 
COSM43702 c.571C>T Sub p.P191S Sub - Missense DBD 1 2.22 
COSM43739 c.467G>A Sub p.R156H Sub - Missense DBD 1 2.22 
COSM437483 c.809T>C Sub p.F270S Sub - Missense DBD 1 2.22 
COSM43871 c.746G>T Sub p.R249M Sub - Missense DBD 1 2.22 
COSM43910 c.245C>T Sub p.P82L Sub - Missense Proline-rich 1 2.22 
COSM43940 c.474C>T Sub p.R158R Sub – CS DBD 1 2.22 
COSM44115 c.350G>A Sub p.G117E Sub - Missense DBD 1 2.22 
COSM44119 c.483C>T Sub p.A161A Sub - Missense DBD 1 2.22 
COSM44192 c.272G>A Sub p.W91* Sub - Nonsense Proline-rich 1 2.22 
COSM44295 c.993+1G>A Sub - intronic - Unknown - 1 2.22 
COSM44300 c.548C>T Sub p.S183L Sub - Missense DBD 1 2.22 
COSM44310 c.738G>A Sub p.M246I Sub - Missense DBD 1 2.22 
COSM44384 c.510G>A Sub p.T170T Sub – CS DBD 1 2.22 
COSM44410 c.559+3G>A Sub - intronic - Unknown - 1 2.22 
COSM44520 c.424C>T Sub p.P142S Sub - Missense DBD 1 2.22 
COSM44524 c.521G>A Sub p.R174K Sub - Missense DBD 1 2.22 
COSM44624 c.399G>A Sub p.M133I Sub - Missense DBD 1 2.22 
COSM44696 c.409C>T Sub p.L137L Sub – CS DBD 1 2.22 
COSM44722 c.630C>T Sub p.N210N Sub – CS DBD 1 2.22 
COSM44739 c.559+24C>T Sub - intronic - Unknown - 1 2.22 
COSM44783 c.744G>T Sub p.R248R Sub - CS DBD 1 2.22 
COSM44787 c.732C>T Sub p.G244G Sub - CS DBD 1 2.22 
COSM44817 c.661G>T Sub p.E221* Sub - Nonsense DBD 2 4.44 
COSM44962 c.774A>T Sub p.E258D Sub - Missense DBD 1 2.22 
COSM45102 c.423C>T Sub p.C141C Sub - CS DBD 2 4.44 
COSM45200 c.233C>T Sub p.A78V Sub - Missense Proline-rich 1 2.22 
COSM45292 c.1057G>A Sub p.A353T Sub - Missense Oligo 3 6.67 
COSM45512 c.252C>T Sub p.A84A Sub - CS Proline-rich 1 2.22 
COSM45622 c.461G>A Sub p.G154D Sub - Missense DBD 2 4.44 
COSM45717 c.1039G>A Sub p.A347T Sub - Missense Oligo 1 2.22 
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COSM45796 c.623A>G Sub p.D208G Sub - Missense DBD 1 2.22 
COSM45841 c.559+25G>A Sub - intronic - Unknown - 1 2.22 
COSM45868 c.678C>T Sub p.G226G Sub - CS DBD 1 2.22 
COSM45918 c.253C>T Sub p.P85S Sub - Missense Proline-rich 1 2.22 
COSM46113 c.987C>T Sub p.T329T Sub - CS Oligo 1 2.22 
COSM46116 c.376-10C>T Sub - intronic - Unknown - 1 2.22 
COSM46153 c.1015G>A Sub p.E339K Sub - Missense Oligo 1 2.22 
COSM46281 c.187G>A Sub p.A63T Sub - Missense Proline-rich 1 2.22 
COSM6549 c.743G>T Sub p.R248L Sub - Missense DBD 2 4.44 
COSM99602 c.743G>A Sub p.R248Q Sub - Missense DBD 3 6.67 
COSM99618 c.637C>T Sub p.R213* Sub - Nonsense DBD 1 2.22 
COSM99668 c.586C>T Sub p.R196* Sub - Nonsense DBD 1 2.22 
COSM99678 c.473G>T Sub p.R158L Sub - Missense DBD 1 2.22 
COSM99720 c.659A>G Sub p.Y220C Sub - Missense DBD 1 2.22 
COSM99914 c.524G>A Sub p.R175H Sub - Missense DBD 2 4.44 
COSM99925 c.844C>T Sub p.R282W Sub - Missense DBD 1 2.22 
COSM99950 c.814G>A Sub p.V272M Sub - Missense DBD 1 2.22 
 
Table 3.2: TP53 variants detected in lung SCC. 
Somatic mutations on TP53 gene were indicated with the respective COSMIC IDs, coding 
DNA sequence (CDS) mutations and amino acid (AA) mutations for each mutation were 
shown (Sub – substitution mutation; CS – coding silent mutation). The region whereby the 
mutation was detected was identified (DBD – DNA-binding domain; Proline-rich – proline-
rich domain; Oligo – oligomerization domain). The frequency and percentage of the 











Summary of findings in Chapter 3.1: 
 
 KRAS, PIK3CA, AKT1, MTOR and RB1 mutations are rare in lung SCC. 
 High mutation frequencies in ALK, TP53, CDKN2A and EGFR genes across all 
samples were detected. 
 A COMSIC mutation on ALK gene that resulted in A1491R was detected in high 
frequency in lung SCC. 
 A common intronic substitution on CDKN2A gene was detected with unknown 
impact on the translated protein. 
 Both codon substitutions on EGFR gene resulted in silent mutations that do not 
affect the functions of EGFR. 
 Despite the high mutational count on TP53, no common COSMIC mutation was 
detected among all samples. 
 ~50% of TP53 mutations found in lung SCC are located on the region encoding the 
DNA-binding domain. 







3.2  Transcriptional and translational diversities amongst lung SCC cell lines 
3.2.1  Somatic mutations in lung SCC cell lines 
Our genomic analyses in Chapter 3.1 had demonstrated a paucity of driver mutation in lung 
SCC, which tallied with the findings by TCGA Research Network (Network 2012). The 
presence of somatic mutations in the panel of lung SCC cell lines was investigated. 
Genomic aberrations of the selected cell lines were curated based on the COSMIC Database. 
As shown in Table 3.3, 5 of the 10 SCC lines are reported with codon deletions on the 
CDKN2A gene (SW900, H2170, H520, SK-MES-1, H226), 2 have mutated KRAS (SW900, 
Calu-1), while mutated RB1 and PIK3CA are observed in only 1 cell line (H596). All the 
selected cell lines, except for H2066 where its information is not available on the database, 
have wild-type EGFR and BRAF genes.  
TP53, an important tumour-suppressor gene, usually determines treatment response to 
various chemotherapeutic agents. However, based on the COSMIC database, there are 
conflicting reports on the mutation status of TP53 gene in 3 of the cell lines (H2170, 
ChaGo-k-1 and H226). Sanger sequencing was performed to determine the somatic 
mutations of TP53 in all cell lines (Table 3.4). The sequencing data confirmed that H226 
has wild-type TP53; Calu-1 is a p53-null cell; while the remaining 8 cell lines contain 
substitution mutations along the TP53 gene. Among those with single-nucleotide 
substitutions, 5 of them result in missense mutations (in H596, H1869, H2170, H2066 and 
ChaGo-k-1) that produce altered amino acid along the DNA-binding domain of the p53 
molecules (Table 3.4). The remaining 3 lines (H520, SK-MES-1 and SW900) have 
nonsense mutations that lead to the production of truncated p53 (Table 3.4).  
Collectively, it was verified that 9 out of the 10 lung SCC cell lines have aberrations in 
TP53 gene, 5 have mutated CDKN2A gene, while mutations at EGFR, KRAS, RB1 and 
PIK3CA genes are rare. These observations demonstrated the lack of driver oncogenic 
mutation in these cell lines. Taken together, the genomic characterization of the selected 
SCC cell lines are comparable to that of the actual SCC, suggesting that these cell lines are 








Gene CDS mutation AA mutation 
SW900 
CDKN2A c.1_471del471 p.0? 
CDKN2a(p14) c.1_522del522 p.0? 
KRAS c.35G>T p.G12V 
NF1 c.889_8520del7632 p.? 
TP53 c.499C>T p.Q167* 
EGFR  - (Wildtype)  - (wildtype)  
BRAF  - (Wildtype)  - (wildtype)  
H2170 
CDKN2A c.1_471del471 p.0? 
CDKN2a(p14) c.1_522del522 p.0? 
TP53 
c.472C>G p.R158G 
- (Wildtype)  - (wildtype)  
EGFR  - (Wildtype)  - (wildtype)  
BRAF  - (Wildtype)  - (wildtype)  
H520 
CDKN2A c.134delG p.G45fs*8 
TP53 c.438G>A p.W146* 
EGFR  - (Wildtype)  - (wildtype)  
BRAF  - (Wildtype)  - (wildtype)  
SK-MES-1 
CDKN2A c.1_471del471 p.0? 
CDKN2a(p14) c.1_522del522 p.0? 
TP53 c.892G>T p.E298* 
EGFR  - (Wildtype)  - (wildtype)  
BRAF  - (Wildtype)  - (wildtype)  
ChaGo-k-1 




EGFR  - (Wildtype)  - (wildtype)  
BRAF  - (Wildtype)  - (wildtype)  
H596 
PIK3CA c.1633G>A p.E545K 
RB1 c.541_542insT p.S182fs*3 
TP53 c.733G>T p.G245C 
MET c.3082+1G>T p.?  
EGFR  - (Wildtype)  - (wildtype)  
BRAF  - (Wildtype)  - (wildtype)  
H1869 
TP53   p.M237I 
BRAF  - (Wildtype)  - (wildtype)  
H226 
CDKN2A c.1_150del150 p.? 
TP53  
 c.998C>G   p.P309A  
- (Wildtype)  - (wildtype)  
EGFR  - (Wildtype)  - (wildtype)  
BRAF  - (Wildtype)  - (wildtype)  
Calu-1 
KRAS c.34G>T p.G12C 
EGFR  - (Wildtype)  - (wildtype)  
BRAF  - (Wildtype)  - (wildtype)  





Table 3.3: Somatic mutations of lung SCC cell lines as stated on COSMIC database. 
All coding DNA sequence (CDS) mutations and amino acid (AA) mutations curated by the 
database are displayed, while EGFR and BRAF are included. Genes with conflicting 
reports on mutation status are highlighted in yellow. Cell line with no available 




CDS mutation AA mutation 
SW900 c.499C>T Substitution p.Q167* Substitution - Nonsense 
H2170 c.472C>G Substitution p.R158G Substitution - Missense 
H520 c.438G>A Substitution p.W146* Substitution - Nonsense 
SK-MES-1 c.892G>T Substitution p.E298* Substitution - Nonsense 
ChaGo-k-1 c.824G>T Substitution p.C275F Substitution - Missense 
H596 c.733G>T Substitution p.G245C Substitution - Missense 
H1869 c.711G>A Substitution p.M237I Substitution - Missense 




Table 3.4: Mutational status of TP53 in lung SCC cell lines. 
Sanger sequencing was performed to verify the mutations on TP53 gene through 
amplication of the ORF region by using both 5’ and 3’ primers. Both CDS mutations and 









3.2.2  Comparative analysis on expression of cancer-related proteins in lung SCC cell 
lines 
The high frequencies of TP53 mutations and the rarity of EGFR and KRAS aberrations 
among SCC were shown in Table 3.3 and 3.4. The abundance of p53 and EGFR were 
examined at the protein level. Three normal lung fibroblast cell lines (MRC5, IMR90, WI-
38) were included as controls for comparison between malignant and non-malignant cells. 
All three normal fibroblast lines and H226, that have wild type p53, expressed low quantity 
of p53. Cell lines with missense mutation on p53 (H2066, H2170, H1869, ChaGo-k-1, H596) 
had high expression of p53, while p53-null cell (Calu-1) and p53-nonsense mutation cell 
(SW900, H520, SK-MES-1) do not express full-length p53 (Figure 3.2). Expression of 
EGFR was high in H2170 cell, undetected in H2066, SW900 and H1869, and consistent low 
in other cell lines. Interestingly, none of these cell lines expressed phosphorylated EGFR 
(Data not shown).  
Mutations and altered expressions of HDACs have been related to tumour development 
through aberrant regulation of cellular functions such as cell proliferation and cell death 
(Glozak and Seto 2007). Furthermore, several class I and class II HDACs have been 
associated with prognosis of lung cancer (Osada, Tatematsu et al. 2004, Minamiya, Ono et 
al. 2011). To better understand the mode-of-action of belinostat, a pan-HDAC inhibitor, the 
basal expression of HDACs was determined. There are four main classes of HDACs. Here, 
the expression levels of representative HDAC from class I (HDAC 1, 2, 3), class II (HDAC 
4, 6) and class III (Sirtuin-1) were examined. Expression levels of HDACs were consistent 
in all three normal fibroblast cells (Figure 3.2), while both HDAC 1 and 2 were universally 
overexpressed in all SCC lines. In relative to normal fibroblast, HDAC 3 had lower 
expression in SW900, H1869, ChaGo-k-1, H596, and H226; HDAC 4 was highly expressed 
in H520 and ChaGo-k-1 but lowly expressed in H1869; reduced expression of HDAC 6 was 
detected in most lung SCC cell lines except for H2170, H520 and SK-MES-1; Class III 
HDAC, Sirtuin-1, was highly expressed in H520, but found in low abundance in H1869, 
H596 and H226 (Figure 3.2). H1869 was found to have minimal expression of HDAC 3, 4, 
6 and Sirtuin-1. 
The results here showed the basal expression of p53, a tumour suppressor protein, EGFR, a 
commonly altered receptor in NSCLC, and various HDACs. The abundance of p53 
molecules corresponded to the mutational status among the lung SCC cell lines, as shown 
by the accumulation of p53 in cell lines harbouring TP53 mutation. Basal expression of 





Figure 3.2: Basal expression of p53. EGFR and HDACs in lung SCC and normal lung 
fibroblast cell lines. 
Western blot analyses were performed on protein lysates harvested from all selected cell 
lines. Western blot data shown are representative of three independent experiments for the 











Summary of findings in Chapter 3.2: 
 
 EGFR, KRAS, RB1 and PIK3CA mutations are rare in lung SCC cell lines. 
 5 of the 10 cell lines have CDKN2A mutation. 
 1 cell line (Calu-1) is p53-null. 
 8 cell lines have mutations on TP53 gene: 5 of these mutations encoded for p53 
with aberrations on DNA-binding domain. 
 The 5 cell lines with missense TP53 mutation expressed high levels of p53. 
 HDAC1 and HDAC2 are highly expressed in all lung SCC cell lines. 
 Lung SCC cell lines have differential expression of EGFR, HDAC3, HDAC4, 
HDAC6 and SirT1. 
 Paucity of targetable driver mutations in lung SCC cell lines. 






3.3  Cytotoxicity and synergy of cisplatin and belinostat in lung SCC cell lines 
3.3.1  Drug sensitivity under anchorage-dependent condition 
The in vitro sensitivities of cisplatin, the first line treatment for lung SCC, and belinostat, a 
pan-HDAC inhibitor, in the selected lung SCC cell lines were next determined. 10-tumour-
derived lung SCC and 3 normal lung fibroblast-derived cell lines were utilised as the initial 
study panel. Within this study panel, the effects of cisplatin and belinostat were quantified 
by determining the half-maximum inhibitory concentration (IC50) of each drug via cell 
proliferation assay. It was observed that lung SCC cells have variable sensitivities to both 
agents. In relation to cisplatin, 4 cell lines (H596, H1869, H226, ChaGo-k-1) have IC50 < 
10μM (classified as cisplatin-sensitive) and the remaining 6 cell lines have IC50 > 10μM 
(classified as cisplatin-resistant) (Figure 3.3 A). All 3 normal fibroblast lines were more 
sensitive to cisplatin with IC50 < 5μM. 
A similar approach was performed to evaluate sensitivity to belinostat with IC50 < 2μM 
designated as belinostat-sensitive and IC50 > 3μM as –resistant (Figure 3.3 B). Interestingly, 
belinostat has stronger repressive effects on the proliferation of cisplatin-resistant cells 
(H2066, SW900, SK-MES-1, H2170, H520, and Calu-1) as well as the normal fibroblast 
lines. Cisplatin-sensitive cells responded poorer to belinostat.  These data suggested that the 
lung SCC cell lines exhibit reciprocally inverse sensitivities towards cisplatin and belinostat. 
To measure the synergistic effects between cisplatin and belinostat, combination index (CI) 
was calculated based on Chou and Talalay’s method for synergy quantification (Chou and 
Talalay 1984). The average CI for effective dose in 50% to 80% of the population (ED50-
ED80) was determined. CI values lower that ED50 will not be optimal for drug efficacy 
studies, while values higher that ED80 will be impractical in term of clinical relevance. The 
average CI suggested that synergistic combination was achieved in all normal fibroblast 
lines and most SCC lines (CI < 0.80), with the exception of ChaGo-k-1 and H2066 whereby 






Figure 3.3: Lung squamous cell carcinoma cell lines exhibit differential in vitro 
sensitivities to cisplatin and belinostat. 
Lung SCC cells and normal lung fibroblast cell lines were drug treated for 72 hours and cell 
viability assay (MTS) was used to determine the IC50 of cisplatin (A) and belinostat 
(PXD101) (B). Data are presented as mean ± SD (n = 3). C, Combination index (CI) of 
cisplatin/belinostat for lung SCC cell lines in anchorage-dependent conditions. The nature 
of drug interaction is defined as synergism (CI < 0.8), additive effect (0.8 < CI < 1.2 ), and 









3.3.2  Drug sensitivity under anchorage-independent condition 
Anchorage-independent cell growth is a marker of the hallmark of oncogenic transformation, 
as it indicates the ability of the tumour cells to survive and proliferate in the absence of solid 
substratum, extra-cellular matrix and cell-cell contact (Mori, Chang et al. 2009). It is widely 
considered as the most accurate and stringent in vitro measurement of malignant 
transformation in tumour cells.  
Anchorage-independent growth of lung SCC cells in the presence of drug treatment were 
performed using soft agar colony forming assay to determine the sensitivities of cisplatin 
and belinostat in the absence of anchorage. Across the 5 tested cell lines (H226, H520, 
H2170, Calu-1 and ChaGo-k-1), cisplatin strongly inhibited colony formation of H226 and 
ChaGo-k-1 cells with IC50 < 100nM. The remaining three lines (H2170, ChaGo-k-1) were 
more resistant to cisplatin (Figure 3.4 A). Inhibitory effects of belinostat in lung SCC cells 
were determined with the similar approach. H226 and H2170 responded better to belinostat 
with IC50 < 400nM while ChaGo-k-1, Calu-1 and H520 had IC50 > 400nM (Figure 3.4 B).  
The calculated average CI at ED50-ED80 indicated that the combined treatment of cisplatin 
and belinostat demonstrated additivity in all five lung SCC lines under anchorage-
independent condition (Figure 3.4 C). Based on the obtained IC50, the dose reduction index 
(DRI) was measured to determine the magnitude of dose reduction allowed for each 
compound when used in dual combination, as opposed to single-drug treatment. Combined 
treatment (1:1 ratio) showed substantial reduction of cisplatin IC50 for H226 (from 70.4nM 
to 43.9nM; DRI = 1.60), H520 (from 311nM to 204nM; DRI = 1.59) and H2170 (from 
213nM to 105.6nM; DRI = 2.42) (Figure 3.4 C, D). Representative images for the dose-
dependent inhibition of cisplatin, belinostat and combination treatment in colony forming 
assay are shown in Figure 3.4 E, F, G, H and I. 
Our data indicated that lung SCC cell lines have consistent sensitivities to cisplatin in both 
anchorage-dependent and –independent conditions (H2170, Calu-1 and H520 as resistant; 
ChaGo-k-1 and H226 as sensitive). However, in comparison to in vitro cell proliferation 
assay, synergy of belinostat and cisplatin was reduced under anchorage-independent 
conditions, implying that combinatorial effect of belinostat and cisplatin is more robust 

















Figure 3.4: Cisplatin and belinostat inhibit malignant transformation in lung SCC cell 
lines. 
Sensitivities of lung SCC cells to cisplatin (A), belinostat (PXD101) (B) and combined 
treatment (C) in anchorage-independent condition were determined by using soft agar 
colony forming assay. Belinostat and cisplatin were combined at 1:1 ratio at the indicated 
doses. Reduction in colony formation was determined by MTT assay. IC50 are shown as 
mean ± SD (n = 3). D, Combination index and dose reduction index of cisplatin for lung 
SCC cell lines in soft agar assay are assessed. The nature of drug interaction is defined as 
synergism (CI < 0.8), additive effect (0.8 < CI < 1.2), and antagonism (CI > 1.2). Data are 
presented as mean ± SD (n = 3). Representative images for colony formations and dose-
dependent colony inhibition in ChaGo-k-1 (E), H226 (F), H2170 (G), Calu-1 (H) and H520 






3.3.3  Belinostat induces histone acetylation in lung SCC cells 
HDAC inhibitors have been reported to promote cytotoxicity via transcriptional and post-
translational modifications, but the precise mechanim(s) remain elusive. To understand the 
mode-of-action of belinostat in lung SCC, the expression of its downstream substrates 
(HDACs) was determined. Belinostat is a pan-HDAC inhibitor that is known to interfere 
with HDAC function by inhibiting its catalytic activity. This promotes the acetylation of 
lysine residues along the histone tails. Core histones such as H3 and H4 form tetrameric 
nucleosomes, which are essential for the helical structure of DNA (Luger, Mäder et al. 
1997). Acetylation of H3 and H4 increases chromatin accessibility, and is associated with 
active transcription (Jenuwein and Allis 2001). 
To prove the efficacy of belinostat in the panel of lung SCC cell lines, Western blotting was 
performed to verify the acetylation of H3 and H4 after belinostat treatment. H3 and H4 were 
extracted through acidic purification, as acid could prevent denaturation of histones and 
provide higher yield. The data showed that belinostat induced acetylation of both H3 
(Lys9/Lys14) and H4 in all 4 tested lung SCC lines (H2170, Calu-1, H226, and H596). Low 














Figure 3.5: Belinostat induces dose-dependent acetylation of H3 and H4 in lung SCC 
cells. 
Western blot analyses were performed on H3 and H4 in H2170, Calu-1, H226 and H596 
after belinostat (PXD101) treatment (0.1, 0.2, 0.3, 1, 3μM) with DMSO as vehicle control. 
Histones were purified through acid extraction. Western blot data shown are representative 












Summary of findings in Chapter 3.3: 
 
 Lung SCC cell lines displayed differential drug sensitivities to cisplatin and 
belinostat under both anchorage-dependent and –independent conditions. 
 H2066, SW900, SK-MES-1, H2170, H520, and Calu-1 were classified as cisplatin-
resistant cells. 
 H596, H1869, H226, and ChaGo-k-1 cells were classified as cisplatin-sensitive cells. 
 Belinostat had stronger cytotoxic effects on cisplatin-resistant cells. 
 Cisplatin and belinostat showed synergistic combination in lung SCC cell lines. 
 Most cisplatin-resistant cell lines showed good synergy (CI < 1) when cisplatin and 
belinostat treatments were combined. 






3.4  Comparative transcriptomic of cisplatin-sensitive and –resistant lung SCC cells 
One key focus of this project was to analyse the transcriptomes of cisplatin-resistant and –
sensitive cell lines. Gene expression profiling using the Affymetrix GeneChip 1.0ST 
microarray was conducted and analysed by GeneSpring Software V12. Basal transcriptome 
profiles were obtained for each cell lines and clustered into study sets according to their IC50 
towards cisplatin (H596, H1869, H226, ChaGo-k-1 as sensitive; Calu-1, H2170, SW900, 
H2066 as resistant). To investigate the possible mechanisms that participate in cisplatin 
resistance, the gene expressions of the resistant study set was compared to that of the 
sensitive study set (fold change > 1.5; P < 0.1). Within the cisplatin-resistant study set, 756 
genes were found to be up-regulated while 804 genes were down-regulated (Appendix 1 and 
2). Heat map for all altered genes > 3 fold was shown with cell lines displayed in column 
and group by cisplatin-response phenotype (Figure 3.6 A). The microarray data was 
validated by performing qPCR on selected genes. Among the enriched genes, GPX2 was 
verified to be highly expressed in two cisplatin-resistant lines (H2170 and H2066), while 
MGST1 was barely detected in two cisplatin-sensitive lines (H226, ChaGo-k-1) (Figure 3.7 
B). Among the down-regulated genes, FAS, DRAM1, PARP9, PARP14, and XAF1 genes 
were consistently down-regulated in cisplatin-resistant lines, while TP53 was highly 
expressed in H2066 and all cisplatin-sensitive lines (Figure 3.6 C). 
Both gene lists were subjected to KEGG pathway mapping via DAVID Bioinformatics 
Resources 6.7 (p < 0.1). This analysis mainly focused on the identification of genomic 
homogeneity (among cell lines with similar responses to cisplatin) and heterogeneity (across 
cell lines with different responses to cisplatin). Among the genes that were down-regulated 
in the resistant study set, several pathways with biological relevance to tumourigenesis were 
identified by the database: p53 signalling pathway (TNFRSF10B, CCND2, SERPINE1, 
CASP8, TP53, SFN, FAS, IGFBP3, PTENP1), apoptosis (TNFRSF1A, IL1R1, TNFRSF10B, 
IL1RAP, CASP8, TP53, NFKB1, BCL2L1, FAS, BIRC3), and MAPK signalling pathway 
(EGFR, FGFR2, IL1R1, PDGFA, FGF9, NF1, TP53, CACNB3, NFKB1, DAXX, FLNB, 
TNFRSF1A, BDNF, DUSP1, MAPK13, RASGRP1, HSPB1, FAS, FGF2, MAP3K13, 
DUSP7, RASA2) (Table 3.5). Interestingly, among those genes enriched in the resistant cell 
lines, pathway analysis revealed several biological terms that are related to glutathione 
metabolism (GSTM1, GSTA1, GPX2, GSTM2, GSR, GSTM3, GSTA4, G6PD, GSTO1, 
GCLM, MGST1, GSTP1), metabolism of xenobiotics by cytochrome P450 (GSTM1, 
AKR1C3, GSTA1, GSTM2, AKR1C2, GSTM3, GSTA4, GSTO1, MGST1, GSTP1), and drug 
metabolism (GSTM1, GSTA1, GSTM2, GSTM3, GSTA4, AOX1, GSTO1, MGST1, GSTP1) 
(Table 3.6). The data implied that cisplatin resistance could be related to suppression of 








Figure 3.6: Comparative transcriptomic analysis of cisplatin-sensitive and –resistant 
phenotypes. 
Gene expression profiling was performed on cisplatin-sensitive (H596, H1869, H226, 
ChaGo-k-1) and cisplatin-resistant (Calu-1, H2170, SW900, H2066) cell lines. Affymetrix 
Microarray analysis was performed in technical duplicates. A, Heat map shows the 
expression of all differentially expressed genes (fold change > 3; P < 0.05). Real time qPCR 
was performed to validate the (B) enriched and (C) suppressed genes in the cisplatin-
resistant phenotypes (n = 1). SW900 and H596 were used as references for (B) and (C) 





Table 3.5: Pathway analysis for differential terms/genes down-regulated in cisplatin 




Table 3.6: Pathway analysis for differential terms/genes up-regulated in cisplatin 
















Summary of findings in Chapter 3.4: 
 
 Comparative transcriptomic were performed on cisplatin-sensitive (H596, H1869, 
H226, ChaGo-k-1) and –resistant (Calu-1, H2170, SW900, H2066) lung SCC cell 
lines, and followed by KEGG pathway analysis. 
 Genes related to apoptosis, p53 signalling pathway and MAPK signalling pathway 
were down-regulated in cisplatin-resistant cells. 
 Genes related to glutathione metabolism, metabolism of xenobiotics by cytochrome 






3.5  Discussion 
3.5.1   The insights of genetic aberrations in lung SCC and tumour-derived cell lines 
A key feature that directly contributed to the success of molecularly targeted therapy in lung 
cancer is the identification of genetic abnormalities. A recent study conducted by TCGA  
Research Network has comprehensively characterized the genomic alterations in lung SCC, 
whereby several genomic assays were performed to dissect the somatic mutations and 
transcriptome expression profiles in each of the 178 samples (Network 2012). This study 
confirmed the scarcity of EGFR and KRAS mutations, two commonly observed oncogenic 
aberrations in lung adenocarcinoma, within SCC. According to this report, TP53 mutation is 
commonly detected in lung SCC, while other common genetic aberrations identified include 
HLA-A, CDKN2A, RB1, FGFR, phosphatidylinositol-3-kinase genes, and receptor tyrosine 
kinase signalling genes (EGFR amplification, BRAF mutation or FGFR amplification). 
These findings reveal the window of opportunity for personalized therapy in lung SCC. For 
instance, Hammerman et. al. have proposed the use of dasatinib, a multi-kinase inhibitor 
that has activity on DDR2, on a small subset of SCC harbouring DDR2 kinase mutation 
(Hammerman, Sos et al. 2011). Furthermore, few studies have shown that FGFR1 is more 
frequently mutated in lung SCC than adenocarcinoma, while demonstrating the efficacy of 
FGFR inhibitor in this subset of SCC (Weiss, Sos et al. 2010, Dutt, Ramos et al. 2011). 
These growing evidences facilitated the personalization of effective therapy for lung SCC 
patients. Despite so, no common oncogene driver mutations have been clearly identified in 
lung SCC to guide therapy. 
In this study, lung SCC specimens were obtained from 45 locally diagnosed cases. Somatic 
DNA alterations within 15 lung cancer-related genes were characterized by using NGS. 
Similar to earlier reports (Pacifico and Leone 2007, Network 2012), mutations of TP53 and 
CDKN2A are commonly detected in lung SCC; while KRAS/HRAS/NRAS, PTEN, and BRAF 
mutations are rare (Figure 3.1B). In the study conducted by TCGA, genes related to 
phosphatidylinositol-3-kinase pathway were found to be mutated in 47% of tumours 
(Network 2012). Among these samples, however, only 8 samples (17.78%) were found with 
mutated PIK3CA, AKT1 or MTOR (Figure 3.1 A, B). Furthermore, despite detecting at least 
a codon substitution on EGFR gene in 80% of lung SCC, majority of these mutations was 
soon identified to be silent mutations. Collectively, these implicated the lack of efficacy of 
EGFR TKIs in lung SCC. As the NGS run was performed on targeted amplification of 
specific exons, the presence of ALK fusion proteins could not be identified. Despite so, at 
least one mutated ALK variant was detected in every sample (Figure 3.1 B). More 
importantly, an ALK protein with altered kinase domain (K1491R) was identified as a 
common mutation (Table 3.1). Mutations at the kinase domain of ALK had been reported to 
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cause resistance to ALK kinase inhibitor, such as Crizotinib (Choi, Soda et al. 2010, Sasaki, 
Koivunen et al. 2011, Katayama, Shaw et al. 2012). This finding suggested that lung SCC 
patients might not respond to ALK inhibitors. 
Taken together, these sequencing analyses confirmed the paucity of driver oncogenes in 
lung SCC. Therefore, targeted therapies with good clinical efficacy in lung adenocarcinoma, 
such as EGFR and ALK inhibitors, might not be beneficial to these SCC patients. The 
genetic aberrations of the panel of lung SCC cell lines were found to be comparable to the 
genetic characterization of lung SCC specimens (Chapter 3.2). Apart from TP53 gene, 
mutations on EGFR, KRAS, PIK2CA, BRAF, RB1 and STK11 are rare in these cell lines. 
Based on these informations, the selected cell lines are suitable candidates as representative 
tumour models for lung SCC. 
 
3.5.2  Tumour heterogeneity, clonal evolution and cisplatin sensitivity in lung SCC 
One of the major challenges that hinders the progression of curative treatment in solid 
tumour is the presence of heterogenous sub-clones that are intrinsically different on a 
molecular level (Driessens, Beck et al. 2012, Turner and Reis-Filho 2012). The two most 
established aspects of intra-tumour diversity are the existence of metastatic variants and 
presence of inherently resistant clones (Dexter and Leith 1986). While metastases are 
generally seen as the more resilient subpopulation that resulted in acquired resistance to 
chemotherapy, inherently resistant subsets of tumour often result in expansion of more 
malignant clones. Under therapy intervention, the selection pressure may favour the 
evolution and proliferation of tumour sub-clones with survival advantages. Thus it is 
common that after initial response to chemotherapy, tumours relapsed in more aggressive 
forms and are less responsive to chemotherapy. The main driver of tumour heterogeneity is 
believed to be DNA mutation. The high mutation rates in lung SCC thus implied for a 
significant degree of heterogeneity in this disease.  
In this study, lung SCC cell lines were shown to exhibit variable in vitro sensitivities 
towards cisplatin, with 5-fold differences distinguishing the most sensitive cell (H596) from 
the most resistant cell (H2066) (Chapter 3.3.1). This indicated the presence of inherently 
resistant clones within the selected panel of cell lines. Comparatively, normal lung 
fibroblast cell lines were less tolerable to cisplatin treatment than the most sensitive lung 
SCC cell line. This partly explained the adverse side effects experienced by cancer patients 
treated with cisplatin. 
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In addition, the capability to grow in anchorage-independent condition could determine the 
lung SCC cell lines that are more malignantly transformed (Guadamillas, Cerezo et al. 
2011). The close correlation of anchorage-independent growth with tumourigenicity in 
animal models makes it an important assay for investigation of cellular response to anti-
tumour drug (Freedman and Shin 1974, Colburn, Bruegge et al. 1978). In the absence of 
anchorage, only five cell lines were able to form colonies (Chapter 3.3.2), again indicating 
the lack of homogeneity in lung SCC. Furthermore, these cell lines displayed differential 
sensitivity to cisplatin, with a trend concordant with anchorage-dependent cell sensitivities 
(H520, Calu-1 and H2170 cells as cisplatin-resistant).  
Collectively, these findings demonstrated the differences in cellular context of these lung 
SCC cell lines in term of drug sensitivity. The identification of intrinsically drug-resistant 
cell lines allowed for selection of study models to investigate the cisplatin resistance 
mechanisms. An important point to note is that apart from somatic mutations, epigenetic 
factors might initiate and mediate the formation of drug-resistant subclones (Sharma, Lee et 
al. 2010). In the same study, the authors suggested that epigenetic regulations might resulted 
in high tolerance to both traditional chemotherapies and targeted therapies (Sharma, Lee et 
al. 2010). Therefore, restriction of these epigenetic factors by HDAC inhibitor (belinostat) 
was being investigated in this study. 
 
3.5.3  The therapeutic conundrum of belinostat: promising in vitro sensitivity but 
modest clinical outcome 
HDAC inhibitors have displayed strong in vitro anti-neoplastic effects in several tumour 
types. Several studies have demonstrated the combinatorial effect of HDAC inhibitor with 
chemo- and radiotherapy in lung cancer (Kim, Kim et al. 2010, Owonikoko, Ramalingam et 
al. 2010), but this present study was the first to focus on the cytotoxicity of HDAC 
inhibition in lung SCC cells. 
Similar to cisplatin treatment, lung SCC cell lines exhibited variable sensitivities towards 
belinostat treatment (Chapter 3.3.1). Interestingly, cisplatin and belinostat have reciprocal 
sensitivities in lung SCC, as cell lines identified as cisplatin-resistance were more 
susceptible to belinostat treatment. Normal lung fibroblast cells were found to have better 
tolerability to belinostat in relative to the cisplatin-resistant cell lines. Moreover, the 
combination of both agents appeared to achieve synergy in most cisplatin-resistant lines 
(Figure 3.3 C). Taken together, this selectivity of belinostat in targeting cisplatin-resistant 
cell lines clearly emphasized the chemosensitizing effect as well as synergistic cytotoxicity 
of this pan-HDAC inhibitor in lung SCC cells. 
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Although the precise mode-of-action of HDAC inhibitors has remained elusive, the 
accumulation of acetylated histones and transcription factors is well-accepted to be the 
universal determinants of cellular response to HDAC inhibition (Minucci and Pelicci 2006). 
The epigenetic regulations of belinostat in lung SCC cell lines were determind with the 
dose-dependent acetylation of H3 and H4 (Chapter 3.3.3). Intriguingly, the 
hyperacetylations of histones in both belinostat-sensitive and resistant groups were found to 
be regulated in a similar manner, suggesting that the belinostat sensitivity might not be 
dependent on epigenetic alteration of histones (Figure 3.5). Furthermore, belinostat is a pan-
HDAC inhibitor that inhibits the class I, II and IV enzymes. While HDAC 1, 2 and 4 are 
overexpressed in most lung SCC cells, protein levels of HDAC 3, 6 and Sirtuin-1 were 
found to be differentially expressed (Figure 3.2). Taken together, it is unlikely that the 
efficacy of belinostat on SCC cell lines could be predicted by determining the expression of 
histone proteins.  
It has been reported that high doses of HDAC inhibitors used in the clinic could lead to 
extension of DNA damage and impairment of DNA damage repair (Karagiannis, 
Harikrishnan et al. 2007, Wilson, Holson et al. 2011, Wilson, Lalani et al. 2012). These 
often result in rapid induction of cell senescence and cell death that are similar to 
conventional chemotherapeutic agents, which may not be the optimal effects of HDAC 
inhibitors (Azad, Zahnow et al. 2013). At lower doses, the epigenetic effects of HDAC 
inhibitors trigger cellular differentiation and reprogramming, while these effects might be 
compromised when high doses of HDAC inhibitors are used. In truth, despite being tested in 
multiple phase I and II clinical trials (Glaser 2007), clinical development of HDAC 
inhibitors remains challenging from the viewpoint of toxicity and exploiting a therapeutic 
window for tumour control without intolerable adverse event. The usage of HDAC 
inhibitors at non-toxic doses could possibly offer treatment advantage by alteration of 
tumour biology instead of immediate induction of cell death. 
In comparison with other HDAC inhibitors, belinostat is well tolerated, thus allowed for 
combination with chemotherapy without causing bone marrow toxicity. Since its 
development by Topotarget, clinical studies on belinostat have been conducted in 
haematological and solid malignancies. Data from these studies have demonstrated 
beneficial anti-neoplastic effects of belinostat as monotherapy in PTCL, CTCL, liver cancer 
and thymic carcinoma (Giaccone, Rajan et al. 2011, Jain, Zain et al. 2012, Yeo, Chung et al. 
2012, Reimer and Chawla 2013). However, similar to other HDAC inhibitors, belinostat as 
single or combined therapy has minimal anti-tumour effects in advanced solid malignancies 
(Ramalingam, Belani et al. 2009, Mackay, Hirte et al. 2010, Giaccone, Rajan et al. 2011). 
As single agents, HDAC inhibitors are generally limited by clinical toxicity while plasma 
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concentrations achievable in clinical use would likely not reach the amounts required for 
anti-neoplastic activity in solid tumours. To overcome this pharmacological barrier, the 
hypothesis is that reduced concentrations of HDAC inhibitors would be sufficient to 
demonstrate synergism with chemotherapeutic agents and provide adequate therapeutic 
window for clinical utility. Furthermore, elucidating the mechanisms of synergistic 
cytotoxicity between belinostat and cisplatin may reveal treatment strategies that are more 
precise and less toxic.  
 
3.5.4  Comparative analysis of the genetic heterogeneity among cisplatin-sensitive 
and –resistant phenotypes 
Cisplatin is among the most commonly used alkylating cytotoxic agent with a broad 
spectrum of anti-cancer activity. Furthermore, certain lung SCC clones are intrinsically 
more resistant to cisplatin (Figure 3.3). This prompted the investigation on the molecular 
events that determine susceptibility to cisplatin treatment. In order to make broader 
generalization on the cisplatin resistance mechanisms, the geneotypic homogeneity within 
each phenotype was determined (by clustering the transcriptomes of resistant/sensitive cell 
lines as one group), before the transcriptomic diversity across the resistant and sensitive 
phenotypes was investigated (by comparing the clustered transcriptomes across the two 
phenotypes) (Chapter 3.4). 
Several mechanisms of cisplatin resistance have been proposed that include regulation of 
drug influx/efflux, increased drug detoxification, increased DNA repair and inhibition of 
apoptosis. Furthermore, p53 activity had been negatively correlated with the development of 
cisplatin resistance, as tumour cells with functional wild-type p53 were shown to be more 
susceptible to cisplatin (Vekris, Meynard et al. 2004). In addition, cell lines with mutated 
p53 were more tolerable to cisplatin, but could be sensitized when wild-type p53 is 
genetically introduced (Wang, Li et al. 2005). As the genome wide pathway analysis 
revealed that p53 signalling could be repressed in cisplatin-resistant phenotype (Chapter 
3.4), it was initially believed that p53 status is an important predictive biomarker for 
cisplatin sensitivity in lung SCC cells. Expectedly, the normal lung fibroblast cells and a 
lung SCC cell lines with wild-type p53 (H226) were indeed more sensitive to cisplatin. 
However, most lung SCC cells harboured mutation on TP53 gene and yet displayed 
differential sensitivities to cisplatin, strongly suggestive of the presence of other factors that 
determine cisplatin resistance.  
Transcriptomic analysis on lung SCC cell lines further revealed significantly reduced 
transcriptional activity of MAPK signalling pathway and apoptosis (Chapter 3.4). Several 
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preclinical studies have suggested that MAPK/p38 signalling could activate downstream 
Fas/FasL pathway and trigger apoptosis (Mansouri, Ridgway et al. 2003, Brozovic and 
Osmak 2007). Moreover, suppressed MAPK/p38 activation and FasL expression was 
associated with cisplatin resistance (Brozovic, Fritz et al. 2004). In the cisplatin-resistant 
phenotypes, down-regulation of FAS gene (Figure 3.6 C) and genes related to MAPK 
signalling pathway was observed (Table 3.6). These suggested that the cisplatin-resistant 
lung SCC cells could have an attenuated MAPK signalling as a mean of limiting Fas-
induced extrinsic apoptosis, thus reduced cisplatin sensitivity. 
Another key regulator of cisplatin resistance is the intracellular accumulation of cisplatin, 
which is mediated by the balance in drug uptake/efflux as well as drug inactivation. It is 
known that binding of cisplatin to cytoplasmic scavenger molecules, such as GSH, will 
reduced the amount of active cisplatin (Kasahara, Fujiwara et al. 1991). In the study models, 
genes encoding for GSTs (GSTM1, GSTA1, GSTM2, GSTM3, GSTA4, GSTO1, MGST1, 
GSTP1) were predominantly enriched in the resistant phenotypes. High expressions of 
GSTs probably catalyze GSH synthesis (Lewis, Hayes et al. 1988) and induce detoxification 
of cisplatin in resistant cells. 
These findings allowed for better understanding on the genetic context that may confer 
cisplatin resistance in lung SCC cells. Through characterizing the transcriptomes of 
cisplatin-sensitive and –resistant phenotypes, p53 signalling, MAPK signalling, apoptosis 
pathway and drug detoxification mechanism could be associated to cisplatin resistance in 
lung SCC cells. 
 
3.5.5  Conclusions and future directions 
The lack of driver oncogenic transformation, the molecular heterogeneity of lung SCC 
cancer cells, together with the pleiotropic nature of the cellular processes within intrinsically 
resistant clones, have posed a challenging task in the understanding of tumour biology and 
chemotherapeutic intervention in lung SCC. By using several genomic technologies, the 
paucity of oncogene-dependency among lung SCC and cell lines was validated. Moreover, 
the work here provided evidence on the differential drug sensitivities and degree of 
malignancy among lung SCC cell lines.  
In this chapter, several molecular events that could be accounted for the cisplatin-resistant 
phenotype in lung SCC was reported. However, as drug resistance is multifactorial and 
tumour is heterogenic, it is likely that several of these events occur simultaneously within an 
individual tumour, and inhibition of single pathway will not be sufficient to circumvent 
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cisplatin resistance. At present, it remains unclear which of these molecular events should 
be preferentially modulated for optimal sensitization of cisplatin efficacy. Thus, the search 
for more effective treatment strategies is needed. In view of these considerations, targeting 
the universal downstream transduction signalling of cisplatin-resistant cells could be a more 
successful strategy. Accumulating evidence suggests that cisplatin-resistance can be 
sustained by aberrant regulations of signalling cascade, such as the SHC/Grb2/SOS and 
PI3K/Akt1 signalling (Citri and Yarden 2006). Further investigation will be conducted in 
Chapter 4 to identify the possible target(s) that favours cellular proliferation under cisplatin 
treatment. 
HDAC inhibitor is an interesting class of anti-neoplastic compound. In line with current 
knowledge, this study has demonstrated the strong in vitro cytotoxicity of belinostat in lung 
SCC cells (Komatsu, Kawamata et al. 2006, Mukhopadhyay, Weisberg et al. 2006). Despite 
so, the combinatorial effect of belinostat with cisplatin was somewhat compromised in 
anchorage-dependent tumour cell. Furthermore, limited clinical efficacy observed in solid 
tumours has restricted its potential as a blockbuster chemotherapeutic agent. Despite so, the 
selectivity, specificity and synergy of belinostat in cisplatin-resistant lung SCC lines should 
not be overlooked. It was hypothesized that belinostat may alter crucial signal transduction 
pathways that lead to chemosensitization of cisplatin in tumour cells. As such, the 
chemosensitizing mechanisms of belinostat were elucidated, and novel druggable target(s) 









CHAPTER 4 Cisplatin-mediated activation of MAPK: A mechanism of 
cisplatin resistance in lung SCC 
Platinum agents including cisplatin form the backbone of cancer therapy for NSCLC. 
However, the effectiveness of chemotherapy for NSCLC is limited by eventual development 
of resistance. In adenocarcinoma of the lung, advances in care have been improved by the 
development of small molecular inhibitors targeting specific oncogenic signalling. However, 
cisplatin remains as the most potent of therapeutic compounds and one of the few curative 
first-line anti-cancer drugs for lung SCC patients due to the lack of oncogenic driver 
mutation. The development of platinum resistance has limited its clinical efficacy in lung 
cancer treatment. Patients with metastatic SCC of the lung, in particular, ultimately relapse 
despite initial response to platinum containing regimens (Schiller, Harrington et al. 2002, 
Pignon, Tribodet et al. 2008). Combination chemotherapy consisting of platinum 
compounds has since been established as standard treatment regime based on superior 
response and survival over single agent therapy (Souquet, Chauvin et al. 1993, Sandler, 
Nemunaitis et al. 2000). Despite resulting in symptomatic relief and improvement in overall 
survival, adverse side effects were often greater than those of molecular targeted therapies 
due to the non-specificity of chemotherapeutic agents (Group 2008).  As such, recent 
therapeutic approach has focused on developing more effective combination with 
molecular-targeting therapies. Several clinical studies are currently assessing the therapeutic 
intervention of Onartuzumab (anti-c-Met monoclonal antibody), Necitumumab (anti-EGFR 
monoclonal antibody) or Bevacizumab (anti-VEGF monoclonal antibody) plus platinum-
based chemotherapy in patients with advanced or recurrent lung SCC (ClinicalTrials.gov 
Identifier NCT01519804, NCT00981058, and NCT00946712).  
In Chapter 3, several predictive molecular events corresponding to cisplatin sensitivity in 
lung SCC cells were described. These events depict a general cisplatin-resistant model with 
decrease in apoptosis-related signalling pathways and increase in drug metabolic 
mechanisms. However, this model only partially explains the inherent factors that give rise 
to intrinsic cisplatin resistance, while the cisplatin-elicited cellular responses remain elusive. 
As accumulating evidences have reported the involvement of Akt and MAPK signalling 
pathways in regulating cellular response to cisplatin in several tumour types (Pommier, 
Sordet et al. 2004, Wada and Penninger 2004, Citri and Yarden 2006), potential druggable 
kinase targets that could be involved in cisplatin resistance in lung SCC cell lines were 
examined. 
Undoubtedly, the major limitation to clinical efficacy of cisplatin is the high occurrence of 
chemoresistance. While the synergistic effects of belinostat on several cisplatin-resistant cell 
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lines was shown (Chapter 3.3.1 and 3.3.2), the mechanisms leading to sensitization for 
cisplatin treatment have yet to be established.  In this chapter, parallel investigations were 
conducted to: elucidate the signalling transduction pathways that confer cisplatin resistance 
in lung SCCs; and dissect the potential chemosensitizing mechanism(s) of belinostat. 
Exploiting the overlapping mechanisms by which lung SCC cells become refractory to 
cisplatin while remain susceptible to belinostat could reveal not only superior 




















4.1  Identification of cisplatin resistance mechanisms in lung SCC cells 
4.1.1  Transcriptional diversity in sensitive and resistant lung SCC cell lines upon 
exposure to cisplatin 
To identify putative pathways that are modulated differently in cisplatin-sensitive and -
resistant cell lines, gene expression profiling was conducted on the representative cell lines 
under the pressure of cisplatin exposure. Here, cell lines were treated with cisplatin at their 
respective IC50 concentration for a short duration (8 hours) to avoid the induction of 
apoptosis-related genes, which may mask the intrinsic genetic responses to cisplatin. 
Micoarrays were performed and the transcriptomes were compared against the basal gene 
expression profiles obtained in Chapter 3.4.1.  
Across the resistant and sensitive study sets, a total of 150 and 382 genes were found to be 
altered at a fold change of > 1.5 after cisplatin treatment (P < 0.05). Among these genes, 
123 were commonly mediated in both study sets (Figure 4.1 A). Distinctive genes that were 
differentially regulated between the resistant (27) and sensitive (259) phenotypes were 
selected (Figure 4.1 A). The differentially expressed genes are listed in Appendix 3. Heat 
maps generated based on hierarchical clustering enable direct visualization of the altered 
genes in cisplatin-resistant (Figure 4.1 B) and –sensitive (Figure 4.1 C) study sets, with the 
columns displaying differences after cisplatin treatment and paired according to cell lines.  
To identify pathways related to cisplatin resistance, KEGG analysis on the significantly 
modulated gene list was performed (P < 0.05) (Appendix 3) by mapping them on the KEGG 
Pathways database. The database did not identify any relevant pathway among the genes 
that were up-regulated after cisplatin treatment in both sensitive and resistant study sets. 
Among the genes suppressed in the resistant cells, pathway related to systemic lupus 
erythematosus (HIST1H2AC, HIST1H4B, HIST1H3B) was identified (Table 4.1). 
Interestingly, among the genes suppressed in the sensitive cells, three signalling pathways 
that were identified to be closely related to tumour cell survival, cell proliferation and cell 
death: ErbB pathway (PRKCA, CBLB, GSK3B, SOS2, AKT3), MAPK pathway (PRKCA, 
MAP4K3, NF1, SOS2, RAPGEF2, STK3, AKT3, MAP2K5), and phosphatidylinositol 
pathway (PRKCA, INPP4B, PIP4K2A, ITPR2) (Table 4.2).  
This study revealed the possible involvement of these functional pathways (ErbB, MAPK 
and phosphatidylinositol pathways) in determining treatment outcome in lung SCC cell lines. 
Thus, understanding the activation/inhibition of these pathways may provide insights to the 





Figure 4.1: Comparative transcriptomic analysis indentifies differentially-regulated 
pathways in lung SCC cell lines after exposure to cisplatin.  
Cisplatin-sensitive (H596, H1869, H226, ChaGo-k-1) and cisplatin-resistant (Calu-1, H2170, 
SW900, H2066) cell lines were treated with cisplatin at their respective IC50. Affymetrix 
Microarray analysis was performed in technical duplicates. A, Venn diagram represents the 
number of genes altered (fold change > 1.5; P < 0.05) in each phenotype. Heat map shows 
















Table 4.1: Pathway analysis for differential terms/genes down-regulated in cisplatin-




Table 4.2: Pathway analysis for differential terms/genes down-regulated in cisplatin-








4.1.2  Phospho-kinase signalling in cisplatin-treated Calu-1 and H596 cells 
Next, the association of ErbB, MAPK and phosphatidylinositol signalling pathways with 
cisplatin sensitivities was explored using phospho-kinase array. H596 was selected to 
represent the cisplatin-sensitive group as it has the lowest cisplatin IC50. Among the 3 
cisplatin-resistant cell lines, Calu-1 was considered more representative. Despite having 
higher cisplatin IC50, H2066 and SW900 were deemed impractical for further 
experimentations due to their growth conditions: H2066 cell requires multiple supplements 
for optimal growth (Table 2.3). SW900 has to be grown in normal air as CO2 is detrimental 
to this cell. The varying culture conditions for these two lines could potentially introduce 
additional confounding factors that may influence the experiment outcomes. 
Parallel phospho-MAPK array assays were performed on Calu-1 (resistant) and H596 
(sensitive) cells after cisplatin exposure at doses closed to their IC50 (10μM and 5μM 
respective). Intensity of each spot represents the degree of phosphorylation for the indicated 
target (Figure 4.2 A). The pixel intensity of each pair of duplicate spots was measured with 
ImageJ as described in Chapter 2.8.8.2. Densitometry analysis was performed by first 
comparing the absolute pixel intensities of all targets in both resistant and sensitive cell lines 
(Figure 4.2 B, C) and differences in term of fold change of differently regulated kinases 
(Figure 4.2 D). The analyses showed that cisplatin treatment had profound effects on kinase 
phosphorylation in both cell lines. In cisplatin-treated H596, almost all proteins were 
dephosphorylated, except for p53 (Ser15) (Figure 4.2 B). In Calu-1 cells, however, cisplatin 
treatment had variable effects on kinase phosphorylation (Figure 4.2 C). 
To gain a better understanding of the potential pathway perturbations that reflect resistance 
to cisplatin treatment, the differences in fold-change of kinase activation after cisplatin 
treatment were analysed. Fold change is defined as: ratio of post-treatment pixel density to 
that of untreated control with normalization to positive control. The fold changes for each 
kinase in Calu-1 were compared with those in H596. Those kinases with highest differences 
among the two lines were selected and displayed in Figure 4.2 D. By setting a 20% 
induction/reduction threshold to increase the stringency of the analysis, it was observed that 
p-Erk2, p-MSK2, p-p38α and p-p38γ were increased by 1.87, 1.22, 1.47 and 1.15-fold 
respectively in Calu-1 cells following cisplatin treatment. On the other hand, these kinases 
were reduced by 0.51, 0.49, 0.14 and 0.25-fold in H596 cells (Figure 4.2 E), suggesting that 
this subset of kinases may be pertinent to the cisplatin-resistant phenotype. 
Expression of p-Akt, p-GSK3, p-Hsp27, p-MKK3/6, p-p38β/δ, p-RSK1/2 and p-mTOR 
were reduced in both Calu-1 and H596 cells after cisplatin treatment, while expressions of 
Erk1/2, MSK2 and p38α/γ were regulated in opposite manner, suggesting that transduction 
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of DNA-damage signals might be differently regulated in cisplatin-resistant and –sensitive 
cells and possibly mediated cellular responses to cisplatin. The detailed expressions of Erk, 












Figure 4.2: Calu-1 and H596 have dissimilar regulation of signalling pathways upon 
cisplatin treatment.  
A, H596 (cisplatin-sensitive) and Calu-1 (-resistant) cells were cultured overnight and 
treated with cisplatin at 5μM and 10μM respectively for 48 hours (n = 1). Phospho-kinase 
array and densitometric analysis were performed as described in Material and Methods. The 
pixel density of each array spots for H596 (B) and Calu-1 (C) cells were shown. Data are 
shown as an average of duplicate spots ± SD. The bar chart (D) and the table (E) show the 
fold change (in relative to untreated control) of indicated phosphoproteins that were 
expressed differently in Calu-1 and H596 cells in response to cisplatin treatment. Gray-
coloured region indicates the defined boundaries for significant changes (< 80%; > 120%). 
Data are shown as an average of duplicate spots.  






4.1.3  Regulation of signal transduction pathways in cisplatin-treated lung SCC cells  
Next, the findings of the phospho-kinse arrays were validated using Western blotting 
analysis on the various signalling proteins. Western blot analyses were performed on 
independent cell lysates of cisplatin-sensitive (H596, H226 and ChaGo-k-1) and -resistant 
(Calu-1, H2170 and H520) cell lines. The proteomic analysis had earlier indicated that 
phosphorylation of Erk1/2, MSK2 and p38α/γ were suppressed in H596 cells, but up-
regulated in Calu-1 cells. The expressions of p-Erk1/2 (Thr202/Tyr204), p-MSK1 (Ser360) 
and p-p38 (Thr180/Tyr182) across the 6 selected lines were verified after exposure to 
cisplatin. Cleavage of PARP was determined as an indicator of apoptosis. 
The range of cisplatin concentrations (0.5 - 10μM) used in this study is well within the 
achievable concentrations in the plasma of regular doses of cisplatin in patients (van Hennik, 
van der Vijgh et al. 1987). These data validated that p-Erk1/2, p-MSK1 and p-p38 were 
suppressed in cisplatin-treated H596 cells dose-dependently (Figure 4.3 A), and were 
consistent with the phospho-kinase analysis. Among other cisplatin-sensitive cell lines, p-
Erk1/2 was down-regulated H226, but unchanged in ChaGo-k-1; p-MSK1 was lowly 
expressed in H226 and unchanged in ChaGo-k-1; while p-p38 was increased in both H226 
and ChaGo-k-1. The down-regulation of p-Erk1/2 in both H596 and H226 corresponded 
with the cleavage of PARP (Figure 4.3 A).  
Western blotting showed that cisplatin treatment induced phosphorylations of Erk1/2 and 
MSK1 in Calu-1 cells, but did not affect p38 expression. Among other cisplatin-resistant 
cell lines, p-Erk1/2 was reduced at high dose in H2170 and up-regulated in H520; p-MSK1 
was up-regulated in both H2170 and H520; p-p38 was down-regulated in H2170 but 
unchanged in H520. Cleavage of PARP was observed in Calu-1 and H520 only at high 
doses of cisplatin (10μM) (Figure 4.3 B).  
Collectively, it was shown that exposure to cisplatin generated distinct signalling dynamics 
among lung SCC cells. In general, p-Erk1/2 and p-MSK1, but not p-p38, were reciprocally 







Figure 4.3: Phosphorylation of Erk, MSK1, p38 and cleavage of PARP in lung SCC 
cells upon cisplatin exposure.  
Western blot analyses was performed to investigate the expression of PARP, Erk, MSK and 
p38 in (A) cisplatin-sensitive (H596, H226, ChaGo-k-1) and (B) cisplatin-resistant (Calu-1, 
H2170, H520) cells. Cisplatin was given in increasing doses (0.5, 1, 3, 5, and 10μM) for 48 
hours. Data shown are representative of three independent experiments for the indicated 






4.1.4  The signal transduction pathways in belinostat-treated lung SCC cells 
In Chapter 3.3.1, it was shown that cisplatin resistant cell lines were more susceptible to 
belinostat treatment. These selectivity and specificity of belinostat to cisplatin-resistant cells 
implied for the chemosensitization effects of belinostat in lung SCC cells. Therefore, 
elucidating the underlying mechanisms of belinostat susceptibility may reveal 
chemosensitization strategies with significant clinical implications in lung SCC. 
Our data demonstrated that belinostat suppressed p-Erk1/2, p-MSK1 and p-p38 dose-
dependently in H596 and ChaGo-k-1. In H226, however, Erk1/2 and p38 were 
phosphorylated at low doses but dephosphorylated in high doses (3μM) of belinostat. 
Interestingly, cleavage of PARP in these cell lines corresponded with the deactivation of 
Erk and p38, suggesting that apoptosis is dependent on inhibition of these MAPK pathways 
(Figure 4.4 A). In all three cisplatin-resistant cell lines (Calu-1, H2170, H520), belinostat 
abrogated the expression of p-Erk1/2, p-MSK1 and p-p38, while inducing PARP cleavage 
in a dose-dependent manner (Figure 4.4 B) 
These data confirmed that phosphorylation of Erk1/2, MSK1 and p38 were consistently 
abrogated by belinostat in lung SCC cells, particularly in those with higher tolerability to 
cisplatin. Accordingly, the role of these signal transduction pathways in mediating cisplatin 








Figure 4.4: Phosphorylation of Erk, MSK1, p38 and cleavage of PARP in lung SCC 
cells upon belinostat exposure.  
Western blot analysis was performed to investigate the expression of PARP, Erk, MSK and 
p38 in (A) cisplatin-sensitive (H596, H226, ChaGo-k-1) and (B) cisplatin-resistant (Calu-1, 
H2170, H520) cells. Belinostat (PXD101) was given in increasing doses (0.1, 0.2, 0.3, 1, 
and 3μM) for 48 hours with DMSO (0.03%) as vehicle control. Data shown are 






Summary of findings in Chapter 4.1: 
 
 Genes related to ErbB pathway, MAPK pathway and phosphatidylinositol pathway 
were down-regulated in cisplatin-sensitive cells under pressure of cisplatin 
treatment, but not in cisplatin-resistant cells. 
 Phospho-kinase array analysis showed that p-Erk1/2, p-MSK2 and p-p38α/γ were 
up-regulated in Calu-1 (drug-resistant) cells but suppressed in H596 (drug-sensitive) 
cells after cisplatin treatment. 
 Western blotting analysis showed that Erk1/2 was phosphorylated in cisplatin-
resistant cell lines (Calu-1, H520) and dephosphorylated in cisplatin-sensitive cell 
lines (H596, H226) after cisplatin treatment. 
 These data suggested that p44/42 MAPK signalling might mediate cisplatin 
resistance in lung SCC. 
 Belinostat consistently reduced phosphorylation of Erk1/2, MSK2 and p38 in all 
lung SCC cell lines.  
 Belinostat may sensitize cisplatin-resistant lung SCC cells to cisplatin treatment 













4.2  Impact of cisplatin and belinostat on p44/42 MAPK signalling in lung SCC 
cells  
4.2.1  Differential regulation of MAPK-B-Raf-MEK signalling axis by cisplatin and 
belinostat 
Our analysis showed the persistent abrogation of Erk and MSK by belinostat; while the 
reciprocal regulation of Erk and MSK by cisplatin correlated with cisplatin sensitivities. As 
MSK1 is a down-stream kinase of Erk1/2, these findings suggested that p44/42 MAPK 
signalling may be important in regulation of cell survival in these cell lines. The expressions 
of two upstream molecules of Erk1/2, B-Raf and MEK1/2, were investigated. 
Among the cisplatin-sensitive cell lines, both p-B-Raf and p-MEK1/2 were not affected by 
cisplatin treatment in H226 and ChaGo-k-1 cells, but reduced in H596 cells (Figure 4.5 A). 
Among the cisplatin-resistant cells, p-B-Raf and p-MEK1/2 were found to be up-regulated 
by cisplatin in Calu-1 and H520, but down-regulated at high dose (10μM) in H2170 cells 
(Figure 4.5 B). Similar to the trend of Erk1/2, belinostat suppressed the expression of p-B-
Raf and p-MEK1/2 amongst the 6 lung SCC cell (Figure 4.6 A, B). 
Collectively, a consistent trend in the regulation of B-Raf-MEK-Erk signalling axis by 
cisplatin and belinostat was observed. These findings suggested that activation of p44/42 
MAPK pathway could be associated with cisplatin-resistance in lung SCC cells; while 
abrogation of p44/42 MAPK signalling by belinostat resulted in strong cytotoxicity in these 












Figure 4.5: Regulation of MEK1/2 and B-Raf in lung SCC cell lines upon cisplatin 
treatment.  
Western blot analyses were performed to study the expression of p-B-Raf and p-MEK1/2 in 
(A) cisplatin-sensitive (H596, H226 and ChaGo-k-1); and (B) cisplatin-resistant (Calu-1, 
H2170 and H520) cells after exposure to cisplatin (0.5, 1, 3, 5, and 10μM) for 48 hours. 
Data shown are representative of two independent experiments for the indicated targets with 












Figure 4.6: Belinostat treatment suppressed p-B-Raf and p-MEK1/2 in lung SCC cell 
lines.  
Western blot analyses were performed to study the expression of p-B-Raf and p-MEK1/2 in 
(A) cisplatin-sensitive (H596, H226 and ChaGo-k-1); and (B) cisplatin-resistant (Calu-1, 
H2170 and H520) cells after exposure to belinostat (PXD101) (0.1, 0.2, 0.3, 1 and 3μM) for 
48 hours with DMSO (0.03%) as vehicle control. Data shown are representative of two 











4.2.2  Synergistic combination of belinostat and cisplatin on p44/42 MAPK signalling 
in lung SCC cell lines 
4.2.2.1  Induction of apoptosis in belinostat/cisplatin-treated Calu-1 and H520 cells 
As previously discussed, chemosensitization of HDAC inhibitor was observed in several 
tumour types, with the induction of apoptosis a common outcome (Bangert, Häcker et al. 
2011, Häcker, Karl et al. 2011). The drug combination analysis suggested that cisplatin-
belinostat combination was synergistic. Furthermore, p44/42 MAPK was shown to be 
regulated by the cellular processing of cisplatin and belinostat. Accordingly, it was 
hypothesized that belinostat-induced abrogation of p-Erk1/2 potentiates cisplatin 
cytotoxicity in lung SCC cells.   
Here, the combinatorial effect of belinostat and cisplatin in Calu-1and H520 cells was 
investigated, as both of these cell lines showed significant activation of the MAPK-MEK-
Erk in response to cisplatin treatment. The expressions of two apoptotic markers, PARP and 
caspase 3, were determined to monitor drug-mediated apoptosis. The data showed that p-
MEK1/2 and p-Erk1/2 were abrogated by 1μM belinostat and activated by 10μM cisplatin. 
At the indicated doses, belinostat induced mild cleavage of PARP and caspase 3 in H520 
cells but not Calu-1; while cisplatin treatment triggered cleavage of these apoptotic markers 
in both cell lines (Figure 4.7). When both drugs were incubated simultaneously, ciplatin-
induced p-Erk1/2 and p-MEK1/2 activation was suppressed. Importantly, in relation to the 
down-regulation of p-Erk1/2, combination treatment potentiated the cleavage of PARP and 
caspase 3 in relative to single drug treatment (Figure 4.7). 
These data clearly demonstrated that through inhibiting cisplatin-activated p44/42 MAPK 
signalling, belinostat enhanced the induction of apoptosis in two cisplatin-resistant cell lines 
(Calu-1 and H520), thus supporting the hypothesis. Such findings revealed a novel 











Figure 4.7: Belinostat suppresses phosphorylation of Erk1/2 in cisplatin-treated cells, 
and triggers cleavage of PARP and caspase 3.  
Western blot analyses were performed on cisplatin-resistant Calu-1 and H520 cells after 
cisplatin (10μM), belinostat (PXD101) (1μM) and combination treatment with DMSO 
(0.01%) as vehicle control. Western blot data shown are representative of three independent 













4.2.2.2  Nuclear/cytosolic localization of p-Erk1/2 in belinostat- and cisplatin-treated 
Calu-1 and H596 cells 
The Erk phosphorylation cascade plays an important role in the intracellular signalling that 
controls cell proliferation, differentiation and survival. Erk regulates growth factor-
responsive targets in the cytoplasm, as well as translocates to the nucleus for activation of 
downstream transcription factors (Brunet, Roux et al. 1999, Wada and Penninger 2004). In 
current chapter, through identifying the translocalization of phosphorylated Erk1/2 in both 
Calu-1 and H596 cells, the mechanisms involved in cisplatin/belinostat-mediated p44/42 
MAPK signalling in lung SCC were examined. 
Immunofluorescence staining showed accumulation of p-Erk1/2 in Calu-1 cells after 
cisplatin treatment and reduction after belinostat treatment (Figure 4.8 A). High content 
analysis was subsequently performed through segmentation of nuclear and cytoplasmic 
regions to investigate the localization of p-Erk1/2 in Calu-1 cells. The data showed that the 
activated Erk1/2 was increased by 2-fold in cytoplasm and 1.5-fold in the nucleus upon 
cisplatin treatment, while belinostat reduced cytoplasmic and nuclear p-Erk1/2 by about 5-
fold (Figure 4.8 B, C). When administered together, belinostat suppressed the cytoplasmic 
activation and nuclear translocation of p-Erk1/2 (Figure 4.8 B, C). In the H596 cell, 
however, cisplatin treatment did not induce nuclear or cytoplasmic p-Erk1/2 accumulation. 
When belinostat was administered singly or in combination, both cytoplasmic and nuclear 
p-Erk1/2 were reduced (Figure 4.9 A, B, C).  
These observation in p-Erk1/2 staining corresponded with the Western blotting analysis. 
Cisplatin treatment up-regulated p-Erk1/2, and coincided with the increase in cytoplasmic 
accumulation and nuclear translocation in cisplatin-resistant Calu-1 but not cisplatin-
sensitive H596. On the contrary, belinostat suppressed p-Erk1/2 in both cell lines, and 
notably inhibited cisplatin-induced nuclear translocation of p-Erk1/2 in Calu-1 cells. These 
suggested that Erk1/2 was differentially regulated in cisplatin-resistant and –sensitive cells, 




Figure 4.8: Belinostat inhibits nuclear translocation of Erk1/2 in cisplatin-treated 
Calu-1 cells.  
Cisplatin-resistant Calu-1 cells were treated with belinostat (PXD101) (1μM), cisplatin 
(10μM) and combination treatment with DMSO (0.01%) as vehicle control for 48 hours. 
Immunofluorescence staining was performed to determine the translocalization of p-Erk1/2 
(Alexa Fluor-488) in Calu-1 cells. A, Representative confocal fluorescent images at 400x 
magnification were shown for three independent experiments. Grey indicates DAPI and p-
Erk1/2 in single channel; purple indicates DAPI in merge channel; green indicates p-
Erk1/2 in merged channel. High content analyses were performed for p-Erk1/2 signal 
intensity in cell nucleus (B) and cytoplasm (C). Data are normalized against the number of 







Figure 4.9: Belinostat reduces nuclear translocation of Erk1/2 in cisplatin-treated 
H596 cells.  
Cisplatin-sensitive H596 cells were treated with belinostat (PXD101) (1μM), cisplatin (3μM) 
and combination treatment with DMSO (0.01%) as vehicle control for 48 hours. 
Immunofluorescence staining was performed to determine the translocalization of p-Erk1/2 
(Alexa Fluor-488) in H596 cells. A, Representative confocal fluorescent images at 400x 
magnification were shown for three independent experiments. Grey indicates DAPI and p-
Erk1/2 in single channel; purple indicates DAPI in merged channel; green indicates p-
Erk1/2 in merged channel. High content analyses were performed for p-Erk1/2 signal 
intensity in cell nucleus (B) and cytoplasm (C). Data are normalized against the number of 






4.2.3  Upstream regulation of p44/42 MAPK signalling by cisplatin and belinostat in 
lung SCC cells 
4.2.3.1  Regulation of SOS1/SOS2 in cisplatin- and belinostat- treated cells 
Thus far, the data have suggested a correlation between ERK and cellular response to 
cisplatin. However, the factor(s) leading to the differential regulation of p-ERK in relation 
to cisplatin sensitivity remains unclear. It is important to note that EGFR phosphorylation 
was not affected by cisplatin across the panel of SCC cells (data not shown), which 
suggested the involvement of other factor(s) in controlling MAPK/ERK signaling. To 
identify the factor(s), the suppressed genes in cisplatin-treated H596 cells that were 
associated with MAPK signalling were re-evaluated (Table 4.1). Interesting, the genes that 
were profoundly suppressed included Son of Sevenless homolog 2 (SOS2), a key regulator 
of the MAPK signaling cascade. SOS encodes guanine nucleotide exchange protein (GEP). 
GEP is essential for the activation of GTPases through mediating GDP/GTP exchange 
(Cherfils and Zeghouf 2013). In MAPK signalling, SOS1 and SOS2 are two major GEP that 
act as molecular switches that activate Ras (GTPase) (Egan, Giddings et al. 1993). 
Subsequently, the interaction of SOS and Ras triggers the down-stream activation of p44/42 
MAPK signalling (Rogge, Karlovich et al. 1991). Accordingly, it was hypothesized that 
SOS is essential in modulating p-Erk in cisplatin-resistant lung SCC cells.  
As shown in Figure 4.10 A, exposure to cisplatin repressed both SOS1 and SOS2 in H596 
cells, but had no effect in H226 and ChaGo-k-1. In contrast, cisplatin induced the up-
regulation of SOS in Calu-1 and H520, with unchanged expression of SOS in H2170 
(Figure 4.10 B). Importantly, exposure to belinostat resulted in down-regulation of both 
SOS1 and SOS2 in a dose-dependent manner in all tested lung SCC cells (Figure 4.10 C, D).  
Collectively, these data showed the induction of both SOS1 and SOS2 by cisplatin in 2 of 
the 3 resistant cell lines but repressed in cisplatin-sensitive H596 cells. More importantly, 
the observed trends of SOS1 and SOS2 coincided with the patterns in which p44/42 MAPK 
pathway were regulated by cisplatin and belinostat, suggesting that SOS is critical in 





Figure 4.10: Differential regulation of SOS1 and SOS2 by cisplatin and belinostat.  
Western blot analyses were performed to investigate the expression of SOS1 and SOS2 in 
(A) cisplatin-sensitive (H596, H226 and ChaGo-k-1); and (B) cisplatin-resistant (Calu-1, 
H2170 and H520) cells after cisplatin (0.5, 1, 3, 5, and 10μM)  treatment for 48 hours; and 
in (C) cisplatin-sensitive and (D) –sensitive cell lines after belinostat (PXD101) (0.1, 0.2, 
0.3 1 and 3μM) for 48 hours with DMSO (0.03%) as vehicle control. Western blot data 
shown are representative of three independent experiments for the indicated targets with β-







4.2.3.2  Regulatory effects of SOS1/SOS2 in Erk1/2 signalling 
The regulation of SOS1 and SOS2 by co-treatment of cisplatin and belinostat in Calu-1 and 
H520 cells was next investigated. In both cisplatin-resistant lines, belinostat treatment at 
1μM reduced the SOS1 expression while completely abrogated SOS2 expression (Figure 
4.11 A). These trends correlated with the reduction in p-Erk1/2 in these cells when 
belinostat was given singly and in combination (Figure 4.7).  
To validate the association between SOS1/2 and p-Erk1/2, siRNA knockdown was 
performed on both SOS1 and SOS2 in Calu-1 and H520. Mechanistically, individual 
silencing of SOS1 and SOS2 was associated with decreased Erk1/2 phosphorylation (Figure 
4.11 B). Despite achieving complete disruption of SOS1 through siRNA interference, 
knockdown of SOS2 alone appeared to be ineffective; interestingly, expression of SOS1 
was reduced when silencing of SOS2 was conducted (Figure 4.11 B). However, when both 
siRNA were delivered, SOS1 and SOS2 were successfully abrogated (Figure 4.11 B). This 
suggested the essential role of SOS1 in maintaining SOS2 stability. Finally, ablation of both 
SOS1 and SOS2 profoundly suppressed expression of p-Erk1/2 (Figure 4.11 B). 
Taken together, SOS1 and SOS2 are shown to be regulatory upstream molecules of Erk1/2 
in lung SCC cells. Therefore, induction of SOS1 and SOS2 leading to activation of the 
MAPK-Erk axis may be an important mechanism of cisplatin resistance, which could be 









Figure 4.11: Silencing of SOS1 and SOS2 suppresses Erk1/2 phosphorylation.  
A, Regulatory effect of belinostat (1μM), cisplatin (10μM) and combination treatment on 
SOS1 and SOS2 in cisplatin-resistant Calu-1 and H520 cells using western blotting. DMSO 
(0.01%) was treated as vehicle control. B, Western blot analyses on the regulation of p-
Erk1/2 after SOS1 and SOS2 siRNA-silencing in Calu-1 and H520 cells. 50nM of siRNA 
was used per transfection. Western blot data shown are representative of three independent 










Summary of findings in Chapter 4.2: 
 
 Upstream kinases of Erk (B-Raf, MEK) were phosphorylated in cisplatin-resistant 
cell lines (Calu-1, H520) and dephosphorylated in cisplatin-sensitive cell lines 
(H596, H226) after cisplatin treatment. 
 Belinostat abrogated both p-B-Raf and p-MEK1/2 in all tested lung SCC cell lines. 
 Combination of belinostat and cisplatin suppressed cisplatin-induced p-Erk1/2 and 
p-MEK1/2 in Calu-1 and H520 cells. 
 Combination of belinostat and cisplatin potentiated the induction of apoptosis.  
 Cisplatin pressure increased nuclear and cytoplasmic p-Erk1/2 levels in Calu-1 
(drug resistant) cells but not H596 (drug sensitive) cells. 
 Combination of belinostat and cisplatin suppressed cisplatin-induced cellular 
accumulation and nuclear translocation of p-Erk1/2 in Calu-1 cells. 
 Cisplatin treatment up-regulated SOS1 and SOS2 in Calu-1 and H520 cells, which 
corresponded with the increase in p-Erk1/2. 
 Belinostat treatment consistently down-regulated expressions of SOS1 and SOS2 in 
all lung SCC cell lines. 
 Combination of belinostat and cisplatin suppressed cisplatin-induced SOS1 and 
SOS2 in Calu-1 and H520 cells. 
 siRNA silencing of both SOS1 and SOS2 effectively abrogated p-Erk1/2 in Calu-1 






4.3  Targeting p44/42 MAPK signalling in cisplatin-resistant lung SCC cells 
4.3.1  Silencing of Erk1/2 increases cisplatin cytotoxicity in lung SCC cells 
Thus far, Erk1/2 activation is shown to be associated with a lack of cytotoxic response to 
cisplatin treatment in two cisplatin-resistant lung SCC cell lines. However, a direct 
connection between p44/42 MAPK pathway and cisplatin cytotoxicity has not been 
established. In order to evaluate the impact of p44/42 MAPK inhibition in cisplatin 
cytotoxicity, gene-silencing was performed on Erk1/2 at 24 hours prior to treatment with 
increasing doses of cisplatin, and cell viability of Calu-1 and H2170 cells was examined 24 
and 48 hours after drug treatment. The data suggested that siRNA knockdown of Erk1/2 
significantly reduced expression of activated p-Erk1/2 in Calu-1 and H2170 cells at 48 
hours (Data not shown) and 72 hours post-transfection (Figure 4.12 C, D). Down-regulation 
of either Erk1 or Erk2 led to decreased cell viability in Calu-1 and H2170 cells, while 
combined knockdown further potentiated the growth inhibitory effects of cisplatin in a dose-
dependent manner at 48 hours post-treatment (72 hours post-transfection) (Figure 4.12 A, 
B).  
In comparison with scrambled control-transfected cells, ablation of Erk1/2 shifted the dose-
response curve to the left and reduced the IC50 to cisplatin by more than 2 fold in all 3 
cisplatin-resistant cell lines tested (Calu-1, H2170, H520) (Figure 4.13 A, C, D). As Erk 
signalling is mainly regulated by MEK1/2 in the Ras/Raf/MEK/Erk/MAPK pathway, 
siRNA silencing of MEK1/2 was conducted in Calu-1 cells. Ablation of MEK1/2 led to 
abrogation of MEK1/2 and Erk1/2 phosphorylation, and had similar effects as Erk 
knockdown in reducing cisplatin IC50 in Calu-1 cells (Figure 4.13 B). 
These data demonstrated the positive contribution of both Erk1 and Erk2 to cell 
proliferation under drug pressure. Reduced expression of both kinases was essential for 
effective enhancement of growth inhibition. However, despite showing silencing of Erk1/2 
at 48 hours post-transfection, substantial inhibition of cell proliferation was only observed 
72 hours post-transfection (48 hours post-treatment). This observation suggests that Erk-
dependent downstream regulation, rather that immediate Erk signalling, is essential for 
cisplatin sensitization. Furthermore, silencing of MEK1/2 and Erk1/2 indicated that 







Figure 4.12: Individual and dual silencing of Erk1/2 increases cisplatin sensitivities in 
cisplatin-resistant cells.  
Cell viability of (A) Calu-1 and (B) H2170 cells upon cisplatin treatment (24 hours and 48 
hours post-treatment) after Erk1, Erk2 and combined knockdown was measured with MTS 
assay. Data are presented as mean ± SD (n = 4). Western blotting validation of Erk siRNA 
silencing in (C) Calu-1 and (D) H2170 cells at 48 hours post-treatment. Western blot data 
shown are representative of three independent experiments for the indicated targets with β-








Figure 4.13: Silencing of Erk1/2 enhances cisplatin cytotoxicity in cisplatin-resistant 
cells.  
Cisplatin IC50 of Calu-1 cells with respective Western blot validation after (A) Erk1/2 and 
(B) MEK1/2 siRNA silencing. Cisplatin IC50 of (C) H2170 and (D) H520 cells with 
respective Western blot validation after Erk1/2 siRNA silencing (72 hours post-treatment). 
50nM of siRNA was used per transfection. Cisplatin was administered for 72 hours. Data 
are shown as average ± SD for three independent experiments. Western blot data shown are 
representative of three independent experiments for the indicated targets with β-actin as 
input control. Statistical analyses were performed by unpaired t-test. *Significant difference 








4.3.2  Pharmacological inhibition of p44/42 MAPK signalling increases cisplatin 
cytotoxicity in lung SCC cells 
Thus far, inhibition of p44/42 MAPK signalling is shown to enhance cell death in the 
context of cisplatin resistant cell lines. To place clinical relevance to these findings, 
inhibition MAPK/MEK/Erk pathway was performed in concurrent with cisplatin treatment. 
Several pharmacological inhibitors of the EGFR/Ras/Raf/MEK/Erk pathway: EGFR 
antibody (Cetuximab), B-Raf small-molecule inhibitor (GDC0879), and multiple MEK 
inhibitors (PD0325901, RDEA119 and GSK1120212), were tested on Calu-1 cell line. 
Calu-1 has wild-type EGFR and B-raf but mutant Kras. 
The sub-lethal doses of these inhibitors in Calu-1 cells were determined with cell 
proliferation assay (Data not shown). Cetuximab (25μg/mL) treatment did not affect 
downstream signalling of MAPK/Erk; GDC0879 (10μM) treatment reduced p-B-Raf, but 
up-regulated p-MEK1/2 and p-Erk1/2. On the contrary, MEK inhibitors did not prevent 
phosphorylation of MEK1/2 by B-raf, but inhibited MEK functions and abrogated p-Erk1.2 
(Figure 4.14 D). Cetuximab and GDC0879 did not sensitize Calu-1 cells to cisplatin 
treatment (Figure 4.14 A). However, co-incubation of cisplatin and MEK inhibitors 
significantly lowered cisplatin IC50 (Figure 4.14 B). Similarly, inhibiting activity of MEK in 
H520 cells led to substantial abrogation of p-Erk1/2 as well as sensitization towards 
cisplatin treatment (Figure 4.14 C, E). In addition, co-treatment with MEK inhibitors at 48 
hours potentiated cisplatin-induced apoptosis as shown by the cleavages of PARP and 
caspase 3 in cisplatin-treated Calu-1 cells (Figure 4.15). 
The cytotoxicity of cisplatin and GSK1120212 under anchorage-independent condition was 
next assessed. In Calu-1 cells, GSK1120212 displayed strong inhibitory effects on colony 
forming ability, with significant reduction in colony counts after treatment with 10nM 
(Figure 4.16 A). In H520 cells, GSK1120212 has a high IC50 of 1.9μM, but was synergised 
with cisplatin. Reducing its IC50 from 193nM to 132nM (Figure 4.16 B, C), with a CI of 
0.83 and DRI of 1.32 (in relative to cisplatin) (Figure 4.16 D). 
By using 3 different allosteric inhibitors of MEK, it was shown that suppression of Erk1/2 
activation by MEK1/2 at sub-lethal doses consistently augmented cisplatin cytotoxicity 
through induction of apoptosis in lung SCC cells. Moreover, GSK1120212 produces 
favourable growth inhibition on Calu-1 and H520 cells under anchorage-independent 
condition. Therefore, inhibition of Erk appeared to be a clinically applicable therapeutic 





Figure 4.14: MEK inhibitors enhance cisplatin cytotoxicity in cisplatin-resistant cells.  
A, Bar charts show cisplatin IC50 of Calu-1 cells after co-treatment with DMSO, Cetuximab 
(25μg/mL) or GDC0879 (10μM). Bar charts show cisplatin IC50 of (B) Calu-1 and (C) H520 
cells after co-treatment with DMSO or MEK inhibitors (PD0325901, RDEA119 and 
GSK1120212). Drugs were treated for 72 hours. Data are presented as mean ± SD for three 
independent experiments. D, western blot analyses were performed on Calu-1 cells treated 
with DMSO (0.1%), Cetuximab, GDC0879, or MEK inhibitors. E, Western blot analyses 
were performed on H520 cells treated with DMSO (0.01 or 0.015%) or MEK inhibitors. 
Western blot data shown are representative of three independent experiments for the 
indicated targets with β-actin as input control. Statistical analyses were performed by 
unpaired t-test. *Significant difference from vehicle control, P < 0.05. 






Figure 4.15: MEK inhibitors potentiate apoptosis in cisplatin-treated Calu-1 cells. 
Western blot analyses were performed on Calu-1 cells treated with DMSO (0.01%), 
cisplatin (10μM), MEK inhibitors (1μM of PD0325901, RDEA119 or GSK1120212) or 
combination treatment for 48 hours. Western blot data shown are representative of three 







Figure 4.16: Cytotoxicity of GSK1120212 and cisplatin in Calu-1 and H520 cells under 
anchorage-independent condition.  
Soft agar colony forming assay was performed to determine the sensitivities of lung SCC 
cells to cisplatin and GSK1120212 under anchorage-independent condition. Representative 
images for colony formations and dose-dependent colony inhibitions in Calu-1 (A) and 







treatment. Cisplatin and GSK1120212 were combined at 1:1 ratio at the indicated doses. 
Reduction in colony formation was determined by MTT assay. IC50 are shown as mean ± 
SD (n = 3). D, Combination index (CI) and dose reduction index (DRI) of cisplatin for 
H520 cells in soft agar assay are assessed. The nature of drug interaction is defined as 
synergism (CI < 0.8), additive effect (0.8 < CI < 1.2), and antagonism (CI > 1.2). Data are 
















Summary of findings in Chapter 4.3: 
 
 siRNA silencing of MEK1/2 suppressed phosphorylation of Erk1/2. 
 siRNA silencing of Erk1/2 or MEK1/2 sensitized lung SCC cell lines to cisplatin 
treatment. 
 Cetuximab did not affect MAPK signalling in Kras mutant Calu-1 cells. 
 B-Raf inhibitor (GDC0879) abrogated phosphorylation of B-Raf but does not affect 
phosphorylations of MEK and Erk. 
 Both Cetuximab and GDC0879 did not sensitize Calu-1cells to cisplatin treatment. 
 MEK inhibitors (RDEA119, PD0325901 and GSK1120212) induced cellular 
accumulation of p-MEK1/2 and effectively abrogated p-Erk1/2 in Calu-1 and H520 
cells. 
 Sub-lethal doses of MEK inhibitors potentiated cisplatin-induced apoptosis in Calu-
1 cells. 
 Calu-1 cells were sensitive to GSK1120212 under anchorage-independent condition. 
 Synergistic combination of cisplatin and GSK1120212 was observed in H520 cells 







4.4  High p-Erk1/2 expression correlates with shorter progression-free survival in 
HNSCC patients after adjuvant chemotherapy 
It was hypothesized that Erk1/2 activity correlates with occurrence of cisplatin resistance. 
To test the hypothesis that strong Erk1/2 activity-induced cisplatin resistance in SCC, 
clinicopathological analysis was conducted on SCC samples with interval to tumour relapse 
as assessment endpoint. However, acquisition of post-treatment biopsies was technically 
difficult for retrospective studies. Therefore, a retrospective study was conducted to analyse 
the correlation between p-Erk1/2 expression and clinical outcome in SCC. For current study, 
archival resected SCC specimens were retrieved from the Department of Pathology, NUH. 
Lung SCC samples selected for NGS analysis in Chapter 3.1 was initially used for this 
analysis. However, the assessment of clinical data for these lung SCC samples was 
restricted as most lung SCC patients were not treated with single-agent cisplatin, and the 
correlation of p-ERK expression and patient survival may be confounded by the addition of 
a second chemotherapeutic agent. Therefore, clinicopathological analysis was conducted on 
SCC of the head and neck (HNSCC) instead where concurrent single-agent cisplatin 
treatment with radiotherapy is the standard first-line regime. It is generally accepted that 
HNSCC share similar etiology and histopathological characteristics of SCC of the lung. 
(Kaufmann, Fietze et al. 2001, Day, Davis et al. 2003, Agrawal, Frederick et al. 2011, 
Stransky, Egloff et al. 2011). The characteristics of this patient population were presented in 
Figure 4.18 B. Treatment was in the form of a combined modality: surgical resection 
followed by concurrent chemoradiation or primarily concurrent chemoradiation followed by 
salvage surgery for persistent disease. In all patients, the chemotherapy regime was the 
weekly administration of 40 mg/m2 cisplatin of at least 5 cycles of treatment. 
A total of 45 head and neck SCC (HNSCC) paraffin embedded specimens who underwent 
surgery in 2003 – 2010 were obtained and analysed under protocols (Chapter 2.11) 
approved by NUHS Institutional Review Board (IRB). The strength and intracellular 
distribution of p-Erk1/2 expression were evaluated by IHC with anti-p-Erk1/2 antibody 
(Table 2.22). As described in Chapter 4.2.2, Erk activity could be determined by the 
nuclear/cytosolic translocalization of the phosphorylated protein. To investigate the Erk 
level activity in the tissue specimens, whole tissue sections were scored based on staining 
intensity (0 – 3), stained region (nuclear or cytoplasmic) and intracellular distribution of 
stained tumour (0 – 100%). Stained tissues showed different expression patterns with 3 
specimens having no p-Erk1/2 staining. In HNSCC specimens, 1 tumour showed only 
cytoplasmic p-Erk1/2 staining (Figure 4.17 A), while others showed different intensities of 
cytoplasmic and nuclear staining: low intensity (1) (Figure 4.17 B), moderate intensity (2) 
(Figure 4.17 C) and high intensity (3) (Figure 4.18D). Immunoreactive score (ranging from 
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0 to 300) was obtained for each specimen as described in Chapter 2.11.6. Data were then 
grouped into multiple scoring groups (0 – 50; 51 – 100; 101 – 150; 151 – 200; 201 – 250; 
251 – 300). The evaluation of proportion of specimens in each scoring group is shown in 
Figure 4.17 E.   
Detailed clinical records of these cases, which include time to tumour progression, were 
collected from the Computerized Patient Support System (CPSS).  Staining data of p-Erk1/2 
from HNSCC patients were split into high (immunoreactive score > 50; n = 27) and low 
(immunoreactive score < 50; n = 18) scoring categories. Patients who died from factors not 
related to the disease and those who were not followed up during the observation period 
were excluded in the subsequent analysis (censored) as indicated by vertical ticks in Figure 
4.18 A. The disease-free survival (DFS)—defined as the interval between the 
chemoradiation completion to the first histologically or radiologically confirmed tumor 
recurrence locally in the head and neck region or distant metastases—was presented using 
Kaplan–Meier analysis for 45 patients who provided consent for the use of their patient data. 
Significantly shorter DFS was determined for patients with higher expression of p-ERK 
(log-rank test, P = 0.02) (Figure 4.18 A), suggesting that activation of the MAPK/ERK 
pathway is predictive of cisplatin efficacy in the treatment of SCC. It is important to note 
that human papillomavirus (HPV) is a known cause of HNSCC and is associated with better 
prognosis (Liang, Marsit et al. 2012). Using p16 as a surrogate biomarker for HPV infection, 
four patients from each of the p-ERK high and low groups were p16 positive (Figure 4.18 
B). Therefore, the HPV status is not likely a confounding variable in the association of p-
ERK and DFS among the HNSCC cases. 
In conclusion, the clinicopathological analyses demonstrated that high p-Erk1/2 in HNSCC 
contributed to shorter DFS. Interestingly, most positively-stained tumours expressed p-
Erk1/2 in both nucleus and cytoplasm, suggesting both nuclear-bound and cytoplasmic p-








Immunoreactive score No. of specimens 
0 – 50 17 
51 – 100 3 
101 – 150 6 
151 – 200 5 
201 – 250 9 
251 – 300 5 
 
Figure 4.17: p-Erk1/2 staining in human HNSCC tumurs.  
A panel of tissue sections derived from 33 HNSCC patients with known case histories was 
analysed for intracellular distribution of p-Erk1/2 by IHC. Intensities of p-Erk1/2 were 
scored. A, Photomicrograph revealed tumour with predominantly p-Erk1/2 staining at 
cytoplasms than that in nuclei. B – D, Photomicrographs revealed tumours with p-Erk1/2 
staining at both cytoplasms and nuclei. Representative images for positively stained tumours 
with intensity of 1 (B), 2 (C) and 3 (D) were shown. E, Distribution of the immunoreactive 
scores [intensity of p-Erk1/2 (0 – 3) x fraction of stained tumour cells (0 – 100%)] in all 
HNSCC samples was shown. All photomicrographs where taken in 400x magnification. 
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Figure 4.18: High p-Erk1/2 correlates to poor disease-free survival in patients with 
HNSCC following adjuvant cisplatin therapy. 
Intracellular p-Erk1/2 distribution (Figure 4.17) was analysed in all HNSCC samples. A, 
Kaplan Meier curves for DFS are plotted for the high and low p-ERK1/2 populations. Tick 
marks indicate patients for whom data was censored (Data cutoff point: June 2014). B, 
Baseline characteristics of the head and neck squamous cell carcinoma (HNSCC) population, 
classified according to the p-ERK1/2 scoring.Statistical analysis was performed using Chi-
squared test with Gehan-Breslow-Wilcoxon Test. Significant difference between the two 





Summary of findings in Chapter 4.4: 
 
 Immunoreactive scoring of p-Erk1/2 was performed on 45 HNSCC specimens. 
 p44/42 MAPK activity in tumour cells is indicated by nuclear and cytosolic 
accumulation of p-Erk1/2. 
 Patients with higher p-Erk1/2 expression in their tumours had significantly higher 5-
year DFS rates that those with low p-Erk1/2 after adjuvant chemotherapy. 
 p-Erk1/2 expression is a potential predictive biomarker for adjuvant cisplatin 






4.5  Discussion 
4.5.1  The molecular mechanisms of cisplatin resistance in lung SCC 
Over the past 30 years, multiple mechanisms have been proposed to describe cisplatin 
resistance with intensive studies being conducted on clinical settings whereby cisplatin 
represent the major therapeutic intervention, which include ovarian carcinoma, NSCLC, 
head and neck cancer and cervical cancer (Muggia 1991, Lebwohl and Canetta 1998). 
However, despite being the standard-of-care treatment for lung SCC, the underlying 
cisplatin resistant mechanism(s) have not been exploited in this disease.  
In this chapter, the activation of survival signalling that confer cisplatin resistance in lung 
SCC were discussed. Through comparative analyses on the transcriptomic and phospho-
kinetics perturbations (Chapter 4.1), cisplatin treatment was shown to induce differential 
modulation of p44/42 MAPK signalling between the sensitive and resistant phenotypes. 
Cisplatin sensitive cells displayed decreased mRNA expression of MAPK signalling 
pathway-related genes and down-regulation of phospho-MAPK (B-Raf, MEK1/2, Erk1/2 
and MSK1). Conversely, activation of MAPK/Erk was a common phenomenon among 
resistant cell lines. This observation is consistent with previous studies which showed 
stimulation of Erk signalling in a time- and dose-dependent manner upon exposure to 
cisplatin (Cui, Yazlovitskaya et al. 2000, Wang, Martindale et al. 2000). Furthermore, the 
analyses showed that cisplatin treatment reduced the expression of Akt and JNK in both 
resistant and sensitive cell lines (Chapter 4.1.2), while p38 was regulated in random patterns 
(Chapter 4.1.3), thus downplaying the relevance of these kinases in cisplatin resistance. The 
striking differences on cisplatin-induced p44/42 MAPK signalling between resistant and 
sensitive phenotypes implicate the involvement of this pathway in cisplatin resistance. 
Members of the MAPK signalling family (JNK, p38 and Erk) are crucial for the 
maintenance of cellular processing. Erk has been original shown to be important for cell 
survival, while JNK and p38 are widely deemed to mediate cell death (Xia, Dickens et al. 
1995). However, the role of MAPK/Erk in apoptosis regulation is more complicated that 
initially thought as there have been conflicting reports on the functions of Erk in cisplatin-
induced response (Wada and Penninger 2004). While some studies have demonstrated that 
Erk activation promotes cellular survival of cisplatin-treated ovarian and melanoma cancer 
cells (Hayakawa, Ohmichi et al. 1999, Persons, Yazlovitskaya et al. 1999, Wang, Zhou et al. 
2007), several other reports have emphasized the involvement of Erk in cisplatin-induced 
apoptosis (Dent and Grant 2001, Mandic, Viktorsson et al. 2001, Yeh, Chuang et al. 2002). 
These conflicting reports suggest that the relationship between Erk activation and cisplatin 
cytotoxicity is cell-context dependent and could vary among different types of cancer. 
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The role of Erk in determining cellular survival/death in lung SCC cells under cisplatin 
pressure was investigated in this study. The data suggested that siRNA-mediated depletion 
of Erk activity could enhance cisplatin cytotoxicity in several lung SCC cells, while the 
similar observations were seen after silencing of MEK (Chapter 4.3.1). These observations 
provided compelling evidence that p44/42 MAPK signalling favours cell survival instead of 
cell death in cisplatin-treated SCC cells. Interestingly, belinostat specifically disrupted 
p44/42 MAPK signalling in lung SCC lines through suppressing B-Raf, MEK1/2, Erk1/2 
and MSK (Chapter 4.1.3, Chapter 4.2.1). Furthermore, cisplatin-induced up-regulation of 
Erk activity in resistant cells was abrogated in combination with belinostat (Chapter 4.2.2), 
probably resulted in the synergistic cytotoxicity within lung SCC cells. Some recent studies 
have reported that belinostat could repress proliferation of thyroid cancer cells and displayed 
synergistic combinatorial effects with doxorubicin, paclitaxel, pazopanib and dasatinib, 
partially through suppression of Erk signalling (Chan, Zheng et al. 2013, Lin, Lin et al. 
2013). These findings implicate that belinostat possibly sensitizes lung SCC cells to 
cisplatin through inhibition of p44/42 MAPK signalling, 
 
4.5.2  Regulating p44/42 MAPK signalling in lung SCC 
As illustrated in Figure 4.19, the p44/42 MAPK signal transduction pathway is a chain of 
cellular proteins that forms a signalling network linking extracellular stimuli to 
transcriptional activities. Key components of p44/42 MAPK signalling include membrane 
spanning RTK (EGFR), GTPase exchange factors (GEFs) (SOS1, SOS2), GTPase 
activating proteins (GAPs), GTPase binding protein (Ras), kinase cascade (Raf, MEK, Erk) 
and downstream effector kinases [MAPK-interacting kinase (MNK), Ribosomal Protein S6 
kinse (RSK), and MSK] (Buday and Downward 1993, Huang, Marshall et al. 1993). Briefly, 
extracellular signal such as EGF activates the tyrosine kinase activity through 
phosphorylation of the cytoplasmic domain of the receptor, which then recruits Growth 
Factor Receptor Bound Protein 2 (GRB2) (Schulze, Deng et al. 2005) and subsequently 
activates SOS constitutively (Rogge, Karlovich et al. 1991, Li, Batzer et al. 1993). Activated 
SOS molecules facilitate the GDP-GTP exchange  of Ras, allowing it to interact with Raf 
(Avruch, Khokhlatchev et al. 2001). This triggers the activation of Erk kinase cascade, by 
which Raf phosphorylates MEK1/2 and MEK phosphorylates Erk1/2. Upon its activation, 
Erk could indirectly regulate transcription by phosphorylating cytosolic RSK and MNK, 
two transcription factors that regulate cell proliferation through cAMP response-element 
binding (CREB) signalling (Chen, Sarnecki et al. 1992, Waskiewicz, Flynn et al. 1997); or 
directly translocates into the nucleus for phosphorylation of target kinases, such as MSK1 





Figure 4.19: Regulation of the p44/42 MAPK signalling pathway.  
The MAPK pathway could be triggered by binding of EGF to EGFR and assembly of a 
signalling complex that include Src-homology and collagen homology (SHC), GRB2 and 
SOS. This leads to the induction of p44/42 MAPK signalling: SOS activates Ras; Ras 
activates Raf: Raf activates MEK1/2; MEK1/2 activates Erk1/2; and Erk1/2 activates RSK, 
MNK and MSK. 
 
Collectively, the p44/42 MAPK pathway functions as a key regulator for cellular 
proliferation, survival, differentiation and apoptosis. Dysregulations of Erk cascade that lead 
to its inappropriate activation are common aberrations in tumourigenesis (Blume-Jensen and 
Hunter 2001). For instant, EGFR mutations are frequently detected in lung cancer (Blume-
Jensen and Hunter 2001); while Ras mutations are found in almost one-third of all human 
cancer (Pylayeva-Gupta, Grabocka et al. 2011). However, in line with the genomic 
characterization reported by TCGA (Network 2012), the analysis suggested that somatic 
mutations of EGFR and its family members are lacking among lung SCC and cell lines 
(Chapter 3.1). Therefore, the sustained activity of Erk signalling was proposed as a cisplatin 
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resistance mechanism. In this study, up-regulation of SOS (Chapter 4.2.3.1), constitutive 
activation of Erk1/2 (Chapter 4.1.3), nuclear translocation of activated Erk (Chapter 4.2.2.2), 
and phosphorylation of MSK1 (Chapter 4.1.3) occurred simultaneously in cell lines that are 
more tolerable to cisplatin. Taken together, it is likely that in cisplatin-resistant cells, Erk1/2 
is activated via regulation of SOS under cisplatin pressure, and eventually promotes cellular 
survival through downstream activation of MSK and other transcription factors (Deak, 
Clifton et al. 1998, Brunet, Roux et al. 1999) (Figure 4.20). Therefore, a novel correlation 
between SOS and B-Raf-MEK-Erk signalling in conferring cisplatin resistance was 
proposed in lung SCC cells.  
In the present study, belinostat was shown to effectively abrogate p44/42 MAPK activity in 
concurrent with the down-regulation of SOS expressions in all lung SCC cell lines (Chapter 
4.2.3.1). It was further demonstrated that gene silencing of SOS1 and SOS2 significantly 
attenuated Erk phosphorylation in lung SCC cell lines irrespective of the mutational status 
of Kras (Calu-1), suggesting that belinostat negatively regulated the p44/42 MAPK pathway 
by suppression of SOS molecules (Chapter 4.2.3.2). However, currently available SOS 
inhibitors are limited only to research purposes (Patgiri, Yadav et al. 2011, Maurer, 
Garrenton et al. 2012). Therefore, these findings highlighted the need for strategies that 






Figure 4.20: Activation of p44/42 MAPK via SOS up-regulation as a mechanism of 
cisplatin resistance in lung SCC cells and selection of inhibitors for suppression of Erk 
signalling.  
Cisplatin treatment induces activation of Raf/MEK/Erk/MSK in cisplatin-resistant lung SCC 
cells through up-regulation of SOS1 and SOS2. Belinostat (PXD101) deactivates p44/42 
MAPK through inhibition of SOS; Cetuximab turns off EGFR signalling; GDC0879 blocks 
B-Raf activity; MEK inhibitors (PD0325901, RDEA119 and GSK1120212) block Erk1/2 
activity through allosteric inhibition of MEK1/2. 
 
4.5.3  Targeting p44/42 MAPK as a chemosensitization strategy in lung SCC 
Our findings suggested Erk suppression as the mechanism behind the synergistic 
cytotoxicity of cisplatin and belinostat in lung SCC cell lines. However, with the exception 
of CTCL (Mann, Johnson et al. 2007), clinical trials on HDAC inhibitors have not achieved 
superior progress in advanced solid malignancies despite the strong in vitro anti-neoplastic 
effects (Bradley, Rathkopf et al. 2009, Ramalingam, Belani et al. 2009, Mackay, Hirte et al. 
2010). Thus, the combinatory effects of cisplatin and various MAPK-targeting inhibitors 
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were explored. For years, inhibition of the EGFR/Ras/Raf/MAPK/Erk pathway has been 
one of the key focuses in developing anti-cancer agents. For instance, gefitinib and erlotinib 
have shown improved clinical response in NSCLC patients with EGFR mutation (Paez, 
Jänne et al. 2004, Tsao, Sakurada et al. 2005); B-Raf inhibitor, vemurafenib, has been 
proven to inhibit metastatic melanoma with mutated B-Raf (Flaherty, Puzanov et al. 2010, 
Flaherty, Infante et al. 2012); while several MEK inhibitors have progressed to phase II 
trials on NSCLC and melanoma patients (Haura, Ricart et al. 2010, Catalanotti, Solit et al. 
2013).  
For the current study, several MAPK-targeting inhibitors were selected based on their 
clinical relevance to the disease model. According to COSMIC database, Calu-1 is an EGFR 
wild-type cell line with Kras mutation. Therefore, Cetuximab was chosen over gefitinib and 
erlotinib due to its non-selectivity on the mutational status of EGFR (O'Byrne, Gatzemeier 
et al. 2011, Misale, Yaeger et al. 2012); GDC0879 was selected to inhibit B-Raf; while 
PD0325901, RDEA119, GSK1120212 were selected for MEK inhibition. Cetuximab did 
not affect p44/42 MAPK signalling, probably due to the mutant Kras that constitutively 
activated MEK and Erk (Lièvre, Bachet et al. 2008). Intriguingly, GDC0879 did not affect 
Erk activity of Calu-1 cells despite inhibiting phosphorylation of B-Raf. However, sub-
lethal doses of MEK inhibitors completely abrogated phosphorylation of Erk in Calu-1 cells. 
Among these inhibitors, only MEK inhibitors sensitized Calu-1 to cisplatin treatment 
(Chapter 4.3.2). Consistently, blocking Erk activity in H520 increased cisplatin sensitivity 
as well. Therefore, from a therapeutic perspective, targeting MEK/Erk concurrently with 
cisplatin could improve survival outcome in treatment of SCCs.  
To date, molecularly targeting approaches in lung SCC have achieved limited successes in 
clinical settings. Unlike lung adenocarcinoma, patients with SCCs often provided with 
limited therapeutic options. Identification of biomarkers that could predict sensitivity and 
selection of optimal drug combinations are the two major challenges in designing targeted 
therapy regimen in this disease. This study suggested that attenuation of MEK/Erk activity 
enhanced efficacy of cisplatin. Recently, several MEK inhibitors, such as selumetinib 
(AZD6244) and trametinib (GSK1120212), have progressed to Phase II clinical trial. 
Despite failing to demonstrate superior clinical outcome as a single drug treatment among 
NSCLC patients (Haura, Ricart et al. 2010, Jänne, Shaw et al. 2013), combinations of MEK 
inhibitor with other agents have manifested promising anti-neoplastic activity in several 
clinical trials, particularly among NSCLC patients harbouring Kras mutant. (Chen and 
Sweet-Cordero 2013, Huang, Lee et al. 2013, Jänne, Shaw et al. 2013). Consistently, 
GSK1120212 strongly inhibit colony formation in Kras mutant Calu-1 cells under 
anchorage-independent growth conditions (Chapter 4.3.2). Currently, several active trials 
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are exploring the combination of cisplatin and MEK inhibitors in NSCLC 
(ClinicalTrials.gov Identifier NCT01809210; NCT01192165), but mutation on Kras remains 
as the key selection criteria for these studies. The findings provided strong indication to 
assign MEK/Erk activity as predictive biomarker to recruit patients for these studies. 
Previously, clinical study on treating NSCLC with PD0325901 had been terminated due to 
the ocular and neurological toxicity (ClinicalTrials.gov Identifier NCT00174369; A4581001) 
(Huang, Yang et al. 2009), while serious ocular neuropathy was recognized as common 
dose-limiting toxicity across all MEK inhibitors (Akinleye, Furqan et al. 2013). Both the in 
vitro assays under anchorage-dependent and –independent conditions suggested that low 
doses of MEK inhibitors were sufficient to induce synergic combination with csiplatin 
(Chapter 4.3.2). These findings supported the combination of cisplatin and MEK inhibitor at 
tolerable doses in patients with relapsed to adjuvant cisplatin therapy. 
 
4.5.4  High p-Erk1/2 expression correlates with shorter progression-free survival in 
SCC cases 
Since high p-Erk1/2 has been linked with cisplatin resistance in lung SCC cell lines, the 
clinical relevance of Erk expression in SCC was next investigated. However, selection of 
lung SCC samples was limited due to the lack of appropriate cases that had undergone 
adjuvant chemotherapy with long-term follow-up. In view of these limitations, HNSCC 
samples were utilised as an alternative model to test the hypothesis on p-Erk1/2 expression 
and drug resistance. Interestingly, both lung SCC and HNSCC were often detected in the 
same patient. For instance, patients with laryngeal carcinoma had an increased risk of lung 
cancer (Levi, Randimbison et al. 2003), while pulmonary SCC often developed following 
HNSCC (Geurts, Nederlof et al. 2005). These new lung lesions observed in patients with 
prior history of HNSCC might represent second primary tumours or metastases from 
previously treated head and neck tumours (Leong, Rezai et al. 1998, Geurts, Nederlof et al. 
2005). Furthermore, both lung SCC and HNSCC shared highly similar characteristics, as 
site of origin of SCC were often indistinguishable based on traditional histopathological 
examination. Common SCC markers such as p63 and CK5/6 were positively detected in 
both lung SCC and HNSCC specimens (Kaufmann, Fietze et al. 2001). Furthermore, both 
cancers were shown to share common etiological and risk factors such as tobacco smoking 
(Day, Davis et al. 2003). Moreover, recent studies have demonstrated that HNSCC shared 
multiple genetic alterations common in lung SCC without evidence of HPV infection and 
these include aberrations in TP53, CDKN2A, PTEN, PIK3CA, HRAS and NOTCH1 
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(Agrawal, Frederick et al. 2011, Stransky, Egloff et al. 2011). Taken together, all these 
findings suggested that these two diseases could share similar tumour biology.  
While genetic aberrations in MAPK signalling are not common in lung SCC (Network 2012) 
(Chapter 3.1), the findings in this study have otherwise suggested Erk as a predictive 
biomarker triggered by treatment pressure and could account for cisplatin resistance in lung 
SCC cell lines. Clinically, these findings indicate that Erk activity may facilitate resistance 
to adjuvant cisplatin treatment in SCC, which commonly results in cancer relapse 
(Ledermann and Kristeleit 2010, Beck and Blanpain 2013). The correlation between 
endogenous p-Erk1/2 expression and DFS was examined in the selected HNSCC. Despite 
the well-characterized differential functions of nuclear and cytosolic Erk, high expressions 
of Erk were seen in both regions in most positively stained tumours. This result indicates 
that activation of p44/42 MAPK signalling may involve intracellular accumulation of Erk 
molecules in nucleus and cytoplasm. In concordant with the hypothesis, high expression of 
p-Erk1/2 is found correlated with significantly higher 5-year DFS (Figure 4.18 B).  
Clinically, the analysis on 45 NSCC specimens suggested that p-Erk1/2 could be utilised as 
an independent predictive biomarker for cisplatin treatment outcome in SCC with a clear 
difference in DFS between the high and low scoring categories. Collectively, these findings 
provide ample evidence on p-Erk1/2 as a predictive indicator for shorter DFS among 
HNSCC patients treated with adjuvant cisplatin-containing therapy.  
 
4.5.5  Conclusions and future directions 
Growing understanding of tumourigenesis has led to the development of a wider range of 
anti-neoplastic agents targeting specific oncogenic pathways. However, the current 
understanding of lung SCC suggests a paucity of driver oncogenic mutations (Lynch, Bell et 
al. 2004, Shukuya, Takahashi et al. 2011, Rekhtman, Paik et al. 2012). Furthermore, despite 
showing initial response to cisplatin treatment, lung SCC usually relapsed more 
aggressively by acquiring mechanisms which include pathway redundancy and oncogenic 
bypass (Holohan, Van Schaeybroeck et al. 2013). In the current study, the observation of 
synergistic cytotoxicity on SCC cells with belinostat, a HDAC inhibitor, and cisplatin, a 
standard chemotherapy drug for SCC, has led to an analysis of possible mechanisms to 
explain this.  
In summary, this study describes that up-regulation of MEK/ERK is induced by cisplatin 
treatment in cisplatin-resistant cells and inhibition of this pathway may improve cisplatin 
sensitivity. Although there are other known mechanisms of cisplatin resistance including 
 179 
 
reduced influx transport via the copper transporter, conjugation by glutathione and 
methionine, and enhanced DNA repair, the relative importance of each of these pathways is 
still not defined in SCC. However, given the complexity of drug bioavailability and tumour-
stroma interaction, it remains debatable whether cell lines are suitable models for 
understanding of drug resistance, identification of clinically relevant biomarkers as well as 
evaluation of drug combination. Cancer cell-derived xenograft models that imitate tumour 
microenvironment may provide better assessment of the proposed therapeutic approach. For 
this study, H520-derived xenografts are in progress to evaluate the potency of cisplatin and 
PD0325901.  
Furthermore, the clinicopathological analyses on HNSCC specimens strongly support the 
role of p-Erk1/2 as a predictive biomarker for adjuvant cisplatin chemotherapy. More 
crucially, the data suggest a role for the combined use of cisplatin with the MEK inhibitor, 
or belinostat, for patients with up-regulated MAPK/ERK signaling in SCC of the head and 
neck and lung. Several MEK inhibitors currently undergoing clinical development have 
shown promising endpoint results in various trials on NSCLC (Chen and Sweet-Cordero 
2013, Huang, Lee et al. 2013, Jänne, Shaw et al. 2013). Furthermore, both MEK inhibitors 
and belinostat have demonstrated favorable tolerability profiles and side effects. Cisplatin is 
well established and has a non-overlapping toxicity profile, which lends its potential to be 
combined with a MEK inhibitor or belinostat. For a proof-of-concept, it will be critical to 
study the combination of cisplatin and a MEK inhibitor in patients whose tumors 





CHAPTER 5 Restoration of p53-mediated apoptosis: A gain-of-function 
event in mutant p53 
There has been a rapid advancement in the understanding on the anti-neoplastic activities of 
HDAC inhibitors. As a class of epigenetic therapeutic agents, HDAC inhibitors exert a 
broad spectrum of cellular mechanisms over a range of doses, including cell death, cell 
senescence, and cell differentiation (Chapter 1.5.4.1). The diverse activities of this class of 
compounds have offered much therapeutic potential as anti-cancer agents, however, the 
clinical efficacy of HDAC inhibitors have been limited by the many adverse side effects and 
poor bioavailability (Bruserud, Stapnes et al. 2007, Elaut, Rogiers et al. 2007) (Chapter 
1.5.4.2). It is known that high doses of HDAC inhibitors often favour the induction of cell 
death over cell differentiation (Marks, Richon et al. 2000). In Chapter 4, belinostat at high 
dose (1μM) was shown to sensitize SCC cells to cisplatin through abrogation of p44/42 
MAPK signalling via inhibition of SOS. However, the capacity of belinostat to interfere 
with cellular reprogramming in lung SCC remains unclear. Interestingly, exposure to 
belinostat for 48 hours at a dose as low as 0.1μM was sufficient to acetylate histones (Figure 
3.5), whereas cleavage of PARP was observed only at 1μM (Figure 4.4). This observation 
strongly suggested that at sub-lethal dose, belinostat could mediate alternative cellular 
responses, rather than the direct induction of apoptosis.  
In Chapter 3.1.2 and Chapter 3.2.1, high frequencies of TP53 mutations were detected in 
both lung SCC specimens and cell lines that resulted in dysfunctional DNA-binding 
domains. Furthermore, mutated TP53 has been correlated to poor treatment response to 
cisplatin (O'Connor, Jackman et al. 1997). In line with the current knowledge, the 
transcriptomic analysis (Chapter 3.4.1) revealed that genes related to p53 signalling pathway 
were down-regulated in cisplatin-resistant cell lines. These observations suggested that 
therapeutic strategies which reactivate p53 activities could offer a new strategic approach in 
cancer therapy. Several treatment strategies, including the use of HDAC inhibitors, have 
been exploited to reinstate p53 functions. Apart from affecting histone hyperacetylation and 
restructuring (Grunstein 1997, Gregory, Wagner et al. 2001), HDAC inhibitors have also 
been reported to acetylate and activate a range of non-histone effector molecules which 
include E2F1, GATA, Hsp90, Ku70, NF-κB, Runx, STAT3, and p53 (Minucci and Pelicci 
2006). Importantly, several classes of HDAC inhibitors have shown anti-tumour activities 
through induction of p53 acetylation (Vaziri, Dessain et al. 2001). 
Taken together, it was hypothesized that belinostat sensitize lung SCC cells to cisplatin 
cytotoxicity via cellular reprogramming that activates p53 signaling. To test this hypothesis, 
the chemosensitization effects of belinostat at low doses was explored in cisplatin-treated 
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lung SCC cells. The synergistic cytotoxicity of cisplatin with belinostat (0.1μM) was first 
determined among a panel of lung SCC cell lines. Next, the molecular mechanisms of this 
drug combination were elucidated and correlated to the mutational status of TP53 gene. In 
this chapter, the loss-of-function mutation in p53, synergistic cytotoxicity of belinostat and 






5.1 Combinatorial effect of cisplatin with sub-lethal dose of belinostat in lung SCC 
cell lines 
To first investigate the synergistic effects of cisplatin with low dose of belinostat, induction 
of cell death was analysed in lung SCC cell lines treated with belinostat (0.1μM), cisplatin 
(3 or 10μM) and combination of both agents. Both H2066 and SW900 cell lines were 
omitted from this investigation for the same reason as mentioned in Chapter 4.1.2. 
Regulation of apoptosis was determined by the cleavages of PARP and caspase 3. 
Across the 8 cell lines tested, cisplatin treatment induced minimal apoptosis in Calu-1, H520, 
SK-MES-1 and H226 cells (Figure 5.1 B, C, D, E). Except for H226, all these cell lines 
were classified as cisplatin-resistant cells. Combination with belinostat potentiated 
expression of cleaved PARP and caspase 3 in H226 cells (Figure 5.1 E) but not in Calu-1, 
H520 and SK-MES-1. On the contrary, H2170, H596, H1869 and ChaGo-k-1 were found to 
be more sensitive to cisplatin treatment (Figure 5.1 A, F, G, H). Combination with belinostat 
increased induction of apoptosis in H2170 and H1869 cell lines. 
The differential response of lung SCC cell lines towards cisplatin and sub-lethal dose of 
belinostat suggest that the underlying synergistic cisplatin-mediated cytotoxicity may be 
context-dependent. Cell lines that showed significantly increased apoptosis, especially the 
cisplatin-resistant H2170 cells, were utilised as study models to elucidate the mechanisms of 






Figure 5.1: Effect of belinostat (at 0.1μM) and cisplatin on cleavage of PARP and 
caspase 3 in lung SCC cell lines.  
H2170 (A), Calu-1 (B), H520 (C), SK-MES-1 (D), H226 (E), H596 (F), H1869 (G) and 
ChaGo-k-1 (H) cells were exposed to PXD101 (PXD101) (0.1μM), cisplatin (3 or 10μM), 
or combination treatment for 48 hours. Western blot analysis was performed to investigate 
the expression of PARP and caspase 3. Data shown are representative of two independent 
experiments for the indicated targets with β-actin as input control. 
A B C 




5.2  Transcriptional activation of apoptosis by belinostat and cisplatin in lung SCC 
5.2.1  Induction of apoptosis in H2170 cells by cisplatin and belinostat  
To characterize the cellular apoptotic pathway trigger by cisplatin and belinostat in H2170 
cells, the regulation of pro-survival (Bcl-2, Bcl-xl and XIAP) and pro-apoptotic (BAX, 
caspase 3 and 9) markers was investigated after trug treatment. In Figure 4.3 B and 4.4 B, 
the cleavage of PARP was shown to be induced by cisplatin and belinostat respectively. The 
data here further demonstrated that both cisplatin and belinostat triggered dose-dependent 
cleavage of caspase 9 and 3. Cisplatin down-regulated Bcl-2 and Bcl-xl but had minimal 
effect on XIAP, while belinostat reduced expression of Bcl-xl and XIAP but not Bcl-2 
(Figure 5.2). Expression of BAX was unchanged for both treatments, probably due to the 
oversaturation of this protein in whole cell lysate. 
Taken together, these data suggested differences in apoptotic activation for the two agents. 
Despite inducing acetylation of H3 and H4 at low doses (0.1μM) (Figure 3.5), belinostat 
triggered cellular apoptosis only at higher doses. Interestingly, as shown in Figure 5.1, 
combination of cisplatin with low doses of belinostat remarkably potentiated apoptosis in 
several lung SCC cell lines. Thus, exploring the mechanisms that lead to the observed 










Figure 5.2: Cisplatin and PXD101 initiate apoptosis in H2170 cells in a dose-dependent 
manner.  
H2170 cells were exposed with cisplatin (0.5, 1, 3, 5, 10μM) or PXD101 (PXD101) (0.1, 
0.2, 0.3, 0.5, 1μM) for 48 hours. Western blot analysis was performed to investigate the 
expression of PARP, BAX, Bcl-2, Bcl-xl, XIAP, caspase 9 and caspase 3. Data shown are 











5.2.2  Belinostat induces acetylation of histones and nuclear proteins in cisplatin-
treated H2170 cells 
Next, the mechanisms by which belinostat enhanced cisplatin cytotoxicity was elucidated. 
As belinostat was developed as a HDAC inhibitor, the degree of histone acetylation was 
examined under exposure of belinostat/cisplatin. Experiments were conducted on H2170 
cells. While cisplatin alone did not induce acetylation of histones, belinostat consistently 
induced acetylation of both H3 (Lys23, Lys9/14) and H4 at 0.1μM with and without 
exposure to cisplatin, confirming its ability to acetylate histone proteins at this low 
concentration (Figure 5.3 A). As HDAC inhibitors are known to alter the acetylation of non-
histone effectors, immunofluorescence staining was conducted to detect the extent of lysine 
acetylation when exposed to belinostat. The data showed an accumulation of acetyl-lysine in 
belinostat-treated cells (Figure 5.3 B). As the detected acetylation was mainly nuclear-
bound, these data thus support that belinostat mainly modifies acetylation of nuclear 
proteins, including histones and non-histone transcriptional factors (Glozak and Seto 2007). 
Modification of cellular acetylation by belinostat at a sub-lethal dose implies that the 
observed synergy between cisplatin and belinostat could be accounted for by two possible 
mechanisms: (1) transcriptional activation of apoptosis-related genes through histone 
acetylation; and (2) modulation of cellular apoptosis through acetylation of non-histone 
targets. These mechanisms could potentially lead to the sensitization of H2170 cells to 
cisplatin. Subsequent chapters will be focusing on elucidating these mechanisms. 
Furthermore, it was shown in this chapter that several cell lines (H226, H1869 and H2170) 
showed synergistic cytotoxicity with combination of cisplatin and belinostat (0.1μM). These 






Figure 5.3: Acetylation of histone molecules is mediated by belinostat independently of 
cisplatin.  
A, Western blot analyses were performed on H3 and H4 in H2170 cells after belinostat 
(PXD101) (0.1μM), cisplatin (1, 2 and 3μM) and combination treatment with DMSO as 
vehicle control. Histones were purified through acid extraction. Western blot data shown are 
representative of three independent experiments for the indicated targets with total H3 as 
input control. B, Representative images for immunofluorescence staining on total acetylated 
lysine in H2170 cells after cisplatin (3μM), belinostat (0.1μM) or combination treatment (n 
= 3). Blue indicates DAPI and green indicates acetyl-lysine. Fluorescent images were 






5.2.3  Belinostat potentiates both intrinsic and extrinsic apoptosis in cisplatin-treated 
H2170 cells 
Prior to elucidate the underlying synergistic mechanisms between belinostat and cisplatin, 
the extent of apoptosis was first verified with Annexin-V and propidium iodide (PI) staining. 
Apoptosis is a programmed cell death mechanism that could be distinguished by early and 
late-stage events. Early-stage apoptosis is characterized by loss of mitochondria potential 
and the translocation of phosphatidylserine from cytosolic to extracellular portion of the cell 
membrane (Li, Sarkisian et al. 2003), while late-stage is usually accompanied by increase 
cell membrane permeability (Krysko, Vanden Berghe et al. 2008). Extent of apoptosis can 
be quantified by determining the amount of cells that could be stained by Annexin-V, which 
bind to phosphatidylserine, and PI, which penetrate leaked plasma membrane (Koopman, 
Reutelingsperger et al. 1994).  
In this study, total number of apoptotic cells was quantified after belinostat, cisplatin and 
combination treatment. These data confirmed that belinostat alone (at a low concentration of 
0.1μM) does not induce apoptosis as the number of Annexin-V and PI-stained cells 
remained unchanged as compared to DMSO treated cells. Cisplatin increased early 
apoptotic cells (Annexin-V positive, PI negative) from 4.6% to 12%, and late apoptotic cells 
(Annexin-V positive, PI positive) from 2.6% to 7.8%, implying that cisplatin alone is 
sufficient to trigger apoptosis. Combination treatment further increased the amount of early 
apoptotic cells to 21.2% and late apoptotic cells to 15.2% (Figure 5.4 A). Total abundance 
of apoptotic cells is determined by the amount of cells stained with Annexin-V. These data 
showed that cisplatin induced dose-dependent increase of Annexin-V stained cells, while 
combination with belinostat at 0.1μM significantly potentiate apoptosis in H2170 cells 
(Figure 5. 4 B). 
Apoptosis involves a series of biochemical events that lead to changes in cell morphology 
and cell death. This process can be controlled by a range of intracellular and extracellular 
cell signals. The results of the analysis indicated that cisplatin induced the cleavages of 
caspase 3/7, 8 and 9 in conjunction with the degradation of PARP, while concurrent 
treatment with belinostat (0.1μM) further augmented these cleavages (Figure 5.6 A). By 
determining the drug-induced effect on the protease activities of caspase 3/7, caspase 8 and 
caspase 9, these data showed that cisplatin produced a dose-dependent increase in all 
caspase activities in H2170 cells. In contrast, belinostat at 0.1μM did not affect caspase 
activity, but significantly increased cisplatin-induced caspase 3/7, caspase 8 and caspase 9 
activities (Figure 5.6 B, C, D).  
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To investigate whether belinostat and cisplatin treatments could affect Bcl-2 family protein 
levels in H2170 cells, the regulations of Bcl-2 family members were investigated. The 
expression of two inhibitors of apoptosis, XIAP and survivin, was examined as well. While 
cisplatin alone has minimal effects on the expression level of Bcl-2, Bcl-xl, Bcl-w, XIAP 
and survivin, belinostat suppressed Bcl-2, Bcl-w and XIAP when used in combination 
(Figure 5.6 E). Among the pro-apoptotic Bcl-2 family proteins, BAX was detected in 
abundance in H2170 cells and may be oversaturated to detect any further increase upon drug 
treatment. Expressions of BAD and BAK were unaffected by cisplatin alone, but 
remarkably increased upon combination treatment. Among the three isoforms of BIM, BIMS 
and BIML were significantly expressed upon combination treatment (Figure 5.6 F). The 
shortest isoform, BIMS, is reported to be cytotoxic and only expressed during apoptosis 
(O'Connor, Strasser et al. 1998). BID is another crucial pro-apoptotic Bcl-2 member that 
interacts with BAX to form MAC on the outer membrane of mitochondria. BID is a 
common effector of both intrinsic and extrinsic apoptosis (Wang, Yin et al. 1996), and 
cleavage of BID to its activated form, tBID, is mediated by caspase-2 and caspase-8 (Li, 
Zhu et al. 1998, Upton, Austgen et al. 2008). Cisplatin as a single agent induced BID 
cleavage, while combination with belinostat further increased the release of tBID (Figure 
5.6 F). Through siRNA silencing of BAX in H2170 cells, drug-induced PARP cleavage and 
caspase 3 activation were both reduced in comparison to scrambled siRNA transfected 
control (Figure 5.7) 
While the expressions of most Bcl-2 proteins were unaffected in cisplatin-treated cells, the 
tested anti-apoptotic and pro-apoptotic markers were remarkably modulated by combination 
treatment of belinostat and cisplatin. Moreover, knockdown of BAX partially abrogated the 
drug-induced apoptosis. Figure 5.5 showed a schematic diagram that provides an overview 
of the regulation of apoptosis by belinostat and cisplatin. These data collectively suggest 
that belinostat triggers mitochondrial-controlled apoptosis in cisplatin-treated H2170 cells. 
Furthermore, activation of BID, as well as caspase 8 and 9, were detected upon drug 
exposure. Taken together, it was postulated that combination of belinostat and cisplatin 






Figure 5.4: Belinostat potentiates cisplatin-induced apoptosis in H2170 cells.  
H2170 cells were treated with belinostat (PXD101) (0.1μM), cisplatin (1, 2 and 3μM) and 
combination treatment with DMSO (0.001%) as vehicle control. Annexin-V and propidium 
iodide (PI) staining was performed. A, Dot blots on percentage of Annexin-V (+/-) and PI 
(+/-) cells. B, Bar chart on the percentage of Annexin-V positive cells in H2170. Data are 
shown as mean ± SD for three independent experiments. Statistical analyses were performed 







Figure 5.5: Illustrated schema of both intrinsic and extrinsic pathways of apoptosis 
induced by cisplatin and belinostat treatment.  
Texts highlighted in Red indicate apoptotic markers that are regulated by combination of 

















Figure 5.6: Combination of belinostat and cisplatin triggers the intrinsic apoptotic 
pathways in H2170 cells.  
H2170 cells were treated with belinostat (PXD101) (0.1μM), cisplatin (1, 2 and 3μM) and 
combination treatment with DMSO (0.001%) as vehicle control. A, Western blot analyses 
was performed to investigate the expression of PARP, caspase 3, 7, 8 and 9. Caspase 3/7 (B), 
caspase 8 (C) and caspase 9 (D) activities were monitored by cleavage of the DEVD-
aminoluciferin as described in Material and Methods. Data are shown as mean ± SD (n = 3). 
Statistical analyses were performed by unpaired t-test. *Significant difference from cisplatin 
treatment, P < 0.05. E, Western blot analyses was performed to investigate the expression of 
Bcl-2, Bcl-xl, Bcl-w, XIAP and surviving. F, Western blot analyses was performed to 
investigate the expression of Bad, Bax, Bak, Bim and Bid. Western blot data shown are 
representative of three independent experiments for the indicated targets with β-actin as 
input control. Statistical analyses were performed by unpaired t-test. *Significant difference 







Figure 5.7: Silencing of BAX abrogates apoptosis in cisplatin and belinostat-treated 
H2170 cells.  
BAX siRNA was transfected to H2170 cells. 100nM of siRNA was used per transfection. 
H2170 cells were treated with belinostat (PXD101) (0.1μM), cisplatin (3μM) and 
combination treatment with DMSO as vehicle control for 48 hours. Western blot analysis 
was performed to investigate the expression of BAX, PARP and caspase 3. Western blot 
data shown are representative of three independent experiments for the indicated targets 













5.2.4  Transcriptional activation of apoptosis in H2170 cells 
Activation of apoptosis requires induction of several factors including DNA damage, 
cellular stress, and loss of survival signals (Lessene, Czabotar et al. 2008). In healthy cells, 
majority of the pro-apoptotic proteins are kept inactivated. For instance, 14-3-3, a cytosolic-
bound chaperone, bind to BAX under unstressed condition and inhibit apoptosis (Nomura, 
Shimizu et al. 2003, Clapp, Portt et al. 2012). Apoptosis is triggered upon DNA damage. 
Numerous studies have demonstrated the regulation of key components in both the intrinsic 
(Bcl-2 family) and extrinsic pathways (Fas, DR5) by various transcription factors, such as 
p53 and STAT (Lane 1993, Battle and Frank 2002). In Chapter 5.2.3, it was clearly 
demonstrated that several members of the Bcl-2 family were modulated upon combination 
of cisplatin and belinostat, the transcriptional regulations of these apoptotic markers were 
determined after drug treatment. 
Fas, a cell surface receptor, is an important regulator of the extrinsic apoptosis (Nagata and 
Golstein 1995). Fas is known to be activated through binding of its ligand, FasL, thus 
initiates the formation of DISC complex and caspase-8 activation. According to the 
transcriptomic analysis, FAS gene is down-regulated in cisplatin-resistant lung SCC cells 
(Figure 3.6 C). Importantly, FasL is predominantly expressed by T cells (Muzio 1998). The 
absence of immune regulatory cells in this study model implies that drug-induced activation 
of Fas is probably regulated at the mRNA level within H2170 cells. The data showed that 
mRNA expression of FAS was increased by 2.54-fold and 3.36-fold upon cisplatin and 
combination treatment respectively (Figure 5.8 A). Furthermore, the mRNA expression of 
several Bcl-2 family members was shown to be significantly modified by exposure to drugs. 
These data also demonstrated that both cisplatin and combination treatment, but not 
belinostat alone, down-regulated the expression of Bcl-2 significantly (Figure 5.8 B). When 
used singly, both drugs have insignificant regulatory effects on BAX, BAK1, BAD and BIM, 
but combined treatment with belinostat significantly increased the transcription of these pro-
apoptotic markers by 2.61, 1.78, 2.11 and 1.71-fold respectively (Figure 5.8 C, D, E, F), 
suggesting the transcriptional activation of apoptosis. 
The combined treatment with cisplatin and belinostat induced efficient induction of intrinsic 
and extrinsic apoptosis through transcriptional activation of several apoptosis-related genes. 
Several of these genes are known downstream targets of p53. For instance, induction of FAS 
mRNA expression through p53 transactivation has been reported in several cancer types, 
including lung (Bouvard, Zaitchouk et al. 2000). In addition, p53-response elements have 
been identified in the BAX gene, BAD and Bcl-2 (Thornborrow, Patel et al. 2002). Therefore, 
the hypothesis for the observed synergistic cytotoxicity of belinostat and cisplatin may 




Figure 5.8: Cisplatin and belinostat induce transcriptional activation of apoptosis.  
H2170 cells were treated with belinostat (PXD101) (0.1μM), cisplatin (3μM) and 
combination treatment with DMSO (0.001%) as vehicle control for 48 hours. Total RNA 
was isolated and reverse transcribed to cDNA. Expressions of (A) FAS, (B) Bcl-2, (C) BAX, 
(D) BAK1, (E) BAD and (F) BIM were analysed using real-time qPCR. Data are shown as 
mean ± SD from three independent experiments. Statistical analyses were performed by 










Summary of findings in Chapter 5.1 and 5.2: 
 
 At 0.1μM, belinostat potentiated cisplatin-induced apoptosis in H226, H1869 and 
H2170 cells. 
 In H2170 cells, cisplatin alone decreased Bcl-2 and Bcl-xl; while increased cleavage 
of PARP and caspase 3, 9 in dose-dependent manner. 
 In H2170 cells, belinostat alone decreased Bcl-2, Bcl-xl and XIAP; while increased 
cleavage of PARP and caspase 3, 9 in dose-dependent manner. 
 At 0.1μM, belinostat induced histone acetylation independently of cisplatin in 
H2170 cells. 
 Combination of cisplatin at belinostat (at 0.1μM) triggered both intrinsic and 
extrinsic apoptosis in H2170 cells. 
 Combination of cisplatin at belinostat (at 0.1μM) reduced mRNA level of Bcl-2 
gene. 
 Combination of cisplatin at belinostat (at 0.1μM) increased transcriptional 
activation of several apoptosis-related genes (FAS, BAX, BAK1, BAD, and BIM). 
 Apoptotic pathways activated by cisplatin and belinostat is transcriptional-
dependent. 
 Some of the apoptotic genes affected by this treatment (FAS, BAX, BAD and Bcl-2) 





5.3  Transactivation of mutant p53 is correlated to post-translational modifications 
5.3.1  Transcriptional modulation of mutant p53 by cisplatin, belinostat and Nutlin-
3a 
To assess the relevance of p53 to drug-induced apoptosis in H2170 cells, it was essential to 
first determine the ability of this p53 mutant cell line to induce a p53-responsive promoter. 
H2170 cells were transiently transfected with a luciferase reporter plasmid that contains 
tandem repeat of the p21 promoter as described in Material and Methods. Constructs with 
constitutively expressing luciferase and non-inducible luciferase were transfected as positive 
and negative controls. Both these constructs confirmed the validity of the reporter system, 
with positive control giving a marked activation and negative control showing no response 
after drug treatment (Data not shown). In H2170 cells transfected with p53-responsive 
construct, no significant induction of luciferase activity was observed 24 hours post drug 
treatment. At 48 hours, combination treatment of cisplatin and belinostat showed a profound 
activation of luciferase activity when compared to vehicle control. At 72 hours, both 
cisplatin and combined treatment induced marked activation of this promoter activity 
(Figure 5.9). These findings suggested that the transactivation of p53 proteins in H2170 
cells could be induced by cisplatin alone, but combined treatment of belinostat (0.1μM) 
potentiated this transcriptional activity. 
In Chapter 3.2.1, H2170 was verified to be a p53 mutant line with mutation on its DNA-
binding domain at residue 158 (R158G) by Sanger sequencing. Such mutant is 
conventionally considered to lack the DNA-binding capability and therefore its 
transactivation ability is impaired. Mechanistically, mutant p53 is unable to bind specifically 
to consensus DNA site and activate p53 downstream genes. However, combination 
treatment of both belinostat and cisplatin induced transactivation of p53 promoter activity in 
H2170 cells, therefore suggesting that this combination could restore the transcriptional 
function of p53. To verify the functionality of this mutated p53, the mRNA levels of 
CDKN1A and MDM2 were determined upon Nutlin-3a exposure in H2170 cells. Nutlin-3a 
is a pharmacologic activator of p53 that is known to stabilize p53 through inhibiting the 
p53-MDM2 interaction (Vassilev, Vu et al. 2004). A dose-dependent up-regulation of 
MDM2 and CDKN1A was observed in lung normal fibroblast cells (MRC5) but not H2170 
cells (Figure 5.10 A, B). This confirms the presence of a loss-of-function mutation in H2170 
cells, as blocking MDM2 inhibition on p53 does not induce transcriptional activation as 
displayed in the p53 wild-type cells. 
The results obtained so far suggested that, at least in H2170 cells, p53-mediated 
transcriptional activation can be restored in p53 carrying the R158G mutation. The next step 
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was to elucidate the mechanism of this observation. As Nutlin-3a is an antagonist for 
MDM2, the binding of Nutlin-3a at the p53-binding pocket of MDM2 inhibits p53-MDM2 
interaction, thus releasing functional p53 (Vassilev, Vu et al. 2004). Therefore, activation of 
p53 by Nutlin-3a does not require p53 phosphorylation (Thompson, Tovar et al. 2004). 
Furthermore, cytotoxic agents are known to induce p53 activity through its post-
translational modifications. Therefore, it was believed that activation of p53 by belinostat 




Figure 5.9: Transactivation of a p53-dependent promoter by belinostat and cisplatin.  
H2170 cells were transfected with p53 reporter plasmid (p21 promoter). After 24 hours of 
transfection, H2170 cells were treated with belinostat (PXD101) (0.1μM), cisplatin (3μM) 
and combination treatment with DMSO as vehicle control (0.001% DMSO) for 24, 48 and 
72 hours. Dual luciferase assay was performed as described in Material and Methods. 
Promoter activities are expressed in fold change in relative to DMSO control at 24 hours 
post treatment by using a Renilla reporter as internal normalization. Data are shown as mean 
± SD from triplicates within one representative experiment (n = 3). Statistical analyses were 









Figure 5.10: Nutlin-3a induces mRNA expression of CDKN1A and MDM2 in MRC5 
but not H2170 cells.  
MRC5 and H2170 cells were treated with belinostat (PXD101) (0.1μM), cisplatin (1, 2 and 
3μM) and combination treatment with DMSO (0.001%) as vehicle control for 48 hours. 
Total RNA was isolated and reverse transcribed to cDNA. Expression of (A) MDM2 and (B) 
CDKN1A were analysed using real-time qPCR. Data are shown as mean ± SD for triplicates 









5.3.2  Belinostat and cisplatin induce post-translational modifications of p53  
Through years of intensive research on the molecule, the transcription-dependent activation 
of p53 has been comprehensively characterized. In unstressed cells, p53 level is suppressed 
through continual ubiquitination of p53 (Hock, Vigneron et al. 2011). MDM2, a 
downstream target as well as negative regulator of p53, binds to and mediates the 
degradation of p53, thus maintaining a low basal level of p53 in the nucleus. Upon induction 
by oncogene-activated signalling or genotoxic stress, p53 undergoes post-translational 
modifications which disrupt p53-MDM2 binding and leads to p53 accumulation with 
activation of downstream p53 effectors. Thus, tumour suppressor function of p53 is tightly 
regulated under physiological conditions. DNA damage has been demonstrated to induce 
p53 phosphorylation at Ser15 and Ser20, which then suppressed interaction of p53 and 
MDM2 (Shieh, Ikeda et al. 1997, Siliciano, Canman et al. 1997). While phosphorylation at 
other residues have been reported to influence DNA binding, growth suppression, apoptosis 
and transactivation, acetylation of lysine residues at position 379 and 382 lead to cellular 
accumulation of p53 and enhance DNA-binding capacity of p53 (Sakaguchi, Herrera et al. 
1998, Ito, Lai et al. 2001).  
The role of post-translational modification of mutant p53 was next examined. The data 
indicated that cisplatin induced dose-dependent increase of p53, p-p53 (Ser15) and acetyl-
p53 (Lys379, Lys382). In comparison, belinostat reduced total p53 accumulation in H2170 
cells, while not affecting the phosphorylation and acetylation of p53 up to 1μM (Figure 5.11 
A). When used in combination with cisplatin, belinostat (0.1μM) did not affect expression 
of total p53 and p-p53 but significantly potentiated acetylation of p53 at both lysine residues 
(Figure 5.11 C). 
Generally, p53 activation is coupled with its post-translational modifications that promote 
DNA-binding and inhibit MDM2 interaction. Cisplatin treatment, but not low doses of 
belinostat, induced phosphorylation and acetylation of p53. This contradicts other reports 
that HDAC inhibitors could induce acetylation of p53 (Juan, Shia et al. 2000, Luo, Su et al. 
2000). Interestingly, while low dose of belinostat does not affect p53, combined treatment 
increases acetylation of p53 in cisplatin-treated cells. More importantly, increased acetylated 
p53 correlates with the induction of apoptosis in H2170 cells, further suggesting the 








Figure 5.11: Cisplatin and belinostat regulate post-translational modification of p53. 
A, H2170 cells were treated with cisplatin (0.5, 1, 2, 3, 5μM) or PXD101 (PXD101) (0.1, 
0.2, 0.3, 0.5, 1μM) with DMSO (0.03%) as vehicle control for 48 hours. B, H2170 cells 
were treated with belinostat (0.1μM), cisplatin (1, 2 and 3μM) and combination treatment 
with DMSO (0.001%) as vehicle control for 48 hours. Western blot analysis was performed 
to investigate the expression of p53, p-p53 (Ser15) and acetyl-p53 (Lys379, Lys382). Data 
shown are representative of three independent experiments for the indicated targets with β-









5.3.3  Nuclear and cytoplasmic localization of p53 
The mechanisms by which p53 mediates apoptosis has been a matter of intensive study 
since this was first demonstrated. As a transcriptional factor, p53 accumulates in the nucleus 
and transactivates apoptosis-related genes. More recently, cytoplasmic accumulation and 
mitochondrial localization of p53 have been shown to facilitate the formation of MAC, 
without affecting the cellular transcriptional activities (Marchenko, Zaika et al. 2000, 
Chipuk, Kuwana et al. 2004). These findings suggest that p53 functions can be determined 
by its nuclear and cytoplasmic localization.  
Furthermore, p53 molecules were found in both  nuclear and cytoplasmic fractions of 
H2170 cells. The phosphorylated and acetylated p53, however, were highly detected in the 
nucleus as compared to the cytoplasmic fraction (Figure 5.12 A, B). Confocal images were 
captured after immunofluorescence staining of p53 in H2170 to verify the localization of 
p53 molecules. DAPI and Phalloidin were used to counterstain DNA and cytoplasmic actin 
to allow for better visualization of nuclear and cytoplasmic fractions. These data indicated 
that p53 was predominantly retained in the nucleus after drug treatment (Figure 5.12 C), 








Figure 5.12: Nuclear translocation of p53 after drug treatment.  
H2170 cells were treated with belinostat (PXD101) (0.1μM), cisplatin (3μM) and 
combination treatment with DMSO (0.001%) as vehicle control for 48 hours. Nuclear and 
cytoplasmic fractions of H2170 cells were separated as described in Material and Methods. 
Western blot analysis was performed to investigate the expression of p53, p-p53 (Ser15) and 
acetyl-p53 (Lys379, Lys382) in (A) nuclear and (B) cytoplasmic fraction. Western blot data 
shown are representative of three independent experiments for the indicated targets with 
TATA-box binding protein (TBP) and α-tubulin as input control for nuclear and 
cytoplasmic fraction respectively. C, Immunofluorescence staining of p53 (Alexa Fluor-488) 
in H2170 cells was conducted. DAPI and Phalloidin were used to counter-stain nucleus and 
actin respectively. Representative confocal images are shown at 1000x magnification for 





















Summary of findings in Chapter 5.3: 
 
 H2170 harbours a loss-of-function mutation on the DNA-binding domain of p53. 
 Nutlin-3a failed to activate p53-dependent transcriptional activation of MDM2 and 
CDKN1A in H2170 cells. 
 Combination of cisplatin and belinostat (at 0.1μM) induced transactivation of p53 at 
the CDKN1A promoter region. 
 The p53 signalling pathway is likely restored  in mutant p53 by combined treatment 
of cisplatin and belinostat (at 0.1μM). 
 Cisplatin induced both acetylation and phosphorylation of p53 in H2170 cells in a 
dose-dependent manner. 
 Belinostat (at 0.1μM) did not induce phosphorylation/acetylation of p53 when used 
as a single agent. 
 Belinostat (at 0.1μM) potentiated cisplatin-induced acetylation of p53. 
 The p53 protein was predominantly retained in cell nucleus after cisplatin/belinostat 
treatment. 
 Nuclear-bound acetylated p53 was correlated to the induction of cell death and 







5.4  The role of mutant p53 in cisplatin/belinostat-induced apoptosis 
5.4.1  Synergistic cytotoxicity of belinostat and cisplatin is dependent on p53 
Thus far, the observations have demonstrated that transactivation of p53 downstream genes 
occurred simultaneously with the post-translational modification and nuclear localization of 
p53. These data collectively raise the possibility that p53 function could be induced in this 
mutant cell line. To assess the relative contribution of mutated p53 to transcriptional-
activated apoptosis in H2170 cells, inhibition of p53 through siRNA transfection and 
shRNA infection was conducted.  
Gene silencing of p53 using siRNA was performed in H2170 cells with a scramble siRNA 
as negative control. Western blotting verified that p53 was successfully silenced as shown 
by the ablation of p53 expression (Figure 5.13). Upon drug treatment, induction of apoptosis 
was suppressed in p53-silenced cells as demonstrated by the decrease in cleaved caspase 3 
and cleaved PARP as compared to vehicle control (Figure 5.13). To establish study models 
for further investigations, two independent lentiviral-based p53 shRNAs and two negative 
control shRNAs (non-targeting and luciferase-targeting) were infected to H2170 cells and 
selected with puromycin to obtain stable knockdown clones. Satisfactory inhibitions of both 
p53 mRNA and protein in H2170 were achieved with both shRNAs, sh56 and sh55. The 
mRNA expression of p53 was decreased by approximately 80% by sh56 and 60% by sh55 
in comparison to a non-targeting shRNA control (shNT) (Figure 5.14 A). Protein expression 
of p53 was markedly reduced by sh56 and sh55 as well (Figure 5.14 B). When drug 
treatment was administered, apoptosis was triggered in all three clones. However, cleavages 
of PARP, caspase 9 and caspase 3 were more robust in shNT than sh56 and sh55, implying 
that p53 knockdown clones are more resistant to cisplatin and combination treatment 
(Figure 5.15 A). Quantification of apoptotic cells for each clone was analysed by FACS. 
Similar to parental H2170 cells, cisplatin induced apoptosis in shNT and shLuc cells in 
combination with belinostat further increased the percentage of Annexin-V positive cells. In 
both sh56 and sh55 clones, cisplatin-induced apoptosis was reduced. Unexpectedly, 
knockdown of p53 significantly reduced the synergistic effect with belinostat, as apoptosis 
induced by combination treatment was abrogated (Figure 5.15 B). 
These data suggest an indispensable role of p53 in regulating the cytotoxicity of belinostat 
and cisplatin, supporting the claim that mutant p53 regains wild-type function. Despite 
having minimal effect on cisplatin-induced apoptosis, the synergistic combination of 






Figure 5.13: Silencing of p53 abrogates apoptosis in cisplatin and belinostat-treated 
H2170 cells.  
p53 siRNA was transfected to H2170 cells. 100nM of siRNA was used per transfection. 
H2170 cells were treated with belinostat (PXD101) (0.1μM), cisplatin (3μM) and 
combination treatment with DMSO (0.001%) as vehicle control for 48 hours. Western blot 
analysis was performed to investigate the expression of p53, PARP and caspase 3. Western 
blot data shown are representative of three independent experiments for the indicated targets 












Figure 5.14: Stable shRNA knockdown of TP53 in H2170 cells.  
H2170 was infected with lentivirus packaged with 2 shRNA targeting TP53 (sh55, sh56). 
Stable clones were selected by puromycin (5μg/ml) treatment. Efficiency of knockdown was 
determined by (A) real time qPCR and (B) Western blotting. Real time data are shown as 
mean ± SD (n = 1). Western blot data shown are representative of two independent 







Figure 5.15:  Knockdown of p53 attenuates potentiation of apoptosis by belinostat in 
cisplatin-treated H2170 cells.  
Stable p53 knockdown H2170 clones (Sh55, sh56) were generated by lentiviral transfection. 
All cells were treated with belinostat (PXD101) (0.1μM), cisplatin (3μM) and combination 
treatment with DMSO (0.001%) as vehicle control for 48 hours. (A) Western blot analysis 
was performed to investigate the expression of p53, PARP, caspase 9 and caspase 3. 
Western blot data shown are representative of three independent experiments for the 
indicated targets with β-actin as input control. (B) Annexin-V and propidium iodide (PI) 
staining was performed to investigate the proportion of apoptotic cells in each clone upon 
exposure to belinostat (0.1μM), cisplatin (3μM) and combination treatment with DMSO 
(0.001%) as vehicle control for 48 hours. Two stable clones expressing non-targeting (shNT) 
and luciferase-targeting (shLuc) shRNAs were generated as negative control. Percentage of 
Annexin-V (+/-) and PI (+/-) cells were determined. Bar chart showing the percentage of 
Annexin-V positive cells in each clone was displayed. Data are shown as mean ± SD for 
three independent experiments. Statistical analyses were performed by unpaired t-test. 





5.4.2  In vitro overexpression of human p53 cDNA and characterization of p53 
signalling in lung SCC cells  
5.4.2.1  Belinostat and cisplatin induce transactivation of wild-type p53 in lung 
fibroblast cells 
The p53 molecule mediates cellular processes in response to a variety of stresses by 
activating different downstream signals. As a tumour suppressor, p53 affects the 
transcription of genes related to intrinsic mitochondrial apoptotic pathway and cell cycle 
arrest, thus providing checkpoints to constrain tumourigenesis (Levine, Momand et al. 
1991).  
Pharmacological activation of p53 was achieved with Nutlin-3a treatment in wild-type p53 
MRC5 cells (Vassilev, Vu et al. 2004). The data showed a dose-dependent increase of p53 
upon Nutlin-3a treatment. Two main downstream effectors of p53, p-MDM2 and p21, were 
shown to increase in similar pattern as p53 (Figure 5.16 A). The transcriptional activation of 
CDKN1A and MDM2 was shown  earlier in Nutlin-3a-treated MRC5 cells (Figure 5.10). 
Despite resulting in a significant accumulation of p53 protein, Nutlin-3a reduced the mRNA 
expression of TP53 in MRC5 cells (Figure 5.16 B). In addition, a dose-dependent decline of 
p73 at the mRNA level was observed (Figure 5.16 C).  
Next, the underlying mechanisms in which cisplatin and belinostat trigger p53-dependent 
apoptosis in wild-type cells were investigated. In MRC5 cells, exposure to cisplatin but not 
belinostat induced accumulation of p53, increased acetylation of p53, and triggered 
apoptosis through cleavage of PARP and caspase 3 (Figure 5.17 A). To relate the 
cytotoxicity with p53 signalling, the activation of downstream target genes was investigated. 
Cisplatin and combination treatment, but not belinostat, increased mRNA expression of 
CDKN1A, MDM2, PUMA and Noxa (Figure 5.17 B, C, D, E). However, mRNA expression 
of TP53 and TP73 were reduced (Figure 5.17 F, G). Collectively, these data demonstrated 
the transactivtion of p53 downstream genes upon drug treatment in MRC5. Interestingly, 
mRNA levels of both TP53 and TP73 were reduced, probably due to the auto-regulatory 





Figure 5.16: Activation of p53 signalling pathway by Nutlin-3a in MRC5 cells.  
MRC5 cells were treated with Nutlin-3a (0.625, 1.25, 2.5, 5, 10μM) with DMSO (0.01%) as 
vehicle control for 48 hours. A, Western blotting analysis was performed to investigate the 
expression of p53, p-MDM2 (Ser166) and p21. Data shown are representative of three 
independent experiments for the indicated targets with β-actin as input control. Real-time 
qPCR was conducted to determine the expression of (A) TP53 and (B) TP73. Data are 










Figure 5.17: Exposure to belinostat and cisplatin activate p53 downstream signalling.  
MRC5 cells were treated with belinostat (PXD101) (0.1μM), cisplatin (3μM) and 
combination treatment with DMSO (0.001%) as vehicle control for 48 hours. A, Western 
blotting analysis was performed to investigate the expression of p53, acetyl-p53 (Lys382), 
caspase 9 and caspase 3. Data shown are representative of three independent experiments 
for the indicated targets with β-actin as input control. Total RNA was isolated and reverse 
transcribed to cDNA. Expressions of (B) CDKN1A, (C) MDM2, (D) PUMA, (E) Noxa, (F) 
TP53 and (G) TP73 were analysed using Real-time qPCR. Data are shown as mean ± SD 
from three independent experiments. Statistical analyses were performed by unpaired t-test. 
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5.4.2.2  Belinostat and cisplatin induce downstream signalling that mimicks p53 
transactivation in H2170 cells 
Despite verifying the loss-of-function mutation in H2170 cells, but the data have by far 
demonstrated a contradicting mechanism involving p53 activation that could be trigger by 
cisplatin and belinostat, possibly via post-translational modification of p53. These 
observations were reaffirmed in Figure 5.18 A, as shown by the cleavage of PARP and 
caspase 3. It was earlier discussed in Figure 5.8 that cisplatin and belinostat up-regulated 
BAX and FAS. The regulations of other p53 target genes in H2170 cells were discussed here. 
The data demonstrated increases in CDKN1A, PUMA and Noxa when cisplatin was 
administered singly and in combination with belinostat (Figure 5.18 B, D, E). In contrary, 
expression of MDM2 and TP53 were unaffected by drug treatment (Figure 5.18 C, F). These 
findings suggest that p53 signalling may be involved in cytotoxicity of cisplatin. When 
compared to MRC5 cells, cisplatin and combination treatment induced a similar mRNA 
expression profiles in H2170 cells that mimic p53 activation to a certain extent, with the 
exception of TP53 and MDM2. This unique expression pattern of p53 target genes in H2170 
cells prompted the query as to which extent the tumour suppression effect is restored in 
mutant p53.  
Up to this point, it was demonstrated that exposure to cisplatin and belinostat activated both 
intrinsic and extrinsic apoptosis at the transcriptional level (Chapter 5.2.3 and 5.2.4). 
Unexpectedly, this drug-induced apoptosis was observed in parallel with the increase in p53 
promoter activity (Chapter 5.3.1) and up-regulation of nuclear-bound acetylated p53 
(Chapter 5.3.2). In addition, knockdown of p53 through siRNA and shRNA significantly 
abrogated the induction of apoptosis in this p53 mutant line (Chapter 5.4.1). Accordingly, it 
was hypothesized that a low dose of belinostat (0.1μM) could substantially potentiates the 
cytotoxicity of cisplatin and increases cisplatin-induced acetylation of p53. To prove this 
hypothesis, the functions of wild-type and mutant p53 were investigated through ectopic 





Figure 5.18: Exposure to belinostat and cisplatin induce p53 downstream signalling in 
H2170 cells that is comparable to wild-type p53 cells.  
H2170 cells were treated with belinostat (PXD101) (0.1μM), cisplatin (3μM) and 
combination treatment with DMSO (0.001%) as vehicle control for 48 hours. A, Western 
blotting analysis was performed to investigate the expression of p53, acetyl-p53 (Lys382), 
caspase 9 and caspase 3. Data shown are representative of three independent experiments 
for the indicated targets with β-actin as input control. Total RNA was isolated and reverse 
transcribed to cDNA. mRNA expressions of (B) CDKN1A, (C) MDM2, (D) PUMA, (E) 
Noxa and (F) TP53 were analysed using Real-time qPCR. Data are shown as mean ± SD 
from three independent experiments. Statistical analyses were performed by unpaired t-test. 







5.4.2.3  Ectopic expression of p53 in Calu-1 (p53-null) cells 
The synergistic combination of belinostat and cisplatin in H2170 cells is seemingly 
dependent on p53 activation. However, it remains unclear of how these events take place. 
As H2170 cells harbour a dominant negative loss-of-function mutant p53 (R158G), it is 
possible that the observed pathway activation of p53 may be due to other alternative 
mechanisms that mimick p53 activity. To address the critical question on the role of mutant 
p53, mutant p53 constructs were genetically transfected into p53 null Calu-1 cells. cDNA 
sequences of p53 were obtained from MRC5 (p53 wild-type) and H2170 (p53R158G 
mutant). A HA-tag was inserted at the 5’ end of the amplified p53 cDNA for 
immunoprecipitation studies. Both sequences were cloned into pCMV vector, expanded in 
bacteria culture, and purified to obtained pCMV-p53-HA clones as described in Material 
and Methods. The molecular sequences of both wild-type and mutant clones were verified 
by Sanger sequencing with two vector sequencing primers.  
To establish cellular models with simultaneous presence of p53 molecules, these plasmids 
(pCMV, pCMV-p53wt-HA and pCMV-p53R158G-HA) were transfected into Calu-1 cells, 
and selected with Geneticin (250μg/mL) to obtain stable transfectants. To generate 
homogenous clonal population, single cell cloning was performed on each clone through 
various rounds of limiting dilution under Geneticin selection as described in Materials and 
Methods. The expanded clonal cell populations were subjected to further screening based on 
their morphology and proliferation rates by comparing with the parental cell line. Through 
this process, 1 Empty vector control (EV), 1 wild-type clone (WT 6) and 5 mutant clones 
(R158G) were established. Expression of wild-type and mutant form of murine p53 was 
driven constitutively by the strong CMV immediate-early regulatory element. 
Expression levels of p53 in these clones were verified with Real-time qPCR. In relative to 
WT clone, all 5 mutant clones showed > 40-fold increase in p53 expression, with no 
expression in EV clone (Figure 5.19 A). Western blotting analysis was further performed to 
verify the p53 protein expression. Both p53 and p21 were not expressed by EV clone, while 
WT clone has stable expression of p53 and high expression of p21. In all five mutant clones, 
p53 protein was found in abundance. Interestingly, these mutant clones expressed p21 as 
well (Figure 5.19 B). As p53 is a nuclear-bound transcription factor, immunofluorescence 
staining was conducted to detect the translocalization of the protein. In Figure 5.19 C, both 
EV and WT 6 clones expressed undetected basal p53 (too low in WT clone for detection), 
while all 5 mutant clones expressed high amount of p53 that are mainly positioned in the 




Taken together, expressions of p53 molecules in all genetically modified Calu-1 cells were 
verified. These clones served as study models for investigating whether mutant p53 (R158G) 














Figure 5.19: Overexpression of mutant and wild-type p53 in p53 null Calu-1 cells.  
Calu-1 cells were transfected with p53 (Wild-type), p53 (R158G mutant) and pCMV vector 
plasmids. Single clones with stable cDNA expression were selected by Geneticin (250μg/ml) 
treatment. Empty vector control clone (EV), p53wt clone (WT 6) and p53mutant clones 
(R158G 1, 2, 3, 7, 8) were established. A, Expressions of TP53 cDNA in all clones were 
quantified using Real time qPCR by using p53wt clone as the reference group. Data are 
shown as mean ± SD from three independent experiments. B, Western blotting analysis was 
performed to investigate the expression of p53 and p21 in each clone. Data shown are 
representative of three independent experiments for the indicated targets with β-actin as 
input control. C, Immunofluorescence staining was performed to determine the 
translocalization of p53 molecules (Alexa Fluor-488) in each clone. Representative images 
are shown at 400x magnification for two independent experiments. Grey indicates DAPI 





5.4.2.4  Sensitivities of p53 overexpressing clones to cisplatin and belinostat 
From the earlier analysis, Calu-1 was determined to be a cisplatin-resistant, belinostat-
sensitive lung SCC cell line. If p53 indeed plays a major role in induction of apoptosis to 
cisplatin, the lack of p53 may contribute to this resistance. Using cell proliferation assay, the 
response of the established p53-overexpressing clones to cisplatin and belinostat treatment 
was determined. 
EV clone was shown to have similar sensitivities to cisplatin and belinostat as compared to 
parental Calu-1 cells. Expectedly, p53wt overexpressing clone displayed highest sensitivity 
to cisplatin among the modified clones. All p53R158G clones demonstrated greater 
sensitivity to cisplatin as compared to EV clone (Figure 5.20 A). When treated with 
belinostat, EV clone and p53wt clone have similar IC50 to parental Calu-1cells. However, all 
p53R158G clones have significantly higher belinostat IC50 (Figure 5.20 B). Based on the 
earlier data, mutant p53 may be accounted for the synergy between belinostat and cisplatin. 
Here, the cisplatin IC50 of all clones was determined when combined with belinostat at 
0.1μM.  The data demonstrated that belinostat did not increase cisplatin cytotoxicity in EV 
and p53wt clones. However, in 4 out of the 5 p53R158G clones, combination with 
belinostat significantly reduced cisplatin IC50 (Figure 5.20 C).  
Expectedly, overexpression of wild-type p53 increases sensitivity to cisplatin, but the data 
here suggested that mutant p53 could affect cellular response to cisplatin as well. More 
importantly, synergistic combination of belinostat and cisplatin was observed in p53 mutant 
clones. In addition, p53 mutant clones were shown to be more resistant to belinostat, which 
corresponded with the earlier observation that lung SCC cell lines have reciprocally inverse 
sensitivities to both cisplatin and belinostat. These data clearly supported that mutant p53 





Figure 5.20: p53-expressing Calu-1 clones exhibit differential responses to cisplatin, 
belinostat and combination treatment.  
EV clone, p53wt clone, and p53R158G clones were drug treated for 72 hours and cell 
viability assay (MTS) was used to determine the IC50 of (A) cisplatin and (B) belinostat 
(PXD101). Data are presented as mean ± SD (n = 3). Statistical analyses were performed by 
unpaired t-test. *Significant difference from EV clone, P < 0.05. C, Cisplatin IC50 in 
combination with 0.1μM belinostat of each clone was shown. Data are presented as mean ± 
SD (n = 3). Statistical analyses were performed by unpaired t-test. *Significant difference 





5.4.2.5 Modification of mRNA expression of p53 target genes in p53 overexpressing 
clones 
As demonstrated, p53 signalling was transctivated after drug treatment in H2170 cells. The 
expression levels of several downstream target genes of p53 (MDM2, CDKN1A, PUMA, 
Noxa, BAX, and TP73) were determined in p53-expressing clones. In line with current 
knowledge, wild-type p53 clone expressed higher mRNA level of MDM2, CDKN1A, PUMA 
and Noxa. In reference to EV clone, p53 mutant clones have similar expression of MDM2 
and PUMA (Figure 5.21 A, C), higher expression of p21 and lower expression of Noxa 
(Figure 5.21 B, D). BAX mRNA level was consistent among EV, WT and T158G clones 
(Figure 5.22 E). Unexpectedly, both wild-type and mutant p53 molecules have reduced 
TP73 mRNA expression (Figure 5.22 E). 
From these observations, it could be concluded that transcriptome of p53-related genes was 
modified in the overexpressing clones: a fully functional p53 (WT) consistently activates 
MDM2, CDKN1A, PUMA and Noxa; in mutant cells, MDM2 expression is not affected 
(consistent with the lack of transactivation ability of mutant p53 to MDM2), while CDKN1A 
and Noxa genes were differentially regulated. BAX expression was unaffected in all clones, 
as it requires external stress signal to be transactivated.  In addition, mRNA level of TP73 is 
reduced by approximately 80%, as compared to EV clones. Taken together, these data 
suggested the insertion of mutant p53 partially restored the p53-regulated transcriptomic 






Figure 5.21: p53-expressing Calu-1 clones have dissimilar gene expression profiles for 
p53 downstream genes.  
Total RNA for each clone was isolated and reverse transcribed to cDNA. mRNA 
expressions of (A) MDM2, (B) CDKN1A, (C) PUMA (D) Noxa, (E) BAX and (F) TP73 were 
analysed using real-time qPCR. Untreated EV clone was applied as reference group. Data 






5.4.2.6  Drug-induced modification of p53 target genes in p53 overexpressing clones 
In order to ascertain if p53 signalling is triggered in these mutant clones, the mRNA 
expression of p53 target genes was profiled after belinostat, cisplatin and combination 
treatment. Analysis on the expression of p53-related genes again displayed diverse 
transcriptional regulation among EV, WT and R158G mutant clones upon drug treatment.  
As demonstrated, a classical pattern of activated p53 signalling was observed in p53 wild-
type clone. MDM2 was significantly up-regulated in WT clone by cisplatin and combination 
treatment, but no activity was observed in all EV and p53R158G clones Figure 5.22 A). In 
relative to the untreated EV clones, a substantial increase of CDKN1A was observed in 
drug-treated WT cells. Similar expression pattern of CDKN1A level was observed in all 
mutant clones with a lower magnitude of increase after drug treatment (Figure 5.22 B). 
Cisplatin and combination treatment induced PUMA expression in WT clone and mutant 
clones (especially R158G clone 3 and 8), but not in EV clone (Figure 5.22 C). Expression 
level of Noxa was inducible by cisplatin and belinostat in EV and WT clones but not in 
mutant clones (Figure 5.22 D). As illustrated in Figure 5.21 E, all clones expressed similar 
mRNA level of BAX. Cisplatin exposure induced BAX expression in all clones, while 
combination treatment further potentiated the up-regulation of BAX gene. In comparison, 
EV clone demonstrated the lowest induction (~2-fold) of BAX, with the highest expression 
(~5-fold) observed in WT clone (Figure 5.22 E). In EV clone, TP73 was decreased by both 
belinostat and cisplatin, while combination treatment further reduced its expression. 
However, cisplatin alone did not affect TP73 in all p53 overexpressing clones, while both 
belinostat and combination treatment substantially suppressed expression of TP73 (Figure 
5.22 F). 
MDM2 is commonly described to be mainly mediated by p53 transactivation (Barak, Juven 
et al. 1993). These analyses have verified that belinostat and cisplatin treatments did not 
affect MDM2 expression in EV and p53 mutant clones, strongly indicating the loss-of-
function event through missense mutation at the DNA-binding domain. Despite so, 
concurrent activation of other p53 target genes (CDKN1A, BAX ad PUMA) among mutant 











Figure 5.22: Belinostat and cisplatin differentially mediate p53 downstream genes in 
p53-expressiong Calu-1 clones.  
EV clone, p53wt clone, p53R158G clones were treated with belinostat (PXD101) (0.1μM), 
cisplatin (10μM) and combination treatment with DMSO (0.001%) as vehicle control for 48 
hours. Total RNA for each clone was isolated and reverse transcribed to cDNA. mRNA 
expressions of (A) MDM2, (B) CDKN1A, (C) PUMA (D) Noxa, (E) BAX and (F) TP73 were 
analysed using Real-time qPCR. Untreated EV clone was applied as reference group. Data 






5.4.2.7  Induction of apoptosis by cisplatin and belinostat in p53 overexpressing clones 
Since transcriptional activation of p53-mediated apoptotic genes was detected in p53 mutant 
clones upon drug treatment, the post-translational modification of p53 as well as the extent 
of apoptosis in these clones were next investigated. The activation of p53 signalling in WT 
clone was determined. Upon cisplatin and combination treatment, expression of HA-tag, 
p53, p-p53 (Ser15) and acetyl-p53 (Lys279, Lys382) were up-regulated in WT clones, 
implying that p53 pathway was activated. The downstream targets, p21 and PUMA, were 
increased in concurrent with the cleavage of PARP and caspase 3 (Figure 5.23). 
Expression of p53 and HA tag was undetectable in EV clone, confirming that it is a p53 null 
cell. As anticipated, low expressions of p21, BAX and PUMA were observed, and were not 
significantly altered by cisplatin, belinostat and combination treatment. Minimal PARP and 
caspase 3 cleavage were detected (Figure 5.24 A). Among the 5 p53R158G mutant clones, 
p53 and HA-tag were expressed in abundance, consistent with the reduced ubiquitination of 
p53 and tilt of balance to accumulation of mutant p53. Belinostat alone slightly induced p53 
acetylation, unlike the lack of change in H2170 cells (Figure 5.11). This is consistent with 
the mode-of-action of belinostat as a protein acetylation agent. Similar to H2170 cells, 
cisplatin alone substantially induced p53 acetylation and phosphorylation in all mutant 
clones, while combination with belinostat further acetylated p53. This modification of 
mutant p53 up-regulated downstream targets of p53: p21, BAX and PUMA. Importantly, 
cisplatin-induced apoptosis, as indicated by PARP and caspase 3, was further potentiated by 
belinostat at a sub-lethal dose (especially R158G clone 2, 3 and 8) (Figure 5.24 A, B). 
Despite being regulated by the same CMV promoter, differential expression of p53 was 
observed among WT and mutant clones. This is probably due to the interaction with MDM2, 
as MDM2 serves as a negative regulator of p53 molecule and thus inhibit p53 function in 
healthy cells with wild-type p53 (Kussie, Gorina et al. 1996).  In WT clone, activation of 
p53-mediated apoptosis appeared to be similar to that of MRC5, and was mainly influenced 
by the cytotoxicity of cisplatin. Consistent with previous analysis on H2170 cells, 
combination with belinostat potentiated the cisplatin-induced acetylation of p53. 
Concurrently, drug-induced apoptosis was associated to acetylation of mutant p53. These 
findings provided compelling evidence that apoptosis could be triggered through p53 







Figure 5.23: Belinostat and cisplatin induce apoptosis in Calu-1 cells expressing wild-
type p53.  
Calu-1 p53wt clone was treated with belinostat (PXD101) (0.1μM), cisplatin (10μM) and 
combination treatment with DMSO (0.001%) as vehicle control for 48 hours. Western 
blotting analysis was performed to investigate the expression of p-p53 (Ser15), acetyl-p53 
(Lys279, Lys382), p53, BAX, p21, PUMA, PARP and caspase 3. Data shown are 













Figure 5.24: Belinostat and cisplatin induce up-regulation of acetylated p53, BAX, p21, 
PUMA as well as cleavage of PARP and caspase 3 in Calu-1 cells expressing mutant 
p53.  
Calu-1 EV clone and p53R158G clones were treated with belinostat (PXD101) (0.1μM), 
cisplatin (10μM) and combination treatment with DMSO as vehicle control for 48 hours. 
Western blotting analysis was performed to investigate the expression of p-p53 (Ser15), 
acetyl-p53 (Lys279, Lys382), p53, BAX, p21, PUMA, PARP and caspase 3 in (A) EV, 
R158G (1), R158G (2) and (B) R158G (3), R158G (7), R158G (8). Data shown are 







5.4.2.8  Distribution of acetylated and phosphorylated p53 in p53 overexpressing 
clones 
Next, the distribution of the acetylated/phosphorylated p53 in the established clones after 
drug treatment was determined with immunofluorescence staining [Acetyl-p53 (Green), p-
p53 (Red) and co-localization (yellow)]. Weak signals were detected in WT clone, probably 
due to the low expression of p53 through negative regulation by MDM2. Among the p53 
mutant clones, belinostat induced green signals; cisplatin induced green, red and yellow 
signals; while combined treatment induced all three colours as well with a larger yellow 
population (Figure 5.25 A). The expression and localization of the modified p53 was 
quantified and analysed. 
High content analysis was subsequently performed through segmentation of nuclear fraction 
as described in Material and Methods to determine the expression of 
acetylated/phosphorylated p53 in WT and p53R158G clones. In Figure 5.25 B, acetylated 
p53 (Lys382) was shown to be increased upon belinostat (~6-fold for WT; ~4-fold for 
mutant clones), cisplatin (unchanged for WT; ~4-fold for mutant clones) and combined 
treatment (~10-fold for all clones). Belinostat, however, had no effect on the 
phosphorylation of p53. Cisplatin alone and combination treatment induced similar fold 
increase of p-p53 (50 - 100-fold) for all clones (Figure 5.25 C). Lastly, WT clone expressed 
low basal signal for both acetyl- and p-p53 in relative to mutant clones. 
Image cytometry was next conducted to investigate the distribution and localization of 
acetyl- and p-p53 under drug exposure in each of the mutant clone. The parameters for each 
individual nucleus (integrated densities of acetyl- and p-p53) were first determined by high 
content analyses on the images taken (Figure 5.25 A). Figure 5.26 A and B showed 
representative scatter plots for R158G (3) and (8) clones. The nuclear intensities of both 
targets in DMSO treated cells were set as baseline signals for gating purposes. With these 
gating, nuclei expressing signals higher than that of the vehicle control were identified. 
Comprehensive breakdown analysis on distribution of nucleus signal in each nucleus was 
displayed in Figure 5.26 C. These data showed that belinostat treatment right-shifted the cell 
population, with > 10% increase in acetyl-p53 positive cells; cisplatin shifted the cell 
population diagonally to the top-right, with substantial increases of p-p53 positive cells (> 
30%) and dual-stained positive cells (> 20%). Combination treatment reduced the 
proportion of p-p53 positive cells (~20%) but increased the proportion of cell population 
with both acetylated and phosphorylated p53 (> 50%). 
Defined roles of p53 modifications, such as ubiquitination, phosphorylation and acetylation, 
have been well-characterized. The profound roles of these modifications structured the 
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molecular basis for p53 regulation (Brooks and Gu 2003). Through the analysis on the 
immunofluorescence images, nuclear accumulations of both acetylated and phosphorylated 
p53 under drug pressure were confirmed: belinostat induced acetylation but not 
phosphorylation of p53; while cisplatin induced both acetylation and phosphorylation. In 
line with the earlier analysis on H2170 cells (Figure 5.11 C), combining belinostat and 
cisplatin further increased the cell population with acetylated p53. It is important to note that 
a large population of cell nuclei contained co-localization of both acetyl- and p-p53. These 
observations suggested that belinostat acetylated a proportion of p53 that was initially 
phosphorylated (but not acetylated) under cisplatin exposure. Collectively, combination of 
cisplatin and belinostat concomitantly induced acetylation and phosphorylation of p53 in the 
cell nucleus. Together with the up-regulation of p53 target genes, these observations 









Figure 5.25: Belinostat and cisplatin induce nuclear accumulation of acetyl- and p-p53 
in p53 overexpressing cells.  
A, Calu-1 WT clone and p53R158G clones were treated with belinostat (PXD101) (0.1μM), 
cisplatin (10μM) and combination treatment with DMSO (0.001%) as vehicle control for 48 
hours. Immunofluorescence staining was performed to determine the co-localization of 
acetyl-p53 (Lys382) (Alexa Fluor-488) and p-p53 (Ser15) (Alexa Fluor-568) in WT (6), 
R158G (1), R158G (2), R158G (3), R158G (7) and R158G (8) clones. Eight independent 
fields were taken for each condition with a minimum of 50 nuclei per field. Representative 
confocal images are shown at 400x magnification. Merged images are displayed with blue 
indicates DAPI, green indicates acetyl-p53, while red indicates p-p53. High content 
analyses were performed for (B) acetyl- and (C) p-p53 signal intensity in cell nucleus. Data 
are normalized against the number of nuclei and presented as mean ± SD for 8 independent 
fields within one representative experiment (n=2). Statistical analyses were performed by 














Figure 5.26: Distribution of acetyl- and p-p53 in p53 overexpressing clones after 
belinostat and cisplatin treatment.  
Calu-1 p53R158G clones were treated with belinostat (PXD101) (0.1μM), cisplatin (10μM) 
and combination treatment with DMSO as vehicle control for 48 hours. 
Immunofluorescence staining was performed to determine the co-localization of acetyl-p53 
(Lys382) (Alexa Fluor-488) and p-p53 (Ser15) (Alexa Fluor-568). Integrated density for 
each nucleus was determined by ImageJ as described in Material and Methods. Scatter plots 
of individual nuclei for (A) R158G (3) and (B) R158G (8) are shown (X: log signal for 
acetyl-p53; Y: log signal for p-p53). Each scatter plot consists of > 400 nuclei. Gating was 
determined from vehicle control. C, Tabulation of percentage of cell distribution for all 
p53R158G clones within one representative experiment (n=2) was displayed. Q1: p-p53 
negative, acetyl-p53 negative; Q2: p-p53 negative, acetyl-p53 positive; Q3: p-p53 positive, 


















Summary of findings in Chapter 5.4: 
 
 siRNA silencing of p53 abrogated the apoptosis induced by combination of cisplatin 
and belinostat. 
 Similarly, synergistic cytotoxicity of combination treatment was rescued in stable 
p53 knockdown clones generated by lentiviral infection. 
 In p53wt cells (MRC5), cisplatin and combination treatments induced 
transcriptional activation of p53 downstream genes (CDKN1A, MDM2, PUMA, and 
Noxa) with reduced mRNA expressions of TP53 and TP73. 
 In p53R158G mutant cells (H2170), belinostat (0.1μM) potentiated the cisplatin-
induced transcriptional activation of p53 downstream genes (CDKN1A, PUMA, and 
Noxa) but did not affect the expressions of MDM2 and TP53. 
 Wild-type and mutant p53 (R158G) were cloned into p53 null Calu-1 cells. 
 Overexpression of wild-type p53 sensitized Calu-1 cells to both cisplatin and 
belinostat treatments. 
 Overexpression of wild-type p53 sensitized Calu-1 cells to cisplatin treatment but 
increased tolerance to belinostat. 
 p53R158G clones were more responsive to combination treatment of belinostat 
(0.1μM) and cisplatin. 
 Overexpression of wild-type p53 increased basal mRNA expression of MDM2, 
CDKN1A, PUMA and Noxa in Calu-1 cells. Cisplatin and combination treatments 
up-regulated MDM2, CDKN1A, PUMA, Noxa, and BAX in WT clone. 
 Interestingly, overexpression of p53R158G increased basal mRNA expression of 
CDKN1A but not MDM2 and PUMA in Calu-1 cells. Instead, baseline expression of 
Noxa was reduced in p53R158G clones. Cisplatin and combination treatments up-
regulated CDKN1A, PUMA, and BAX but not MDM2 and Noxa in p53R158G 
clones.  
 In WT clone, cisplatin treatment alone induced p53 acetylation and induced 
apoptosis. Combination with belinostat had little effect on the cisplatin-treated cells. 
 In p53R158G clones, cisplatin-induced p53 acetylation and apoptosis could be 
potentiated by combining with belinostat (0.1μM). 
 In p53R158G clones, belinostat induced p53 acetylation; cisplatin induced both 
acetylation and phosphorylation; combination treatment potentiated p53 acetylation 
but not phosphorylation. 
 Combination treatment of belinostat and cisplatin increased cell population 
expressing both acetylated and phosphorylated p53.  
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5.5  Inducing p53 acetylation as potential therapeutic approach 
5.5.1  Regulation of p53 acetylation by HDACs and HAT 
As Calu-1 clones expressing nuclear-bound mutant p53 are more sensitive to combination 
treatment of cisplatin and belinostat, this observation correlated with the transactivation of 
p53 downstream genes as well as the post-translational modification of p53, suggesting that 
p53 acetylation is responsible for the observed synergy in the lung SCC cells. Next, the 
mechanisms leading to p53 acetylation were investigated. 
The role of HATs and HDACs in determining the balance of acetylated p53 has been 
discussed in Chapter1.3.2.2. Acetylation of p53 could be induced by HATs: CBP/p300 and 
PCAF acetylates N-terminus of p53; while Tip60 acetylates Lys120 (Lill, Grossman et al. 
1997, Liu, Scolnick et al. 1999, Grossman 2001, Tang, Luo et al. 2006). On the contrary, 
deacetylation of p53 is controlled by HDACs. Although several class I HDACs have been 
linked with transactivation of p53 function, only HDAC1 (Luo, Su et al. 2000, Ito, 
Kawaguchi et al. 2002) and HDAC3 (Zeng, Xiao et al. 2006, Karagianni and Wong 2007) 
have been reported to directly deacetylate p53. A class III HDAC, Sirtuin 1 (SirT1), is 
found to suppress p53 activity through p53 deacetylation (Vaziri, Dessain et al. 2001, Haigis 
and Guarente 2006). Furthermore, negative regulation of p53 through SirT1 promotes cell 
survival in response to DNA damage and oxidative stress (Luo, Nikolaev et al. 2001).  
The role of HATs (CBP/p300) and HDACs (HDAC1, HDAC3, SirT1) in drug-treated 
H2170 cells was next investigated. The Western blotting analysis showed that cisplatin 
reduced phosphorylation of HDAC3, but exerted minimal effect on acetyl-CBP/p300, 
HDAC1, p-SirT1, and SirT1 as a single agent. Belinostat alone marginally reduced p-SirT1 
and has no effects on p300 and other HDACs. Combining belinostat and cisplatin reduced 
p-SirT1, SirT1 and p-HDAC3 (Figure 5.27). While neither cisplatin nor belinostat treatment 
affected expression of the acetylated CBP/p300, combination treatment dramatically 
increased acetyl-CBP/p300 (Figure 5.27). These data showed that both cisplatin and 
combination treatment did not affect the expression of HDAC1 (Figure 5.27). 
Cisplatin-induced p53 acetylation is widely believed to be mediated by HATs (Di Stefano, 
Soddu et al. 2005). However, the observations suggest that HDAC3, but not CBP/p300, is 
an indirect downstream target of cisplatin in H2170 cells as shown by the de-
phosphorylation of HDAC3 at Ser424. Decreased phosphorylation of HDAC3 have been 
shown to reduce enzymatic activity of HDAC3 (Zhang, Ozawa et al. 2005). Furthermore, 
acetylation of p53 induced by combined treatment of belinostat and cisplatin correlated with 
the up-regulation of acetyl-CBP/p300 and reduction of p-HDAC3 and p-SirT1. These 





Figure 5.27: Cisplatin and belinostat up-regulate p300 and suppress SirT1 and HDAC 
3.  
H2170 cells were treated with belinostat (PXD101) (0.1μM), cisplatin (1, 2 and 3μM) and 
combination treatment with DMSO (0.001%) as vehicle control for 48 hours. Western blot 
analysis was performed to investigate the expression of acetyl-CBP/p300, HDAC1, p-SirT1 
(Ser27), SirT1, p-HDAC3 (Ser424) and HDAC3. Data shown are representative of three 













5.5.2  Tenovin-6 triggers apoptosis in p53 mutant cells 
Clinically, p53 mutations are commonly detected in most cancers, and accounted for cellular 
resistance to chemotherapy. These observations strongly suggested that p53 signalling could 
be partially restored in mutant p53 through molecular acetylation of key lysine residues. 
This finding may be clinically significant on lung SCC in which majority of the tumour cells 
harbour mutant p53 with defective DNA-binding ability (Chapter 3.1.2). In Chapter 5.5.1, it 
was proposed that p53 acetylation induced by belinostat and cisplatin could be regulated by 
CBP/p300, HDAC3 and SirT-1. A recent finding has described that Trichostatin A (TSA), a 
HDAC inhibitor, up-regulates expression of PUMA through specific inhibition of HDAC3 
(Feng, Pan et al. 2013). Furthermore, specific SirT inhibitors have been developed and 
showed significant pro-apoptotic effects in cancer cells (Lara, Mai et al. 2009, Peck, Chen et 
al. 2010). Therefore, using a specific acetylator of p53 may improve treatment outcome of 
lung SCC patients through p53 activation with less off-target adverse effects. In this chapter, 
the cytotoxicity of tenovin-6, a specific SirT1 inhibitor, was investigated in p53-expressing 
Calu-1 clones. 
Cell proliferation assay was conducted to determine the respective tenovin-6 IC50 of each 
clone. Among the 7 tested clones, EV clone was found to be most resistant (~7μM) to 
tenovin-6 while WT clone was the most sensitive (~2μM) (Figure 5.28 A). Calu-1 cells 
overexpressing p53R158G mutant displayed intermediate sensitivity to tenovin-6, with IC50 
falling in between those of EV and WT clones (~4μM) (Figure 5.28 A). Furthermore, 
tenovin-6 up-regulated acetyl-p53 (Lys379, Lys382) in both p53R158G clone 3 and 8 
without affecting the expression of total p53. However, modification of p53 in WT clone 
was not observed, probably due to the low expression of p53 in this clone. Interestingly, 
extensive cleavage of PARP and caspase 3 were observed in both mutant clones at a high 
tenovin-6 dose (10μM) but not EV clone and WT clone. However, p53 and p21 were 
substantially up-regulated in WT clone after tenovin-6 treatment (Figure 5.28), indicating 
the activation of p53 signalling in this clone.  
The investigations on tenovin-6 improved the understanding on the activity of p53 
signalling, as p53 null, wild-type and mutant cells displayed different responses upon drug 
exposure. In line with current knowledge, functional wild-type p53 induced cell cycle arrest 
before apoptosis, as supported by the up-regulation of p21 in WT clone. Conversely, 
activation of mutant p53 induced apoptosis but not cell cycle arrest. Taken together, these 
findings here strengthened the hypothesis that p53 acetylation leads to a non-conventional 





Figure 5.28: Tenovin-6 induces p53 acetylation and triggers apoptosis in p53 
overexpressing clones.  
EV clone, p53wt clone, and p53R158G clones were treated with increasing doses of 
tenovin-6. A, Individual clones were drug treated for 72 hours and cell viability assay (MTS) 
was used to determine the IC50 of tenovin-6. Data are presented as mean ± SD (n = 3). B, 
p53R158G clones were treated with tenovin-6 (3 and 10μM) with DMSO (0.001%) as 
vehicle control for 48 hours. Western blotting analysis was performed to investigate the 
expression of p53, acetyl-p53 (Lys279, Lys382), p21, PARP and caspase 3 in EV, WT, 
R158G (3) and R158G (8) clones. Data shown are representative of three independent 
experiments for the indicated targets with β-actin as input control. Statistical analyses were 





5.5.3  The correlation of p53 acetylation and apoptosis in drug-treated lung SCC cells 
Among the 8 cell lines tested in Chapter 5.1, H226 was verified as wild-type p53, Calu-1 as 
p53 null and the remaining 6 as p53 mutant (Figure 3.4). The mutations found in these lines 
are predominantly point mutation that occurs along the DNA-binding domain, with 2 
nonsense mutations (H520 and SK-MES-1) and 4 missense mutations (H2170, H596, 
H1869 and ChaGo-k-1). Western blotting was performed to verify the p53 expression 
(Figure 3.2), whereby no p53 protein was detected in H520 and SK-MES-1, while high 
protein expression was detected in H2170, H596, H1869 and ChaGo-k-1. As it has been 
hypothesized that induction of p53 acetylation could synergistically enhance cisplatin 
cytotoxicity, coincidently, cell lines not expressing full length p53 (Calu-1, H520, SK-MES-
1) were less responsive to cisplatin and with poorer synergy with belinostat (Chapter 3.3.1). 
Accordingly, post-translational modifications of p53 among H226, H596, H1869 and 
ChaGo-k-1 cell lines were investigated. 
In H226 (wild-type p53) cells, cisplatin treatment up-regulated p53 and acetyl-p53, while 
combination treatment further increased p53 acetylation (Figure 5.29 A). Among the 
remaining cell lines (H596, H1869, ChaGo-k-1), p53 was highly expressed at basal level 
due to the missense mutations that lead to its loss-of-function. Consistent with the earlier 
observations on H2170 cells, cisplatin but not belinostat acetylated p53 in these cell lines 
(Figure 5.29 B, C, D). However, combination treatment with belinostat only increased p53 
acetylation in H1869 cells (Figure 5.29 C). 
These observations suggested that the induction of p53 acetylation as a result of DNA-
damage is universal across cell lines expressing both wild-type and mutant p53. However, 
the combinatorial effect of belinostat in increasing cisplatin-induced p53 acetylation was 
only observed in H226, H1869 and the previously characterized H2170 cells. More 
importantly, when these findings were compared against the cytotoxicity profile (Figure 5.1), 
cell lines not expressing p53 protein were relatively less responsive to cisplatin and 
belinostat, while synergistic induction of apoptosis by combination treatment was only 
detected in H226, H1869 and H2170. These findings supported the hypothesis that 
acetylation of p53, even in those with mutation within DNA-binding domain, could trigger 









Figure 5.29: Effect of belinostat and cisplatin on p53 acetylation in lung SCC cell lines.  
H226 (A), H596 (B), H1869 (D) and ChaGo-k-1 (D) cells were exposed with PXD101 
(PXD101) (0.1μM), cisplatin (3μM), or combination treatment with DMSO (0.001%) as 
vehicle control for 48 hours.. Western blot analysis was performed to investigate the 
expression of acetyl-p53 (Lys382) and p53. Data shown are representative of two 







Summary of findings in Chapter 5.5: 
 
 Up-regulation of acetyl-CBP/p300 as well as down-regulation of p-HDAC3 and p-
SirT1 were correlated to the increased in acetylated p53 in H2170 cells. 
 Tenovin-6 acetylated p53 molecules in p53R158G clones. 
 Calu-1 cells overexpressing wild-type and mutant p53 were more sensitive to 
tenovin-6 with significantly lower IC50.  
 Cisplatin consistently induced p53 acetylation in H226, H596, H1869 and ChaGo-
k-1 cells. 
 Similar to H2170, belinostat (0.1µM) did not induce acetylation of p53.  
 Combination of belinostat (0.1µM) and cisplatin potentiated cisplatin-induced p53 
acetylation in H226 and H1869 cells. 
 Coincidently, synergistic cytotoxicity of belinostat and cisplatin was observed in 








5.6  Discussion 
5.6.1 The role of p53 functions in lung SCC cells 
Since its discovery in 1979, intensive research has been conducted to characterize the 
impact and functionality of the p53 protein (Lane and Crawford 1979, Linzer and Levine 
1979). Its role as a tumour suppressor gene has since been well-established (Baker, Fearon 
et al. 1989). As the “guardian of genome”, p53 regulates cell proliferation, cell cycle, cell 
death, DNA damage repair, and aging (Lane 1992). The broad spectrum of tumour-
suppressive functions makes it seems unlikely for tumour initiation unless the p53 network 
is inactivated (Vousden and Lu 2002). The regulation of cellular responses by p53 is 
dependent on the cell context as well as the nature of the stimuli, which include DNA 
damage, oncogene activation and hypoxia (Vousden and Lu 2002, Laptenko and Prives 
2006). 
Under unstressed condition, p53 is expressed as an inert protein and is maintained at low 
level. The MDM2 oncoprotein is a direct downstream target but also a main negative 
regulator of p53 (Barak, Juven et al. 1993, Wu, Bayle et al. 1993). Binding of MDM2 to the 
DNA transactivation domain of p53 first block transcriptional activities (Momand, Zambetti 
et al. 1992), and subsequently induce p53 nuclear export and degradation through 
ubiquitination (Wu, Bayle et al. 1993, Haupt, Maya et al. 1997). These justify the low p53 
levels detected in H226 and WT 6 clone. 
Activation of p53 signalling requires the stabilization of p53 as well as the conversion from 
inert to active form, which could be achieved through post-translational modifications 
(Bode and Dong 2004). Upon DNA damage, p53 is phosphorylated by ATM, ATR, Chk1, 
Chk2 and DNA-PK (Lees-Miller, Sakaguchi et al. 1992, Shieh, Ikeda et al. 1997, Banin, 
Moyal et al. 1998, Shieh, Taya et al. 1999, Tibbetts, Brumbaugh et al. 1999, Hirao, Kong et 
al. 2000), and acetylated by HATs (Ito, Lai et al. 2001) (Figure 5.32). Phosphorylation of 
p53 at amino N-terminus alleviates the inhibition by MDM2 (Kussie, Gorina et al. 1996, 
Shieh, Ikeda et al. 1997), while acetylation appears to promote the stability of p53 and 
enhance DNA-binding ability (Ito, Lai et al. 2001). Upon its activation, wild-type p53 
usually functions as a nuclear-bound, sequence-specific transcription factor that induces or 
suppresses the downstream signalling mechanisms such as cell cycle regulation (CDKN1A) 
(el-Deiry, Tokino et al. 1993); apoptosis (BAX, BID, FAS, PUMA, Noxa) (Miyashita and 
Reed 1995, Owen-Schaub, Zhang et al. 1995, Oda, Ohki et al. 2000, Nakano and Vousden 
2001, Sax, Fei et al. 2002); and auto-regulation of p53 (MDM2, TP73) (Barak, Juven et al. 
1993, Chen, Zheng et al. 2001, Grob, Novak et al. 2001). In line with this knowledge, a 
similar profile of these direct downstream genes was observed in p53 wild-type clone. 
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Consistently, CDKN1A, MDM2, PUMA, BAX, and PUMA were up-regulated upon genetic 
insertion of wild-type p53, while TP73 was reduced probably due to the dominant negative 
feedback loop (Grob, Novak et al. 2001) (Figure 5.21).  
Among the panel of lung SCC cell lines, H226 is the only one with wild-type p53. 
Consistent with current knowledge, this cell line has low level of p53 expression (Figure 3.2) 
and was shown to be highly sensitive to cisplatin (Figure 3.3 A). Furthermore, H226 was 
unable to grow under anchorage-independent condition (Data not shown but discussed in 
Chapter 3.3.2), probably due to the tumour-suppressive effects that prevent malignant 
transformation in this cell line. Cisplatin treatment up-regulated p53 (Figure 5.29 A) 
induced apoptosis (Figure 5.1 E) in H226 cells. These observations demonstrated the 
functions of wild-type p53 in lung SCC cell lines 
 
5.6.2  Mutational spectrum of TP53 and alterations of p53 functions in lung SCC 
Initiation of tumourigenesis usually involved the inactivation of p53 pathway through 
somatic mutations of p53 or other alternative mechanisms. For instance, amplification or 
aberrant activation of MDM2 is commonly observed in tumour cells (Leach, Tokino et al. 
1993, Manfredi 2010); while p14ARF (encoded by CDKN2A), a tumour suppressor that 
inhibit MDM2 (Bates, Phillips et al. 1998), is frequently inactivated through gene deletion 
or mutation as well as chromosomal hypermethylation (Liggett and Sidransky 1998, Esteller, 
Tortola et al. 2000, Esteller, Cordon-Cardo et al. 2001). Despite so, functional inactivation 
of p53 by somatic mutation is frequently observed in half of all tumours (Olivier, Hollstein 
et al. 2010). Figure 5.30 shows the spread of p53 mutations across multiple tumour types 
(Cerami, Gao et al. 2012, Gao, Aksoy et al. 2013). Among these cancer types, mutated p53 
is commonly detected in ovarian (~90%), lung SCC (~80%), head and neck and pancreatic 
carcinoma cases (Cerami, Gao et al. 2012, Gao, Aksoy et al. 2013).  
The genetic alterations of p53 pathway in lung SCC were verified by the deep sequencing 
data as 71.11% of the lung SCC specimens were identified with TP53 mutations (Chapter 
3.1.2). Despite the high mutation frequency, CDKN2A gene was found mutated mostly in 
the intronic region (Table 3.1). These recapitulate TP53 mutation as the most common 
phenomenon that alters p53 functions n lung SCC cells. Importantly, missense mutations of 
p53 frequently occur within the DNA-binding domain (DBD).  There are six common 
“hotspot” amino acids that are commonly detected in all human cancers: residue 282 (2.9%), 
249 (2.9%), 245 (3.3%), 175 (5.1%), 273 (6.7%) and 248 (7%) (Freed-Pastor and Prives 
2012). However, based on the TP53 mutation database published by TCGA, these well-
documented “hotspots” are uncommon among the lung SCC cases (Figure 5.31) (Cerami, 
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Gao et al. 2012, Network 2012, Gao, Aksoy et al. 2013). While majority of the TP53 
mutation in lung SCC are found to occur mostly along the region encoding for the DNA-
binding domain (DBD), arginine residue at position 158 is found to be the most frequent 
mutated amino acid among the 178 cases (8/178; 4.5%) (Figure 5.31). In the attempt to 
verify the mutational status of TP53 in lung SCC, 6 out of the 45 tumours (13.33%) of the 
specimens are mutated on residue 248 (Table 3.2). Somatic mutations of TP53 on the other 
“hotspots” are rare, with 2 mutations observed on each of residue 249 and 175, as well as 1 
on residue 175. Interestingly, 3 tumours are detected with mutation on residue 158 
(R158L/P/R) (6.67%) (Table 3.2). Among the SCC cell lines that have substitution mutation 
on TP53 gene, only one (H596) has altered amino acid residue on a common “hotspot” 
(Table 3.4). Coincidently, H2170 cell line has its arginine residue mutated to glycine at 
position 158 (R158G) (Table 3.4).  
Contrary to that observed in H226 cells, p53 protein is found to be accumulated in mutant 
p53 cells (H2170, H1869, H5796, ChaGo-k-1 and R158G clones), probably due to the lack 
of negative feedback mechanisms. In H2170 cell, full length p53 was synthesized but was 
non-responsive to Nutlin-3a. This simple experiment confirmed the loss-of-function 
mutation in R158G mutant, as inhibition of MDM2 by Nutlin-3a failed to transactivate p53 
(p21 and MDM2) (Figure 5.10). In addition, MDM2 gene was not activated in p53R158G 
clones after cisplatin treatment (Figure 5.22 A), thus verifying the loss of p53 functions in 
mutant cells. As missense mutations are common in lung SCC, these data suggest that p53 








Figure 5.31: Distribution of TP53 mutations in lung SCC (Cited from cBioPortal).  
Somatic mutations of TP53 genes in 178 patients were reported by TCGA (TCGA 2012). 
Green region is the transcriptional domain; red region is the DNA-binding domain; and 
blue region is the tetramerization domain. Corresponding frequency of any mutation at a 
given residue is shown. 
 
5.6.3 Induction of apoptosis by cisplatin and belinostat in lung SCC cells: A p53-
dependent event? 
The cellular outcome of p53 has been shown to be crucial for the tumour suppressive 
functions of wild-type p53 through genetically modified mouse models. Experimentations 
on mice expressing a p53 mutant (R172P), which has been previously described to retain 
regulatory effect on cell cycle arrest but not apoptosis (Rowan, Ludwig et al. 1996), 
demonstrate an overall delay in spontaneous tumour development by maintaining 
chromosomal stability (Liu, Parant et al. 2004). On the contrary, a mouse model consisting 
of p53  protein that lacks its proline-rich domain but retains apoptotic function is sufficient 
to provide cellular protection against spontaneous tumourigenesis (Toledo, Krummel et al. 
2006). These findings suggest that all wild-type p53 activities are essential for the tumour 
suppressive ability, but regulation of programmed cell death may contribute to a bigger role 
in preventing oncogenesis. It is now certain that p53 is involved in the transcriptional-
regulation of both extrinsic and intrinsic apoptosis (Haupt, Berger et al. 2003). However, 
cytoplasmic-bound p53 has also been reported to induce apoptosis through direct interaction 
with BAX and caspases (Ding, Lin et al. 2000, Chipuk, Kuwana et al. 2004) (Figure 5.32). 
Both p53-regulated transcriptional-dependent and –independent apoptotic pathways are 
described in Chapter 1.3.2.3. Nonetheless, cell death could still be mediated by several other 
mechanisms that bypass p53, such as the dysregulation of mitochondria pathway through 
ROS (Kim, Yun et al. 2013), disruption of 14-3-3 (Nomura, Shimizu et al. 2003, Clapp, 
Portt et al. 2012), and binding of death ligands (Lanni, Lowe et al. 1997, Ossina, Cannas et 
al. 1997).  
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In this study, the mechanisms behind synergistic cytotoxicity of belinostat and cisplatin 
were studied. Among the tested cell lines, the cisplatin-resistant H2170 cells showed 
promising response towards combination treatment of cisplatin and belinostat (Chapter 5.1). 
Belinostat and cisplatin have synergistic effects on H2170 cells, which harbours a 
homozygous R158G mutation in p53 DNA binding domain (Chapter 3.2.1). This mutation 
renders the inability to activate normal p53 function in the presence of cisplatin treatment. 
For example, Nutlin-3a treatment did not induce p53 dependent activity. In addition, 
cisplatin and belinostat did not activate p53 function in the luciferase reporter assay, but the 
combination of both drugs showed clear induction of p53 activity (Chapter 5.3.1). Silencing 
of BAX, a pro-apoptotic p53 effector, abrogated the apoptotic activity of cisplatin with 
belinostat, suggesting that p53 is important for this apoptotic effect (Figure 5.7). Moreover, 
stable p53 knockdown H2170 clones showed loss of synergistic combinatory effects of 
cisplatin and belinostat (Figure 5.15). To further support this, several downstream effectors 
of p53 (CDKN1A, PUMA and Noxa) were up-regulated when cisplatin was administered 
singly and in combination with belinostat (Figure 5.18). At the same time, acetylation of 
p53 at residues Lys379 and Lys382 appear to correlate with this synergistic activity (Figure 
5.11). The hypothesis is that combination of belinostat and cisplatin acetylates the R158G 
mutant and, to a certain extent, induces pro-apoptotic functions of this mutant p53.  
The hypothesis on p53 reactivation prompted the investigation on the treatment response of 
lung SCC cell lines to combination of belinostat and cisplatin. Among the cell lines with 
chromosomal deletion (Calu-1) and nonsense mutation (H520, SK-MES-1), there were no 
obvious increase in PARP and caspase 3 cleavage upon drug combination (Figure 5.1 B, C, 
D). Unexpectedly, 2 out of 4 lung SCC cell lines with missense mutation along DBD 
(H2170, H1869) had higher expression of apoptotic markers that correlated with the 
increase in acetylated p53 after combination treatment of belinostat and cisplatin (Figure 5.1 
A, G). These observations strengthened the hypothesis on the gain-of-function event in 
mutant p53. Despite so, convincing conclusion could not be drawn as the observed 
phenomenon could be confounded by the cell-cell variation and signalling complexity of 
these tumour cells.  
The paradigm of p53 in treatment of lung SCC cells was assessed by extopic expression of 
wild-type p53 and p53R158G mutant into a p53 null cell line (Calu-1). Under treatment 
pressure, two key observations were made in these clones: firstly, apoptosis was induced 
together with the transcriptional activation of several p53 apoptotic target genes (BAX, 
PUMA, Noxa) in WT clone (Figure 5.22 and 5.23); secondly, apoptosis was also triggered 
in p53R158G clones with an unique transcriptional profile that was similar to the classical 
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p53 apoptotic pathway (up-regulation of BAX and PUMA) (Figure 5.22 and 5.24). These 





Figure 5.32: Cellular processing of functional wild-type p53.  
DNA damage by chemotherapy induces post-translational modifications that stabilize p53 
protein, and lead to transcriptional-dependent and -independent regulation of cell cycle 





5.6.4  Non-conventional apoptotic response in mutant p53: Gain-of-function or loss-
of-function event? 
The first indication that mutated p53 carries specific functions was provided even before the 
molecule was characterized to be a tumour-suppressor. Initial studies on p53 proteins have 
demonstrated that overexpressing p53 could transform primary cells (Eliyahu, Raz et al. 
1984) as well as promote cellular proliferation (Mercer, Avignolo et al. 1984, Reich and 
Levine 1984, Shohat, Greenberg et al. 1987, Deppert, Buschhausen-Denker et al. 1990). As 
the experimented p53 cDNAs was eventually recognized as mutated proteins (Levine and 
Oren 2009), the transformation of primary cells by p53 and oncogenic Ras probably 
involved mutated p53 (Hinds, Finlay et al. 1989). Thus, instead of detailing the wild-type 
p53 functions, these contradictory findings were indeed reporting the role of mutant p53 in 
tumourigenesis.  
More recently, murine models harbouring p53 mutants that mimic common “hotspots” in 
human p53 revealed that the more metastatic tumours were developed in comparison to p53 
knock-out mice (Liu, McDonnell et al. 2000, Lang, Iwakuma et al. 2004, Olive, Tuveson et 
al. 2004). Several in vitro and in vivo studies have associated mutant p53 with key factors of 
tumourigenesis, such as cell proliferation (Bossi, Lapi et al. 2006), chemoresistance 
(Blandino, Levine et al. 1999, Bristow, Peacock et al. 2003), somatic cell reprogramming 
(Sarig, Rivlin et al. 2010), metastasis and invasion (Adorno, Cordenonsi et al. 2009, Muller, 
Caswell et al. 2009, Morton, Timpson et al. 2010). Conclusively, despite losing the 
transcriptional ability of wild-type p53, it is now widely accepted that mutant p53 is indeed 
a proto-oncogene.  A recent finding by Freed-Pastor et. al. demonstrated the direct associate 
of mutant p53 with mevalonate pathway, and inhibition of this pathway by statins is 
sufficient to reduce malignancy in breast cancer cells (Freed-Pastor, Mizuno et al. 2012). 
This finding emphasizes that understanding the oncogenic functions of mutant p53 may 
provide new insights into strategizing therapeutic approaches. 
Despite so, gain of oncogenic mechanisms was not observed within the five mutant R158G 
clones as they display comparable in vitro growth rate and anchorage-independent growth 
ability to their parental Calu-1 cells (Data not shown). Moreover, these mutant lines have 
better drug sensitivity towards cisplatin, which contradict the reported chemoresistant 
property of mutant p53 (Blandino, Levine et al. 1999, Bristow, Peacock et al. 2003). Taken 
together, mutant p53 does not behave like an oncoprotein in Calu-1 cells as illustrated by 
others. Instead, a possible activation of p53-mediated apoptosis was observed in these 
clones. However, drug-induced apoptosis in R158G clones differed from that in WT clone. 
While BAX and PUMA were up-regulated, cisplatin and combination treatment did not 
induce MDM2 (Figure 5.22), a key target gene of p53 (Wu, Bayle et al. 1993). Furthermore, 
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the magnitude of CDKN1A expression was not comparable to wild-type cells despite 
increasing in similar pattern. The transactivation of Noxa, which was induced in EV and 
WT clones, was somehow abrogated in all mutant clones (Figure 5.22). Taken together, 
these data indicate the presence of a p53-dependent, transcriptional-dependent apoptotic 
mechanism that is different from the classical p53 signalling (Haupt, Berger et al. 2003). 
Several mechanisms have been proposed to explain the oncogenic functions of mutant p53. 
However, no unifying mechanism could be agreeable upon to explain the unique ability of 
mutant p53 to mediate such a wide range of target genes despite losing its DNA-binding 
ability. Moreover, a defined DNA response element for mutant p53 has yet to be identified. 
One common hypothesis is that mutant p53 could interact with other transcription factors, 
such as NF-Y, PML, Sp1, and VDR (Bargonetti, Chicas et al. 1997, Di Agostino, Strano et 
al. 2006, Haupt, di Agostino et al. 2009), and enhance the downstream target responses that 
lead to enhancement in cell proliferation, induction of chemoresistance and alteration of cell 
metabolism. As various promoters of mutant p53 shared minimal sequence homology, it has 
been hypothesized that binding of mutant p53 is likely dependent on unique structural 
changes of DNA motifs instead of sequence specific response elements (Kim and Deppert 
2004, Kim and Deppert 2007). Interestingly, Di Agostino et. al. reported that both wild-type 
and mutant p53 have differential preference in recruitment of transcriptional cofactors: 
while wild-type p53 is commonly bound to HDAC1 (Juan, Shia et al. 2000), mutant p53 
forms a complex with p300 (Di Agostino, Strano et al. 2006, Ali, Wang et al. 2013). These 
suggest that the interaction with different histone-modifying enzymes may signal for 
opposing transcriptional activity among wild-type and mutant p53. Finally, it has been 
demonstrated that several mutant p53 proteins are able to interact with p63 and p73 (Di 
Como, Gaiddon et al. 1999, Gaiddon, Lokshin et al. 2001), two members of the p53 family 
that exhibit high degree of homology to the DBD of  p53 (Irwin and Kaelin 2001). 
Furthermore, p73 has been further reported to be essential for induction of apoptosis by 
several chemotherapy (Soussi 2003), it is thus hypothesize that mutant p53 may affect 
p63/p73-dependent transcriptional activity by inhibiting the interaction with their respective 
target gene promoter (Gaiddon, Lokshin et al. 2001). 
As illustrated in Figure 5.33, these hypotheses on the possible oncogenic mechanisms of 
mutant p53 provide clues for the gain-of-function event in lung SCC cells with p53R158G 
mutant. Firstly, the data suggested that co-treatment of a sub-lethal dose of belinostat 
sufficient to induce histone acetylation synergistically increased cell death in cisplatin-
treated cells (Chapter 5.2.3).  Next, HDAC inhibitors have been well documented to modify 
the histone tails, thus resulting in remodelling of chromatin structure en route to mediate 
gene expression (Gregory, Wagner et al. 2001, Thiagalingam, Cheng et al. 2003). 
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Concurrently, several p53 downstream target genes were transactivated after drug 
treatments. Finally, combination treatment substantially acetylates CBP/p300 and p53. By 
taking all these observations into consideration, it was postulated that low dose of belinostat, 
despite not inducing cell death, may facilitate mutant p53 transactivation through chromatin 




Figure 5.33: Proposed gain-of-function mechanisms of mutant p53.  
There are multiple mechanisms that are postulated for the gain-of-function activities of 
mutant p53 that include both transcriptional-dependent or –independent mechanisms. These 
include: (A) direct binding to sequence-specific response elements; (B) direct binding to 
structural specific gene promoters, such as matrix-attachment regions (MARs); (C) 
inhibition of tumour-suppressive functions of p63 and p73 through protein-protein 
interaction; (D) direct recruitment of HATs thus leading to histone acetylation and 
transcriptional activation; and (E) direct interaction with other transcription factors, such as 
NF-Y, PML, Sp1, and VDR, to induce transactivation of downstream target genes. The 








mechanism. These interactions resulted in the oncogenic functions of mutant p53, such as 
inhibition of apoptosis, cell proliferation, chemoresistance, somatic cell reprogramming, 
metastasis and invasion 
 
5.6.5  Understanding the activation of mutant p53 through post-translational 
modification 
Post-translational modification of p53, especially phosphorylation and acetylation, is a key 
process by which p53 pathway is activated (Sakaguchi, Herrera et al. 1998). These 
modulations directly influence p53’s stability, nuclear localization and DNA-binding ability. 
Therefore, belinostat possibly induces p53 reprogramming or modification that 
subsequently triggers apoptosis in cisplatin-treated cells. 
In line with current knowledge, p53 acetylation and phosphorylation occurred concurrently 
in dose-dependent manner after cisplatin treatment in H2170 cells (Sakaguchi, Herrera et al. 
1998) (Chapter 5.3.2). It was further demonstrated that post-translational modifications of 
mutant p53 were responsible for the synergistic cytotoxicity: firstly, potentiation of 
apoptosis in the belinostat/cisplatin-treated cells correlated with p53 acetylation but not 
phosphorylation (Chapter 5.3.2), thus downplaying the significance of phosphorylation in 
the observed synergy; secondly, image cytometry revealed that combination treatment 
increased number of nuclei with acetylated p53 (Chapter 5.4.2.7); thirdly, treatment with 
tenovin-6 induced p53 acetylation and more robust apoptosis in p53R158G clones in 
comparison to EV and WT clones (Chapter 5.5.2). Taken together, these data suggest that 
inducing p53 acetylation may be sufficient to trigger cell death in mutant p53. 
It was next ask the question of whether acetylation alone is sufficient to recover p53 
function. In the p53 overexpressing clones, the extent of post-translational modification in 
individual nuclei was examined upon cisplatin and belinostat treatment. The sub-
populations of nuclei containing acetylated and phosphorylated p53 were assessed upon 
drug response. Combination treatment of cisplatin and belinostat is associated with the 
largest cell population of acetylated and phosphorylated p53, but the increase in acetylation 
is more indicative of the induction of apoptosis. Despite so, these data are insufficient to 
convincingly exclude the role of p53 phosphorylation in the observed apoptotic phenotype, 
as concurrent induction of both of these modifications may still be required. A possible 
approach to study this is to systematically mutate most, if not all, of the lysine residues 
found on p53 protein to efficiently attenuate acetylation in the study model. Despite being 
classified previously to be a C-terminal-specific modifications (K357, K370, K372, K373, 
K381, K382, K386), several acetylation sites have been recently identified along the DNA 
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binding domain (K120, K164) and oligomerization domain (K305, K319) (Gu and Roeder 
1997, Sakaguchi, Herrera et al. 1998, Wang, Tsay et al. 2003, Tang, Luo et al. 2006, Ivanov, 
Ivanova et al. 2007, Li, Piluso et al. 2007, Kurash, Lei et al. 2008, Tang, Zhao et al. 2008, 
Joubel, Chalkley et al. 2009). Interestingly, it has been shown that non-acetylated p53 could 
still mediate the p53-MDM2 feedback loop, but lack of acetylation substantially abolished 
the p53-dependent cell cycle arrest and apoptosis (Tang, Zhao et al. 2008). Acetylation of 
p53 at lysine residue 120 (K120) is indispensable for p53-mediated apoptosis but not 
necessarily crucial for p53-dependent cell cycle arrest (Sykes, Mellert et al. 2006, Tang, Luo 
et al. 2006). Unlike phosphorylation, the individual function of each acetylated residues has 
yet to be comprehensively characterized. In the present study, the primary focus was on the 
acetylated sites along the C-terminus of p53 protein, where lysine residues are most 
frequently detected. Generation of acetylation-defective p53 could facilitate investigation on 
the role of acetylation in p53-mediated apoptosis. 
More importantly, several reports have illustrated that site-directed mutation of specific 
phosphorylation sites in p53 could not rescue cells from p53-induced cytotoxicity upon 
DNA damage (Slingerland, Jenkins et al. 1993, Fiscella, Zambrano et al. 1994, Blattner, 
Tobiasch et al. 1999). A further attempt to mutate all known phosphorylation sites on the 
p53 molecule again confirmed that p53 transactivation occurs independently of 
phosphorylation, as the mutated molecule retained its transcriptional activity (Ashcroft, 
Kubbutat et al. 1999). It is thus possible that other post-translational modifications, such as 
acetylation, could sufficiently trigger p53-dependent functions. Furthermore, acetylation of 
p53 is more associated with its sequence-specific DNA-binding ability (Gu and Roeder 
1997, Lill, Grossman et al. 1997, Liu, Scolnick et al. 1999). Therefore, acetylated p53 may 
bind to sequence-specific response elements that are involved in the observed phenotype. It 
is also important to note that phosphorylation is generally associated with p53 stability and 
inhibition of MDM2-mediated degradation (Shieh, Ikeda et al. 1997, Siliciano, Canman et al. 
1997), while in the case of mutant p53, the protein is highly expressed. Further 
investigations are needed to identify the possible mutant p53-interacting DNA sequence.  
 
5.6.6 Restoration of p53-mediated apoptosis in mutant p53  
Many chemotherapeutic agents are activator of p53 by causing DNA-damage. However, 
efficacy of chemotherapy could be hindered in tumours by mechanisms that negatively 
regulate p53 signalling. Recently, much effort has been dedicated to identify and synthesize 
small molecules that could reinstate transcriptional activity of p53. As p53 functions could 
be dysregulated by amplification of MDM2, inhibitors that disrupt the interaction between 
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p53 and MDM2 are developed, such as Nutlins (Vassilev 2004, Vassilev, Vu et al. 2004). 
Nutlins have promising p53-dependent anti-tumour effects (Vassilev, Vu et al. 2004), as 
demonstrated in MRC5 cells with the transactivation of MDM2 and CDKN1A (Figure 5.10). 
However, Nutlins are selective to tumours that retained wild-type p53. As missense 
mutation of p53 is commonly detected in lung SCC, inhibitors that disrupt p53-MDM2 
interaction may not be effective, as shown in H2170 cells.  
A second class of compounds, known as the sirtuin inhibitors, is currently under 
investigation. Sirtuins, class III NAD+ dependent histone deacetylases, are shown to be 
aberrantly up-regulated in several cancer types (Bradbury, Khanim et al. 2005, Huffman, 
Grizzle et al. 2007) and its expression could destabilize p53 through deacetylation at lysine 
382 (Vaziri, Dessain et al. 2001). More importantly, knockdown of sirtuin-1 resulted in 
hyperacetylation of p53 and increased p53-dependent transcriptional activity (Luo, Nikolaev 
et al. 2001, Ford, Jiang et al. 2005). Till date, multiple inhibitors for sirtuins have been 
synthesized but, except for sirtinol and tenovins, majority of them do not induce p53 activity 
as a single agent (Ota, Akishita et al. 2007, Lain, Hollick et al. 2008). In this study, targeting 
SirT1 in p53 mutant clones using tenovin-6 increased p53 acetylation and induced apoptosis 
(Figure 5.28 B). Interestingly, although WT 6 were shown to be more sensitive to tenovin-6 
(Chapter 5.5.2), expression of p21 but not PARP cleavage was increased upon drug 
treatment, suggesting that  induction of cell cycle arrest preceded cell death in wild-type p53 
overexpressing cells. These findings implicate the favourable specificity of the proposed 
approach in targeting lung SCC, which consist of mostly p53 mutant cells, over normal lung 
cells with wild-type p53.  
In an approach to investigate the molecular mechanisms that explain drug-induced p53 
acetylation in the study models, it was observed that both HDAC3 and SirT1 were down-
regulated, while acetyl-CBP/p300 was up-regulated (Figure 5.27). Therefore, regulation of 
specific HDACs and HATs may control p53 acetylation. Intriguingly, although cisplatin is 
known to induce activity of HATs (Di Stefano, Soddu et al. 2005), the data demonstrted that 
combination treatment, but not cisplatin alone, substantially activated CBP/p300. 
Furthermore, belinostat is a hydroxamic acid HDAC inhibitor that is known to inhibit 
enzymatic activity of class I and II but not class III HDACs (Imai, Armstrong et al. 2000, 
Johnstone 2002). In this study, however, expressions of both HDAC3 (Class I HDAC) and 
SirT1 (Class III) were reduced upon combination treatment. Thus, it was believed that the 
observed inhibition of SirT1 and activation of CBP/p300 may involve the combinatorial 
effects of both cisplatin and belinostat instead of specific targeting of single agent. While 
the inhibition of SirT1 using tenovin-6 had demonstrated promising cytotoxicity effect in 
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p53 mutant cells, the outcome of activating CBP/p300 by HAT activating agents, such as 
CTPB (Mantelingu, Kishore et al. 2007), has yet to be validated. 
In this present study, two potential treatment regimes have been explored: combination of 
belinostat with cisplatin, and single drug treatment with tenovin-6, that could acetylate p53 
in a dose-dependent manner. A study conducted by Solomon et. al. had shown that 
concurrent inhibitions of SirT1 and HDAC dramatically increased p53 acetylation at lysine 
382 residue (Solomon, Pasupuleti et al. 2006). However, this author also reported that 
acetylation of p53 did not affect cell survival after DNA-damage, suggesting that the ability 
of acetylated p53 to induce apoptosis may be a cell-context dependent mechanism. Among 
the four lung SCC cell lines with mutated p53, combination with belinostat increased 
cisplatin-induced acetylation of p53 in H2170 and H1869. In addition, apoptosis was 
synergistically induced in these two cell lines. However, these regulations of acetylated p53 
and cell death were not observed in H596 and ChaGo-k-1 cells. These observations 
emphasized that cellular response to belinostat in term of p53 acetylation may be cell-
context dependent.  
 
5.6.7  Conclusions and future directions 
Inactivation of p53 signalling is a common feature in various human tumours. Thirty years 
of extensive research have provided a comprehensive understanding on the structure, 
modification and function of p53. The loss of its tumour suppressive function is widely 
regarded as an almost universal phenomenon in the initiation of tumourigenesis. In this 
chapter, the role of p53 functions and its aberrant loss-of-function mutation in lung SCC 
were discussed. More recently, however, multiple reports have suggested that p53 mutants 
harbour more phenotypic changes than just a loss of its wild-type tumour suppressive 
functions. The progressive understandings on p53 and its mutant form suggest that there is 
still much to be explored on a protein that is initially thought to be thoroughly understood.  
The p53 overexpressing clones generated from Calu-1 cells are seen as suitable study 
models for investigating the roles of p53, especially the mutant clones, in tumour biology of 
lung SCC. Although the gain-of-function events in the mutant clones have been extensively 
characterized, however, the detailed mechanisms remain elusive. The postulation is that p53 
functions can be reinstated in mutant cells either by interaction with transcriptional co-
factors, direct binding to DNA through sequence-specific affinity or chromosomal 
remodelling (Figure 5.34). However, the concept of mutant p53 to regain DNA binding 
affinity remains highly dubious. Interestingly, though wild-type p53 is unable to interact 
with p73 and p63, several reports have demonstrated the oligomerization of mutant p53 with 
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other p53 family members through their DBD (Gaiddon, Lokshin et al. 2001, Strano, 
Munarriz et al. 2001, Strano, Fontemaggi et al. 2002). These observations suggest that 
missense mutation occurring at the DNA-binding site may alter the local or global 
conformation structure of p53 and possibly modulate the binding specificity of mutant p53. 
This implicates that a single codon mutation is sufficient to disrupt the classical p53-DNA 
binding while supplement with other non-conventional gain-of-function mechanisms, which 
may include binding to novel gene promoters. To elucidate the underlying mechanisms, co-
immunoprecipitation and chromatin immunoprecipitation could be performed on mutant 
p53 for identification of binding partners or sequences. In addition, site-directed 
mutagenesis can be conducted to verify the significance of acetylation in the observed 
phenotype. 
In view of the potential of p53 acetylators as treatment options for lung SCC, the 
mechanisms to effectively acetylated p53 has emerged as an interesting direction for future 
study. The findings here suggested that p53 acetylation could be induced by a DNA-damage 
agent, cisplatin, in combination with belinostat, possibly via inhibition of HDAC3 and 
sirtuin-1 as well as activation of CBP/p300. However, it is important to note that other 
molecules, such as Tip60 and sirtuin-2, are known modulators of p53 activity (Frye 2000, 
Vakhrusheva, Smolka et al. 2008). These molecules were not investigated in the present 
study. Therefore, the search is on for therapeutic targets that will provide synthetic lethal 
associations with mutant p53. 
In conclusion, despite the increased understanding on p53 pathway and rapid advances in 
p53-based cancer therapy, many key questions remain unanswered. How does mutant p53 
selectively activates cellular apoptosis under drug treatment? Is p53 acetylation sufficient to 
induce the observed phenotype? What are the key regulators of p53 acetylation in lung SCC? 
Could these regulator(s) be targeted? How do the modified mutant forms of p53 impose its 
transcriptional regulation of target genes? What is the role of p73 in this model? Is the 
observed phenomenon a universal phenotype in all mutant p53, or is it only vital to certain 
point mutations? The findings in present study emphasize on the functional biology of 
mutant p53 which lay the groundwork for future discoveries of strategies that are applicable 













Figure 5.34: A schematic diagram showing the proposed mechanisms of p53-mediated 
apoptosis in R158G mutant cells through drug-induced p53 acetylation.  
Cytotoxic agents (Tenovin-6; cisplatin and belinostat) that induce p53 acetylation 
substantially trigger cell death in p53 mutant (R158G) cell lines, probably via 
transcriptional-dependent p53-mediated apoptosis as shown by the induction of p53 target 
genes (CDKN1A, BAX, PUMA). This novel observation is postulated to be regulated via: (A) 
direct recruitment of mutant p53 to unique sequence-specific response elements; (B) direct 
binding to structural specific DNA motifs; (C) direct recruitment of HATs; and (D) direct 
interaction with other transcription factors to induce transactivation of downstream target 
genes. The dashed arrow indicates the lacking of supportive evidence to support these 









CHAPTER 6  CONCLUSIONS 
 
Despite a reduction in the incidence rate, the mortality burden of squamous cell carcinoma 
(SCC) remains high. This could be due to a lack of oncogenic driver lesions that could guide 
treatment. Historically, the efforts at characterizing the molecular underspinnings of SCC 
have lagged behind those of adenocarcinoma. Many of the driver oncogenes found in lung 
adenocarcinoma are rarely detected in SCC. These properties of lung SCC have been 
verified in SCC tumours of Asian patients by performing deep sequencing after targeted 
enrinchment. As a consequence, patients with metastatic SCC have fewer options that those 
with non-squamous NSCLC. For instance, targeting EGFR mutations in the tyrosine kinase 
domain, ROS1 and EML4-ALK rearrangements have yielded impressive gains in 
therapeutic efficacy in adenocarcinoma of the lung, as have the use of Bevacizumab and 
Pemetrexed chemotherapy for non-SCC histologies (Lynch, Bell et al. 2004, Paez, Jänne et 
al. 2004, Soda, Choi et al. 2007, Patel, Socinski et al. 2013); for SCC histologies, however, 
Cetuximab remains as the only approved non-cytotoxic agent to date (Lynch, Patel et al. 
2010). Therefore, cisplatin remains as the backbone of chemotherapy for SCC of different 
histotypes either as a single agent or alongside other chemotherapeutic agents of 
radiotherapy. However, resistance to cisplatin inevitably developed, and the overall survival 
rates in SCC patients remain low.  
Since its approval in 1978, the mechanism-of-action of cisplatin have been well studied, 
together with the mechanisms that lead to resistance. Understanding these pathways are 
believed to reveal new therapeutic strategies that could improve clinical outcome. For 
instance, inactivation of hMLH1 gene through promoter methylation was known to confer 
resistance to platinum-containing compounds. A recent clinical study on the combination of 
decitabine, a demethylating agent, with carboplatin was conducted in ovarian cancer 
patients based on the hypothesis that reactivation of hMLH1 promoter through the 
hypomethylating effect of decitabine could improve the efficacy of carboplatin (Glasspool, 
Brown et al. 2014). However, this study has failed to achieve good clinical outcome, 
possibly due to the non-specificity of decitabine (Glasspool, Brown et al. 2014). Therefore 
in this study, the drug-induced perturbations to gene and protein expression that mediated 
cisplatin resistance was elucidated; while the strategies that counteract these mechanisms 
were being explored. 
Two main findings have been described in this thesis. The first finding demonstrates a 
mechanism involving the drug-induced SOS-mediated MAPK/Erk activation that confers 
resistance to cisplatin. More recent investigations, which are not being included in this 
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thesis, have shown that activated p-Erk1/2 phosphorylates and induces degradation of pro-
apoptic Bim, therefore preventing cisplatin-induced cell death. Clinicopathological analysis 
on patients with locally advanced SCC treated with concurrent cisplatin and radiotherapy 
has demonstrated that patients with stronger p-Erk1/2 expression have significantly shorter 
disease-free survival. Taken together, these observations implicate the potential roles of 
phosphorylated Erk both as a predictive biomarker and a therapeutic target for SCC patients. 
Accordingly, pharmacological interventions of MAPK/Erk pathway through MEK 
inhibitors and belinostat are shown to facilitate induction of apoptosis in SCC cells. For a 
proof-of-concept, it will be critical to study the combination of cisplatin and a MEK 
inhibitor or belinostat in patients whose tumors demonstrate evidence of Erk 
phosphorylation. Such studies are currently being planned.   
The second finding in this study describes a gain-of-function events in mutant p53 SCC 
cells, which facilitates induction and apoptosis and is shown to correlate with the acetylation 
at the C-terminus. These observations was made while investigating the therapeutic 
potential of belinostat in combination with cisplatin in SCC cells. When used at 0.1µM, 
which is achievable in patient’s plasma, belinostat enhanced cisplatin-induced apoptosis in 
H2170 cells that has a loss-of-function mutation along the DNA-binding domain of the p53. 
Importantly, this observed cell death could be rescued with effective knockdown of 
p53R158G mutant in H2170 cells; while activated with ectopic expression of p53R158G 
mutant in p53-null Calu-1 cells. These observations led to the discoveries that drug 
treatment that induced p53 acetylation, such as belinostat/cisplatin or tenovin-6, could 
trigger the cell death mechanisms in p53 mutant cells. This is a clinically significant finding 
as most tumour cells harbour p53 mutation, especially in the case of lung SCC, where there 
is a lack of oncogenic driver lesions to guide treatment. However, the mechanisms leading 
to this pro-apoptotic gain-of-function events remain elusive and are currently being 
investigated. 
In conclusion, this thesis has addressed two main hypotheses: one involving Erk activation 
under treatment pressure that confers cisplatin resistance, and the other demonstrating a 
restoration of p53-induced apoptosis in p53 mutant cells through acetylation at the C-
terminus. The first hypothesis targets SCC patients that have developed refractoriness to 
cisplatin with tumours that showed Erk up-regulation; the second hypothesis paves way for 
development of new therapeutic strategies in SCC patients with tumours that have TP53 
mutations. Importantly, the proposed treatment regimens utilize clinically available anti-
cancer agents (MEK inhibitors, belinostat and cisplatin) at tolerable doses. The efficacy of 
these drug combinations is currently being investigated in mouse xenograft models. 
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Appendix 3: Genes that were differentially regulated in both cisplatin-resistant and –
sensitive phenotypes after cisplatin treatment.  
The table showed the cluster of genes that were significantly up or down-regulated at 1.5 
fold after cisplatin treatment in either cisplatin-sensitive or cisplatin-resistant phenotypes. 
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